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GENERAL INTRODUCTION
This thesis deals with the clinical and immunohistochemical 
effects o f retinoids on two distinct groups o f skin disorders: pso­
riasis and (pre)malignancies. Retinoids are known to influence 
proliferation and differentiation, processes that are disturbed 
in these disorders. In this thesis the effects o f a newly developed 
retinoid and the effects o f established retinoids for new indi­
cations are described. The introduction comprises the m ain  
features o f psoriasis, premalignant- and m alignant skin dis­
orders, retinoids, and the approaches that were used in the 
individual studies. Each will be discussed in a separate part.
11
R X R - A N D  R A R - S E L E  C T I V E R E T I N O I D S  I N  P S O R I A S I S  A N D  ( P R E ) M  A L I G N A N T S K I N  D I S O R D E R S
12
R X R - A N D  R A R - S  E L E  C T I V E R E T I N O I D S  I N  P S O R I A S I S  A N D  ( P R E ) M A L I G N A N T S K I N  D I S O R D E R S
PART I
PSORIASIS
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1.1
History
The oldest medical records on skin disorders originated in ancient Egypt. The Ebers 
papyrus is the longest of the medical papyri and is dated to the ninth year of the reign of 
pharaoh Amenhotep I, about 1534 BC. It comprises 110 pages and contains a few sec­
tions on the treatment of skin disorders. In one paragraph topical therapies for wehau 
(skin rash) are described in the form of gesu (ointments) and iner-sepdu (minerals). 
Honey, red natron and salt were used to sepena (renew) and senefer (beautify) the inem 
(skin).1;2 Unfortunately, there is no clue in  the hieroglyphs which enables us to identify 
these disorders, but it is clear that these ancient Egyptian therapeutic approaches may 
well have had some effect in an erythematous disease like psoriasis. Many studies have 
confirmed the beneficial effects of honey in woudhealing of the skin.3;4 In psoriasis oint­
ments and salt baths are common basic treatments even nowadays.
The first real descriptions that included the typical hallmarks of psoriasis came from 
Hippocrates (460-377 BC) and Celsius (25 BC-45 AD), but it was Galen (133-200 AD) 
who introduced the Greek name psora (itching eruption) for this disease that often fea­
tures complaints of itching.5;6 “Scabbiness” is another meaning for the word psoriasis,7 
but this translation is rather misplaced nowadays. Although Robert Willan (1808) de­
scribed the various forms of psoriasis, he still designated the disease as lepra. In 1841 
Hebra eliminated the term lepra for this disease and substituted it psoriasis, however, 
until 1900 many psoriatics still suffered the same fate as lepers. They were believed to be 
unclean and infectious and therefore were excluded from society.5;6
14
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1.2
Epidemiology
Psoriasis is a chronic disease with a prevalence of 1-3% in the European, North 
American, East African, and South Asian population.8;9 However, in certain ethnic 
groups these indices may differ. In the American Indians, Samoans, Laps, and Eskimos 
psoriasis is scarcely seen, suggesting the involvement of genetic factors in this disease. 
8;i0;ii Psoriasis equally affects men and women.12-14 The age of onset is variable; first 
manifestations of the disease may occur at any age from birth to even at the age of 108 
years.15;16 However, a study on the age of onset of psoriasis carried out in 2147 patients 
revealed two peaks of incidence: one occurring at the age of 16 years (women), and 
another at the age of 60 years (women) or 57 years (men).17 A n onset before the age of 
5 is rare. In families where psoriasis is commonly seen, there appears to be an earlier 
onset.18
15
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1.3
Clinical aspects
1.3.1 Subtypes and cutaneous manifestations
In dermatology many diseases comprise of several different subtypes instead of one 
single typical clinical picture. With respect to cutaneous manifestations of psoriasis the 
following common subtypes are seen, that may or may not coexist.18
Plaque-type psoriasis or psoriasis vulgaris
This is the most common form of psoriasis, accounting for 90% of all cases. Lesions 
are symmetrically distributed over the body showing classical psoriatic aspects such as 
erythema, induration, and silvery scaling. Predilection sites are the elbows, knees, scalp, 
and the sacral region, but spreading all over the patient’s body may occur. The course is 
mostly chronic with exacerbations and remissions. This thesis deals with this common 
subtype of psoriasis; in  corresponding sections where “psoriasis” is mentioned, the read­
er should interpret this as “plaque-type psoriasis”.
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Psoriasis guttata
This subtype features a pattern of droplet-like (2 millimeters to 1 centimeter) ery­
thematous and scaly lesions disseminated over the body. Compared to plaque-type psoria­
sis scaling is normally less present, but these droplet-like lesions may confluent to larger 
and more scaly lesions as seen in plaque-type psoriasis. Psoriasis guttata is often preceded 
by an upper respiratory tract infection, and is mostly seen in children and adolescents. 
When a preceding infection is cured, a complete remission of this form of psoriasis can 
generally be expected after a couple of weeks, although patients are more prone to devel­
op plaque-type psoriasis later on in life.
Erythrodermic psoriasis
This is a rare form of psoriasis in  which the entire skin becomes erythematous with 
variable scaling. It may occur in patients with no history of psoriasis, but this form is 
often seen in patients with plaque-type psoriasis after withdrawal from corticosteroids, 
after irritation by dithranol or phototherapy, or it may have been triggered by drugs 
which are known to induce psoriasis. This type of psoriasis may cause severe sickness. 
Itching is more common and patients are at risk for hypothermia, dehydration, and 
protein loss. Therefore, admission at the inpatient department is often required.
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Pustular psoriasis
This is actually a group of psoriasis subtypes that feature macroscopic pustules. Both 
localized and generalized forms can be distinguished. Localized forms are pustulosis 
palmoplantaris, acrodermatitis continua of Hallopeau and other non-acral, non-palmo- 
plantar localized forms. Generalized forms comprise pustular psoriasis of Von Zumbusch, 
impetigo herpetiformis, annular pustular psoriasis, juvenile and infantile pustular psoria- 
sis.19 These forms are more recalcitrant and often need systemic therapy.
The following subtypes are frequently seen in combination with the above men­
tioned forms of psoriasis and may therefore be seen as a modification by site; on the other 
hand these forms are often solitary manifestations of psoriasis that justifies a classifica­
tion as a separate subtype.
Flexural psoriasis or psoriasis inversa
This subtype is mostly localized in  the submammary, axillary, and anogenital fold. It 
is more common in  females and in  the elderly and often lacks scaling. It is noticed in 
about 30% of patients with plaque-type psoriasis.
18
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Figure 4:
Pustular psoriasis norm ally represents 
typical ye llow  and brown pustules.
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Psoriasis of the scalp or psoriasis capitis
In scalp psoriasis typical scaly and erythematous plaques that are spread over the 
hairy scalp are seen, but they are often interspersed with normal skin. Frequently scalp 
psoriasis advances beyond the scalp margin. Significant hair loss is rare.
Psoriasis of the hands and feet or psoriasis palmoplantaris
In this form lesions may present as typical scaly patches or as a pustulosis. It may 
strongly resemble eczema. A relationship with trauma and occupational irritants has 
been postulated.18
Psoriasis of the nails or psoriasis unguium.
Involvement of the nails is common in psoriasis and percentages up to 86.5% have 
been reported in  psoriatic arthritis.20 Typical signs of nail psoriasis are pitting, discolor­
ation (e.g. ‘oil drop’ sign: circular areas of discoloration of the nail bed and hyponychium 
resembling an oil drop below the nail),21 onycholysis, subungual hyperkeratosis, splinter 
hemorrhages, as well as crumbling and grooving of the nails.22-24 This subtype is usually 
very recalcitrant. Patients may suffer from pain caused by nail changes and are often 
restricted in  their daily activities.25
Figure 6:
Psoriasis of the nail showing typ ica l signs 
of p ittin g .
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1.3.2 Extracutaneous manifestations
Psoriasis is basically a disease of the skin and appendices (nails). However, psoriatic 
arthropathy or arthritis psoriatica is a complication of psoriasis that occurs in  5-10% of 
the patients.26 It equally affects men and women, although differences exist: in  men, 
arthritis of the distal interphalangeal joints of the fingers and spinal disease is pre­
dominantly seen, whereas in women symmetrical polyarthritis is more common.27 Pso­
riatic arthropathy can be seen in patients without cutaneous lesions. A serological test 
for rheumatoid factors is negative. In patients with psoriatic arthropathy an increased 
frequency of HLA B27 and HLA Bw38 is found.10
Figure 7:
Distal onycholysis and subungual 
hyperkeratosis in psoriasis of the nails.
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1.3.3 Clinical hallmarks of plaque-type psoriasis
The proper diagnosis plaque-type psoriasis or psoriasis vulgaris is not difficult, as the 
clinical appearance of this erythematosquamous disorder is so characteristic that a 
diagnosis ‘a vue’ is possible. Typical cutaneous manifestations of plaque-type psoriasis 
are sharply demarcated-, silvery-, elevated- and non-coherent scales on a homogenous 
base of erythema. This indicates that both the dermal compartment (erythema), and the 
epidermal compartment (elevated scales) are involved. The lesions may vary in size 
between pinpoint lesions and large plaques. Larger lesions have developed out of smaller 
lesions by centrifugal expansion. Lesions may coalesce and thus form polycyclic, annular 
or gyratory configurations of plaques. The lesions have a fairly symmetrical distribution 
pattern.
The clinical picture of psoriasis may depend on the localization of the lesions. Areas 
of predilection are the elbows, knees, scalp, and sacral region. On the scalp plaques are 
in  general very thick with rather severe scaling, whereas intertriginous psoriasis is milder 
and generally without scaling. In the sacral area fissures and lichenification can be seen. 
W ith respect to erythema slight pink discoloration and very intense redness with almost 
a livid aspect can be seen, the latter especially on the lower legs. Sometimes a so-called 
‘ring of Woronoff can be seen, a clear peripheral zone of blanching around the erythema­
tous center.
A phenomenon characteristic for psoriasis is the ‘candle phenomenon’, which means 
that if scales are scratched off from a lesion, the scales cohere similar as the wax flakes 
scraped from a candle. W hen all the scales are scratched off from a lesion, characteristic 
pinpoint bleedings can be observed. This phenomenon is called ‘Auspitz sign’.
Psoriatic lesions are normally not very itching and painfulness is rare. As described 
above, psoriatic arthropathy and involvement of the nails are frequently seen in this 
group of patients and many suffer from restrictions in daily life activities.
There is no such thing as a typical course of psoriasis. Psoriasis is a chronic disease 
that may remain stable for years,28 but exacerbations and remissions are the rule.18 The 
following 130-year old quote did not loose strength over the years: “It is impossible to say, 
in  any particular case, how long the disease will last, whether a relapse will occur, or for 
what period of time the patient will remain free from psoriasis”.29 With respect to exacer­
bations or the development of new lesions triggering factors are important; these will be 
discussed in section 1.5.2.
Although the characteristics as described above usually may lead to a correct diagno­
sis of the disease, difficulty may arise in atypical cases, in particular sites, and when 
psoriasis is complicated by or alternates with other diseases. The differential diagnosis of 
psoriasis comprises disorders like seborrhoeic dermatitis, eczema, hyperkeratosis palmo­
plantaris, lichen simplex, secondary syphilis, candidiasis and parapsoriasis or even cuta­
neous lymphoma. For an explanation of these disorders the reader is referred to a text­
book of dermatology.
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1.4
Histopathology
In psoriasis both pathological changes in  the dermal and epidermal compartment are 
seen. Controversy exists as to the location of the initiating events in  early psoriasis with 
respect to both compartments.30;31 However, data obtained from early pinpoint psoriatic 
lesions show that the earliest changes consist of a superficial perivascular infiltrate of 
lymphocytes and histiocytes, with dilatation and tortuousity of the blood vessels in  the 
dermal papillae. Subsequently, with the upward movement of some lymphocytes into the 
suprabasal compartment of the epidermis, slight intercellular edema develops. Above 
these spongiotic foci, the granular cell layer disappears, the cornified layer becomes com­
pact, and parakeratosis and epidermal hyperplasia evolve.32-36 In the psoriatic lesion, 
mitoses are not limited to the basal cell layer, as seen in  normal skin, but are also found 
in the first two to three rows of cells in  the suprabasal compartment.37 Polymorpho­
nuclear lymphocytes or neutrophils (PMN) may accumulate in the basal and suprabasal 
layer, and together with remnants of eosinophylic epidermal strands form characteristic 
spongiform pustules: the micropustules of Kogoj, that are highly diagnostic for psoriasis. 
38-40 Sometimes, small sterile abscesses develop, the so-called Munro abscesses. Munro- 
abscesses represent an accumulation of PMN within the parakeratotic stratum corneum 
and are easily found in early psoriatic lesions, but may be difficult to find in  old 
lesions.41;42 In pustular psoriasis, not only microabscesses are formed within the epider­
mis, but also macroabscesses.43 The migration of PMN transepidermally from the blood 
vessels in  the dermal papillae to the stratum corneum, is also known as the ‘squirting 
papillae phenomenon’.44 The inflammatory infiltrate in  the upper dermis and papillae 
mainly consists of T-lymphocytes, but PMN are also present, especially during exacer­
bation periods of the disease. It has been postulated that also mast cells are increased.45 
On the interface between the dermis and epidermis, the dermal papillae are hypertrophic, 
and the epidermal rete-ridges are elongated and thickened at the base with suprapapillary 
thinning of the epidermis. In spontaneously resolving lesions, the disappearance of in­
flammatory cells is the first change that can be seen, followed by the other features men­
tioned above, but tortuousity of the blood vessels in the dermal papillae may persist for 
some time.32 It is obvious that the histological picture of plaque-type psoriasis may vary 
with the stage of the lesion. Early lesions and the margin of advancing plaques are the 
best sites to see most histological signs of psoriasis.30;31 Figure 8 depicts a representative 
histological picture of a psoriatic lesion.
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1.5
Etiology
The primary etiological factors that lead to psoriasis are not known. Psoriasis is a 
disease that still keeps its mysteries. It is well established that a combination of genetic 
abnormalities and environmental factors are responsible for the heterogeneous picture of 
the disease. Psoriasis is undoubtedly an inherited disease, bu t several triggering environ­
mental factors are known.
Figure B:
A histological p ic ture  of psoriasis 
showing epiderm al rete-ridges th a t are 
elongated and th ickened a t the base, 
hyperortho- and parakeratosis w ith  
characteristic Munroabscessess, and 
derm al perivascular T-cell in filtra tes.
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1.5.1 Genetics
A genetic base for psoriasis is confirmed by family and twin studies. In twin studies 
the concordance rate was 73% for monozygotic twins, compared to 20% for dizygotic 
twins, suggesting a significant heritability of psoriasis.46 A large population studies in 
Faroer Island inhabitants indicated that 91% of the psoriatic patients had at least one 
affected first or second degree relative.47 Although a genetic component is indisputable, 
there is still controversy over the mode of inheritance and therefore genetic counseling 
remains difficult.48 However, if one parent has psoriasis, and no brother or sister has the 
disease, the risk to become affected is 10%. If one parent and one brother or sister is 
affected, the risk is 16%, and if both parents have psoriasis, the risk of getting the disease 
is even 50%.
HLA subtypes B13, B17, A13, A17, B37, and Cw6 are indicated to be associated 
with psoriasis.27;49;50 Cw6 appears to be the HLA that has the strongest association with 
psoriasis of the subtypes yet known.18 The risk of those bearing the HLA-Cw6 phenotype 
to develop psoriasis has been reported as 9 to 15 times normal.18 This association is 
unique as no other disease is known to be primarily linked with the HLA-C locus. Other 
loci associated with psoriasis include the alpha-1-antitrypsin gene locus,51 and a poly­
morphism of the IL-1 receptor antagonist gene.52
A gene localized to the distal region of hum an chromosome 17q has been demon­
strated to be involved with psoriasis in some families.53 In these families psoriasis suscep­
tibility is due to variation at a single major genetic locus other than the hum an lympho­
cyte antigen locus. Other psoriasis susceptibility loci have been suggested on chromo­
some 6p,54 17q, and 20p.55
1.5.2 Triggering factors
Several environmental factors may provoke new episodes of psoriasis or cause an 
exacerbation of the disease.10;56
Traumata
The ‘Kobner phenomenon’, the fact that traumata may elicit a lesion in previously 
uninvolved skin, is a typical phenomenon that is seen in  psoriasis. This phenomenon is 
probably the best evidence that injuries of the skin are triggering factors for psoriasis. 
10;57Any physical injury of the skin may induce a Kobner reaction, such as surgery, 
shaving, rubbing, pressure, radiation, burning, tattooing, and scratching.58 Usually the 
Kobner phenomenon appears 7 to 14 days after the injury.59 The incidence of this phenom­
enon ranged from 38 to 76% in psoriatic patients.28
Infections
Infections have also been noted as triggering factors for psoriasis. The best example 
may be tonsillitis. Tonsillitis, especially caused by streptococcal infection and in children, 
may provoke guttate psoriasis.60;61 In plaque-type psoriasis an association with throat in­
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fections is also present; even subclinical streptococcal infections have been reported to be 
responsible for refractory chronic plaque-type psoriasis.62 HIV infection is a well-known 
risk factor causing deterioration of psoriasis.63-70 This association, however, is somehow 
paradoxically, as in HIV infection and AIDS the number of CD4+ T-cells is decreased, 
whereas psoriasis has been postulated to be a T-cell mediated disease.
Endocrine and metabolic factors
As the incidence of psoriasis shows a peak at puberty and at the menopause, an 
endocrine factor may be associated with the disease.17;71 Hormonal changes during preg­
nancy have been mentioned to influence psoriasis in individual cases.28;72;73 From a 
metabolic point of view, alterations in  blood calcium levels and dialysis have been report­
ed to worsen psoriasis.
Climatological factors
In colder regions the prevalence of psoriasis is higher than in warmer and humid 
regions. Patients can experience an aggravation of psoriasis when they move into colder 
climates, whereas a sunny and warm environment generally improves the disease.28;72 It 
is not well understood that in about 5.5% of the psoriatic patients an exacerbation can 
be induced by sunlight.74
Drugs
Some 200 drugs have been described that might aggravate or induce the expression 
of the disease.75;76 In fact, any drug that has the potential to induce a drug eruption can 
exacerbate psoriasis as a Kobner reaction.58 However, several drugs have a marked in­
creased risk to aggravate psoriasis. These include lithium,76-79 beta-adrenergic blocking 
drugs,80 anti-malarials,81;82 nonsteroidal anti-inflammatory drugs,83 indomethacin,84 in- 
terferon-alpha,85-87 and the withdrawal of corticosteroids.19
Psychological stress
Although the relevance of psychological stress is not fully understood, it has been 
suggested and documented by several authors to be a triggering factor in  psoriasis.88-93 As 
psychological stress and immunological alterations are associated with each other, and as 
psoriasis is a disease where immunological factors play an important role, psychological 
stress as a causative factor for psoriasis may have its somatic substrate in neuro-immuno- 
logical mechanisms. There is evidence that reduction of psychological stressors may 
improve psoriasis and that therefore it could be regarded as part of anti-psoriatic treat- 
ment.90;93
Alcohol, smoking, and obesity
These factors are clearly associated with psoriasis as they have a higher prevalence 
in  psoriatic patients.94;95 However, it remains to be seen whether these factors are actu­
ally etiologically related rather than confounding factors related to psychosociological 
problems because of the psoriatic disease.18
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1.6
Pathogenesis
The most striking features of psoriasis are the erythematosquamous plaques. These 
are the results of three major processes in  psoriatic skin: inflammation, hyperprolife­
ration, and disturbed differentiation. Below the simple characteristic clinical picture of 
the disease lies a world of factors that are more or less involved in the elicitation of these 
lesions. As mentioned before, both alterations in dermis and epidermis are seen. A 
difficulty exists in determining whether these factors are causative or secondary to other 
events. In psoriasis many cell types play a role in the pathological process. In this section
I will go through the different cell types that are involved in the psoriatic process.
1.6.1 Cellular aspects
T-lymphocytes
The mononuclear cell infiltrate in  psoriasis is dominated by T-lymphocytes, whereas 
B-lymphocytes are rarely found in lesional skin.96 The major part of the T-lymphocytes 
are T-helper cells (CD4 + ). T-suppressor cells (CD8 + ) account for only 25% of all T- 
cells in  lesional skin of chronic plaque psoriasis.97 The CD4/CD8 ratio is increased 
compared to normal skin.98;99 Furthermore, this ratio varies with the different activity 
stages of the lesion: active psoriasis is associated with CD4+ T-lymphocytes in  the 
epidermis, whereas CD8+ T-lymphocytes are mainly found in regressive plaques.100-102
The last decade more evidence has been accumulated for a central role of the T-lym- 
phocyte in the onset of psoriasis. An intriguing case report described a patient without 
neutrophils and monocytes in the peripheral circulation, who developed psoriasis.103 
Depletion of circulating T-lymphocytes by intravenous administration of anti-CD3/CD4 
monoclonal antibodies resulted in  improvement of psoriasis.104 Furthermore, cyclosporin 
A, an immunomodulating drug with high specificity for inhibition of cytokine product­
ion of T-cells (and therefore frequently used in  renal transplant recipients; see part II), is 
very effective in  the treatment of psoriasis. And in  early psoriatic lesions the involve­
ment of T-lymphocytes is described.105 T-cells from peripheral blood of psoriatic patients, 
in the absence of added antigen, show a clear proliferative response in vitro to autologous 
epidermal cells from lesional as well as uninvolved skin.106;107 It is unclear whether this 
response is antigen driven. All these data strengthen the hypothesis that psoriasis is a 
disease of keratinocyte proliferation induced by T-lymphocytes and T-cell derived pro- 
inflammatory mediators.
Another recent hypothesis in which the T-cell plays a prominent factor, is the 
‘super-antigen theory’. This theory has been highlighted by several groups to be of rel­
evance in the pathogenesis of psoriasis.108-110 Superantigens are a group of bacterial and
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viral proteins that are capable of inducing massive T-cell proliferation and cytokine pro­
duction, without any cellular processing. They bind directly to the major histocompat­
ibility complex class II molecule on the antigen presenting cell (APC) and crosslink the 
APC with T-cells expressing specific variable segments of the T-cell receptor beta-chain 
(V-beta), leading to polyclonal T-cell activation and activation of resting keratinocytes.111 
Staphylococcus aureus and streptococci secrete a large repertoire of exotoxins, which may 
act as superantigens. In this respect M proteins of group A beta-hemolytic streptococci 
may be of importance.112 Studies have demonstrated increased representation of V-beta2 
and, to a lesser extent, V-beta5-expressing T-cells in lesional skin of patients w ith guttate 
and chronic plaque psoriasis when compared to peripheral blood T-cells from the same 
patient.113 Other data that support the superantigen theory are the clinical findings that 
psoriasis is triggered by infections where these bacteria play a role (e.g. pharyngitis) and 
(especially in  guttate psoriasis) the lesions often disappear after the infection has 
resolved.
Langerhans cells, dermal macrophages, and keratinocytes are the known antigen 
presenting cells in  the human epidermis and are involved with processing these bacteria. 
However, psoriasis is not a skin disease ‘sensu strictiori’, as systemic involvement in  the 
form of psoriatic arthritis is often seen in these patients. Also in rheumatoid arthritis an 
immune response to such antigens has been proposed as a causative factor.114
Another hypothesis forms the ‘autoreactive hypothesis’. According to this theory, 
CD8+ “killer” T-cells generated in the skin or systemically is inappropriately specific to 
epidermal keratinocytes, producing sublethal damage that triggers regenerative or 
woundhealing activation.
It is remotely possible that different pathogenic mechanisms could be linked to dif­
ferent genetic loci, especially when considering the genetic heterogenicity and the differ­
ent theories.
Polymorphonuclear lymphocytes (PMN)
Polymorphonuclear lymphocytes or neutrophils are important, especially in early 
and active psoriatic lesions. Many abnormalities in blood neutrophils from psoriatic 
patients have been reported, such as enhanced chemotaxis, phagocytosis, increased cyto­
toxic activity, and adherence.115-118 As described in Chapter 1.4, in  psoriasis PMN are 
abundantly present in  spongiform pustules in  the epidermis (pustules of Kogoj) and in 
microabscesses in  the stratum corneum (microabscesses of Munro). Maximal infltra- 
tion of PMN in dermis and epidermis is seen in pustular psoriasis.119;120 Interestingly, 
accumulation of PMN seems to be associated with parakeratosis in chronic plaque pso­
riasis, as Munro abscesses were only found within parakeratotic foci.39 In plaque-type 
psoriasis 49% of the patients had a clear infiltrate of PMN.39 A number of inflammatory 
mediators can attract and activate PMN. Of these, the most important are leukotriene B4 
(LTB4),121;122 and the cytokine interleukin 8. 123 From a therapeutic point of view, the 
migration of PMN into the skin seems important, as several anti-psoriatic treatments 
such as corticosteroids, UVB, PUVA (psoralens + UVA), dithranol, and retinoids have
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proven to inhibit intra-epidermal accumulation of PMN in normal skin after epicuta- 
neous application of leukotriene B4, but the exact role of PMN in psoriasis remains to be 
elucidated.124-127
Keratinocytes
The thick and scaly lesions are typical for psoriasis and are clinical manifestations 
of a disturbed differentiation and hyperproliferation of the underlying keratinocytes. So 
the keratinocyte is an important cell in  the whole psoriatic process. Hyperproliferation 
in psoriasis has first been described by Scott and Van Ekel and can be concluded from the 
higher number of mitotic figures and the greater number of cells labeled with tritiated 
thymidine.128;129 It has been postulated that a shortening of the cell cycle time of the kera­
tinocytes causes epidermal hyperproliferation.130 However, more recently other studies 
have conclusively shown that not an intrinsic abnormality in the cell cycle, but an in­
creased recruitment of cycling keratinocytes from the resting GO-compartment is respon­
sible for this phenomenon.131
Besides hyperproliferation, alterations in  differentiation are seen in  psoriatic kera­
tinocytes. In the healthy epidermis, keratinocytes undergo a complex process of terminal 
differentiation finally leading to formation of the dead stratum corneum. In this process 
keratinocytes move from the basal compartment, where they are initially fixed to the 
lamina lucida of the basement membrane by hemidesmosomes and tonofilaments, up­
wards through the suprabasal compartment until they finally reach the skin surface and 
are being shed. During this movement inside the keratinocyte a process called ‘keratin- 
ization’ takes place. Hereby, keratin filaments aggregate into bundles through the action 
of the histidine-rich basic protein filaggrin. During the final differentiation stage the 
stratum corneum cells have normally lost their nuclei and other recognizable organelles, 
and basically contain insoluble cysteine-rich, disulphide cross-linked, fibrous proteins or 
keratins.132 Intermediate keratin filaments are present in  all keratinocytes, however, the 
type of keratins that are expressed, normally depends on the state (and therefore the loca­
tion in the epidermis) of the keratinocytes in this differentiation process.133 At least 20 
different epithelial types of keratins have been described.134;135 Keratins can be subdivid­
ed into basic (type II, numbered 1 to 8) and acidic (type I, numbered 9 to 20) subgroups, 
each the product of a distinct keratin gene.134;136 Keratins are present in pairs. In normal 
skin keratin 1 and 10 are abundantly expressed throughout the suprabasal layers of the 
epidermis, while in  the basal layers keratin 5 and 14 are present.137 In addition, epider­
mal differentiation involves the synthesis of new envelope proteins, including involu- 
crine, specific enzymes involved in  envelope cross-linking, such as transglutaminase, and 
alterations in  membrane glycoproteins.132
In psoriasis, however, normal keratinization is incomplete and parakeratosis is seen. 
With respect to keratin expression a reduction in keratin 1 and 10 has been reported. 
138;139 Keratins 1 and 10 are replaced by keratins 6 and 16 in psoriatic lesions and there­
fore keratinocytes show less expression of keratin 1 and 10 when compared to normal 
skin.140-143 Keratins 6 and 16 are associated with hyperproliferative conditions and can
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be seen in  suprabasal epidermal cell layers.144;145 Keratin 16 is a parameter that is, apart 
from the hair follicle, not present in  normal skin.139;145-149 Keratins 17 and 20 are also 
associated with hyperproliferation, and expression of these keratins in  psoriasis has been 
reported.148 Other differentiation related parameters, such as involucrin, filaggrin, and 
transglutaminase, demonstrate alterations in psoriasis as well.150;151
Langerhans cells
As discussed in the section on lymphocytes, Langerhans cells may play an important 
role in  the onset of psoriasis with respect to their function as antigen presenting cells 
(APC). Clustering of Langerhans cells has been observed in psoriasis, but it remains 
controversial whether their numbers are altered in the epidermis.99;152;153
Monocytes
These cells are also involved in  psoriasis and demonstrate increased locomotion,154 
increased phagocytosis,155 and enhanced cytotoxic activity.115
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1.7
Therapy
We do not know the exact cause of psoriasis, so there is no single treatment that can 
cure this disease, but to keep psoriasis under control and suppress its symptoms, a spec­
trum of treatments is available. Several factors are of relevance to select the optimal treat­
ment for each patient, e.g. type, extent and history of psoriasis, but also personal factors 
like age, sex, occupation and co-morbidity. In order to enhance the clinical efficacy and 
to limit side effects, combinations of several anti-psoriatic therapies are often worth­
while.
1.7.1. Topical therapies
Emollients
Although emollients, such as lanette wax cream and vaseline, do not contain any 
pharmacologically active metabolites, and are therefore frequently used as a vehicle to in­
vestigate the activity of new compounds, they do have a slight therapeutic effect on pso­
riasis and can therefore not be considered as a placebo treatment.156 Emollients hydrate 
the skin and improve the hyperkeratotic and scaly psoriatic plaques.156;157 The greasier 
the emollient, the higher its potential effect, but unfortunately the less well accepted it 
will be from cosmetic point of view.156 A significant reduction in  redness, itching, sore­
ness, and pain has been noticed in about 35% of the patients when applied twice daily.158 
Therefore, many psoriatic patients use emollients as maintenance therapy to relieve their 
symptoms.
Keratolytics
Salt baths may well be the oldest keratolytic treatment that we know of. As we have 
seen before, even the ancient Egyptians were aware of the beneficial effects of salt and 
red natron in  skin disorders, and often used them in combination w ith emollients.1 How­
ever, nowadays more potent keratolytics, like salicylic acid and urea, are used. Kerato- 
lytics reduce scaling of the elevated psoriatic plaques and therefore reduce the thickness 
of the lesions. They also promote absorption and penetration of other psoriatic drugs, 
which make them a perfect combination therapy with tar, corticosteroids, dithranol, but 
also photo(chemo)therapy.156 Nevertheless, high concentrations of salicylic acid should 
be used carefully, because of its irritating effects on the surrounding uninvolved skin 
(cave Kobner reaction) and, when applied to large body surface areas, the risk of salicylic 
intoxication.159
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Vitamin D3 analogues
Vitamin D3 analogues are the first choice of treatment in  mild to moderate psoriasis. 
A t this moment there are three vitamin D3 analogues available for topical treatment: 
calcipotriol (Daivonex®), calcitriol (1a,25-dihydroxy vitamin D3, Silkis®), and tacalcitol 
(1a,24-dihydroxy vitamin D3, Curatoderm®). The latter has not been registered in the 
Netherlands so far. These vitamin D3 analogues have in common that they are easy to 
use from cosmetic point of view and that they are safe and effective in  the treatment of 
psoriasis. A main advantage of these treatments compared to topical corticosteroids is the 
hold off of dermal atrophy, however, vitamin D3 analogues may alter systemic calcium 
metabolism when large quantities are applied.
Calcipotriol is an effective treatment that has hardly any side effects when applied 
twice daily for long-term periods.160 A dose below 100 gram per week is supposed to have 
no effect on calcium metabolism.161 However, calcipotriol can give irritant reactions and 
therefore facial treatment is less suitable. Calcipotriol can easily be used with several 
other treatments. A common approach is calcipotriol alternating with a potent topical 
corticosteroid. Tacalcitol shares similar features with calcipotriol with respect to side 
effects, although it can be administered once daily.162 This comparative study has shown 
that tacalcitol is less effective than calcipotriol.162 Calcitriol is the natural active vitamin 
D3 and was recently introduced as a topical treatment in  dermatology. It is more effective 
than a placebo.163 Double-blind randomized comparative studies of calcipotriol and 
calcitriol are not available.
Vitamin D3 analogues inhibit epidermal proliferation,164-167 and modulate differen­
tiation. They can enhance cornified envelope formation and increase transglutaminase 
activity in  vitro.165;168 Furthermore, vitamin D3 analogues have anti-inflammatory 
effects, as they inhibit the production of IL-1, IL-2, and IL-6, and the release of arachi- 
donic acid by PMN.169;170 Vitamin D3 analogues bind to the vitamin D3 receptor (VDR), 
which is together w ith the retinoid and other receptors, a member of the nuclear receptor 
family.170 See paragraph 1.16 for a more detailed discussion on nuclear receptor mecha­
nisms.
Corticosteroids
Topical corticosteroids are the most frequently used treatment for psoriasis now­
adays. W hen applied correctly, they are effective, have no primary irritative potential, do 
not smell, do not stain clothes and are easy to apply. Topical corticosteroids can be cate­
gorized in four increasing classes of potency (I, II, III, and IV). They possess anti-proli­
ferative, anti-inflammatory, and immunosuppressive effects.171;172 The mode of action is 
via the glucocorticoid receptor in the cytoplasm, where it forms a complex that is then 
transported to the nucleus. This is followed by binding to the glucocorticoid response 
element (GRE) on the DNA and so it can regulate transcription of genes adjacent to this 
GRE, leading to modulation of inflammation.173;174 A n important target of cortico­
steroids are the T-cells; these cells are known to play a major role in psoriasis as described 
in  paragraph 1.6.1.
Despite their efficacy and ease of use, topical corticosteroids have disadvantages 
(especially when more potent corticosteroids are applied for longer periods). The most
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prominent side effect is atrophy of the skin. This phenomenon can already be seen 
microscopically after 3 to 14 days of application. Initially this atrophy is reversible, how­
ever, when applied chronically, dermal changes will become evident. A direct anti­
proliferative effect on fibroblasts is responsible for the dermal atrophy.175 In a later phase 
vascular dilatation, telangiectasias, striae, and purpura may be seen. Other side effects are 
hypertrichosis, hypopigmentation, dermatitis perioralis, and suppression of the pituitary- 
adrenal axis.176 Therefore, the use of class IV corticosteroids should be limited to 50 
grams per week; less potent corticosteroids may be used to a maximum of 100 grams per 
week.177 Topical corticosteroids can be used with all kinds of other anti-psoriatic treat­
ments to increase efficacy.178 They can also be used under hydrocolloid occlusion.
Dithranol
Dithranol is also known as anthralin or cignolin. It is a chemically synthesized 
analogue of chrysarobin, an extract derived from the aroroba tree that has accidentally 
been found to be of value in  the treatment of psoriasis.179;180 The exact mode of action is 
still unknown, although it is likely that the anti-psoriatic effect may be caused by its 
induction of free radicals that can affect the mitochondria and lead to an antiproliferative 
effect.181-183 These free radicals are also responsible for the well-known skin irritation 
that can be seen already at very low concentrations of dithranol. Short-contact applica­
tion can minimize the skin irritation and is therefore preferable.184-186 Besides its irritant 
properties another disadvantage is its irreversible staining of hair and clothes that may 
limit the use of this treatment outside the clinic.187;188 In clinical studies dithranol has 
been proven to be a very effective and safe treatment for psoriasis.184-186 Dithranol is a 
promotor of carcinogenesis in  mice,189 however, in humans no carcinogenic effects due 
to dithranol have been reported in psoriatic patients so far.18
Tar
Tar can be derived from several sources, but coal tars are the most frequently used 
in dermatology.190 Coal tar contains over 1000 ingredients and is a mixture of aromatic 
hydrocarbons manufactured by primary condensation of coal. Its precise mechanism of 
action is unknown, but an antimitotic effect has been assumed.191 Its major beneficial 
effect is a reduction in  pruritus. For over one century tar has remained a common treat­
ment for psoriasis.
It is considered to be a safe and effective therapy, although carcinogenic and terato­
genic properties have been reported.192;193 Therefore, it should not be given to pregnant 
women and breastfeeding mothers. Tar is generally well tolerated, but disadvantages are 
its odor, the irreversible staining effect on clothes, the induction of folliculitis, skin 
irritation, and the enhancement of sunburn. Due to its irritative potential, coal tar is less 
suitable for erythrodermic and pustular psoriasis. It can be used in  combination with 
photo (chemo) therapy (see paragraph 1.7.1). However, its sunburn enhancing effects 
may need to take precautions. Coal tar can be applied on psoriatic lesions as pure coal tar 
(pix lithantracis, 1-10%) or as a tar solution (solutio carbonis detergens, 5-20%). For 
treatment of psoriasis capitis several tar shampoos and lotions are available.
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Retinoids
Retinoids are natural or synthetic derivatives of vitamin A. Unlike systemic reti­
noids (see paragraph 1.7.3) topical retinoids are infrequently used in psoriasis, especially 
in  the Netherlands. Topical retinoids have been proven to be effective in  erythemato- 
squamous disorders, such as ichthyosis vulgaris, and also in  acne, but their therapeutic 
potencies in  psoriasis are generally less worthwhile. Currently, only all-trans retinoic acid 
(tretinoin) may be used. In other countries more topical retinoids have been registered, 
such as isotretinoin, motretinoin, adapalene, and tazarotene.194 In Part III retinoids, their 
effects, and their receptor mechanisms will be discussed.
1.7.2 Photo(chemo)therapy
It has been known for years that sunlight may have beneficial effects in  psoriasis for 
most patients. Especially when larger body surface areas are involved with psoriasis and 
when previous therapies w ith topical treatments were insufficient, photo(chemo)therapy 
is the treatment of choice above systemic regimens. Photo(chemo)therapy comprises all 
forms of irradiation therapy that use the ultraviolet spectrum.
Broad spectrum UVB
Goeckerman was the first who thoroughly documented the use of UVB irradiation 
after coal tar applications to treat psoriasis.195 Much later several studies demonstrated 
that UVB therapy alone, if given in a slightly erythematogenic dosage, was capable of 
clearing psoriasis.196-198 UVB radiation (290-320 nm) induces free radicals and 
subsequently inflammation. This may be the result of activation of the arachidonic acid 
pathway.199 The number of Langerhans cells decreases during UVB treatment and the 
shape of these cells changes. The mode of action may be through DNA damage, but the 
precise mechanism is still not fully known.200 A common and effective irradiation sched­
ule is three times a week, once daily.196 The duration of remission after UVB therapy is 
relatively long compared to corticosteroids. A limitation of UVB therapy is its carcino­
genicity, although follow-up studies comparing the prevalence of premalignant and malig­
nant skin lesions among extensively UVB-treated psoriatic patients and healthy controls 
has not shown an increased risk in  the psoriatics group.201-203
Small spectrum UVB
Small spectrum UVB irradiation is a rather new therapeutic approach in psoriasis 
UV treatment. For this type of irradiation TL01 lamps are used that emit radiation in  a 
narrow band of 311-312 nm. The emission spectrum of small spectrum UVB has an im­
proved ratio between anti-psoriatic and erythematogenic effects. It is the preferred UVB 
treatment.
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PUVA
UVA radiation (320-400 nm) causes markedly less erythema compared to UVB 
radiation and it requires an almost 1000 fold higher intensity than UVB to be therapeuti­
cally effective. However, the addition of psoralens as a skin sensitizer to UVA light 
dramatically improves therapeutic efficacy. PUVA (psoralens + UVA) is a very effective 
treatment and is even more potent than UVB. Due to the addition of psoralens this treat­
ment is also known as broadspectrum ‘photochemotherapy’. Side effects include ery­
thema, pruritus, and sometimes nausea.200;204 However, its major limitation is the fact 
that PUVA strongly increases the risk of developing squamous cell carcinomas.203 The 
risk increases sharply once a cumulative total dose of 2000J/cm2 is reached. However, in 
a sun-sensitive population of Celtic subjects an increased risk of developing non-mela­
noma skin cancer was already found w ith cumulative doses above only 250J/cm2.205 
Another limitation of UVA-light is the acceleration of photoaging. Therefore, long-term 
PUVA treatment is not encouraged.
Photo(chemo)therapy is frequently used in combination with topical or systemic 
retinoids to obtain an enhanced therapeutic effect and/or a reduction in the cumulative 
UVB or UVA dose necessary to achieve clearance of the disease. However, some experts 
believe that retinoids may have photosensitizing effects and that patients who are treated 
with topical or systemic retinoids may need to take precautions with respect to sunlight 
exposure. In Chapter 4 the presumption of photosensitizing properties of retinoids is 
challenged.
1.7.3 Systemic therapies
Systemic retinoids
In this section, I will briefly mention the main features of acitretin (Neotigason®), 
the retinoid which is most frequently used, and which has become a mainstay in  modern 
psoriasis treatment.194 Other retinoids like etretinate (Tigason®) and isotretinoin (Ro­
accutane®) have more or less lost their significance in psoriasis treatment since the 
introduction of acitretin, due to its shorter half-life. Isotretinoin, however, is still of major 
importance in severe acne. With respect to efficacy, etretinate and acitretin are equally 
effective in psoriasis. 206;207 For pustular and erythrodermic psoriasis retinoids are the 
treatment of first choice.194;208 In plaque-type psoriasis retinoids are also indicated, often 
in combination w ith topical therapy and/or photo(chemo)therapy, as monotherapy for 
plaque-type psoriasis is less effective.208 Because both efficacy and side effects can vary 
substantially among individual patients, proper dosing of acitretin requires a balance 
between optimizing response and minimizing toxicity for each patient. Optimal dosing 
for individual patients may be achieved through a dose-escalation strategy involving 
initiation of therapy at low doses (10 to 25 mg/day) and, if necessary, gradually increas­
ing the dose as tolerated until optimal response is achieved.209 The mode of action of 
retinoid therapy, their receptor mechanisms and side-effects will be discussed in Part III.
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Apart from direct retinoid treatment, an increased concentration of retinoic acid in the 
cell can be achieved by retinoic acid metabolism blocking agents (RAMBA’s). The 
imidazol derivative liarozole is such a RAMBA. It is an inhibitor of cytochrome P-450 
and causes inhibition of 4-hydroxylation of retinoic acid, leading to increased intra­
cellular retinoic acid levels.210
Methotrexate
Methotrexate is one of the most effective anti-psoriatic drugs.211 In 1951 the effect of 
aminopterin, a folic acid antagonist, on psoriasis was first described by Gubner.212 Since 
1971 another folic acid antagonist, amethopterin (methotrexate, MTX), has been regis­
tered for the treatment of severe forms of psoriasis.213;214 MTX inhibits epidermal DNA 
synthesis and decreases mitotic activity.215-217 MTX causes a G1-phase arrest of cycling 
keratinocytes and MTX kills keratinocytes in the S-phase.218 However, MTX has also 
been claimed to inhibit chemotaxis of PMN and thus to decrease inflammation,219 but 
some other mechanisms have been postulated as well, including inhibition of intracel­
lular T-cell signaling.220
Low dose MTX is a relatively safe therapy, provided that a careful patient selection 
and regular monitoring for side effects and drug interactions is carried out. Its side effects 
can cause serious limitations, especially myelosuppression and hepatotoxicity. The latter 
is related to a high cumulative dose of MTX. The most common side effects comprise 
nausea, headache, gastric complaints, bone marrow depression, and abnormal serum 
(liver) transaminases.
In order to minimize the toxicity of MTX, combinations or rotational therapy should 
be considered. Contraindications for MTX treatment are pregnancy, excessive alcohol 
intake, abnormalities in renal and liver function, hepatitis, liver cirrhosis, severe anemia, 
leukopenia, thrombocytopenia, infectious diseases, and non-compliance of the patient.221
Fumarates
The first report of the beneficial effects of fumarates for psoriasis came in  1959 from 
the German chemist Walter Schweckendiek, who was a psoriatic patient himself. He 
hypothesized that psoriasis is caused by a malfunctioning citric acid cycle in  the mito­
chondria, leading to a relative deficiency in  the generation of one or more of its important 
metabolites. 222 Therefore, in  an autoexperiment, he orally administered various original 
and chemically modified citric acid cycle metabolites. Of the tested compounds, only 
fumarates were able to clear his psoriatic lesions.222 After a decade of neglecting, fumar­
ates slowly became more accepted in  psoriasis treatment and several studies have demon­
strated their efficacy.223 The exact mode of action of fumarates is still unknown, but 
alterations of the Th1/Th2 lymphocytes balance have been described.
‘Fumaric acid’ is a frequently used, but incorrect term for therapy with fumarates. 
Due to its acidity, pure fumaric acid (1,2-ethylenedicarboxylic acid; C4H4O4) is not suit­
able for oral therapy in  psoriasis. Therefore, (m)ethyl ester derivatives of fumaric acid are 
being used, and these proved to be clinically effective.223-230
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The most frequently observed adverse events are flushing, gastro-intestinal discom­
fort, diarrhea, lymphocytopenia, and fatigue, but these are generally well tolerated. 
222;223;226-23i Other adverse events are urticaria, osteomalacia, and occasionally nephro­
toxicity.232-235 Gastro-intestinal adverse events tend to diminish during prolonged treat­
ment.
Long-term benefit/risk ratios of orally administered fumarates are such that it per­
mits effective and safe management of psoriasis. However, as this treatment has not yet 
been approved in the Netherlands, this therapy should only be performed under strictly 
controlled conditions.
Cyclosporin A
It is generally accepted that psoriasis is at least to some extent a T-cell mediated dis­
ease, although the precise pathogenesis remains to be elucidated (see paragraph 1.6.1).105 
Therefore, T-cell specific immune-modulating agents have been extensively investigated 
since the last decade. Cyclosporin A, an immunosuppressive agent used primarily in  or­
gan transplant recipients, has also been approved for treatment of severe psoriasis, in 
whom conventional therapy is either ineffective or inappropriate.236-239 Besides its appli­
cation in  plaque-type psoriasis, it can also be used in pustular and erythrodermic psoria- 
sis.240-243
A well-established treatment regimen is to start w ith 3 mg/kg/day, in two divided 
doses, and to increase to a maximum of 5 mg/kg/day, with subsequent tapering to the 
minimum effective dose. A dose-response relationship has been demonstrated by several 
studies w ith respect to both the numbers of patients who responded and the time to re- 
sponse.236 In a large study in plaque-type psoriasis, cyclosporin A in  a dosage of either 
2.5 or 5.0 mg/kg/day was effective in  respectively 52% and 92% of the patients.244
Cyclosporin A binds to cyclophilin, a family of isomerases found in almost all mam­
malian cells. This newly originated complex inhibits the enzyme calcineurin, which is a 
key factor in  calcium-dependent signaling processes. Calcineurin plays an important role 
in the signal transduction of the T-cell with respect to cytokine production. By inhibiting 
calcineurin, the transcription of many cytokines, including T-cell growth factors IL-2 and 
IL-4 is inhibited.245
Adverse events that may be seen during cyclosporin A therapy are nephrotoxicity, 
hypertension, gastro-intestinal problems, hypertrichosis, gingival hyperplasia, paresthe­
sia, headache, vertigo, muscle cramps, tremor, and (malignant) tumors (e.g. skin cancer 
and lymphoma; see Part II). A detailed study on nephrotoxic aspects of cyclosporin A 
indicated that patients who had less than 30% increase in creatinin level did not have 
nephropathy.246 However, to reduce the risk of nephropathy, monitoring guidelines have 
been developed. 247;248 Contra-indications for cyclosporin therapy are impaired renal 
function, uncontrolled hypertension, past or present malignancy, infection, concomitant 
immunosuppressive therapy, immunodeficiency, pregnancy and lactation.236
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1.7.4 Potential new therapies
1.7.4.1 RXR-selective retinoids
Current retinoid treatment for psoriasis is limited to retinoids that favor the retinoic- 
acid-receptor (RAR) pathway. However, besides the retinoic-acid-receptors there is a 
sub-family of retinoid receptors, the retinoid-X-receptors (RXR), that elicit different tran­
scriptional gene responses, and therefore may provide a completely new approach in  pso­
riasis therapy.
It is known that transcripts of RXRa, representing 90% of RXR in the epidermis,249 
is 58% lower in lesional versus non-lesional psoriatic skin, together with a reduced RXRa 
: RARy ratio from 3.2 to 1.5, suggesting rexinoid-signaling in psoriasis is abnormal. 250 
RXRa has been found in the suprabasal compartment of the epidermis and has been 
suggested to play a function in the transition from proliferation to differentiation in  epi­
dermal keratinocytes.251 Furthermore, RXRa has been postulated to be an early differ­
entiation marker.252 In the skin, apart from the RXR-RAR heterodimer, the RXR-PPAR 
heterodimer may also play a central role, as it modulates keratinocyte proliferation and 
differentiation, and plays a role in inflammation control.253 The PPAR (peroxisome pro- 
liferator-activated receptor) agonist troglitazone in  the treatment of psoriasis indeed 
showed a clinical and histological response.254
Investigations on the potential role of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetra-hydro- 
2-naphthyl)ethenyl]benzoic acid (bexarotene, Targretin®), a new compound with a short 
half-life of 7 hours,255 that selectively binds the RXRa, p, and y subtypes of the nuclear 
retinoic acid receptor family, in  the treatment of plaque-type psoriasis will be presented 
and discussed in  Chapter 2 of this thesis.
Figure 9:
M olecule s tructure of bexarotene 
(Targretin®).
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1.7.4.2 Cyclic immunosuppressive agents (macrolactams)
Ascomycin (ASM 981, Pimecrolimus, Elidel®)
Ascomycins represent a novel class of anti-inflammatory macrolactams currently 
under development for the treatment of skin diseases. ASM-981 is at the most advanced 
stage at this moment. The main biological effect of ascomycin is an inhibition of the 
synthesis of cytokines of both Th1 (interleukin-2, interferon y) and Th2 (interleukin-4 
and interleukin-10) lymphocytes.256 In chronic plaque-type psoriasis it is only effective 
if applied under semi-occlusive dressings with similar effectiveness to clobetasol-17-pro- 
pionate (0.05%),257 however the safety profile of ASM 981 is better than that of topical 
corticosteroids. Only low systemic exposure has been reported even when applied to 
large areas of skin, and ASM 981 does not induce skin atrophy. Furthermore, ASM 981 
holds promise in  overcoming the drawbacks of topical corticoids.258 A topical application 
of 1% ASM 981 in a cream base is currently available as Elidel®, however, applications 
in psoriasis are limited, as that formulation is ineffective without occlusion.
Tacrolimus (FK506, Prograf®, Protopic®)
Tacrolimus has been shown to be a powerful suppressor of the immune system and 
is a common treatment for the prevention of allograft rejection in  kidney, liver, and heart 
transplant recipients. Tacrolimus shares many of the immunosuppressive properties of 
ASM 981. Systemically (Prograf®), it has been demonstrated to be effective in  treating 
psoriasis, probably by inhibiting T-cell infiltration.259-261 However, another study with 
topical tacrolimus (Protopic®) proved non-effective in  chronic plaque psoriasis.262 The 
major side effects of tacrolimus include nephrotoxicity and hypertension.
Sirolimus (rapamycin, Rapamune®)
Sirolimus is an immunosuppressive agent that interferes with T-cell activation. It 
blocks T-cell proliferation in the G1 phase of the cell cycle, but it also inhibits growth of 
the keratinocytes.263 Its inhibition appeared more potent than that of cyclosporin.264 
However, severe adverse events of sirolimus include fever, anemia, thrombocytopenia, 
and capillary leak syndrome.265;266 The application of sirolimus in combination w ith a 
subtherapeutic dose of cyclosporin in severe psoriasis has been opted for permitting a 
reduction in their respective toxicities, notably cyclosporin-induced nephrotoxicity.266
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1.7.4.3 Monoclonal antibodies and fusion proteins
In the next couple of years we may see the registration of several new single target 
compounds for the treatment of psoriasis that act by a completely new and selective 
approach. These compounds are monoclonal antibodies or fusion proteins that specifi­
cally target receptors or other components involved in the psoriatic pathogenesis. As 
proteins do not penetrate the skin when applied topically, and oral administration will 
lead to immediate breakdown of the protein by gastric enzymes, intravenous (IV), intra­
muscular (IM), and subcutaneous (SC) administration is indicated. For detailed informa­
tion on this subject the reader is referred to a recent review.267 Here, we will restrict to a 
few promising new opportunities.
LFA3tip (Alefacept, Amevive®)
LFA3tip is a recombinantly engineered LFA-3/IgG1 hum an fusion protein that 
modulates immune responses through direct interaction with the T-lymphocytes via the 
CD2 receptor on the cell surface of the T-lymphocytes.268 LFA3tip depresses the number 
of memory effector T-cells and is therefore a relevant new therapy in the T-cell mediated 
disease psoriasis.269
Infliximab (Remicade®)
Infliximab is a monoclonal antibody against tumor necrosis factor alpha (TNFa). 
TNFa is thought to play a role in  the pathogenesis of psoriasis, as this proinflammatory 
cytokine is present in increased concentrations in  the skin. A high degree of clinical 
benefit and rapid time to response in plaque-type psoriasis has recently been demon­
strated.270-272
Etanercept (Enbrel®)
Etanercept is another TNF inhibitor that has shown efficacy in clinical studies in 
psoriasis.273
Efalizumab (Raptiva®)
Leukocyte function-associated antigen 1 (LFA-1), consisting of CD11a and CD18 
sub-units, plays an important role in T-cell activation and leukocyte extravazation. The 
humanized anti-CD11a monoclonal antibody efalizumab has recently demonstrated sig­
nificant clinical and histologic improvement in the T-cell mediated disease psoriasis.274
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1.8
Research targets
Improved insight in  pathogenesis of psoriasis may reveal targets for future drug 
development. Two major areas of drug development exist:
I Specific single target molecules interfering with immunity.
II Modulation of retinoid signaling.
In the present thesis we will focus on RXR-signaling in  psoriasis and study the clinical 
and immunohistochemical effects of the RXR-selective ligand bexarotene.
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PART II
(PRE)MALIGNANT SKIN 
DISORDERS
43
R X R -  A N D  R A R - S E L E  C T I V E R E T I N O I D S  I N  P S O R I A S I S  A N D  ( P R E ) M A L I G N A N T  S K I N  D I S O R D E R S
1.9
Mechanisms of cutaneous carcinogenesis
1.9.1 History
Since the 19 th century many carcinogens have been identified. Especially the car­
cinogenic potential of both chemicals and radiation was recognized quite early. The first 
carcinogen that was recognized was soot, as Percival Potts noted a high incidence of scro­
tal carcinoma in young chimney sweeps. In 1887 a correlation between arsenic adminis­
tration and subsequent development of both cutaneous and systemic malignancy has 
been discovered. After the discovery of X-rays by Wilhelm Conrad Röntgen, scientists 
became aware of its carcinogenic potential. Hyde was the first to recognize that UV radia­
tion is also carcinogenic. Nowadays many carcinogenic factors are known, including a 
third group: viruses (see paragraph 1.9.3).275
1.9.2 Stages of carcinogenicity
1.9.2.1 Cellular (functional) stages
In order to become a malignant cell, a normal cell should surpass several stages. Each 
stage has specific functional biologic properties that enable a cell to finally become a 
metastasizing tumor after clonal expansion. The following stages can be determined:275
1. Controlled growth to autonomous growth w ith normal differentiation.
2. Autonomous growth with abnormal differentiation.
3. Both 1 and 2 plus additional nuclear atypia.
4. The ability to pass through the normal natural barrier of the basement membrane.
5. To pass through the dermis to enter the vascular channels.
6. To arrest in  nodes (or organs such as the liver and lungs if blood borne).
7. To undergo the clonal expansion of metastases in these sites.
It is important to understand that not all the cells in  an early carcinoma in situ (stage 
3) have the capacity to complete all these steps. Throughout the stages of tumor devel­
opment there is also a continuous selection of cells with the functional capacity to pro­
ceed to the next stage. In order to facilitate the synthesis of new vascularization in the 
tumor area for providing nourishment and creating a network for distant dissemination 
of the tumor cells, some tumors can secrete tumor angiogenic factors.
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1.9.2.2. 3-stage m odel of carcinogenesis
Apart from the functional biologic stages, animal studies have conclusively shown 
that there are several identifiable steps in the progression from a normal to a malignant 
cell with metastatic capacity. A t several points in this stepwise progression to malig­
nancy, the process can become arrested or can even partially reverse.276 Three steps have 
been identified so far: initiation, promotion, and conversion.277 There is evidence that 
the 3-stage model of carcinogenesis derived from animal studies is also the mechanism 
involved in skin cancer. These include (1) the concordance between known carcinogens 
such as polyaromatic hydrocarbons and UV radiation in  mice and humans, (2) evidence 
for oncogenic activation or tumor suppressor gene inactivation by these agents in  the 
skin of mice and humans, and (3) the long latency between initial exposure to carcino­
gens and tumor development.275
The state of initiation can already be achieved by only one topical or systemic dose 
of a carcinogen. Initiators have in  common that they can bind to nucleotide sites, which 
interfere with normal basepair reactions in  DNA synthesis. This mutation may affect the 
ras proto-oncogenes and/or p53 tumor suppressor genes among others (see paragraph
1.9.4 and 1.9.5). Initiated cells contain a mutational change in the genome and this 
remains for the rest of its life; this stage does not seem to be reversible. Initiated cells do 
not necessarily have to continue with the other steps of malignant progression. In fact, 
as long as promoting agents are lacking, the cell remains in the initiation phase. Initiated 
epidermal cells are not malignant, bu t are insensitive to the normal signals for terminal 
differentiation in  the epidermis. With respect to the skin, however, no clinical signs can 
be seen at this stage.275
The stage of promotion can follow the stage of initiation. A promotor must be 
applied after an initiator to fulfil its carcinogenic effect. Generally, a promotor stimulus 
needs to be repeated to be effective in carcinogenesis. Collectively these agents produce a 
tissue environment that is conductive to the selective clonal outgrowth of the initiated 
cell population, resulting in a clinically apparent premalignant tumor, with features of 
hyperkeratosis and scaling in  the case of squamous skin tumors, e.i. actinic keratosis, 
Bowen’s disease. However, withdrawal of the promotor may lead to a decrease in carcino­
genic capacity, and reversal of the clinical symptoms.
Conversion is the final stage when continued stimulating effects of a promotor lead 
to progression of the lesion to a malignant carcinoma with metastatic capacities, e.i. squa­
mous cell carcinoma. However, the third stage of carcinogenesis may also occur spon- 
taneously.275
Some substances are both initiating and promoting agents, and are therefore called 
‘complete carcinogens’. A well-known complete carcinogen is UV radiation. Further­
more, in cutaneous carcinogenesis, the concept of co-carcinogenesis may be relevant in 
humans. This term describes that two substances that may be weak carcinogens when 
used singly, may have additive or even synergistic effects when used in combination. An 
example of co-carcinogenesis is the combination of UV irradiation and nitrogen mustard.275
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Thus, carcinogens can cause DNA defects that can lead to faulty DNA synthesis 
thereafter, which may eventually lead to carcinomas. In normal epidermis, however, 
DNA repair is continuously taking place. Several enzyme systems can identify and excise 
the faulty strands and have a preventative effect in carcinogenesis. In some diseases these 
mechanism are defective. This is the case in  xeroderma pigmentosum, an autosomal re­
cessive disorder, where patients have a 1000 times greater incidence of UV-induced skin 
cancer.
1.9.3 Carcinogens
Chemicals
Several chemicals are known to be initiator, promotors or complete carcinogens. In 
general, cancer induction by chemicals is dose dependent. However, there are inter­
species differences with respect to the type of tumor they can induce. Typical initiators 
are nitrosamines, alkylating agents, and polycyclic aromatic hydrocarbons, such as dimethyl 
benzanthracene, methylcholanthrene and benzpyrene. Well-known promotors are di­
thranol, benzyl peroxide, and TPA.278 However, in  humans the promoting potential of 
dithranol does not seem to play an important role in  carcinogenesis, if such a role even 
exists in humans, as in clinical practice during more than 80 years no increase in carcino­
genicity has been observed in dithranoltreated patients so far.18
UV irradiation
UV irradiation is probably the most important cutaneous carcinogen. As mentioned 
before, UV radiation is a complete carcinogen with most active wavelengths in the UVB 
range (290-320 nm). UV light may produce free radicals that cause alterations in DNA. 
UV irradiation causes immunosuppression, which may play a further role in cutaneous 
carcinogenesis.279 UV exposure in hum an leads to both structural and functional damage 
to the Langerhans cell, a cell believed to play an important role in antigen presenting in 
the epidermis. This temporary down-regulation of the immune system may allow geneti­
cally altered keratinocytes (that normally are recognized as abnormal) to pass unrecog­
nized.
Viruses
The carcinogenic potential of viruses has been discovered the last few decades. To 
date there are two groups of viruses associated with cutaneous carcinogenesis: the hu­
man papillomaviruses (HPV), and retroviruses, such as the hum an T-cell leukemialym- 
phoma virus group. The latter group is of particular interest in  the origin of cutaneous 
lymphomas. The papillomavirus group comprises over 80 identified genotypes of HPV. 
Only a few genotypes are associated with carcinogenesis. The E region of the HPV genes 
code for two particular genes, E6 and E7e, which respectively bind to p53 and retinoblas­
toma (RB) protein. HPV viruses can increase the risk of malignant transformation by 
inactivation of wild-type p53 or RB, and this leads to a loss of contact inhibition and im­
mortalization of keratinocytes.280;281
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The best known HPV genotypes that are associated with cancer are HPV-16 and 
HPV-18. Both viruses are highly related to genital cancer, in particular cervix carcinoma. 
282;283 HPV-5 and HPV-8 are important in the development of squamous cell carcinomas 
arising on epidermodysplasia verruciformis. HPV-5 and HPV-8 are also hypothesized to 
play an etiological role in (pre)malignant tumors in immunosuppressed organtransplant 
recipients.
1.9.4 Oncogenes
Oncogenes can simply be defined as virally or mutational activated cellular genes 
that stimulate proliferation. Oncogenes are frequently the result of an activating muta­
tion in some normal cellular genes. These genes are designated as proto-oncogenes. Such 
a mutation has a dominant effect, as, from genetic point of view, only one copy of the two 
alleles needs to be mutated. W hen proto-oncogenes are transformed to oncogenes by 
mutations, carcinogenesis is stimulated.
Several other proto-oncogenes have been hypothesized to be associated with non­
melanoma skin cancer (NMSC). The ras, fos, and myc proto-oncogene families are prob­
ably the best known. Ras mutations are common in murine chemical carcinogenesis of 
the skin. In hum an skin the Harvey ras gene, also known as Ha-ras, has been the subject 
in several studies in  NMSC. However, ras mutations show a wide scatter between 0 and 
30% for basal cell carcinoma,284-288 and between 0 and 46% for squamous cell carci- 
noma.285;287;289-293 Pelisson et al suggested that ras and myc oncogenes are involved in 
skin carcinogenesis and that these oncogenes may even cooperate with HPV infections 
in carcinogenesis.294 They found higher Ha-ras DNA amplification in squamous cell 
carcinoma than in actinic keratoses. In normal skin myc and ras mutations were not 
detected. Moreover, no significant differences were observed in  the detection of these 
oncogenes between transplant recipients and non-immunocompromized patients in  this 
study.294 Pierceall et al designated some mutations in  Ha-ras to UV-irradiation, as these 
mutations occurred at high frequency in  NMSC found in  sun-exposed areas and were 
located opposite C-C sites.295
However, experiments with targeted overexpression of Ha-ras and c-fos only in­
duced hyperkeratosis and papillomas but never malignant progression, while overexpres­
sion of the E6 gene of the HPV-18 virus caused the induction of verrucous lesions that 
sometimes progressed to squamous papillomas. These, upon analysis, were found to 
harbor an activating Ha-ras gene mutation. It has been proposed that activation of onco­
genes is not an early event in the genesis of NMSC, bu t could be important in  the later 
phase when a tumor progresses from a slow growing carcinoma in  situ to a rapidly 
expanding malignant tumor. However, Ha-ras mutations have also been found in pre- 
malignant lesions. The exact role of oncogenes has to be elucidated.
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1.9.5 Tumor suppressor genes
In the human genome several genes are involved with the regulation of controlled 
proliferation and differentiation. These genes are of major importance in normal cellular 
growth and in the prevention of malignancies. Therefore, they are called “tumor sup­
pressor genes”. However, if these genes become structurally altered by point mutations, 
amplification or translocation to a different position on a different chromosome, their 
normal role of assisting in controlled growth and differentiation may be lost, leading to 
uncontrolled growth, lack of differentiation, and malignancies.
The most important human tumor suppressor gene is p53. This gene, when 
unaffected and functioning normally, is the ‘wild-type’ p53. It controls cell proliferation 
at critical points in the cell cycle and prevents cells with damaged DNA from entering. 
Therefore p53 functions as the ‘guardian of the genome’. P53 can act both in the G1 and 
G2 phase of the cell cycle. P53 is believed to be able to shut down the cell cycle when 
faulty DNA is detected. W hen the cell cycle is stopped, enzymes have time to repair the 
faulty DNA, or when such is impossible, to eliminate the cell from the cycling pool by 
directing the damaged cell along the pathway of apoptosis (see paragraph 1.9.6). By these 
mechanisms duplication of m utant DNA is prevented. The importance of p53 can also 
be learnt from the Li Fraumeni syndrome, which is characterized by childhood occur­
rence of various malignancies. In this syndrome patients often have a germline mutation 
in  one p53 allele, which, after loss of heterozygosity (LOH) in the opposing allele carry­
ing the wild-type p53 gene, may lead to a high incidence of various types of cancers. How­
ever, patients with the Li Fraumeni syndrome do not show an excess of NMSC.296 In 
transgenic mice where the p53 alleles were knocked out, an increased tumor incidence 
is found.
Abnormal expression of p53 is common in basal cell carcinomas and squamous cell 
carcinomas,297-302 and in premalignant disorders, such as Bowen’s disease and actinic 
keratoses.303;304 In many instances this increased expression is overexpression of wild­
type p53. Wild-type p53 protein expression is increased in  hum an skin following expo­
sure to even doses of ultraviolet radiation too small to induce erythema.305;306 The largest 
p53 protein expression has been noted by UVB-light in experiments where equierythe- 
mal doses for UVA, UVB, and UVC-light were used.305 It is assumed that the 
upregulation of wild-type p53 protein expression in response to UV-radiation is a direct 
result of DNA damage, although more modest increases are seen following a range of 
stimuli that are not known to cause DNA damage.306
M utant p53 seems to play an important role in  NMSC as p53 mutations have been 
detected in 20-60% of basal cell carcinomas,285;297;307;308 and in 10-90% of squamous cell 
carcinomas.285;288;304;308-312 A specific type of mutation, the CC ^ T T  mutation, is strong­
ly associated with UV exposure. Another mutation, the C ^ T  mutation, is likely related 
to UV irradiation. Interestingly, these mutations have been found in p53 in  actinic 
keratoses and in cutaneous squamous cell carcinomas,304;309 but not in  p53 from other 
types of (non-cutaneous) malignancies. Furthermore, inactivated p53 in  murine skin 
reduced the number of sunburn cells following UV-irradiation, implying a reduction in
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apoptosis, and a subsequent increase in  DNA-damaged cells retaining in the cycling 
pool.304 These data provide evidence for an important role of UV-light in p53 associated 
cutaneous carcinogenesis. A correlation between the presence of p53 mutations, and the 
morphology and growth patterns of the corresponding squamous cell carcinomas has 
been demonstrated.313
1.9.6 Apoptosis
Cell death is not exclusively a pathological mechanism, as cell death plays an impor­
tant role in homeostasis of living tissues in multicellular organisms. A balance between 
cell proliferation and cell death maintains homeostasis. Two distinct forms of cell death 
have been described: necrosis and apoptosis.
Necrosis is a passive and pathological form of cell death resulting from acute cellular 
injury. Necrotic cells are typified by swelling of cells and organelles, blebbing, vacuo­
lization, and lysis. Cell death by necrosis leads to release of potentially toxic and immuno­
genic intracellular contents into the surrounding tissue, as necrosis is associated w ith loss 
of cell membrane integrity. Next the cytoplasmic contents invoke an inflammatory 
reaction.
Apoptosis is a functionally different mechanism of cell death. It represents an active 
and physiological process, by which the nucleus and cytoplasm shrink and often frag­
ment.314-316 This is followed by phagocytosis by macrophages and other cells. The pheno­
menon of apoptosis was observed by Wylie et al,317 however, the term apoptosis was 
introduced by Kerr et al.318 Apoptosis is also known as ‘programmed cell death’, a term 
derived from developmental biology. In apoptosis, the nucleus chromatin becomes py- 
knotic and packed into smooth masses applied against the nuclear membrane. The 
nucleus breaks up into small pieces (karyorhexis). Finally, the cell itself shrinks and 
breaks up into membrane-enclosed fragments called ‘apoptotic bodies’.319;320 These apop- 
totic bodies are recognized and rapidly phagocytosed by neighboring cells including 
keratinocytes or macrophages. These are effectively degraded and removed within the 
lysosomes of these cells. Important is the fact that removal occurs before lysis, so the 
release of intracellular contents from the apoptotic cells into the surrounding tissue is 
prevented and therefore an inflammatory response, as seen in necrosis, does not occur. 
The whole apoptotic process takes as long as 1-3 hours in lymphocytes but may last up 
to 72 hours in keratinocytes.321 In contrast to necrosis, apoptosis is a process that usually 
affects individual cells in  a more scattered pattern.
Apoptosis is an evolutionary conserved genetic mechanism from insects to mam­
mals where several genes that actively are involved in activating or suppressing apopto- 
sis.322 The process of apoptosis comprises 3 different phases: initiation, execution, and 
degradation.323 During the initiation phase a variety of extrinsic and intrinsic factors can 
induce or inhibit apoptosis (Table I). At some point the apoptosis-inducing factors 
activate inducers of apoptosis, controlled by several regulators, then the decision to die is 
defined. This is the execution phase. The execution phase is followed by the degradation
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Table I:
Factors which induce or inhib it apoptosis. (Modified from Teraki et Shiohara518).
Inducers Inhibitors
TNF-a/FasL Growth factors
Perforin/Granzyme Cytokines (IL-2, IL-3, IL-4, IL-6)
TGF-ß CD40 ligand
Glucocorticoids Zinc
Retinoids Estrogen
Ceramid Androgens
Vitamin D3 Virus genes
Zinc deficiency Calplain inhibitors
Calcium Cystein proteinase inhibitors
Growth factor withdrawal
Heat
Cold
Virus
X-ray
UV-radiation
Chemotherapeutic agents
Figure 10:
Schematic overview of a variety of pro-apoptotic stimuli inducing cell death signals that can trigger the 
central executioner (e.g. caspases) leading to cleavage of death subtrates and finally resulting in apoptosis. 
Fas/Fas Ligand and TNF/TNFR can bypass regulation by Bcl-2 and can directly activate caspases.
(Adapted from Teraki et Shiohara518)
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phase, in  which the activation of the central effector of apoptosis takes place. Here the 
different private pathways converge into a few common pathways leading to the 
activation of several caspases, catabolic enzymes (mostly proteases). In the final stage the 
typical changes of the cell can be seen. In contrast to the initiation phase and the 
execution phase, the degradation phase is similar in all kinds of cells. The Bcl-2 family of 
dimerizing proteins controls this pathway. However, members of the TNFR family 
bypass the regulation of Bcl-2 and can directly activate caspases (Figure 10).
In the regulation of apoptosis many factors are involved. Two factors have been 
extensively investigated: Fas and Bcl-2. Fas (also known as APO-1 or CD95) is a trans­
membrane receptor. Binding of its ligand, Fas L, to the Fas receptor leads via a number 
of caspases and other proteins to apoptosis of the Fas-expressing cell. Fas can be ex­
pressed by a variety of cells, including skin, liver, ovary, heart, and lung. Expression of 
Fas L, however, is more limited to mainly activated T-cells and neutrophils. Fas/Fas L 
interactions control the peripheral lymphocyte life span and thereby participate in 
peripheral elimination of no longer needed lymphoid populations. However, certain 
tumor cells also express Fas L and are capable of killing other cells that express Fas (e.g. 
cytotoxic T-cells), thus providing malignant cells with resistance to tumor immunity. 
Several viral infections can lead to increased Fas and/or Fas L expression and increased 
sensitivity to Fas/Fas L-dependent apoptosis.324 Other ways of virally infected cells to 
escape destruction by this Fas/Fas L mechanism comprise of clearing Fas from the cell 
surface or the encoding of Bcl-2 homologues.
Bcl-2 is a proto-oncogene that has apoptosis inhibiting properties. It prolongs the sur­
vival of cells, even in the presence of stimuli such as chemotherapeutical agents, irradia­
tion, TNF and transfection with p53 or c-myc. Thus, genes that inhibit Bcl-2 can 
stimulate apoptosis. Many tumors act by Bcl-2 involved mechanisms to escape cell death. 
Many Bcl-2 related Bcl family members are co-expressed in  the same cells and can inhibit 
but also activate apoptosis, so the ratio of anti-apoptotic versus pro-apoptotic proteins 
may determine whether a cell will undergo apoptosis or not.325;326
The best-known histological examples of apoptotic cells in  the skin are sunburn 
cells. These cells are seen in the epidermis as small cells with a very shrunken nucleus 
and bright pink cytoplasm and can be seen after UV-exposure. In UV-exposed skin p53 
is upregulated, and, as shown in paragraph 1.9.5, can push damaged keratinocytes in  the 
direction of apoptosis, thus preventing them from becoming malignancies.327 UV- 
irradiation induces both Fas and Fas L. In psoriasis Fas L induction by UV-light has a 
beneficial effect that may lead to the destruction of fas-bearing T-cells,328 whereas in 
NMSC Fas L expression may prevent these tumor cells to be eliminated by the immune 
system. Apoptosis not only plays a role in  the pathogenesis of skin diseases, but possibly 
also in normal homeostatic terminal differentiation of the keratinocytes in  healthy skin. 
Terminal differentiation has been postulated to be a special form of apoptosis because of 
the typical apoptosis-associated features in terminal differentiating cells, such as endo­
nuclease activity and DNA fragmentation.329 Proliferation of keratinocytes may be 
regulated by apoptotic cell death in order to maintain a constant thickness of the epider­
mis.
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Keratinocytes undergo apoptosis by several mechanisms.325 Fas-expressing keratino- 
cytes can become apoptotic by binding to Fas L-expressing cytotoxic T-cells. Apoptosis 
can also be induced via the release of effector cell granules, such as granzyme B and 
perforin that can activate caspase family members. CD8+ T-cells and NK (natural 
killer) cells partially use this mechanism for apoptosis. TNF released from mast cells and 
activated T-cells in the skin may have similar potentials. However, keratinocytes have 
been mentioned to be able to produce granzyme B, perforin, and Fas L, which can be used 
to protect the epidermis from pathogens and immune-mediated damage.330 By expressing 
Fas L keratinocytes may destruct Fas-expressing keratinocytes (e.g. due to viral infection, 
drug exposure or malignant transformation) and thus contribute to the elimination of 
abnormal keratinocytes. In psoriasis (see Part I), however, there is no microscopic 
evidence for the presence of apoptotic keratinocytes, despite the expression of Fas in 
lesional skin keratinocytes. Therefore, further studies on the apoptotic mechanisms in 
psoriasis are indicated.331
In non-melanoma skin cancer apoptosis is likely to be of importance. In basal cell 
carcinomas a high mitotic activity if found, despite a low growth profile. Apoptosis may 
be the explanation for this discrepancy, as apoptotic cells normally outnumber proli­
ferating cells in BCC.314 Bcl-2 may play a role in  BCC, as has been opted by several stud­
ies. BCC cells express Fas L, but not Fas, which may allow tumor growth by destroying 
Fas-bearing activated T-cells.332-334 Interferon-a treatment is highly effective in BCC and 
may work by this Fas/Fas L mechanism, as in interferon-a treated patients the BCC cells 
also express Fas. Increased proliferation rather than decreased cell death is responsible 
for the more rapid growth profile in  squamous cell carcinoma, which is in contrast to 
BCC. Spontaneous regression can occasionally be seen in many skin tumors where apop­
tosis may play an important role. Keratoacanthomas (KA) have been proposed to be a 
special subgroup of squamous cell carcinomas where the immune system is capable of 
destructing the tumor and complete regression is the outcome. In regressing KA apop­
tosis can be observed indeed. In the proliferative stage of KA Bcl-2 is frequently ex­
pressed, whereas in  the regressive stage such is rarely seen.
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1.10
Premalignant skin disorders
The field of premalignant skin disorders comprises many subtypes, such as cuta­
neous horn, Bowen’s disease, erythroplasia of Queyrat, leucoplakia (of mucosal sur­
faces), actinic porokeratosis, and actinic keratosis. This thesis mainly deals with actinic 
keratoses, probably the most frequent premalignant skin disorder in  dermatology. In the 
next section actinic keratoses will be discussed more detailed.
1.10.1 Actinic keratoses
Actinic keratoses are erythematosquamous and often hyperkeratotic lesions 
occurring in sun-exposed adult skin, which carry a risk of progression to squamous cell 
carcinoma. Actinic keratosis (AK) was first identified as ‘keratoma senilis’ by Freuden­
thal in 1926. In 1958 Pinkus introduced the term ‘actinic keratosis’. Actinic keratoses are 
also known as solar keratoses or senile keratoses.275
Apart from the sunlight-induced actinic keratoses, several other types of keratoses 
exist that strongly resemble actinic keratoses. These keratoses are associated with specif­
ic external factors and comprise postionizing radiation keratoses, tar keratoses, and ar­
senic keratoses. In this thesis only the sunlight-induced actinic keratoses will be dis­
cussed.
1.10.1.1 Epidemiology
Actinic keratoses are especially seen in  elderly and fair-skinned people with a his­
tory of significant sun exposure.277 The global prevalence of these lesions varies strongly. 
In Western Europe, in  Wales, the prevalence for actinic keratosis was 23%.335 In Queens­
land, Australia, actinic keratoses are most common with prevalence up to 60%.336 In 
African blacks, however, actinic keratoses are rarely seen. In immunodeficient and im- 
munosuppressed patients a higher prevalence of actinic keratoses is common.
1.10.1.2 Etiology and pathogenesis
As mentioned in  paragraph 1.9.2.2 the 3-stage model of carcinogenesis is believed to 
be the mechanism involved in  carcinogenesis of the skin. The most important etiological 
factor for actinic keratosis is UV-light. UV-light is a complete carcinogen, as it has both 
initiating and promoting capacities. It can damage DNA, including the relevant proto­
53
R X R - A N D  R A R - S E L E  C T I V E R E T I N O I D S  I N  P S O R I A S I S  A N D  ( P R E ) M A L I G N A N T  S K I N  D I S O R D E R S
oncogenes and tumor suppressor genes, leading to disturbed cell proliferation and car­
cinogenesis.
Impaired DNA repair mechanism is another factor that is important in the onset of 
actinic keratoses. Immunosuppressive agents such as azathioprine inhibit DNA syn­
thesis and therefore impede DNA repair.337 Transplant patients need to take lifelong 
immunosuppressive drugs in order to prevent from graft rejection, but a side effect of this 
immunosuppressive state is the formation of a variety of benign and malignant skin 
tumors. In paragraph 1.12 the skin-related problems in  renal transplant recipients will be 
discussed in  detail. Also in  some genetically determined disorders, including xeroderma 
pigmentosa and Bloom’s syndrome, DNA repair is impaired.
Genetic factors are important in  the development of actinic keratoses. Caucasians 
with blond hair and blue eyes are more susceptible to solar-induced injury.277 A n asso­
ciation with the skin-type is obvious as pigmented skin prevents from development of 
actinic keratoses.
Actinic keratoses are not seen in childhood. They appear in midlife and its pre­
valence rises with age. This is partially due to a higher total sunlight exposure over the 
years, but other agerelated factors may play a role, such as the decrease in epidermal 
thickness in elderly persons.
Human papillomavirus (HPV) infections have been of particular interest in carcino­
genesis since the last two decades. Especially in  grafted patients, but also in immuno­
competent patients, it has been suggested HPV DNA is involved in  carcinogenesis.338-343
Radiotherapy, although therapeutically also effective in  actinic keratoses, is another 
etiological factor in the long-term development of actinic keratoses, due to its DNA- 
destructive properties.
1.10.1.3 Clinical aspects
The formation of a typical actinic keratosis is preceded by a local collection of 
telangiectatic capillaries. This initial sign is often unnoticed by the patient. Once the 
lesion will demonstrate sandpaper-like scaling with dry, rough, adherent and often 
yellow- or brown-colored scales (keratosis) on a hyperemic base, one can speak of an 
actinic keratosis. The scale can be picked off w ith difficulty, often leading to small bleed­
ing points. Actinic keratoses are mostly well demarcated with sharp edges. They tend to 
be multiple. Itching, ulceration, and induration may occur.
Actinic keratoses are mostly found on sun exposed areas. Predilection areas are the 
backs of the hands and forearms, the face, the upper chest, and the lower legs. The 
cheeks, temples and forehead are more commonly affected than the lower parts of the 
face. The ears and vermilion of the lip (actinic cheilitis) are also frequently affected, 
especially in men.
Actinic keratoses can transform into a squamous cell carcinoma (SCC). The like 
lihood of a fully developed SCC evolving from a given actinic keratosis varies depending 
on the number of risk factors present. It has been estimated to occur at a rate of 0.075% 
to 0.096% per lesion per year,344 up to values of even 20% per lesion per year.345 Despite
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Figure 11:
An ac tin ic  keratosis between the 
m etacarpophalangeal jo in ts  of the hand 
fea tu ring  typ ical (sharply) dem arcated 
hyperkeratosis at an erythem atous base.
its premalignant potential, actinic keratoses may regress spontaneously, especially in the 
earliest stages. So far there are no parameters available that predict which specific actinic 
keratosis will progress to squamous cell carcinoma and which actinic keratosis may 
regress spontaneously, 346 but lesions are at particular risk when they are indurated 
and/or ulcerated.
1.10.1.4 Histopathology
Histologically, five types of actinic keratoses can be distinguished: hypertrophic, atro­
phic, Bowenoid, acantholytic, and pigmented. Multiple types can be found in  a single 
subject and even in  a single actinic keratosis combinations of these types can be seen 
sometimes. In general, actinic keratoses are characterized by hyperkeratosis and para­
keratosis, often in columns, with a thin or missing granular layer, some acanthosis, and 
the presence of actinic elastosis and inflammatory cells in  the dermis. The interpapillary 
ridges may be reduced in number and broader than normal. The affected zone tends to 
grow under the normal epidermis and around the epithelial ducts, and may separate from 
it by a cleft or lacuna, resembling Darier’s disease. The basement membrane, however, is 
still intact but basaloid cells may form multiple buds at the junction. In the dermis the 
papillary vessels are irregularly increased. Variable degeneration of dermal collagen and 
deposition of material staining like elastin is seen in  the upper half of the dermis. A 
lymphoid infiltrate is seen beneath the lesion.
The transition from AK to SCC is heralded by acanthosis, by the extension of 
atypical cells into the dermis with ultimate detachment from the surface and by auto­
nomous growth. There is an association with capillary proliferation.
The histological types of actinic keratoses that are summarized above are all charac­
terized by atypical keratinocyte proliferation in  the epidermis, but this does not say
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anything specific on their malignant potential. Recently, the KIN grading system for 
actinic keratoses has been proposed that is based on clinical as well as histological data 
and that is aimed at describing the degree of atypical keratinocyte proliferation.344 This 
grading system is analogous to the scoring system used in evolving carcinoma of the 
uterine cervix (cervical intraepithelial neoplasia or CIN score). It is based upon the vision 
that actinic keratoses are malignant neoplasms in  evolution (keratinocytic intraepider­
mal neoplasia, KIN) and that they demonstrate histologic and molecular genetic features 
of malignancy. However, it remains to be seen whether the KIN score may represent a 
new prognostic parameter for predicting the risk of progression to squamous cell carci­
noma.
The KIN score is based upon 3 different levels: Grade I lesions are flat, pink macules 
on solar damaged skin, without roughness or hyperkeratosis. Lesions are often sub- 
clinical. Histologically, focal atypia of the keratinocytes is seen, but is not exceeding the 
lower one third of the epidermis. Grade II lesions are pink to red with a hyperkeratotic 
surface and variable induration. Histologically, focal atypia of the keratinocytes remains 
limited to the lower two thirds of the epidermis. Common features comprise alternating 
orthokeratosis and parakeratosis, among others. Grade III lesions are red, scaly and 
indurated plaques. Histologically, atypical keratinocyte proliferation spreads throughout 
the full thickness of the epidermis. All features of actinic keratoses can be seen. KIN III 
lesions are currently referred to as squamous cell carcinoma in  situ or Bowen’s disease.
1.10.1.5 Im m unohistochem istry
There is only a small number of studies available in actinic keratoses where epider­
mal proliferation, keratinization, differentiation, and apoptosis-associated parameters 
have been investigated by immunohistochemical analysis. Considering proliferation, a 
high number of proliferating epidermal cells is found in  the lower part of the epidermis, 
as demonstrated by the proliferation parameter Ki67; and most of them are atypical 
cells.347 In a study by Caldwell et al, the proliferation index (PI) of actinic keratoses ap­
peared to be nearly 3 times higher than the PI of normal skin, and is intermediary in 
between the PI for psoriasis and the PI for poorly differentiated squamous cell carci­
nomas; the latter having the highest PI.
With respect to differentiation parameters keratin 1 and 10 a decreased expression 
was found in  hyperkeratotic areas of actinic keratoses, whereas in  the atrophic areas the 
staining pattern was similar to that in normal epidermis and in well-differentiated 
squamous cell carcinomas.348 Hyperproliferation-associated keratin 16 is usually not 
present in normal skin, but in actinic keratoses, like in psoriasis, it is predominantly 
expressed in  the suprabasal cell layers.349
Keratin 13 and keratin 19, retinoid-treatment-associated and embryonic keratins, 
have previously been found in squamous cell carcinomas, but not in  actinic keratoses. 
350;351 In Bowen’s disease keratin 19 has been found incidentally and mainly in poorly 
differentiated areas.348 Therefore, it has been suggested that these simple epithelial kera­
tins are markers for malignant transformation in human epidermis. In mice, keratin 13
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expression has already been identified to be a good marker for malignant transformation 
and skin tumor progression in papillomas.352;353
Filaggrin and involucrin expression can be variable in  actinic keratoses, but there 
appears to be no distinct pattern from normal skin and squamous cell carcinoma.354;355 
Involucrin is expressed already in  the upper stratum spinosum.347 There are no data avail­
able on transglutaminase staining in  actinic keratoses, but in  squamous cell carcinoma, 
depending on the degree of tumor differentiation, transglutaminase expression is disturb­
ed and generally an increase in transglutaminase is seen. The latter is also the case in  pso­
riasis.356
P53 protein has been detected in  up to 85% of actinic keratoses in  several studies. 
357;358 It is abundantly expressed throughout the lower regions of the epidermis. Super­
ficial keratinocytes are often spared and the granular cell layer is negative for p53 stain­
ing. Nuclear labeling is variable both in intensity and in distribution within a given 
lesion, but is mostly diffuse.357 A correlation between the pattern of p53 expression and 
histological subtype of actinic keratoses (e.g. atrophic, Bowenoid, and hyperkeratotic) has 
been demonstrated. Diffuse p53 expression is especially seen in hyperplastic and Bowen­
oid actinic keratoses; focal expression is common in the other types. The adnexa are 
mostly negative for p53 staining. Atrophic foci often exhibit a stronger and more diffuse 
p53 labeling.357 A significant positive correlation w ith MIB-1 and w ith the number of 
atypical cells has been demonstrated.358;359 Overexpression of p53 in actinic keratoses 
might be associated with stabilization of wild-type p53 protein as well as p53 gene muta­
tion.360 Accumulation of p53 could also be due to enhanced synthesis in  response to 
DNA damage.361 Abnormal p53, either m utant or stabilized p53 protein, probably loses 
its normal function and might induce or stop prohibiting proliferation or tumorigenesis 
of the cells. Sim et al have shown that p53 expression in actinic keratoses is mainly due 
to accumulation of mutant-type p53 protein rather than wild-type p53.
1.10.1.6 Treatment
Destructive measures
Destructive measures are the standard of care for treatment of actinic keratoses.362 
Many effective approaches are available depending on factors, such as, the aspect, the 
number, and the localization of the lesions. Cryotherapy is among the oldest treatment 
regimens and is considered the standard method of destructive therapy for these lesions. 
363 Superficial lesions are easily removed by rapid freezing with liquid nitrogen, but even 
hyperkeratotic actinic keratoses do often respond well to cryotherapy, especially when 
applied 2 or 3 times repeatedly.
Other destructive therapies are curettage, desiccation and electrocoagulation. These 
are all equally effective as cryotherapy, but more likely to leave superficial scaring. There­
fore, these approaches should be considered when other therapies are not effective enough.
Biopsy or surgical excision is the therapy of choice for indurated actinic keratoses, 
so pathological examination of the base can be performed to exclude early invasive squa­
mous cell carcinoma. These approaches are especially indicated for solitary actinic kera-
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toses. For multiple actinic keratoses on larger body surface areas other therapies are 
preferable.
Topical retinoids
Topical retinoids are a popular treatment for actinic keratoses. Many articles have 
been published on topical retinoids in  premalignant disorders and photodamaged skin. 
345;364-390 In general, topical retinoids improve photodamaged skin clinically and histo­
logically. With respect to the more advanced actinic keratoses most studies report benefi­
cial clinical effects, although several studies do not confirm its therapeutic potential. 
From histological and especially immunohistochemical point of view little information is 
available to strengthen the overall clinical beneficial impression. In the subpopulation of 
renal transplant recipients no histological and immunohistochemical data on topical 
retinoids are available. A well-known side-effect of topical retinoids is the irritant effect 
on the skin. This “retinoid dermatitis” is frequently seen and may limit the use of these 
topical agents. However, many studies report that retinoid dermatitis will subside with 
continued treatment several weeks after initiation. The exact mode of action of retinoids 
remains to be elucidated.
All-trans retinoic acid (ATRA) or tretinoin has been used for some decades now and 
is by far the most frequently used topical retinoid for photodamaged skin and actinic 
keratoses. Applications with doses varying from 0.01 to 0.3 % have been reported to be 
effective, although its efficacy is less than with standard destructive procedures.
Partial efficacy has been observed with topical isotretinoin 0.1% in a cream base. In 
a placebo controlled study 66% of the patients had a more than 30% reduction in the 
number of actinic keratoses for lesions on the face. However, no significant drug effect 
was seen for lesions on the scalp or upper extremities.371
Tazarotene has been registered recently for acne and psoriasis and has been reported 
to be effective in basal cell carcinoma.391 Whether Tazarotene may have some effect in 
actinic keratoses, remains to be elucidated.
Topical cytotoxic agents
Topical cytotoxic agents can be used in  the treatment of actinic keratoses and other 
premalignant skin disorders. Topical 5-fuorouracil (Efudix®) has been extensively stud­
ied in  actinic keratoses.392-394 This fluoridated pyrimidin acts as an anti-metabolite. An 
effective treatment regimen is twice daily application for about 4 weeks. During this 
treatment period the epidermis becomes erosive, ulcerative and necrotic and patients 
may complain of worsening of the lesions, which can lead to non-compliance. After the 
treatment period the skin surface will heal again with renewed epithelialization and, 
idealically, the actinic keratoses will have disappeared. To improve compliance, 5-fuor­
ouracil can be applied four times daily for shorter periods of time, resulting in  clearing of 
actinic keratoses and patient acceptability.395 Topical 5-fuorouracil is a highly effective 
and frequently used approach for actinic keratoses nowadays, however, its use is limited 
to skin surface areas of about 500 cm2 per treatment. Therefore, especially in renal trans­
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plant recipients w ith often very large areas involved with actinic keratoses, other thera­
pies may be necessary.
Photodynamic therapy
Photodynamic therapy (PDT) is a rather new effective method in  which actinic 
keratoses are pretreated with a photosensitizer, 5-aminolevulinic acid (5-ALA), followed 
by illumination w ith (broad-spectrum) visible light, leading to destruction of epidermal 
cells.396-398 Application of 5-ALA leads to the accumulation of the endogenous photo­
sensitizer protoporphyrin IX (Pp IX) in  epidermal cells. Conversion of 5-ALA to Pp IX 
occurs in skin cells by enzymes in the haem biosynthetic pathway. Rapidly proliferating 
cells, such as those in actinic keratoses, convert more 5-ALA to Pp IX than do less rapidly 
proliferating normal epidermal cells.399 Moreover, since 5-ALA in aqueous solution 
passes readily through abnormal keratin, but not through normal keratin, the topical 
application of 5-ALA in aqueous solution to actinic keratoses or superficial basal cell or 
squamous cell carcinomas induces Pp IX photosensitization that is restricted primarily 
to the abnormal epithelium. Subsequent exposure to photoactivating light selectively 
destroys such lesions. Pp IX photosensitization can be induced in cells of the epidermis 
and its appendages, but not in the dermis. By choosing red (laser) light (630nm) for 
illumination a deeper penetration can be achieved. But pathologic changes in actinic 
keratoses are superficially placed in the epidermis and therefore fluorescent (non-laser) 
blue light is sufficient, especially while Pp IX is more efficiently photo-activated by blue 
light.398
Photodynamic therapy offers the advantages of being non-invasive, well tolerated in 
slow healing sites, and tissue sparing, leaving the surrounding normal skin intact and 
functional. Photodynamic therapy is especially effective in  superficial actinic keratoses, 
such as atrophic and Bowenoid actinic keratoses. In general this treatment is less effec­
tive in hyperkeratotic actinic keratoses.
Systemic retinoids
In patients with widespread actinic keratoses, systemic retinoid therapy may be an 
option, especially in immunocompromized patients, where multiple actinic keratoses are 
the rule. Systemic retinoids clinically also improve hyperkeratotic actinic keratoses, 
probably by enhancing desquamation of the lesions via mechanisms that are not com­
pletely understood, leading to a decrease in thickness of the actinic keratoses.
Systemic retinoid treatment has become of interest since the 1980ies, when several 
clinical studies were undertaken with oral administration of isotretinoin, etretinate, and 
later on acitretin, in premalignant skin disorders.400-410 Efficacy has been claimed for all 
three retinoids in  several of these studies with highest efficacy rates for etretinate and 
acitretin. However, efficacy was often partial and recurrences after discontinuation were 
frequently seen.
Etretinate, in  doses 50 -  100 mg/day, is effective in  the clinical setting for actinic 
keratoses, both in immunocompetent and immunocompromized patients.406;408 Side ef­
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fects of systemic etretinate mainly comprise cheilitis, exfoliation, eye irritation, pruritus, 
and sweating. Cheilitis and exfoliation were reported in  all patients and were often 
troublesome, but not sufficiently severe to necessitate stopping. These symptoms were 
most marked in the first m onth of treatment, and on reducing the dose the symptoms 
resolved in the majority of patients. After completing therapy all side effects resolved 
within a month.408 Other adverse events like hyperlipidemia and elevation of serum 
transaminases can be seen and, importantly, teratogenicity.
Acitretin shares similar features with etretinate with respect to efficacy, but has a 
more favorable side-effect profile, especially w ith respect to teratogenicity, as the half-life 
time of acitretin is only 2 days, compared to 80-120 days for etretinate.194
Isotretinoin is especially used for severe acne. In actinic keratoses a combination of 
isotretinoin 20 mg daily and 5-fuorouracil is highly effective, but data on monotherapy 
with oral isotretinoin for actinic keratoses are not available. In Part III retinoids will be 
discussed in more detail.
Other approaches
Radiotherapy is a paradoxical treatment for actinic keratoses, as radiotherapy itself 
may induce the formation of these lesions after prolonged periods of treatment. However, 
in  elderly persons with multiple actinic keratoses (and suspicion for Bowen’s disease or 
even squamous cell carcinoma) in areas where surgery or other effective destructive 
treatments are difficult, radiotherapy may be an option.411;412
Repeated intralesional injections with interferon alpha or beta have demonstrated 
some efficacy in actinic keratoses, but topical application of interferon alpha was not
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effective. 413;414 Although interferons are not a common treatment for actinic keratoses 
so far, their mode of action may be relevant for the development of new potential effec­
tive treatments. An example is imiquimod (Aldara®) that is registered for the treatment 
of genital and perianal warts, due to its immune response mediating properties. It mainly 
acts by induction of interferon alpha (IFN-alpha) and other cytokines in  the skin, which 
stimulate several other aspects of the innate and acquired immune response.415
Chemical peelings have been used, as monotherapy or in combination with other 
treatments in actinic keratoses. These peeling agents comprise glycolic acid, lactic acid, 
trichloroacetic acid, phenol, and salicylic acid among other less frequently used peeling 
agents.416;417 Chemical peeling promotes the regeneration of new, healthy skin and there­
fore improves actinically damaged skin and actinic keratoses.
A promising new therapy may be topical colchicines. Complete healing of actinic 
keratoses was observed in a pilot-study in  7 out of 10 patients with 1% colchicine gel ap­
plied twice daily for 2 months.418 No recurrence was observed after 2 months follow-up. 
First efficacy occurred already in  the first week of treatment. Systemic signs of colchici­
nes toxicity did not occur. However, further studies are necessary to define the optimal 
concentration and the mode of application.
Topical and systemic vitamin D3 analogues have been investigated in  several (pre)- 
cancerous types of lesions and have been claimed to be effective.419 However, no studies 
with vitamin D3 derivatives have been performed in actinic keratoses so far, but in this 
type of lesions efficacy may be expected as well.
Prevention: sunscreens and clothes
Last but not least, apart from therapeutic interventions, prevention of actinic kera­
toses is important to reduce the risk of developing new lesions with time. Especially in 
high-risk patients, such as immunocompromized patients and fair-skinned individuals 
who live in areas with a high exposure to sunlight. Encouraging patients to avoid (vivid) 
sunlight and to cover the skin with appropriated clothes and in some cases to wear a hat, 
is a first important step for prevention of further actinic damage. The application of sun­
screens with a high sunlight-protecting factor (SPF) is a second sensible step.
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1.10.2 Other premalignant disorders
The previous section dealt with actinic keratoses, the most common premalignant 
skin disorder. Here, I will briefly describe some other premalignancies that are frequently 
seen in the normal, but especially in  the immunocompromized population.
1.10.2.1 Bowen’s disease or Bowenoid actinic keratoses
Bowen’s disease can be defined as a progressive, non-elevated, erythematosquamous 
or scaly plaque due to an intraepidermal carcinoma (carcinoma in  situ). Bowen’s disease 
is mentioned as a separate entity in literature, however, it may be regarded identical to 
KIN grade III actinic keratoses. Therefore, Bowen’s disease may be part of a continuous 
spectrum that ranges from sun damaged skin to squamous cell carcinoma.420
The initial well-demarcated small, red and scaly lesion gradually enlarges, which 
may take several years, mostly without any subjective symptoms. Although Bowen’s dis­
ease is usually flat, it may become hyperkeratotic or may ulcerate. The latter is a sign 
suggestive of development of invasive carcinoma. Lesions are often multiple and may be 
widespread.
Sunlight is the most important etiological factor and, therefore, these lesions are 
mostly found on sunlight exposed areas. Arsenic ingestion in the past also plays a role in 
its etiology.421
Figure 13:
A cutaneous horn resembles the horn of 
an anim al and o ften looks qu ite  
surrealistic.
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The main histopathological feature is proliferation of atypical keratinocytes through­
out the whole thickness of the epidermis, but without invasion through the basement 
membrane. These atypical cells have hyperchromatic nuclei, often larger than normal, 
giving a freckled appearance to the epidermis. Giant forms of multinucleate cells are seen 
and mitotic figures may be present. Variable acanthosis is seen with increase in the length 
and thickness of the interpapillary ridges. The epidermal organization is disturbed and 
keratinocytes often prematurely keratinize and lose their intercellular connections. The 
papillary dermis shows an inflammatory infiltrate that is often quite dense. Sometimes 
the atypical proliferating cells may be surrounded by a relatively normal keratinocyte 
population, which is called ‘Borst-Jadassohn appearance’. The atypical cells often grow 
down around and along the appendages like a collar and can become invasive. The epi­
dermis above the appendages may even be normal. Parakeratosis is present on the sur­
face.
Differential diagnostically the lesion must be distinguished from lichen simplex, 
superficial basal cell carcinoma, and erythematosquamous disorders such as psoriasis. 
Topical steroid treatment may be used for diagnostic purposes; if the lesion does not 
respond, Bowen’s disease is highly suspected. Histological investigation (biopsy) may be 
necessary to obtain a proper diagnosis.
There are several therapeutic options for Bowen’s disease. Recurrences are common, 
and may be due to extension of the carcinoma in  situ around the appendage ducts that 
were not effected by treatment. Therefore, surgical excision is the best option if the lesion 
is not too large. Other remedies are cryotherapy, cauterization, topical cytotoxic agents 
(5-fluor-ouracil; Efudix®), and photodynamic therapy.422
1.10.2.2 Cutaneous horn
Cutaneous horn is strictly not a histological diagnosis, but a diagnosis obtained from 
clinical examination. Various underlying dermatological conditions, such as epidermal 
naevus, viral wart, keratoacanthoma, actinic keratosis, and squamous cell carcinoma 
may cause the typical horny aspect of this lesion. Of these underlying conditions, actinic 
keratoses were the lesions most commonly found in a large study (37.4%); less than 25% 
of the underlying disorders was malignant.423 The lesion resembles the horn of an 
animal. Its consistency is mostly friable but the lesion can be very hard. It has a yellowish 
brown color and is often curved with circumferential ridges. The adjacent skin is often 
normal-looking. The base of a cutaneous horn may be erythematous, which is suggestive 
of malignant transformation. These lesions are mostly found on sunlight-exposed areas 
and can be solitary but may also be multiple. Signs of UV-damage of surrounding skin, 
such as solar keratoses, are often present.
A cutaneous horn is the result of dysplastic epidermal changes similar to those seen 
in an actinic keratosis. Histologically, the granular cell layer is often deficient or absent. 
In long-standing lesions there may be budding from the basal layer, indicating early 
development of a squamous cell carcinoma. Surgical treatment is indicated when an 
underlying squamous cell carcinoma is suspected.
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1.11
Squamous cell carcinoma
The field of skin cancer is very large and comprises non-melanoma skin cancers, 
melanoma skin cancers, and many dermal skin tumors. This thesis is focussed on actinic 
keratoses and non-melanoma skin cancers, especially squamous cell carcinomas. There­
fore, this subtype will be discussed more detailed in the next paragraph.
1.11.1 Definition
Squamous cell carcinoma is a malignant epithelial tumor that may metastasize and 
arises from keratinocytes.
1.11.2 Epidemiology
The incidence of squamous cell carcinoma is related to geographical latitude and 
skin-type and is about 5-10 times lower than basal cell carcinoma. In sunny areas annual 
incidences up to 338 per 100,000 for males and 164 per 100,000 for females have been 
reported in Australia. In temperate climates, however, the incidence is much lower. Its
Figure 14:
A squamous cell carcinoma on the 
proximal thumb in a renal transplant 
recipient. Another squamous cell 
carcinoma on the distal thumb presented 
as a cutaneous horn.
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incidence is positively related to albinism, but data on its relationship to vitiligo are 
contradictive.424;425 Previous injury, burns, and radiant heat have been proposed as risk 
factors for the arising of squamous cell carcinoma.426;427 A higher incidence is found in 
xeroderma pigmentosum patients and in long-standing chronic granulomas.
1.11.3 Clinical aspects
Squamous cell carcinoma frequently arises in actinically damaged skin. Predilection 
areas are the backs of the hands and forearms, the upper part of the face, the upper chest 
and, especially in males, the lower lip and the ears. The first sign of malignancy is indura­
tion. The tumor may present as a small, slightly raised and wart-like hyperkeratotic 
papule or plaque, sometimes with ulceration. The growth pattern is normally slower than 
in keratoacanthoma, but faster than in basal cell carcinoma. Initially, pain is uncommon 
and the tumor may remain indolent, but when growth progresses rapidly, the lesion may 
become painful. This is especially the case with ulcerating tumors. A hyperkeratotic 
crust that may shed often caps well-differentiated tumors, whereas less-differentiated 
tumors frequently have a nodular structure without an overlaying crust. The surface 
sometimes easily bleeds and the surrounding skin is inflamed. The presentation may be 
different on mobile structures, comprising a fissure, a small erosion or an ulceration that 
fails to heal.
The tumor may spread to soft tissues, cartilage or bones. It can spread along the 
nerves for considerable distances. Metastasis occurs primarily to the local lymph nodes. 
Metastasis to other organs occurs relatively late. Spread by the bloodstream is uncom- 
mon.428 The frequency of metastasis varies with the grade of differentiation and the 
subtype; frequencies up to 7% have been reported in transplant recipients.429 The 3-year 
cause-specific mortality in a group of 71 patients with metastatic SCC was 54%.430 In 
immunocompromized patients squamous cell carcinoma behaves more aggressively and 
a higher percentage of the tumors metastasizes. Tumors arising in keratoses on the dor­
sum of the hand are particularly late in metastasizing. This in contrast to anaplastic squa­
mous cell carcinoma, which may resemble a keratoacanthoma. This subtype quite early 
metastasizes in up to 50% of the tumors. Tumors of 2-3 centimeter generally can be 
cured in about 90% of cases. However, when squamous cell carcinoma occurs on muco­
sal tissues, like the vulva or tongue, the prognosis is worse.
1.11.4 Pathogenesis
Several etiological factors have been identified for squamous cell carcinoma, such as 
genetic factors, x-rays, chemical carcinogens, immunosuppression, viral infections 
(HPV), arsenic, tar, and the most important factor, sunlight or UV-irradiation. The me­
chanisms of carcinogenesis and the development of premalignant actinic keratoses that 
may transform to squamous cell carcinomas have been described previously in para­
graphs 1.9.2.2 and 1.10.1.3.
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1.11.5 Histology
When atypical keratinocytes breach the basement membrane, one can no longer 
speak of a premalignant lesion, such as Bowen’s disease or actinic keratosis, but here is 
where squamous cell carcinoma starts. Thus, the distinction is based on architectural 
rather than cytological features. With respect to cellular aspects, squamous cell carci­
noma cells may vary from large, well-differentiated polygonal cells with vesicular nuclei, 
prominent nucleoli, numerous tonofibrils in the cytoplasm, and well-developed inter­
cellular bridges, to completely anaplastic cells, which lack a link to their cytological ori­
gin. The latter type is often seen in rapidly growing tumor margins.
Well-differentiated tumor cells tend to keratinize, as do normal suprabasal keratino­
cytes. Tumors that consist of these cells show areas of maturation that form parakeratotic 
horny pearls, but also dyskeratosis, with lacunae and lumina that contain shed rounded 
degenerating tumor cells. These tumors may have a pseudoglandular aspect and are 
called ‘acantholytic squamous cell carcinomas’.431;432
Anaplastic tumors often show hyperchromatic nuclei, decreased eosinophilia, a 
decrease in cytoplasmatic tonofibril formation and intercellular adhesions, and an in­
creased number of mitoses with abnormal mitoses.
In the dermis an inflammatory reaction is seen with lymphocytes, plasma cells, 
histiocytes, and mast cells, together with an increased number of blood vessels.433 Most 
tumors penetrate the dermis as coherent strands and columns. In case a squamous cell 
carcinoma metastasizes, the metastasis normally features the same structure of strands 
and columns.
To estimate the risk of metastasizing, squamous cell carcinomas can be classified 
into 4 grades according to Broders. This classification is based on the number of undiffer­
entiated tumor cells in proportion to the number of differentiated tumor cells. However, 
Broders’ classification is somewhat obsolete nowadays, as the risk for metastasizing not 
only depends on the proportion of undifferentiated cells, but also on the volume and 
depth of the tumor.
Table II:
P opula tion-based standard ized inc idence  ra tios o f skin  cancer in organ tra n s p la n t rec ip ien ts . 
(A dapted from  Berg and O tley430)
Skin cancer Increase in incidence
SCC 6 5 -fo ld
SCC o f the  lip 2 0 -fo ld
BCC 1 0-fo ld
M elanom a 3 .4 -fo ld
Kaposi sarcom a 8 4 -fo ld
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Table III:
M echan ism s o f action  and newer im m unosuppress ive  m e d ica tions. (A dapted from  Berg and O tley430)
Medication Mechanism of action
Cyclosporin  A  (N eoral® ) In h ib its  tra n sc rip tio n  o f in te rle u k in  2 and enzym es 
essentia l to  cy to to x ic ity
A za th iop rine  (Im uran® ) In h ib its  p ro life ra tion  o f T- and B -e ffec to r ce lls  by 
in h ib it in g  n uc le o tide  synthesis
P redn isone In h ib its  p ro life ra tion  o f T ce lls  aga inst an tigens
M urom onab-C D 3 (O K T3) A cts  as an ti-T -ce ll im m un o g lo b u lin
M ycophenola te  m o fe til (CellCept® ) In h ib its  nuc le o tide  syn thesis  c r it ic a l to  T- and B- 
ce ll p ro life ra tion ; s im ila r  to  azath iop rine
Tacro lim us (Prograf®) In h ib its  tra n sc rip tio n ; s im ila r  to  cyc losporin  A
Rapam ycin (S iro lim us® ) B ind s  to  im m u n o p h ilin s  and in h ib its  cy tok ines;
in h ib its  grow th fa c to r and tra n sd uc tio n ; po ten tia tes  
cyc losporin  A
1.11.6 Treatment
As for many other types of tumors, surgery is the treatment of choice when the 
tumor can be excised by primary closure. Sometimes by means of additional plastic 
surgery. It is important to have a margin of at least 3mm from the visible and palpable 
tumor to minimize the risk of non-radical excision. Surgery is also the treatment of 
choice when cartilage or bone invasion has occurred or when lymph nodes are involved. 
Surgery makes an adequate histopathological examination possible for assessment of the 
radicality of the tumor.
Radiotherapy is an option in poorly-differentiated tumors, particularly when located 
on the head and neck and not being metastasized. Radiotherapy often leaves fine fragile 
scars, but radionecrosis may occur. Especially in elderly patients or in patients with 
contraindication for excision radiotherapy is an option.
For inoperable tumors and metastases of squamous cell carcinoma systemically 
administered bleomycin can be used. This cytotoxic drug can also be used in combination 
with other chemotherapeutic agents or in combination with radiotherapy or surgery. In 
some cases intralesional bleomycin may be tried.
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1.12
Skin lesions in renal transplant recipients
1.12.1 Introduction
Organ transplant recipients receiving immunosuppressive treatment are at risk for 
developing a broad spectrum of benign, premalignant and malignant skin disorders, as 
well as internal malignancies, such as lymphoma, leukemia, and lung tumors. The major­
ity of cancers in this group of patients are derived from the skin. Organ transplant recipi­
ents have a 65-fold increased incidence for developing squamous cell carcinoma, which 
represents the most common malignancy in this population (Table II) .430 A 3- to 4-fold 
increased risk for developing malagnancies in general has been suggested for this popula­
tion of organ transplant recipients.434 Typically, this increased risk applies specifically to 
the high therapeutic doses of immunosuppression after organ transplantation, and not, 
for example, to immunosuppressive therapy for autoimmune diseases. In the department 
of dermatology of the University Medical Center Nijmegen a large number of immuno- 
compromized renal transplant recipients visit the outpatient department on a regular 
base for dermatological follow-up and treatment of the lesions of the skin.
1.12.2 Immunosuppressive therapy
Renal transplant recipients use life-long immunosuppressive therapy to prevent 
rejection of the graft. Since the 1960s several treatment regimens have been used, such 
as prednisone in a dose of 7.5 to 10 mg per day in combination with azathioprine (Imuran®)
2 to 2.5 mg/kg/day, cyclosporin (Neoral®) in a dose based on the lowest blood levels, and 
relatively new approaches with mycophenolate mofetyl (Cellcept®) and tacrolimus 
(FK506, Prograf®) or sirolimus (Rapamune®). Brief courses of antithymocyte globulin 
(ATG) or antilymphocyte globulin (ALG) are sometimes used as well. Table III repre­
sents the most commonly used immunosuppressive medications. The development of 
carcinomas and other skin lesions is directly related to time from transplantation and the 
intensity of immunosuppression. In heart transplant patients, who generally experience 
a greater degree of immunosuppression than renal transplant recipients do, the develop­
ment of skin cancer occurs earlier and lesions progress more rapidly.435;436 The arising of 
carcinomas seems to be independent of the immunosuppressive regimen used. However, 
with respect to the newer approaches, no long-term follow-up data are available at the 
moment to strengthen this presumed hypothesis. Two mechanisms have been proposed 
for the accelerated carcinogenesis associated with immunosuppressive agents: decreased 
immunosurveillance resulting in uncontrolled proliferation of abnormal cells and a direct 
carcinogenic effect of the drug, including azathioprine and cyclosporin.437 Immuno­
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suppressive agents with powerful antilymphocytic activity, such as cyclosporin, ALT or 
ALG, may enhance viral oncogenesis because of the alteration of function- or elimination 
of T-lymphocytes.
A reduction in the level of immunosuppression may lead to a decrease in the number 
of internal and cutaneous malignancies.438 Cessation of immunosuppression has been 
shown to result in a deceleration of cutaneous carcinogenesis within 1 or 2 years and to 
subjective improvement in skin quality with respect to hyperkeratotic lesions.437 How­
ever, reduction or cessation of immunosuppressive treatment may harbor a greater risk 
of allograft rejection and is therefore generally not an option.
In the near future the use of immunosuppressive monoclonal antibodies may be­
come more important in organ transplant recipients. The use of immunosuppressive 
monoclonal antibodies is actively being studied as a means of selectively impairing recipi­
ent immune activation against allograft antigens. These blocking antibodies, such as anti- 
CD40, anti-interleukin 2 receptor antibody, have shown interesting preclinical data with 
respect to effective immunosuppression without associated pharmacologic toxicities.439;440
1.12.3 Human papillomaviruses
Apart from the immunosuppressive state and well-known risk factors, such as UV- 
irradiation, genetic aspects, skin-type, age and radiotherapy, oncogenic viruses may play 
a role in the etiology of (pre)malignant skin disorders in renal transplant recipients. 
Several viruses have been identified to play a role in carcinogenesis, including Epstein- 
Barr virus, herpes simplex virus, herpes zoster virus and polyoma viruses. A special role 
is reserved for human papillomaviruses (HPV). HPV-16 and HPV-18 have been identi­
fied as carcinogenic in cervix carcinoma. In epidermodysplasia verruciformis (EV), a 
rare genetic disorder in which patients have defective cell-mediated immunity, HPV sub­
types 5, 8, 9, 12, 14, 15, 19-25, 36-38, and 47 were found in squamous cell carcinomas 
and the skin of these patients is usually covered with multiple wart-like lesions.441 In 
renal transplant recipients several HPV types, especially those types found in EV, may be 
involved in the carcinogenic process as well, as HPV-DNA is frequently found in squa­
mous cell carcinoma.340;442;443 Even normal skin in renal transplant recipients harbors at 
least one type of (especially EV-associated) HPV in nearly all patients.444
First reports on HPV-DNA in renal transplant recipients came from Pfister (1979), 
445 and Lutzner (19 80),446 who discovered HPV-3, respectively HPV-5 in carcinomas of 
renal transplant recipients. Since then a large number of studies has been performed in 
premalignant and malignant skin disorders in both immunosuppressed and immuno­
competent patients, revealing discrepancies in the prevalence and spectrum of HPV types 
in these lesions, basically due to different techniques used to detect HPV DNA in the 
skin. The largest study performed so far with the most comprehensive technique com­
prising 148 samples of both immunosuppressed and immunocompetent patients demon­
strated no significant differences between the prevalence and spectrum of squamous cell 
carcinoma, basal cell carcinoma, and premalignant skin diseases in both groups. How­
ever, significant differences were seen as to the prevalence of HPV-DNA in these lesions
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between both groups; in immunosuppressed patients this prevalence varies between 75 
and 88.2%, whereas in immunocompetent patients much lower prevalences were found, 
ranging from 27.2 to 54A447
However, the presence of EV-associated HPV-DNA is not exclusive for (pre)-malig- 
nant lesions and normal skin in renal transplant recipients. In the hyperproliferative 
disease psoriasis EV-associated HPV-DNA is also frequently found and percentages up to 
89.4% have been reported.448
Furthermore, in contrast to the well-known carcinogenic potencies of UV-irradia- 
tion, up to now no relationship between HPV status and p53 mutation could be esta- 
blished.449
In conclusion, despite the high number of HPV-DNA found in (pre)malignant 
lesions in renal transplant recipients, it remains to be established whether HPV plays a 
primary role in the evolution of non-melanoma skin cancer, or that it is an epipheno- 
menon.
1.12.4 Epidermal disorders
Common warts and plane waits
Viral skin lesions in transplant patients consist essentially of common and plane 
warts. Their prevalence increases with the duration of immunosuppression. One year 
after transplantation the occurrence of warts is seen in 15-42% of the patients.450;451 
Already after 5 years this percentage is increased to 85%.452 Viral lesions are particularly 
localized in uncovered areas, such as the back of the hands and forearms and the face. 
Clinical features are rather similar to those found in non-immunocompromized patients, 
however, in RTR especially on severely sun-damaged skin warts may be difficult to 
distinguish from other keratotic lesions, including actinic keratoses and even SCCs. 
Warts in RTR are generally multiple and recurrent. HPV-1 and HPV-2 are the viruses 
particularly related with common warts. Transformation of warts into malignant neo­
plasms has been described.337 Apart from common and plane warts, several other wart­
like lesions can be seen in renal transplant recipients, such as skin tags (soft warts) and 
seborrhoeic keratoses (seborrhoeic warts). These lesions, however, have not been asso­
ciated with malignant transformation in this group of patients, but sometimes may 
resemble actinic keratoses or non-melanoma skin cancer.
Actinic keratoses
The frequency of actinic keratoses in renal transplant recipients is much increased 
as compared to the general population. Four to 5 years after transplantation incidences 
of 24-38% have been reported,453;454 but no data on incidences with longer follow-up 
periods are available unfortunately. However, with time this percentage seems to in­
crease dramatically and it is likely that eventually (nearly) all renal transplant patients 
will develop actinic keratoses.
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Actinic keratoses in immunosuppressed individuals behave different in several 
aspects. Their clinical aspect is often less typical and a broad scala of skin lesions 
characterized by adherent scaling and erythema may be seen in this population. Wide­
spread and multiple actinic keratoses in sunlight-exposed areas are the rule instead of 
solitary lesions. Histologically, confluent parakeratosis, hyperkeratosis, increased mitotic 
activity, bacterial colonization, and verrucous changes are moreoften seen.455 In renal 
transplant recipients actinic keratoses tend to recur and behave more aggressive. They 
rapidly evolve into SCC and higher numbers of metastatic spread are reported in this 
group.337 Therefore, effective treatments, both for treatment of actinic keratoses and for 
prevention of squamous cell carcinomas, are urgently needed in these patients. In Chap­
ter 3 several topical and systemic approaches with retinoids will be investigated in actinic 
keratoses, to obtain further information on this category of potential chemopreventive 
treatments, especially in renal transplant recipients.
Figure 15:
Several common warts located 
on a finger.
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Porokeratosis
This is a typical dermatological condition in which an erythematosquamous macula 
slowly expands superficially due to clonal expansion of abnormal epidermal cells. Clini­
cally, these lesions resemble actinic keratosis or Bowen’s disease, but have a raised kera- 
totic edge. They are frequently found on the legs. Histologically, a distinct pattern is seen 
whose hallmark is a cornoid lamella. Porokeratosis may transform into squamous cell 
carcinoma in approximately 7% of the cases. In RTR a high incidence of about 10 % is
seen.456;457
Morbus Bowen
Bowen’s disease or Bowenoid actinic keratoses may already be hard to differentiate 
from actinic keratosis in the normal population, but in RTR this is even more difficult. 
In RTR all kinds of warty and hyperkeratotic benign, premalignant and malignant le­
sions may coexist, making a proper diagnosis sometimes impossible. Data on the inci­
dence of Bowen’s disease in renal transplant recipients is limited. A study in 115 renal 
transplant patients mentions that 2.6% of these subjects had at least one Bowen’s disease 
in an average follow-up period of 12.5 years post transplantation.458 Another study 
reports a much higher percentage (36%) of Bowen’s disease in 580 renal transplant 
recipients who were inspected when they were referred for various dermatological con- 
ditions.435
Figure 16:
A typical keratoacanthoma showing a 
central keratin-filled crater. Although this 
is a benign entity in immunocompetent 
patients, in immunosuppressed patients it 
may strongly resemble or transform into a 
squamous cell carcinoma.
72
R X R -  A N D  R A R - S  E L E  C T I V E R E T I N O I D S  I N  P S O R I A S I S  A N D  ( P R E ) M  A L I G N  A N  T S K I N  D I S O R D E R S
Squamous cell carcinoma
The incidence of cutaneous carcinomas in RTR is related to the duration of immu­
nosuppressive treatment. Several studies have reported on the incidence of non-mela­
noma skin cancer. In the Netherlands 40% of the patients developed non-melanoma skin 
cancer 20 years after transplantation,459 but values up to 70% after 20 years have been 
reported.460 Skin cancers in transplant recipients are found predominantly in sunlight 
exposed areas, as is the case in non-immunocompromized patients. They occur at a much 
younger population than is seen at the non-inmmunocompromized group. The average 
difference is about 30 years.461;462 In the normal population basal cell carcinomas out­
number squamous cell carcinomas by 5-10 to 1. Interestingly, in RTR this ratio is revers­
ed and squamous cell carcinomas outnumber basal cell carcinomas by 1.8 to 1. The inci­
dence of SCC in RTR is estimated to be 40 to 250 times higher than in the normal 
population. Squamous cell carcinomas in RTR behave more aggressive.337 In the majority 
of patients who have a squamous cell carcinoma multiple tumors will develop. Node 
metastases are more frequent than in the general population, ranging between 5.7 and 
7% in the different studies.429;463
Keratoacanthoma
In the normal population keratoacanthoma is a benign tumor with a rapid growth 
pattern that usually presents on sun-exposed skin. It features a typical central keratin- 
filled crater. Keratoacanthoma is normally self-limiting and regresses spontaneously. 
However, in RTR differential diagnosis with SCC is often difficult, both on clinical and 
on histological grounds. Transformation of a keratoacanthoma into a SCC may be pos­
sible, but is hard to prove. The incidence of keratoacanthomas is highly increased com­
pared to the normal population. Euvrard et al reported in a total number of 580 renal 
transplant recipients, who were referred for dermatological investigation, a percentage of 
15.7% keratoacanthomas.
Basal cell carcinoma
As mentioned earlier, in contrast to the normal population, in renal transplant re­
cipients basal cell carcinoma is not the most common skin malignancy. Its incidence is 
about 10 times higher in RTR compared to non-immunosuppressed individuals. The risk 
of basal cell carcinoma increases in a linear fashion with time, whereas the risk of squa­
mous cell carcinoma increases exponentially.464 With respect to the clinical course of 
basal cell carcinoma in this group of patients only limited information is available.
Kaposi sarcoma
At present there are 4 different clinical subtypes of kaposi sarcoma. One of them is 
the subtype that is associated with non-HIV-induced immunosuppression, which is seen 
in the population of renal transplant recipients. This form of kaposi sarcoma is 400-500 
times more frequent in graft patients than in control groups.465 Its incidence varies from
0.4 to 0.5% in Western countries to 4.1% in Saudi Arabia. The difference in incidence 
is related to the geographical distribution of the major etiological factor of kaposi sarcoma
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in transplant patients: kaposi sarcoma-associated herpesvirus (KSHV) or HHV-8. HHV- 
8-DNA is present in nearly all kaposi sarcoma tissues in grafted patients.466;467 The role 
of HHV-8 in kaposi sarcoma has initially been distinguished by Moore et al.468 Kaposi 
sarcoma appears relatively early after initiation of the immunosuppression with nearly 
half of the tumors developing already in the first year.469;470 Most transplant patients who 
present with kaposi sarcoma are infected with the virus before transplantation,471 how­
ever, a smaller number is infected by an infected allograft or transfusions.472 The prog­
nosis depends largely on the extent of the lesions and the degree of immunosuppression. 
On reduction or cessation of these agents a partial or complete regression is usually seen.
Malignant melanoma
Malignant melanoma is seen more frequently in renal transplant recipients. A 4 to 
5 times higher incidence has been mentioned.337
Merkel-cell carcinoma
Merkel-cell carcinoma is a rare tumor originating from the neuroendocrien Merkel 
cells in the skin. In transplant patients this tumor is also frequently seen and is charac­
terized by rapid progression, locoregional recurrences and a high nodal and visceral 
metastatic power.
Last but not least, one should not forget other side effects of immunosuppressive 
agents to the skin that may have a serious impact on the quality of life, such as an atro­
phic friable skin, poor wound healing, skin dryness, hirsutism, acne, hypertrichosis, and 
opportunistic bacterial and fungal infections.
1.12.5 Treatment
Renal transplant recipients often have multiple skin lesions in all sorts that are 
located preferentially on sunlight-exposed areas. In this population lesions may even 
develop as coexisting lesions, leading to disorders with mixed histological structures; for 
example a basal cell carcinoma originating in an actinic keratosis, or a squamous cell 
carcinoma that arises from a common benign wart. Skin lesions in RTR are sometimes 
difficult to distinguish from each other both clinically and histologically. Therefore, the 
different and sometimes difficult presentation of skin disorders in RTR in combination 
with the fact that (pre)malignant skin disorders in this group of patients generally behave 
more aggressive, implicates a different and more intensive follow-up in this group of 
patients.
In clinically atypical verrucous or hyperkeratotic lesions a biopsy may be necessary 
to exclude an underlying squamous cell carcinoma. Keratoacanthoma, although normally 
a benign type of lesion, may behave like a squamous cell carcinoma with metastatic 
spread in RTR. Therefore, these lesions must be met with suspicion and surgery is often 
indicated.
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Figure 17:
A superficial spreading basal cell 
carcinoma showing erythema, 
desquamation and the typical shiny 
aspect.
Furthermore, patients need to be thoroughly instructed to prevent their skin from 
UV-damage and to urgently visit the outpatient department in case a rapidly growing 
lesion arises on the skin.
In general the therapeutic approaches for benign and (pre)malignant skin disorders 
in RTR are the same as in the normal population. However, with respect to immuno- 
stimulating agents, such as immiquimod, caution should be paid as these agents in theory 
may lead to rejection of the kidney graft. Studies with these agents in immunocompro- 
mized patients are carried out at the moment to assess the effect and risk of graft rejec­
tion. Furthermore, the atrophic skin that is seen in many renal transplant recipients may 
be a limitation for several treatments with respect to side effects.
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1.13
Research targets
In order to diagnose actinic keratoses and Bowen’s disease and to differentiate these 
conditions from squamous cell carcinoma, the clinical features and histopathological 
assessment will allow adequate differentiation. In immunocompromized patients the 
number of non-melanoma skin cancers and of their premalignant conditions can be 
enormous and the progression to invasive malignancies relatively fast. The occurrence of 
multiple non-melanoma (pre)canceroses is a major problem that may affect these pa­
tients for many years. But also in immunocompetent individuals, which have been 
exposed extensively to ultraviolet radiation, the number of these lesions can be high and 
may influence their quality of life for long periods of time.
Treatment approaches that limit the total number of premalignant conditions and/ 
or their malignant behavior, reducing the number of biopsies to be taken in one individ­
ual are of major importance. Therapeutic approaches, which are well-accepted, well 
tolerated and applicable during long-term use, are indicated. In this respect it is attractive 
to hypothesize that systemic and topical retinoids might serve for this purpose and may 
provide major opportunities. In Chapter 3 the impact of retinoids on reduction in num­
ber and/or alteration in behavior of premalignant conditions will be discussed.
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PART III
RETINOIDS
The molecule structure of etretinate and 
its principal metabolite acitretin.
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1.14
History
Around 1900 the biological significance of the liposolubile vitamin A was dis­
covered. By that time little information was known on its effects and biological functions 
on proliferation, differentiation, and inflammation. So therapeutic applications were not 
available. It took until the 1930s when phrynoderma, a characteristic hyperkeratotic dis­
order with excessive follicular keratinization, was discovered as a result of vitamin A de- 
ficiency.194
Since that time vitamin A has been used therapeutically for hyperkeratotic disorders 
such as psoriasis. Oral application of vitamin A, however, often led to the hypervitami- 
nosis A syndrome, especially when high doses were used for longer periods. Therefore, 
topical application of vitamin A acid was tried since 1962 for hyperkeratotic disorders, 
but so far only low efficacy was reported in combination with a high toxicity profile.473
In 1968 Bollag et al started to chemically alter the vitamin A molecule in order to 
achieve more effective vitamin A analogues with a lower side-effects profile. With the 
development of synthetic retinoids a new treatment era started for hyperkeratotic con­
ditions in dermatology.474
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1.15
Generations
Since the chemical alteration of vitamin A (retinol) began, 3 generations of retinoids 
have been developed so far that are of importance for dermatological treatment both for 
topical and systemic application. The clinical application of retinoids was possible after 
modifications of the structure to minimize vitamin A toxicity.
The first generation is the group of non-aromatic retinoids. The best-known mono­
aromatic retinoids are all-trans retinoic acid (ATRA, tretinoin) and 13-cis retinoic acid 
(isotretinoin, Roaccutane®). ATRA is used topically for disorders such as ichthyosis 
vulgaris, and has been prescribed since the last couple of decades in the treatment for 
photodamaged skin and for premalignant hyperkeratotic disorders, such as actinic kera­
toses. However, it has a similar side-effect profile compared to vitamin A. Isotretinoin 
was synthesized thereafter. This retinoid is very effective in the treatment of severe acne 
after oral application and it has been used for other diseases like severe pustular psoriasis. 
It is also used for prevention of skin cancer.194
The second generation is the group of mono-aromatic retinoids. Retinoids such as 
etretinate and acitretin belong to this generation. Both retinoids significantly improve 
oral retinoid treatment for a broad scala of skin conditions, including psoriasis, Darier’s 
disease, ichthyosis vulgaris and pityriasis rubra pilaris. Beneficial effects of etretinate and 
acitretin have been demonstrated in (pre)malignant skin disorders as well.405-408 Etreti­
nate, however, has a long elimination half-life (80-120 days), which can be a problem in 
women of childbearing potential with respect to its teratogenicity. Acitretin, the principal 
metabolite of etretinate, was developed later on. Although acitretin has an elimination 
half-life of only 2 days due to lower lipid binding properties, it can re-esterificate into 
etretinate, especially in patients with substantial alcohol-intake, and therefore long-term 
storage in the subcutaneous adipose tissue account for detectable plasma levels for at 
least 2 years. Nevertheless, acitretin is the drug of first choice for systemic retinoid treat­
ment of most retinoid sensitive skin disorders nowadays.194
The third generation is the group of polyaromatic retinoids or arotinoids. The search 
for more effective, non-teratogenic retinoids with a shorter elimination half-life and a 
favorable side-effect profile continued. So far all these retinoids are teratogenic and have 
similar lipophylic properties as etretinate, leading to long elimination half-life periods. A 
few polyaromatic retinoids are used in the topical treatment of acne (adapalene, Differ- 
in®) and psoriasis (tazarotene, Zorac®) nowadays.475;476 Bexarotene (Targretin®) is a 
polyaromatic retinoid that has recently been developed for oral application in the treat­
ment of cutaneous T-cell lymphoma (CTCL or mycosis fungoides).477 This retinoid is the 
first RXR-selective retinoid (see the next paragraph) that has become available for 
human use and will be discussed in Chapters 2 and 4 of this thesis for its potential role 
in psoriasis and in UV-mediated inflammation.
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1.16
Retinoid signaling
Retinoids belong to a superfamily of ligand depending transcription factors that 
includes receptors for steroid hormones, thyroid hormones, vitamin A, and vitamin D, 
and peroxisome proliferator-activated receptors. Most members of this receptor family 
are nuclear in both the absence and presence of the ligand, but some are found in the 
cytoplasm.478
Unlike membrane-receptor second messenger systems, in this pathway the retinoid 
receptor itself becomes the signal to the nucleus, where it interacts with hormone re­
sponse elements (HREs) in a target gene and thereby it elicits a transcriptional response. 
HREs function as transcription enhancers and can be found both upstream and down­
stream of the transcription start sites of various genes.479
Once a retinoid has passed the cellular membrane it is free to interact with intra­
cellular proteins: the Cytoplasmatic Retinoid Binding Proteins (CRBPs). These proteins 
bind to retinoids and are likely to function as specific transport proteins for retinoids to 
the nucleus and by steeping up the intracellular concentration gradient of retinoids. 
CRABP I and II are cellular retinoic acid binding proteins. These molecules do not seem 
to regulate transcription themselves.479
The retinoid acid family as part of the superfamily of ligand depending transcription 
factors, comprises two different types of subfamilies: the Retinoic-Acid-Receptors (RAR) 
and the Retinoid-X-Receptors (RXR). Each subfamily contains 3 different receptor sub­
types: a , P, and y. The first retinoid receptor, RARa, has been recognized in 1987, follow­
ed by RARP and RARy. In 1990 the 3 RXR receptors were found. All retinoid receptor 
genes are located on different chromosomes. RARa, RARP, and RARy are mapped on 
chromosomes 17, 3, and 12, respectively, whereas RXRa, RXRP, and RXRy are located 
on chromosomes 9, 6, and 1 respectively.480-484
Two retinoid signaling pathways
Figure 18:
ATRA and bexarotene have different 
binding properties with respect to binding 
of the retinoid receptors.
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Figure 19:
An example of retinoid signaling: bexaro- 
tene penetrates the cellular membrane 
and enters the nucleus, where it can bind 
to an RXR. The bexarotene-RXR complex 
then binds to an HRE of a specific target 
gene and thereby it elicits a 
transcriptional response. As shown, the 
RXR can form heterodimers with other 
nuclear receptors (NR).
Each retinoid receptor exists of 6 functional domains designated A to F. The most 
important domains are domain E and domain C. Domain E is the Ligand Binding Do­
main (LBD), the locus were the retinoid binds to its receptor, and domain C is the DNA 
Binding Domain (DBD), or the place where the retinoid receptor can bind to the DNA 
of the target genes (the HREs).479
There is a difference in the capacity of the retinoids in stimulating or suppressing 
the receptor subtypes. So there is receptor specificity. For example, ATRA especially 
binds to the RAR receptor subtypes and only in high concentrations it can bind to the 
RXR receptors. The new retinoid bexarotene, on the other hand, especially binds to the 
RXR receptors and only in high concentrations it may bind to the RAR receptors. But 
other retinoids, such as 9-cis retinoic acid bind rather equally to both RAR and RXR 
receptor subtypes. Interestingly, acitretin does not bind to but activates specifically the 
RAR receptors by an unknown mechanism.478;479
The RXR receptor seems to be unique to other nuclear receptors, as it can make, 
besides the homodimer with itself, also heterodimers by binding to other receptors like 
the RAR, vitamin D receptor (VDR), and the thyroid receptor (TR). Therefore, in con­
trast to the RAR receptor, it can act as a master regulator of hormonal signaling. How­
ever, vitamin D and thyroid effects do not seem to be RXR dependent, but RXR-selective 
retinoids may influence these effects. The formation of heterodimers is dependent on the 
concentration of RXR and is influenced by both the concentration of 9-cis retinoic acid 
(as this is the major RXR activator) and by the concentration of RAR (mainly retinoic 
acid). These heterodimers can be activated by either of the two receptor ligands alone or 
with both ligands simultaneously, yielding in three discrete levels of activation.479
Retinoids like retinoic acid can enter the cell directly from the circulation or can be 
synthesized from retinol and retinal in the target cells. They can be converted intra-
Receptors
Ligand 
Z  Bexarotene (Targretin®)
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Figure 20:
E ffec ts  o f re tino ids . (A dapted from  G o lln ick  and D u m m le r194)
cellularly into other types of retinoids. For example, 9-cis retinoic acid can be converted 
into ATRA. By the mechanism of conversion the cell may favor specific pathways and 
so might have control in the different retinoid induced effects.479
The concentration of RAR and RXR receptors in human tissue differs. RARa and 
RXRP are found in almost all human tissues, but the other receptors are much more re­
stricted to specific tissues. In the skin the total amount of RXR is 5 times higher than the 
total amount of RAR. RXRa is the predominant RXR subtype. With respect to the RAR 
receptors the RARy receptor is the predominant one. Therefore, the RXRa-RARy is pos­
tulated to be the main regulating protein complex of retinoid sensible targetgene expres­
sion in human skin.485;486
Nuclear receptors bind to specific DNA sequences known as hormone response 
elements (HREs), but the retinoid receptors differ in affinity for binding these HREs. In 
other words, there is target-gene specificity. There are two types of HREs for retinoid 
receptors: RAREs and RXREs. Each of the two has several subtypes and these subtypes, 
subsequently, require different amounts of retinoid receptors for eliciting a similar re­
sponse in strength. Furthermore, these HREs can have stimulatory effects as well as inhi­
bitory effects on the transcription of the target genes. The RXREs are predominantly 
found in the promotors of genes involved in vitamin A, lipid and fatty-acid metabolism, 
and therefore, RXR-selective retinoids may have an important function in regulating 
lipid and cholesterol metabolism.479
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1.17
Cellular effects
Retinoids have a broad spectrum of effects, but most of them still need to be elucidat­
ed. A figure derived from Dummler and Gollnick depicts the most important effects of 
retinoids in a nutshell (Figure 20).194 Here, I will briefly mention some retinoid effects 
that are important for (hyperkeratotic) skin and that are relevant for the studies describ­
ed in this thesis. Data are derived from RAR-selective retinoids, as these are the retinoids 
that are commonly used in dermatology nowadays.
Retinoids do have regulatory effects on epidermal keratinization, proliferation, and 
inflammation.478 In psoriasis retinoids have a keratolytic effect. They decrease the cohe­
siveness of the stratum corneum with enhanced fragility of the skin and increased epi­
dermal water loss.487 Therefore, in combination with other topical treatments retinoids 
may enhance their permeability. The keratolytic effect is probably caused by a reduction 
in size and number of desmosomes, especially in the stratum corneum and in the stratum 
spinosum. However, many other factors have been postulated to play a role, such as 
widening of the intercellular spaces in the stratum spinosum and stratum corneum asso­
ciated with deposition of amorphous material. The latter may be a result of rupture and 
leakage of cells containing the material or might be secondary to serum infiltration into 
the epidermis.478
Retinoids modulate the expression of the cornified envelope protein transglutami­
nase. They stimulate transglutaminase expression in vivo in normal skin.488 In hyper- 
keratotic psoriatic skin, however, retinoids and agents that increase retinoid concentra­
tions reduce transglutaminase activity.489;490
With respect to keratinization, retinoids influence expression of cytokeratins. Reti­
noids alter terminal differentiation towards a non-keratinizing mucosa-like epithelium. 
491 They induce expression of retinoids that are normally not present in adult human 
skin, but that are only seen in embryonic skin and in other adult human tissues, such as 
the esophagus. Examples of these keratins are keratin 13 and 19 that are induced by reti­
noids in vitro.491;492 In vivo in normal skin induction of keratin 13 expression by reti­
noids has been demonstrated by Rosenthal et al.364 Concerning other keratins, in vitro 
data have shown that retinoids suppress the expression of keratin 3, 5, 10, 14, and 16. 
With respect to keratin 6 both a reduction as well an increase due to retinoid treatment 
have been suggested.493 In psoriasis and other hyperkeratotic disorders hyperproli­
feration-associated keratin 6 and 16 are abundantly present, while keratin 10 is less ex­
pressed. Retinoids inhibit the expression of keratin 6 and 16 in psoriasis,490;494 and in 
contrast to in vitro data, keratin 10 expression tends to normalize.495
Epidermal proliferation is influenced by retinoids. In normal skin retinoids promote 
proliferation, but in psoriatic skin they may act towards normalization of the hyper­
proliferative state by reducing the number of cycling cells.496;497 In lesional psoriatic skin 
the large body of evidence is that RARy mediated signaling is already upregulated.
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CRABP II, a protein which is upregulated by RARy activation clearly shows such. In 
contrast RXRy signaling has been shown to be reduced in lesional psoriatic skin. In view 
of these features it is attractive to speculate that psoriatic skin is more responsive to RXR 
stimulation and less to RARy stimulation.
Retinoids have both immunostimulating and immune-inhibiting effects on humoral 
and cellular immunity. They can inhibit the migration of neutrophils from the dermal 
capillaries to the epidermis,498 decrease inflammation-associated proteins and T-lympho- 
cyte subsets,497 and increase the number of Langerhans cells in psoriasis, although these 
effects may be secondary to the clearing of the lesions, as this is a normal feature in heal­
ing psoriatic skin. The increase in the number of Langerhans cells in psoriasis due to 
retinoids is paradoxically, as other effective anti-psoriasis therapies, such as UVB and 
topical corticosteroids decrease the number of these cells. Retinoids can also inhibit the 
antigen presenting properties of epidermal cells and of dendritic cells. Retinoids can 
enhance antibody production and can increase peripheral blood T helper cells, but not 
natural killer cells.478 It has been demonstrated in chicken that antigen-specific responses 
may be directly influenced by ATRA via modulation of RARa expression.478
Retinoids have also been reported to have inhibitory effects in skin cancer. The 
mechanism for this modulation is not known, but may be two-fold: retinoids control cell 
growth and differentiation, and they also induce apoptosis. Especially when multiple le­
sions are present, such as in renal transplant recipients, retinoids may be a good alter­
native. In this group of patients many studies have been performed with topical and 
systemic retinoids for the treatment of actinic keratoses and non-melanoma skin cancer. 
410 However, only one placebo-controlled study by Bouwes-Bavinck et al has been con­
ducted so far in this group of patients.410 In general, these studies reported beneficial ef­
fects of retinoids with respect to the number and aspect of the premalignant lesions and 
beneficial effects in the prevention of carcinomas. However, immunostimulating effects 
of retinoids, in theory, could lead to an increased risk of transplant rejection. Until now, 
no signs of an increased rejection incidence have been found in over 60 treated patients. 
4i°;499 In patients with basal cell naevus syndrome, xeroderma pigmentosum, and psoria­
tic patients overtreated with PUVA, retinoids have been reported to decrease the occurr­
ence of new carcinomas. In keratoacanthomas beneficial results of oral retinoid treat­
ment have also been reported.500;501 However, so far, no controlled studies are available 
to substantiate these impressions based on case reports.
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1.18
Pharmacokinetics, metabolism and interactions
The absorption of the different retinoids after oral intake is varying. For acitretin, 
the most used retinoid in dermatology, this is about 60%, but can be increased if com­
bined with a meal rich in fat.502 Absorption is followed by rapid isomerization of acitretin 
to 13-cis isoacitretin.478 The biological effects of isoacitretin are unknown, as rapid re­
isomerization to acitretin occurs. Acitretin and isoacitretin are metabolized in the liver 
via hydroxylation of the aromatic ring and via cytochrome-P450 dependent oxidation of 
the side chain to biologically inactive metabolites. Clearance of these metabolites occurs 
via the kidneys and the liver.503 A small quantity of acitretin is converted into etretinate, 
especially under influence of alcohol. The teratogenic etretinate is stacked in lipoid 
tissue.
Acitretin and 13-cis isoacitretin are almost completely bound to albumin; binding to 
retinol binding protein does not occur. Steady state concentrations are reached after 7-10 
days. After three months of treatment, terminal half-life is 50-60 hours,503;504 and no 
trans- and 13-cis acitretin is detected anymore after 1 month.505
In patients with systemic illnesses pharmacokinetics of retinoids can be different. In 
patients with renal insufficiency, which is often present in renal transplant recipients, a 
reduced renal clearance may be seen, as well as a low serum albumin.506 However, the 
clinical relevance of such has not been investigated thus far.
Interactions with retinoids and other drugs may occur. Renal transplant recipients 
usually take a large number of drugs apart from the inevitable immunosuppressive agents 
(cyclosporin, azathioprine, prednisone, etc) and therefore many interactions are possible. 
Cyclosporin is metabolized by the cytochrome P450-3A4 system. Retinoids also have an 
influence on the cytochrome P450 system. Webber has claimed that etretinate is meta­
bolized via a subtype of cytochrome P450 different from the system that metabolizes 
cyclosporin, and therefore the author suggested that an interaction at this point is un- 
likely.507 However, in vitro studies showed that etretinate as well as acitretin do decrease 
cytochrome P450 activity, and therefore lead to an increase in cyclosporin levels.508 Reti­
noids do not seem to influence metabolism of azathioprine and prednisone.509
When prescribing drugs with a high protein binding capacity (anticoagulants, anti­
biotics) in combination with oral retinoids, there is the possibility of competition be­
tween these drugs for the available binding sites, eventually leading to an increased free 
fraction of these drugs, thus leading to more side-effects. However, data are scarce and 
conflicting.503;506
Another possible interaction at the level of cytochrome P450 exists between reti­
noids and antiepileptic drugs: isotretinoin led to an increase in the dose needed of car- 
bamazepine, and Phenobarbital led to a decreased efficacy of isotretinoin. No data are 
available regarding possible interactions between acitretin and antiepileptic drugs.
Combination of retinoids and tetracycline is contra-indicated, as both may lead to a 
cerebral pseudotumor.503
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1.19
Side-effects
The most common side-effects of retinoids are summarized in Table IV. Incidences 
are related to the retinoid used, its dose, and the duration of treatment. Apart from 
presumed skeletal abnormalities, all adverse events are fully reversible on cessation.
Mucocutaneous side-effects are seen in nearly all patients and comprise dryness of 
mucous membranes (mouth, lips, nose, eyes, urethra, vagina), erythema, desquamation, 
thinning of normal skin and local or generalized loss of hair.194 Tolerability of these 
mucocutaneous adverse events largely depends on the dose. In the appropriated doses 
most mucocutaneous adverse events are generally well-tolerated, but for some patients 
lowering of the dose is necessary to prevent from cessation of the treatment.
Hyperlipidemia is a frequent complication of the use of retinoids. Particularly an 
elevation in triglycerides, but also an elevation in total cholesterol and a decrease in high- 
density lipoprotein cholesterol have been found. Patients with renal insufficiency or after 
renal transplantation frequently have hyperlipidemia, often aggravated by the use of 
immunosuppressive drugs. The additional development of retinoid-induced hyperlipi- 
demia could be very deleterious, as cardiovascular morbidity already is very high in these 
patients.510
Shortly after starting retinoids, a rise in alkaline phosphatase, bilirubin and trans­
aminases has been found in some patients. These effects usually disappear on continued 
use of retinoids. Hepatitis has been described rarely.511
Hemeralopia (diminished vision in bright light) or a decrease in night vision may 
occur, probably due to interference with 11-cis retinaldehyde formation. Cataract has also 
been described occasionally.478
Arthralgia and myalgia may occur in 2 to 5% of individuals receiving oral retinoids 
>0.5 mg/kg/day, especially in adolescents and young adults.478
Pseudotumor cerebri has been documented in patients receiving high doses of 
isotretinoin, particular in combination with tetracyclines.512 However, in recommended 
dosages of acitretin no pseudotumor cerebri has been reported, but papilledema should 
be considered in patients with pre-existing intra-ocular hypertension or glaucoma.
In patients on long-term treatment with high doses of retinoids, notably isotretinoin 
and etretinate, several effects on the skeleton have been described: osteoporosis,513 dif­
fuse ideopathic skeletal hyperostosis (DISH),514 and degenerative changes mainly occurr­
ing in the lumbar spine. In patients treated with etretinate and acitretin these changes 
have been reported. However, no dose-response relationship could be shown and there­
fore these hyperostoses have been interpreted as idiosyncrasy. No data are available 
regarding the possible effects of retinoids on the skeleton of patients with renal insuf­
ficiency or after renal transplantation. The latter group has several additional risk factors 
for skeletal problems, like the use of corticosteroids, persistent hyperparathyroidism, and 
vitamin D deficiency. However, in the few available studies on the use of retinoids in
86
R X R -  A N D  R A R - S  E L E  C T I V E R E T I N O I D S  I N  P S O R I A S I S  A N D  ( P R E ) M  A L I G N  A N  T S K I N  D I S O R D E R S
Table IV:
M ost com m on s ide -e ffec ts  o f re tino ids.
M ucocu taneous C he ilitis , dryness o f eyes, nasal and oral m ucosa (1 0 0 % ) 
Ep is tax is  (1 0 % )
Xerosis, p ru ritu s  (1 0 0 % )
B rittle  na ils  (2 0 % )
H air loss (2 0 -5 0 % )
Feeling o f b u rn in g  o r s ticky  skin  (2 0 % )
M usculoske le ta l S p ina l- and extrasp ina l hyperostoses, o ss ifica tion  of 
ligam en ts  (sp ine ), degenera tive  spondylosis, osteoporosis
Liver E levation o f liver enzym es (2 0 % ), 
severe liver dam age (< 1 % )
L ip id  m etabo lism Increase in serum  trig lyce ride s  and cho leste ro l; 
decrease o f H D L-cholestero l
Tera togen ic ity C ranofac ia l, th y m ic , ca rd iac, ske le ta l, and centra l 
nervous system  m a lfo rm a tio n s
O ther Fatigue, headache, nausea
these patients, no negative effects of retinoids on the skeleton have been described.407;410
Teratogenicity is a limiting factor for women of childbaring potential. Due to the 
strong teratogenic effect of retinoids and the slow release from the lipid tissue, retinoids 
should be stopped at least two years before an unadverted pregnancy and retinoids are 
strictly prohibited during pregnancy and nursing.504;506;510;515;516 Severe liver dysfunc­
tion, severe hyperlipidemia, and excessive alcohol intake are other contra-indications for 
acitretin therapy.194
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1.20
Research targets
Innovations in retinoid treatment of psoriasis are to be expected from RXR-selective 
ligands, as RXR signaling is deficient in psoriasis.250 Therefore, the clinical and cellular 
responses of psoriasis to the RXR-selective retinoid bexarotene will be evaluated in the 
present thesis.
In view of circumstantial evidence that treatment with systemic and topical RAR- 
selective agents results in RAR transactivation and might be effective in non-melanoma 
(pre)canceroses in immunocompetent and immunosuppressed patients, studies were 
designed to evaluate the role of RAR-selective retinoids in these conditions.
Available information on photosensitizing properties of retinoids is not conclusive. 
Therefore, a series of studies was carried out to further clarify this issue.
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1.21
Aim of the thesis
This thesis focuses on the role of retinoids in the treatment of hyperkeratotic skin 
disorders. Although retinoids have been used for several decades in psoriasis, current 
retinoid treatment for this disease is via oral and topical retinoids that favor the retinoic 
acid receptor (RAR) pathway, such as acitretin, tretinoin and tazarotene. Up to now it is 
unknown to what extent retinoid X receptors (RXR) may play a role in psoriasis and 
whether RXR-selective retinoids, or rexinoids, may provide a new therapeutic approach.
Retinoids like acitretin and tretinoin have been claimed to ameliorate actinic 
keratoses, the most frequently observed premalignant skin disorder. Furthermore, these 
compounds are used for chemoprevention of non-melanoma skin cancer, in the normal 
population as well as in immunosuppressed patients, due to their postulated anti-carcino­
genic effects. Their clinical effects are well-described, but there are few studies on their 
immunohistochemical effects in these patients.
Retinoids are frequently used in combination with UV-irradiation therapy to obtain 
an enhanced therapeutic effect in combination with a reduction in the cumulative UVB 
or UVA dose necessary to achieve clearance of the disease. Furthermore, it is supposed 
that retinoids alter the reaction to UV-light and that patients who are treated with topical 
or systemic retinoids may need to take precautions with respect to sunlight exposure. 
Effects of a single irradiation with UVB-light, in a dose which is enough to produce a 
distinct erythema on retinoid pretreated skin, have not been studied so far.
In order to achieve further information on these issues, the following aims were 
formulated:
I. To investigate efficacy and side-effects of oral application of the RXR-selective 
retinoid bexarotene in the treatment of plaque-type psoriasis, with respect to 
clinical and immunohistochemical features. (Chapter 2)
II. To analyze mechanisms of action of topical and systemic retinoid treatment 
with RAR-selective retinoids in (pre)malignant skin disorders, in the normal 
population and in immunosuppressed renal transplant recipients, regarding 
clinical and immunohistochemical parameters. (Chapter 3)
III. To elucidate the modulation of the effect of a single exposure of broadspectrum 
UVB-light on the skin by RAR-selective retinoids and RXR-selective retinoids. 
(Chapter 4)
In order to study these items, the following approaches were used as explained in the 
next paragraphs.
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1.22
Clinical observations
1.22.1 Psoriasis
Clinical scoring of the psoriatic lesions was performed by the previously documented 
and standardized Physicians Global Assessment (PGA) and the Plaque Elevation (PEL), 
and by a modified Psoriasis Area and Severity Index (mPASI).
Modified PASI score (mPASI)
To determine the mPASI score, the percentage (0-100%) of body surface area that is 
involved with psoriasis for each of 4 regions of the body (head, trunk, upper limbs and 
lower limbs) was evaluated. The percentage of involvement was assigned as an integer 
value by the following scoring method: 0 = 0%, 1 = 1-10%, 2 = 11-30%, 3= 31-50%, 
4 = 51-70%, 5 = 71-90%, and 6 = 91-100%. The lesions in each of these body regions 
were evaluated for erythema, induration, desquamation and pustulation on a 4-point 
scale as follows: 0 = none, 1 = slight, 2 = moderate, 3 = severe. The regions of the body 
correspond approximately to the following percentages of total body surface area, which 
is used to adjust the sum of severity scores from each region: head = 10 %, trunk = 
30%, upper limbs = 20% and lower limbs = 40%. The following formula was used for 
calculating the modified PASI score for each of the 4 body areas: integer of involvement 
(1-6) X percentage of total body surface area X (sum of erythema, induration, desquama­
tion and pustulation scores). The sum of these 4 values of each body area was the final 
mPASI score, which could range from 0 to 72.
Physicians Global Assessment (PGA)
A physicians global assessment score (PGA), that evaluated the improvement or 
worsening of the psoriatic plaques as a percentage related to the condition at baseline, 
was used on a 7-point scale: 0 = completely cleared (100% improvement), 1 = almost 
cleared (>90 to <100% improvement), 2 = marked response (>75 to <90% improve­
ment), 3 = moderate response (>50% tot <75% improvement), 4 = slight response 
(>25 to <50% improvement), 5 = condition stable (<25%  change), 6 = condition 
worsened.
Plaque elevation (PEL)
The overall plaque elevation was scored using a 9-point scale: 0 = no plaque elevation 
(0 mm), 1 = minimal elevation (> 0  to <0.5 mm), 2 = mild elevation (>0.5 to <1 mm),
3 = mild elevation (>1 to <1.5 mm), 4 = moderate elevation (>1.5 to <2 mm), 5 = 
moderate to marked elevation (>2 to <2.5 mm), 6 = severe elevation (>2.5 to <3) mm, 
7 = very marked elevation (>3 to <3.5 mm), 8 = very severe elevation (>3.5 mm).
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Furthermore, the Psoriasis Disability Index questionnaire was used to get an im­
pression of the psoriatic condition as observed by the patients themselves. Patients had 
to fill in this questionnaire at specific time points.
1.22.2 Actinic keratoses
In contrast to psoriasis, for actinic keratoses no standardized scoring methods are 
available. Therefore, we had to develop our own methods inspired by scoring methods 
used in other studies. In the retinoid-treated areas the number of actinic keratoses was 
counted at specific time-points. Hereby, the total body surface area was divided into 
several parts based on natural anatomic borders. Actinic keratoses, especially in renal 
transplant recipients, are sometimes difficult to demarcate, as spectra with verrucae and 
other types of lesions can be seen, as well as erythematous actinically damaged skin 
without the well known scaling patterns of actinic keratoses. Therefore, only the typical 
erythematous, scaling and often hypertrophic lesions were counted.
Erythema, desquamation, and induration of the actinic keratoses in each body 
surface area was assessed by the following 5-point semi-quantitative score: (0 = none, 1 
= slight, 2 = moderate, 3 = moderate-severe, 4 = severe). With respect to adverse event 
monitoring special attention was paid to mucocutaneous side effects (e.g. cheilitis, con­
junctivitis, peeling, hair loss, nail deformations, sweaty and sticky hands). These adverse 
events were graded as ‘absent’, ‘mild’, ‘moderate’ or ‘severe’. Pruritus was scored by a 5- 
point semi-quantitative method as follows: (0 = none, 1 = slight, 2 = moderate, 3 = 
moderate-severe, 4 = severe).
To evaluate subjective findings of the patients with respect to “redness of the skin”, 
“thickness of the lesions”, “scaling of the lesions” and “general contentment with the 
skin” (including mucocutaneous side effects), visual analogue scores (VAS) were per­
formed on a 10-point scale.
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1.23
Immunohistochemistry
1.23.1 Parameters
To assess epidermal proliferation, the monoclonal antibody MIB-1 against the Ki67 
antigen was chosen for identification of the number of epidermal cells in the G1, S, G2, 
and M-phases of the cell cycle.
For determination of epidermal differentiation (keratinization) the following set of 
antibodies was used: DE-K10 was chosen for assessment of keratin 10 expression, a 
parameter for normal differentiation of the keratinocytes. The monoclonal antibody 
LL025 is directed at keratin 16, a parameter for hyperproliferation-associated differen­
tiation, and was used in all actinic keratoses. Ks8.12 was used for detection of keratin 16 
in the psoriatic tissues. The monoclonal antibodies 1C7 and 2D7 for keratin 13 expres­
sion, respectively, and RCK108 for keratin 19 expression, were chosen to determine 
retinoid-associated keratinization. The monoclonal antibody BT621, directed to trans­
glutaminase, was used as parameter for terminal differentiation and assessment of the 
cornified envelope formation.
Dermal and epidermal T-cell mediated inflammation in psoriasis was scored by 
mononuclear antibodies against CD4 and CD8 positive T-lymphocytes, respectively 1F6 
and 4B11. Furthermore, a global inflammation score was used on hematoxylineosin 
stained sections for assessment of the overall dermal infiltrate. The same global scoring 
method was used in the studies with actinic keratoses.
The monoclonal antibody DO-7 for p53 protein detection was chosen to provide 
information on programmed cell-death or apoptosis in the actinic keratoses and psoriatic 
skin. The cyclindependent kinase inhibitor p16INK4, was additionally chosen to assess 
differences in cell-cycle inhibition in actinic keratoses.
1.23.2 Biopsies and staining procedures
For assessment of immunohistochemical parameters using paraffin embedded tissue, 
punch biopsies of 3, 4 or 6 mm were taken in the different studies under local anesthesia 
with xylocain/1% adrenalin. For psoriasis, the center of a representative erythematous 
and scaly plaque was chosen, preferably on the lower back or the upper legs. After treat­
ment biopsies were taken from the same psoriatic lesion.
In actinic keratoses biopsies were taken from the center of identical lesions that were 
identified at the baseline, preferably on the lower arms. For determining the actinic 
keratoses that fulfilled our purpose for biopsy, the lesions had to have a distinct erythe­
matous zone and evident desquamation or hyperkeratosis, but no signs of verrucous 
origin or clinical features seen in other lesions that may coexist in sunlight exposed skin, 
especially in renal transplant recipients.
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All biopsies were fixed in formalin for 4 hours and then after ethanol washing steps 
embedded in paraffin cubes. From these paraffin cubes slices of 6|am thickness were cut 
with a microtome and they were placed on slides that were coated with 3-aminopropyl- 
triethoxysilane (Sigma Chemicals, St. Louis, USA). Sections were dewaxed in Histosafe, 
dipped in graded ethanol series, and rehydrated in demineralized water.
To unmask the epitopes that the antibodies are able to recognize, the following 
procedures were carried out:
• MIB-1, LL025, P16INK4A, 1C7, 2D7, 1F6, 4B11, and DO-7 staining required a high 
temperature microwave antigen retrieval technique. In brief: the slides were placed in 
10mM citrate buffer (pH = 6.0) in a microwave oven (760 W) and heated to boil. 
Subsequently sections were heated twice at 480 W for 5 minutes (boiling was pre­
vented) and slowly cooled down to room temperature (20°C).
• For DE-K10 staining a 15-minute incubation period at 37°C with trypsin 0.1% was 
necessary.
• For Ks8.12 staining a 45-minute incubation period in 10mM citrate buffer (pH = 6.0) 
was needed.
• BT621 staining required a 7-minute incubation period with 0.02% protease.
• RCK108 staining required a 7-minute incubation period with 0.1% pronase.
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An indirect immunoperoxidase staining technique was used for all antibodies. Slides 
were incubated with 20% normal horse serum (Vector laboratories, Burlingame, USA) 
for 15 minutes, with subsequent incubation with the primary antibody (diluted in 1% 
bovine serum albumin (Organon Technika, Boxtel, the Netherlands)/PBS) for 1 hour. In 
the cessation study of acitretin (paragraph 3.3) and in the study in warts and Bowen's 
disease (paragraph 3.6) overnight incubation at 4°C of the primary antibodies was done, 
instead of this one-hour incubation period. Sections were washed in PBS for 15 minutes. 
Secondary horse anti-mouse biotinylated IgG antibody (ABC kit-mouse, Vector Labora­
tories) (dilution 1:200 in 1% BSA/PBS) was added for 30 minutes, and again a 15 
minutes wash in PBS was performed. Sections were treated with avidin-biotin complex 
antibody (ABC kit-mouse, Vector Laboratories)/(avidin/biotin diluted 1:50 in 1% BSA/ 
PBS) for 30 minutes. Slides were washed in PBS for 15 minutes. To visualize staining for 
MIB-1, DE-K10, 1C7, RCK108, and Ks8.12 3-amino-9-ethylcarbazole (AEC; Calbiochem- 
Novabiochem Corporation, San Diego, USA) was used. Counterstaining occurred with 
Mayer’s haematoxylin (Sigma Chemicals, St. Louis, USA). Finally, sections were mount­
ed in glycerol gelatin (Sigma Diagnostics, St. Louis, USA). Staining for the other markers 
was visualized with diaminobenzoyl (Pierce, Rockford, USA). These slides were mount­
ed in permount (Fisher Chemicals, Fair Lawn, USA).
The staining procedures described in paragraphs 3.3 and 3.6 were slightly different 
from the above mentioned protocol, with a longer incubation time (24 hours) at a lower 
temperature (4°C), as these were performed in another department.
For global infiltrate scores a heamatoxylin-eosin staining was performed as follows. 
After dewaxing in Histosafe and dipping in graded ethanol series a haemaluin solution 
was added to the slides for 10 minutes, followed by a 10-minutes washing step in tap­
water. Then an eosin solution was added to the slides for 90 seconds. After washing steps 
in ethanol and Histosafe, the slides were mounted in permount.
1.23.3 Immunohistochemical and histological scoring methods
MIB-1 and DO-7 positive keratinocytes (nuclei) were counted per mm length of 
section in all studies, with the exception of the cessation study of acitretin (paragraph 
3.3), where scoring occurred by using the following 4-point semiquantitative scale:517 
0 = only basal layer positivity, 1 = positivity confined to basal 1/3 of epidermis, 2 = posi- 
tivity confined to basal 2/3 of epidermis or 3 = transepidermal positive staining. Trans­
glutaminase scores were assessed as the ratio of BT621 positive epidermal cell layers 
divided by the total number of epidermal cell layers. Transglutaminase scoring occurred 
both in the papillary and the interpapillary epidermis. Figure 21 represents an example 
of transglutaminase staining in an untreated psoriatic lesion.
For DE-K10, 1C7, RCK108, LL025, Ks8.12, 1F6 and 4B11 staining the following 
semi-quantitative scale was used: 0 = no staining, 1 = sporadic staining, 2 = minimal 
staining, 3 = moderate staining, 4 = moderate-pronounced staining, 5 = pronounced 
staining, 6 = whole epidermis stained. In the cessation study of acitretin (paragraph 3.3) 
and in the study in warts and Bowen's disease (paragraph 3.6), scoring of 1C7, 2D7, and
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Figure 23:
A consecutive slide from the former slide 
shows that CD8 positive T-cells are the 
minority in the (epi)dermal infiltrates.
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RCK108 occurred by a different semi-quantitative scoring system on a 3-point scale: 0 = 
negative staining, 1 = suprabasal single cell positivity, 2 = zebroid pattern.
Regarding CD4 and CD8 positive lymphocytes scoring occurred both for their global 
dermal and epidermal scores as well as for the subset of CD4, respectively CD8 positive T- 
cells in the dermal infiltrate areas. For the subset of CD4, respectively CD8 positive T-cells 
in the dermal infiltrate areas the following 6-point score was used: 0 = no staining, 1 = 
sporadic staining, 2 = 1-25% staining, 3 = 26-50% staining, 4 = 51-75% staining, 5 = 
76-99% staining, 6 = 100% staining. Figures 22 and 23 are examples of CD4, respec­
tively CD8 staining in consecutive slides of a biopsy from a representative psoriatic lesion.
Total dermal infiltrate scores were performed by using a semi-quantitative score on 
a 5-point scale: 0 = no infiltrate, 1 = minimal infiltrate, 2 = moderate infiltrate, 3 = 
moderate-pronounced infiltrate, 4 = pronounced infiltrate.
Keratinocytic epidermal neoplasia scores (KIN) were assessed according to 
Cockerell’s criteria based on clinical and histological observations.344 KIN grade I was 
defined as a flat, pink macula or patch on solar-damaged skin without roughness or 
hyperkeratosis and focal atypia of basal keratinocytes restricted to the lower one third of 
the epidermis. A KIN grade II actinic keratosis shows focal atypia of keratinocytes 
restricted to the lower two thirds of the epidermis in combination with the appearance 
of other typical hallmarks of actinic keratosis, such as alternating orthokeratosis and 
parakeratosis; clinically a pink to red papule or plaque with a rough, hyperkeratotic 
surface and variable induration is seen. KIN grade III is designated to actinic keratoses 
where diffuse atypical keratinocytic proliferation involves the full thickness of the epi­
dermis in combination with other typical clinical and histological features of actinic 
keratoses.
All immunohistochemical and histological scoring was performed under blinded 
conditions.
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1.24
Irradiation experiments
Irradiation tests were performed in order to assess the influence of retinoids on the 
minimal erythema dose and on the degree of erythema after irradiation with broad- 
spectrum UVB-light.
Patients were pretreated with a topical or systemic retinoid using a certain dose, 
application schedule and for a distinct period that is known to be sufficient for retinoid­
effects to be expressed. In paragraph 4.1 a color matched vehicle cream was used, con­
sisting all ingredients of the comparable cream, but lacking the active metabolite. In the 
bexarotene study (paragraph 4.2) no placebo-treatment was used, but instead, irradiation 
tests were also performed before starting with the intake of bexarotene capsules.
After a distinct pre-treatment period with the topical or systemic retinoid, patients 
were irradiated with a series of 6 (tretinoin study) or 9 (bexarotene study) ascending 
intensities of UVB-light adjusted for the skin-type of the patient. These different irradia­
tion intensities were performed on circular skin areas of 2.5 cm diameter each.
Irradiation occurred in a Waldman UV7001K cabin, using broad-spectrum UV21 
lamps with a spectrum ranging from 285-350 nm and a maximum intensity between 310­
315 nm. As sunlight-exposure may bias the study outcome, these tests were performed 
on the lower back of the subjects, thus using areas that are normally not exposed to high 
intensities of sunlight. For practical reasons, the 3 series of irradiation tests in the study 
with tretinoincream were performed on the vertrolateral upper parts of the upper legs. 
Irradiation always occurred on normal skin (tretinoin study) or uninvolved psoriatic 
skin (bexarotene study). Patients were instructed not to wash or scrub the test areas 
during the scoring period, they had to avoid sunlight exposure, and they were not allowed 
to use emollients or other kinds of topical treatments in the test areas.
Visual scoring occurred 24 hours (bexarotene study), or 24 and 48 hours (tretinoin 
study) after irradiation, as post-irradiation erythema is highly visible after 24 to 48 hours. 
The MED was determined by visual scoring and was defined as the lowest UVB-dose 
that caused a distinct erythema with sharp margins after irradiation. The intensity of the 
erythema for each irradiated area was measured by visual scoring using a 5-point scale: 
0 = no erythema, 1 = weak erythema, 2 = moderate erythema, 3 = dark erythema and
4 = very dark erythema. The total erythema score before and after treatment (bexaro- 
tene study) or in the parallel sessions (tretinoin study) was assessed as the sum-score of 
all individual circular areas in each irradiation series. Visual scoring occurred under 
standardized conditions of temperature and light. During this scoring period patients 
continued with the same retinoid application schedule to assure maximum potential of 
retinoid modulating effects on irradiation-induced inflammation.
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2.1
Clinical effects of oral bexarotene 
in plaque-type psoriasis
Abstract
Bexarotene, a novel and unique synthetic RXR-selective retinoid, is available 
as a treatment for cutaneous T-cell lymphoma. In psoriasis, a common retinoid 
sensitive disease, no data are available on bexarotene-treatment. In this phase II 
study in psoriasis we investigated the safety, tolerability, and effectiveness of 
bexarotene at doses from 0.5 to 3 mg/kg/day. Fifty patients with moderate to 
severe plaque-type psoriasis were treated with bexarotene in 4 sequential dose- 
defined panels of 12-13 patients at doses of 1, 2, 0.5, and 3 mg/kg/day for 12-24 
weeks. Patients were monitored for safety and clinical efficacy. No serious ad­
verse events related to drug occurred. Bexarotene was well tolerated in most 
patients. Most frequently observed adverse events related to bexarotene were 
hypertriglyceridaemia (56%) and decrease in free T4 serum levels (54%). Signifi­
cant improvement of psoriasis after bexarotene at all doses was confirmed by a 
modified psoriasis area and severity index (mPASI), plaque elevation (PEL), and 
physician’s global assessment (PGA). Overall response rates (>50% improvement) 
for mPASI, PEL, and PGA, were 22%, 52%, and 36% respectively. No significant 
dose-response effect was established for these parameters. The present study indi­
cates an anti-psoriatic effect of bexarotene. Further studies are necessary to assess 
the optimal dose and the potential for bexarotene as a new therapy for psoriasis.
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Introduction
Retinoids are frequently used for the treatment of psoriasis. Retinoid receptors 
belong to a superfamily of ligand-dependent nuclear receptors that includes hormone 
receptors for glucocorticoids, thyroid, androgens, estrogen, vitamin D and vitamin A 
among others. Ligand-receptor complexes of this superfamily are transcription factors 
that bind to the hormone response element of target genes and elicit a transcriptional 
response. For a detailed review on retinoid signal transduction and general biological 
aspects of retinoids, the reader is referred to an article by Joseph L. Napoli.1
There are 2 subfamilies of retinoid receptors in the superfamily: the retinoid acid 
receptors (RAR) and the retinoid X receptors (RXR). Each of these subfamilies has three 
subtypes, designated RARa, RARp, RARy, and RXRa, RXRp and RXRy. These 
receptors function as dimers and receptor subtypes may control both overlapping and 
unique target genes.
Each retinoid may bind and activate retinoid receptor subtypes differentially; there 
is receptor-ligand specificity. All-trans retinoic acid preferentially binds to the RAR sub­
types and in vivo does not significantly bind to the RXR subtypes. 9-cis-Retinoic acid is 
a natural panagonist that binds with equal affinity to both RAR and RXR receptor 
subtypes, but so far RXR-selective ligands are synthetic.
Interestingly, the RXR receptors are unique compared to other nuclear receptors, as 
they function as heterodimers with other nuclear receptors (e.g., RAR, VDR, TR). 
Furthermore, there are different patterns of expression of retinoid receptors in all tissues 
of the body. In the skin the total concentration of RXR is 5 times higher than the total 
concentration of RAR. Of these RXR receptors RXRa is most abundantly present. As 
RARy is also abundantly expressed in the epidermis, the RXRa-RARy heterodimer is 
postulated to be one of the predominant regulating receptor complexes of retinoid 
sensitive target-gene expression in normal human skin. Furthermore, the heterodimer of 
the RXR receptor and the vitamin D3 receptor, RXR-VDR, is of major importance in 
RXR signaling in human skin.
Recently, a novel synthetic retinoid, bexarotene (Targretin®), has been developed for 
the treatment of cutaneous T-cell lymphoma (CTCL).2 Bexarotene selectively binds to 
the RXRa, RXRp and RXRy subtypes.3 This RXR-selective retinoid or “rexinoid” might 
also provide a new approach in the treatment of psoriasis. Animal studies demonstrated 
that bexarotene has antiproliferative effects in a number of tumors of breast, hematopo­
ietic and squamous cell origin.4-7 It can also induce apoptosis (programmed cell death) in 
specific tumor cell types.8 Bexarotene causes thinning of the stratum corneum and in the 
rhino mouse, possesses antikeratinizing activity when topically applied. Bexarotene has 
been shown to inhibit T-cell accumulation in cutaneous T-cell lymphoma which is also 
an important feature of psoriasis.2"9
The unique receptor binding profile of bexarotene and the great relevance of RXR 
to human skin suggested the present dose ranging clinical study. In particular, we 
investigated the safety profile and tolerability of bexarotene in patients with moderate to 
severe plaque psoriasis and we addressed the question whether bexarotene can improve 
chronic plaque-type psoriasis, as measured by mPASI, PEL and a PGA.
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Materials and Methods
Study design
The study was a phase II multicenter, open-label, dose-ranging study to investigate 
the safety and tolerability, and the clinical effect of systemic bexarotene in patients with 
moderate to severe plaque psoriasis.
Patients were enrolled at 4 study centers: the Department of Dermatology of the 
University Medical Center Nijmegen (The Netherlands), the Department of Dermato­
logy of the University Hospital Antwerp (Belgium), the Department of Dermatology of 
the University Hospital Brussels (Belgium), and the Department of Dermatology of the 
University Hospital Ghent (Belgium). Ethics Committee approval prior to this trial was 
obtained at these 4 study-centers and all patients gave written informed consent prior to 
study enrollment.
Patients were entered in this study in four sequential dose-defined treatment panels 
in the following order: 1 mg/kg/day, 2 mg/kg/day, 0.5 mg/kg/day and 3 mg/kg/day (circa 
44, 88, 20 and 102 mg/m2/day). The 0.5 mg/kg/day panel was added to the other three 
panels by protocol amendment after the study had already started. Enrollment of this 
panel occurred after completion of the 1.0 and 2.0 mg/kg/day panels. This approach of 
enrollment in sequential dose panels was chosen to provide maximum safety for the 
patients. Each panel consisted of 12-13 patients. The treatment period was 12 weeks, 
with the possibility of treatment continuation for another 12 weeks for patients with at 
least 50% improvement of psoriasis.
For the 0.5 mg/kg/day panel 10 mg capsules of bexarotene were used and for the 1,
2 and 3 mg/kg/day panels 75 mg capsules of bexarotene were used. Patients took the 
capsules once daily at the evening meal.
Patient population
To be eligible for inclusion, patients needed to be 18 years or older with moderate to 
severe psoriasis involving at least 15% body surface area at the baseline visit, as well as 
an overall plaque elevation score of at least moderate (grade 4 on a 9-point scale). Patients 
could not have a history of pancreatitis or clinical risk factors for it. Organ system func­
tions assessed by blood screening parameters had to be within a protocol-defined range. 
All patients were required to have normal fasting triglycerides levels before enrollment 
in this study. The use of emollients and medicated psoriasis shampoos was to be dis­
continued for 24 hours before each study visit. All drugs that could significantly affect 
hepatic or renal excretion needed to be on a stable dose throughout the study period.
Exclusion criteria were: erythrodermic, pustular, guttate or inverse psoriasis; spon­
taneously improving or rapidly deteriorating plaque psoriasis; a history of any dermato- 
logical condition that would interfere with protocol evaluations; the use of systemic 
retinoids within 3 months prior to study entry or etretinate within 1 year prior to study 
entry; treatment with PUVA, UVB, methotrexate, cyclosporin, azathioprine, mycopheno-
119
R X R -  A N D  R A R - S E L E  C T I V E R E T I N O I D S  I N  P S O R I A S I S  A N D  ( P R E ) M A L I G N A N T  S K I N  D I S O R D E R S
late mofetil, systemic steroids, or fumarates within 4 weeks prior to study entry; the use 
of vitamin A supplements >15,000 IU or any topical anti-psoriatic therapy (except 
emollients or detergent shampoos) within 1 week prior to study entry; the use of other 
experimental therapies; the use of medicated or detergent shampoos or cleansers or 
emollients within 24 hours prior to study entry. Women who were of childbearing po­
tential, pregnant or actively breast-feeding were excluded from participation and male 
subjects had to use contraceptive devices. Patients had to avoid prolonged exposure to the 
sun or UV-light sufficient to produce mild erythema.
Safety and tolerability evaluation
At the pre-study visit the medical history was recorded, an ECG was taken, an 
ophthalmology examination was made and a physical examination including vital para­
meters (e.g. blood pressure, pulse, weight, temperature) was completed. Urinalysis and 
laboratory blood tests for biochemistry and hematology parameters were evaluated.
Patients began treatment with bexarotene within 14 days from the pre-study visit. 
Clinical evaluations occurred every 2 weeks until Week 12 of treatment. Vital functions 
were checked at every visit and changes in the physical examination from baseline were 
recorded. Adverse events reported by patients spontaneously or from inquiry were 
recorded.
Blood draws were performed every 2 weeks until Week 12 for biochemistry and 
hematology. If serum triglycerides levels were above the normal laboratory range, anti- 
lipidaemic treatment was started or increased. If serum triglycerides rose above 400 
mg/dL, blood draws were performed weekly until they were below 400 mg/dL for 2 
consecutive lab reports. If fasting triglycerides levels became higher than 800 mg/dL, 
then a reduction in dose with a possible suspension of treatment was required. Triglyce­
rides levels over 1200 mg/dL required discontinuation from the study medication.
Serial photography of 5 selected psoriatic lesions occurred every 4 weeks. Patient 
quality of life during treatment was assessed every 4 weeks using the Psoriasis Disability 
Index10 and the SF-36™ Health Survey.11-12
When patients continued with bexarotene therapy after Week 12, the visits and the 
blood draws were scheduled every 4 weeks until Week 24. A follow-up visit was per­
formed within 4 weeks after patients stopped bexarotene treatment, both for premature 
withdrawal and for completion of the study period.
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Clinical efficacy evaluation
Overall psoriasis plaque elevation (PEL) was scored using a 9-point scale in 0.5 mm 
steps: 0 = no plaque elevation (0 mm), to 8 = very severe elevation (>3.5 mm).13-14
A modified PASI score (mPASI) summing area of disease, erythema, induration, 
desquamation and pustulation on a 4-point scale (0-3) for 4 body regions was evaluated 
instead of the regular PASI score, in order to assess potential changes in pustulation. The 
mPASI score could range from 0 to 72.
A physician’s global assessment score (PGA) that evaluated the improvement or 
worsening of the psoriatic signs and area as a percentage relative to the condition at base­
line was evaluated on a 7-point scale: 0 = Clear (100% improvement); 1 = Almost Clear 
(> 90% improvement); 2 = Marked Response (> 75% to < 90% improvement); 3 = 
Moderate Response (> 50% to < 75% improvement); 4 = Slight Response (> 25% to 
<50% improvement); 5 = Stable (< 25% change); 6 = Worse (> 25% worse).13
Statistical analysis
Potential significant differences in baseline values of mPASI, PEL and PGA, were 
analyzed by Analysis of Variance (ANOVA). The differences in mPASI and PEL between 
baseline and bexarotene treatment were analyzed by a paired T-test. The onset and 
duration of response as defined above were analyzed by using the Kaplan-Meier method. 
Adverse event comparisons between the 4 dose panels were performed using a two-tail 
Fisher’s exact test. For significant differences in laboratory analytes a paired T-test was 
used. SF-36™ Health and Psoriasis Disability Index questionnaires were summarized 
using descriptive statistics and analyzed over time using paired T-tests. The data for each 
questionnaire were summed at each time period by patient. The data at each study time 
point were also examined by both assigned dose and by all patients who were treated.
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Results
Patient characteristics
Fifty patients were enrolled and treated with bexarotene capsules (panel 0.5 mg/kg/ 
day 13 patients; panel 1 mg/kg/day 12 patients; panel 2 mg/kg/day 12 patients and panel
3 mg/kg/day 13 patients). The patient population consisted of 44 males and 6 females; 
with a mean age of 42.9 years ± 13.0 (SD). All patients had prior topical or irradiation 
therapies and 28 (56%) of the patients had prior systemic therapies for their psoriasis, 
of which acitretin (38%) and methotrexate (18%) were most frequently used. Forty-two 
patients (panel 0.5 mg/kg/day 12 patients; panel 1 mg/kg/day 9 patients; panel 2 mg/kg/ 
day 10 patients and panel 3 mg/kg/day 11 patients) completed the 12-weeks treatment 
period. Eight patients were withdrawn from the study before the week 12 visit: 1 patient 
due to elevated ALT and AST levels, 3 patients due to hyperlipidaemia, 1 patient due to 
neck arthralgia, 1 patient for non-compliance, 1 patient for progressive disease, and the 
remaining 1 patient withdrew consent. Eighteen patients continued therapy after the 
week 12 visit; 13 of them completed the maximum treatment period of 24 weeks (2 pa­
tients in panel 0.5 mg/kg/day; 5 patients in panel 1 mg/kg/day; 4 patients in panel 2 
mg/kg/day and 2 patients in panel 3 mg/kg/day).
Table I:
C om m on adverse events a t least possib ly re la ted to  bexarotene tre a tm e n t w ith  an ind idence  >  3 %  fo r the  
d if fe re n t dose panels.
Adverse event 0 .5  m g/kg /day 1 m g/kg/day 2  m g/kg /day 3  m g/kg /day A ll pane ls
N =  13  N (% ) N =  12 N (% ) N =  12  N (% ) N =  13  N (% ) N =  5 0  N (% )
H ype rtrig lyce ridaem ia 5 (3 8 .5 ) 8  (6 6 .7 ) 7 (5 8 .3 ) 8  (6 1 .5 ) 2 8  (5 6 .0 )
S erum  free  T 4  decrease 2 (1 5 .4 ) N ot Done N ot Done 12 (9 2 .3 ) 1 4  (5 3 .8 )*
A sthen ia 1 (7 .7 ) 1 (8 .3 ) 0  (0 .0 ) 5 (3 8 .5 ) 7 (1 4 .0 )
P ru ritu s 1 (7 .7 ) 0  (0 .0 ) 2 (1 6 .7 ) 4  (3 0 .8 ) 7 (1 4 .0 )
C h e ilitis 0  (0 .0 ) 1 (8 .3 ) 2 (1 6 .7 ) 2 (1 5 .4 ) 5 (1 0 .0 )
In fe c tio n s 0  (0 .0 ) 1 (8 .3 ) 2 (1 6 .7 ) 0 (0 .0 ) 3  (6 .0 )
S erum  ALT increase 1 (7 .7 ) 1 (8 .3 ) 1 (8 .3 ) 0 (0 .0 ) 3  (6 .0 )
W orsening  o f psoriasis 1 (7 .7 ) 0  (0 .0 ) 0  (0 .0 ) 2 (1 5 .4 ) 3  (6 .0 )
Pain 1 (7 .7 ) 1 (8 .3 ) 1 (8 .3 ) 1 (7 .7 ) 3  (6 .0 )
S erum  AST increase 0  (0 .0 ) 1 (8 .3 ) 1 (8 .3 ) 0 (0 .0 ) 2 (4 .0 )
C o n ju n c tiv itis 1 (7 .7 ) 0  (0 .0 ) 1 (8 .3 ) 0 (0 .0 ) 2 (4 .0 )
H a ir d iso rde r 0  (0 .0 ) 0  (0 .0 ) 2 (1 6 .7 ) 0 (0 .0 ) 2 (4 .0 )
C h ills 1 (7 .7 ) 0  (0 .0 ) 0  (0 .0 ) 1 (7 .7 ) 2 (4 .0 )
V asod ila ta tion 1 (7 .7 ) 0  (0 .0 ) 1 (8 .3 ) 0 (0 .0 ) 2 (4 .0 )
* N = 26 subjects.
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Safety and tolerability evaluation
Bexarotene was well tolerated overall in most patients. Four patients were with­
drawn from the trial because of laboratory-related adverse events; hyperlipidaemia (3 
patients) and mild to moderately elevated ALT/AST levels (1 patient). Hyperlipidaemia 
was the most frequently observed related adverse event; 56% of the patients had lipid 
values (mainly triglycerides) above the upper limit of normal during bexarotene treat­
ment. In 4 patients in panels 1, 2, and 3 the increase in triglycerides rose to levels more 
than 800 mg/dL. One of these patients began atorvastatin therapy and completed 24 
weeks of study, but three other patients were discontinued because of elevated triglyce­
rides. A significant increase in patient serum triglycerides was found in each dose panel 
(p<0.01), however, no significant dose related increase could be observed between the 4 
panels. Serum free T4 and TSH values were only monitored in the last dose panels con­
ducted at 0.5 mg/kg/day and 3 mg/kg/day. In both panels a significant decrease in free 
T4 levels was found (p<0.001). Free T4 levels decreased to levels below normal in 2/13 
(15%) of patients in the 0.5 mg/kg/day dose group and 12/13 (92%) of patients in the
3 mg/kg/day dose group. No statistically significant differences were observed in TSH 
values. Adverse events that were observed during bexarotene treatment and that could 
possibly be related to bexarotene-induced hypothyroidism were asthenia (p = 0.049), a 
decrease in systolic blood pressure (p<0.001), and hair disorders. However, these symp­
toms did not require thyroid hormone supplements in any patient.
Typical retinoid-related adverse events like pruritus and cheilitis were found in only 
14%, and 10% of the patients, respectively (Table I) . Other adverse events with an inci­
dence >3% that were possibly related to bexarotene were asthenia (14%), infections 
(6%), increase in serum ALT values (6%), increased psoriasis (6%), pain (6%), increase 
in serum AST (4%), conjunctivitis (4%), hair disorder (4%), chills (4%), and vasodi­
latation (4%). Moderately elevated ALT/AST levels (2-3x upper limit of normal) asso­
ciated with withdrawal of 1 patient appeared to be a function of the patient’s prior condi­
tions. Changes in these enzyme levels in other patients were not reported as adverse 
events at higher doses or longer treatment durations. A statistically significant decrease 
in ALT values could be demonstrated in panel 2 mg/kg/day (p = 0.009) and panel 3 mg/
Table II:
m PASI, PEL, and PGA scores (m ean ±  SEM ) fo r  the  4  dose panels at th e  base line  v is it  and a t the  latest 
v is it on bexarotene tre a tm e n t (e n d p o in t) fo r all p a tie n ts  who fu lf i lle d  at least 6  w eeks tre a tm e n t (N = 4 3 ).
mPASI (0 -72 ) PEL (0 -8) PGA (0-6)
Baseline Endpoint p-value Baseline Endpoint p-value Baseline Endpoint p-value
0.5  mg/kg/day 8.6  ±  0.7 5.7 ±  0.8 0.003 4.2  ±  0.3 2.8 ±  0.5 0 .004 5.0 ±  0.0 3.8 ±  0.4 0.009
1 mg/kg/day 9.1 ±  0.7 5.8 ±  0.6 0.005 4.8  ±  0.3 3.3 ±  0.4 0.005 5.0 ±  0.0 3.8 ±  0.4 0.022
2 mg/kg/day 9.9 ±  1.1 7.1 ± 1 .2 0.027 4.7 ±  0.3 2.8 ±  0.4 0.001 5.0 ±  0.0 3.8 ±  0.6 0.119
3 mg/kg/day 8.2  ±  0.5 4.7 ±  0.5 < 0.001 4.0  ±  0.2 2.6 ±  0.3 < 0.001 5.0 ±  0.0 3.7 ±  0.3 0.001
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Figure 1:
Mean mPASI scores for the 4  different 
dose panels during 12 weeks bexarotene 
treatment (N = 42).
0.5 mg/kg/day
- 1 mg/kg/day 
2 mg/kg/day
- 3 mg/kg/day
2 4 6 8
Bexarotene treatment (weeks)
Figure 2:
Mean PEL scores for the 4  different dose 
panels during 12 weeks bexarotene 
treatment (N = 42).
0.5 mg/kg/day
- 1 mg/kg/day
- 2 mg/kg/day
- 3 mg/kg/day
4 8
Bexarotene treatment (weeks)
12
Figure 3:
Mean PGA scores for the 4  different dose 
panels during 12 weeks bexarotene 
treatment (N = 42).
0.5 mg/kg/day
- 1 mg/kg/day
- 2 mg/kg/day
- 3 mg/kg/day
Figure 4:
Response rates defined as > 50% 
improvement in mPASI, respectively PEL, 
respectively PGA, for the 4  different dose 
panels.
□  0.5 mg/kg/day
□ 1 mg/kg/day
□  2 mg/kg/day 
■ 3 mg/kg/day
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kg/day (p = 0.048) after bexarotene treatment. No significant differences in urinalysis 
and hematological parameters were seen in this study. Ophthalmologic examinations 
included 1 worsened cataract and new cataracts in both eyes in 1 patient that were not 
observed in the baseline examination.
Clinical efficacy parameters
There were no significant differences in mean scores for body surface area (BSA), 
mPASI, PEL and PGA among the 4 dose panels at baseline. The BSA at baseline was 
25.8% ± 13.2% (mean ± SD; N = 50). Figures 1, 2, and 3 demonstrate respectively the 
mean scores for mPASI, PEL, and PGA during 12 weeks treatment with bexarotene for 
the 4 different dose groups. According to a paired T-test, significant reductions in mean 
scores for mPASI (p<0.05) and PEL (p<0.01) were found for all dose panels between 
baseline and study drug endpoint, which is defined as the last evaluation on treatment 
for each patient. No pustulation of psoriatic lesions occurred during the study. With 
respect to PGA scores, significant differences (p<0.05) between baseline and endpoint 
were observed in all dose panels except for the 2 mg/kg/day dose group. (Table II). No 
significant dose-response effect could be established for the investigated parameters.
The criteria for response were a 50% or more decrease in mPASI or in PEL, or a 
50% or more improvement in psoriasis evaluated by PGA, at the week 12 visit. Responses 
needed to be confirmed over at least 2 consecutive assessments separated in time by at 
least 4 study weeks. Figure 4 shows the overall response rates for mPASI, PEL and PGA 
by dose group. No significant differences in response rates among the 4 dose panels could 
be demonstrated for mPASI, PEL or PGA. At baseline, no differences between the 
responding population and the non-responders were observed with respect to clinical 
parameters, including prior systemic treatments and severity of psoriasis (mPASI, PEL, 
BSA). Almost complete clearance of >90% according to PGA was observed in 4 patients 
(8%); the distribution was comparable in all dose panels. Figures 5 and 6 represent the 
same psoriatic plaque in one of the responders before and after 12 weeks treatment.
The onset of response by mPASI, PEL, and PGA for the 4 dose panels was seen after 
2 -  20 weeks of bexarotene treatment. The duration of response is the time from the 
onset of response (>50% improvement) to the time of relapse (<50% improvement) or 
to the end of the final study visit, in case the response was ongoing at that moment, for 
each efficacy endpoint (mPASI, PEL, or PGA). Duration of response varied from 8 -  16 
weeks.
Figure 7 represents the mean scores for mPASI, PEL, and PGA for all responders 
who completed bexarotene treatment until week 24 (N=13). These figures suggest no 
incremental benefit from bexarotene after the initial 12-week treatment period.
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Figure 6:
The same psoriatic plaque as depicted in 
figure 5 after 12 weeks treatment with 
bexarotene.
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Figure 7:
mPASI, PEL, and PGA scores (mean ± 
SEM) during the study from all 13 
responders who completed the maximum 
bexarotene treatment period of 24 weeks.
SF-36™ Health and Psoriasis Disability Index questionnaires
No statistically significant differences were observed in the SF-36™ General Health 
questionnaires. The mean QOL response scores did not improve or worsen substantially 
in any dose panel. The Psoriasis Disability Index demonstrated a significant improve­
ment in the 2 mg/kg/day panel after 24 weeks treatment (p = 0.027) and the 3 mg/kg/day 
panel after 12 weeks treatment (p = 0.002). However, the small number of patients, espe­
cially the remaining patients who continued bexarotene until week 24, may limit the sig­
nificance of this outcome. No significant differences were observed in the lower dose 
panels of 0.5 and 1 mg/kg/day.
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Discussion
Bexarotene was studied at various doses in 50 patients with moderate to severe 
plaque psoriasis. Overall, this RXR-selective ligand demonstrated a statistically signifi­
cant improvement of psoriasis (>50%) with mean response rates of 22% for mPASI, 
52% for PEL and 36% for PGA. No significant dose response relationship was demon­
strated at the doses studied. It’s intriguing that during the evaluation of the large dose 
finding study of acitretin in psoriasis no dose response relationship could be shown 
either.15 Studies performed in psoriasis with acitretin showed response rates (>50% im­
provement) for PASI scores up to 53.8%,15 so data obtained at doses in the present study 
suggest the RXR-selective retinoid bexarotene is not superior to the currently used RAR- 
selective retinoids. However, as increases in dose up to the occurrence of mild cheilitis is 
relevant to reach maximal clinical efficacy in individual patients, and as in this study 
cheilitis has been observed in only 10% of the patients, it is tempting to speculate that 
bexarotene has not yet expressed maximal clinical efficacy at a dose of 3 mg/kg/day. On 
the other hand it is possible that the dose of maximal efficacy for bexarotene does not 
coincide with cheilitis due to its unique RXR binding profile. The lack of a dose response 
relationship in the present study and during acitretin treatment suggests that the optimal 
therapeutic dose in individual patients might be highly variable.
Clinical experience suggests that a large variation occurs in the bioavailability of oral 
acitretin among patients and that the dose has to be individualized in order to reach 
optimal efficacy. It should be stressed that no placebo group was included in the present 
study design, which aimed to find the dose that is tolerated well in patients with mod­
erate to severe psoriasis.
Side effects such as a decrease in free T4 and hyperlipidaemia may restrict the use 
of higher doses of bexarotene in psoriatic patients. The decrease in free T4 levels that 
occurred at 3 mg/kg/day can lead to the clinical symptoms of hypothyroidism and may 
be related to heterodimer formation of the RXR with the thyroid receptor.16 Although a 
dose-related reduction in free T4 levels was observed in this study, the clinical symptoms 
of hypothyroidism were absent or mild at doses up to 3 mg/kg/day and did not require 
thyroid supplements. Hyperlipidaemia is a well-established limitation of systemic reti­
noid treatment.17-18 During acitretin treatment in a dose of 30-60 mg/day a 35% increase 
in serum triglycerides was observed.18 Indeed 56% of the patients treated with bexaro­
tene developed hyperlipidaemia as reported as an adverse event in the present study, but 
this effect was satisfactorily controlled with atorvastatin anti-lipaemic therapy in almost 
all patients.
In a study of bexarotene in CTCL in 48% (27 of 56) of the patients who received a 
dose of 300 mg/m2/day (approximately 6.8 mg/kg/day) a partial or complete response (> 
50% improvement) was found in PGA.2 In the present study in psoriasis, where lower 
doses of bexarotene were given, we found in 36% (18 of 50) of the patients a partial or 
complete response (> 50% improvement) with respect to PGA. Concerning the adverse 
events, in the CTCL study similar adverse events were seen as in the present study, al­
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though the frequency and severity was mostly higher in the CTCL study. The main ad­
verse event in both studies is hyperlipemia (CTCL study: 82%; psoriasis study: 56%).
The present study suggests an anti-psoriatic effect of bexarotene. Based on clinical 
data, doses higher than 3 mg/kg/day and lower than 0.5 mg/kg/day should be investi­
gated by using a placebo-controlled design that includes physician blinding with respect 
to laboratory findings in order to find the maximum effective dose of bexarotene. How­
ever, side effects, especially hypertriglyceridaemia and hypothyroidism, may be im­
portant factors requiring intervention. Bexarotene should also be evaluated in combina­
tion with other anti-psoriatic therapies.
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2.2
Immunohistochemical effects of oral 
bexarotene in plaque-type psoriasis
Abstract
Bexarotene, a novel synthetic RXR-selective retinoid, has been reported to 
have anti-proliferative and apoptotic stimulating effects in cutaneous T-cell 
lymphoma. In benign, hyperproliferative and retinoid sensitive disorders, such as 
psoriasis, bexarotene has not been evaluated so far and no information on these 
parameters is available. In the present study immunohistochemical parameters 
for proliferation, differentiation, inflammation, and apoptosis were investigated 
in a group of bexarotene-treated psoriatic patients. Twenty-nine patients with 
plaque-type psoriasis were treated for 12 weeks with oral bexarotene in four dose- 
defined treatment panels. Treatment was initiated in the following consecutive 
order: 1 mg/kg/day, 2 mg/kg/day, 0.5 mg/kg/day, and 3 mg/kg/day. Biopsies for 
immunohistochemical analysis were taken at baseline and after 12 weeks treat­
ment. Significant reductions in Ki-67, keratin 16, transglutaminase, dermal CD4, 
epidermal CD8 and inflammation scores were seen after bexarotene treatment, in 
combination with a significant increase in keratin 10 score. No induction of kera­
tin 13 and 19 and no alterations in apoptosis-associated p53 expression were 
observed. Apart from a weak significant dose-response effect for Ki-67, no other 
significant dose-response effects were seen. We have demonstrated efficacy of oral 
bexarotene in psoriasis in doses up to 3 mg/kg/day during 12 weeks treatment for 
proliferation, differentiation, and inflammation parameters. Studies investigating 
higher doses of bexarotene in a larger number of patients are necessary to reveal 
potentially dose-related immunohistochemical effects of this new rexinoid and to 
elucidate the role of RXR-signaling in retinoid-associated keratin expression.
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Introduction
Epidermal hyperproliferation, disturbed differentiation and cutaneous inflamma­
tion are the most important hallmarks of psoriasis. Retinoids have been demonstrated to 
modulate these processes and, therefore, they are frequently used in the treatment for 
this disease. Oral acitretin in a dose of 25 mg/day has been shown to reduce epidermal 
proliferation (Ki-67), hyperproliferation associated keratin 16, terminal differentiation 
(transglutaminase) and dermal inflammation.1 However, retinoids currently used, such 
as acitretin and isotretinoin, only activate the retinoic acid receptor (RAR) pathway, 
even though they do not bind the RARs directly.2 Agents that selectively bind to the 
retinoid X receptor subtypes or selectively activate this pathway, have not been investi­
gated in psoriasis so far. As each retinoid receptor subtype controls a series of over­
lapping as well as unique target genes, and as RXR is abundantly expressed in human 
skin,3 RXR-selective retinoids, like RAR-selective retinoids, may have beneficial effects 
in this retinoid sensitive disease.
Recently, a novel synthetic RXR-selective retinoid, bexarotene (Targretin®, 
LGD1069), has been developed for the treatment of cutaneous T-cell lymphoma (CTCL). 
4 Bexarotene has been shown to cause thinning of the stratum corneum. Furthermore, 
bexarotene inhibits the growth of tumor cell lines of breast, hematopoietic and squamous 
cell origin5-7 and induces apoptosis (programmed cell death) in a number of tumor cell 
lines.8 In the rhino mouse topical application of bexarotene demonstrated antikera- 
tinizing activity.
The present study was undertaken to analyze the impact of bexarotene on epidermal 
proliferation, keratinization, inflammation, and p53 protein expression in plaque-type 
psoriasis.
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Materials and Methods
Study design
The study was conducted as a satellite laboratory study of the phase II multicenter, 
open-label, dose-response study designed to investigate the safety and tolerability, and the 
clinical efficacy of oral bexarotene in patients with moderate to severe plaque-type pso­
riasis. In the present study the immunohistochemical effects of bexarotene with respect 
to proliferation, differentiation, inflammation, and p53 protein-expression in psoriasis 
were investigated. Ethics Committee approval for this trial was obtained and all patients 
gave written informed consent prior to study enrollment.
Patients were entered in this study in four sequential dose-defined treatment panels 
in the following consecutive order: 1 mg/kg/day, 2 mg/kg/day, 0.5 mg/kg/day, and 3 mg/ 
kg/day. The treatment period was 12 weeks. For the 0.5 mg/kg/day panel Targretin® cap­
sules of 10 mg were used; for the 1, 2 and 3 mg/kg/day panels Targretin® capsules of 75 
mg were used. Patients had to take the capsules daily at the evening meal.
Patient population
Only patients entered at the University Medical Center Nijmegen were included in 
the present study. To be eligible for inclusion, patients had to meet the criteria of the 
multicenter clinical study, including: age older than 18 years; moderate to severe psoria­
sis involving at least 15% body surface area at the baseline visit; an overall plaque eleva­
tion score of at least moderate (grade 4 on a 9-point scale); discontinuation of emollients 
and medicated psoriasis shampoos 24 hours before each study visit. In case of itching, 
patients were allowed to use an emollient (cremor lanette I) on the target lesion that had 
been chosen for biopsy purposes, but not in the 24 hours before each biopsy.
Protocol exclusion criteria were defined: erythrodermic, guttate or inverse psoriasis; 
spontaneously improving or rapidly deteriorating plaque psoriasis; a history of any der- 
matological condition that would interfere with protocol evaluations; the use of systemic 
retinoids within 3 months prior to study entry or etretinate within 1 year prior to study 
entry; treatment with PUVA, UVB, methotrexate, or cyclosporin within 4 weeks prior to 
study entry; the use of vitamin A supplements >15,000 IU or any topical anti-psoriatic 
therapy (except emollients or detergent shampoos) within 1 week prior to study entry; 
the use of medicated or detergent shampoos or cleansers or emollients within 24 hours 
prior to study entry. Patients had to avoid prolonged exposure to the sun or UV-light suf­
ficient to produce mild erythema.
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Table I:
A n tib od ies  used in the  study.
Antibody Specifity Marker for Concentration Source
MIB-1 Ki-67 Epidermal proliferation 1:50 Immunotech, Marseilles, France
DE-K1O Keratin iO Normal keratinization 1:100 Monosan, Uden, Netherlands
1C7 Keratin iS Retinoid-induced keratinization i : iO Monosan, Uden, Netherlands
Ks8.12 Keratin 13,15,16 Hyperproliferation 1:100 Sigma Chemicals, St. Louis, USA
RCK1O8 Keratin 19 Retinoid-induced keratinization i:5O Monosan, Uden, Netherlands
BT621 Transglutaminase Terminal differentation 1:10 Biomedical Technologies Inc., 
Stoughton, MA, USA
DO-7 p53 Apoptosis 1:200 DAKO, Glostrup, Denmark
1F6 CD4 T-helper lymphocytes 1:100 Novocastra laboratories Ltd, 
Newcastle Upon Tyne, UK
4B11 CD8 Cytotoxic T-lymphocytes i:iO O Novocastra laboratories Ltd, 
Newcastle Upon Tyne, UK
Biopsies and staining procedures
For assessment of immunohistochemical parameters punch biopsies of 3 mm were 
taken from the same, representative psoriatic lesion, under local anesthesia with xylo- 
caine/1% adrenaline: one biopsy at the baseline and one after 12 weeks of treatment 
with bexarotene. All biopsies were fixed in formalin for 4 hours and then embedded in 
paraffin cubes after ethanol dehydration. From these paraffin cubes slices of 6 mm thick­
ness were cut with a microtome and were placed on slides that were coated with 3- 
aminopropyl-triethoxysilane (Sigma Chemicals, St. Louis, USA). Sections were dewaxed 
in Histosafe, dipped in graded ethanol series, and rehydrated in demineralized water.
The following parameters were investigated: Ki-67 for proliferation, keratin 10 for 
keratinization, keratin 13 and keratin 19 for retinoid-induced keratinization, keratin 16 
for hyperproliferation-associated differentiation, transglutaminase for terminal differen­
tiation, p53 for apoptosis, CD4 and CD8 for inflammation and a hematoxylineosin stain­
ing for global infiltrate scores (Table I) .
To unmask the epitopes that the antibodies are able to recognize, the following 
pretreatments were necessary:
• MIB-1, 1C7, 1F6, 4B11 and DO-7 staining required a high temperature microwave 
antigen retrieval technique. In brief: the slides were placed in 10 mM citrate buffer 
(pH= 6.0) in a microwave oven (760 W) and heated to boil. Subsequently sections 
were heated twice at 480 W for 5 minutes (boiling was prevented) and slowly cooled 
down to room temperature (20°C).
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• For DE-K10 staining a 15-minute incubation period at 37°C with trypsin 0.1% was 
necessary.
• For Ks8.12 staining a 45-minute incubation period in 10 mM citrate buffer (pH = 6.0) 
was needed.
• RCK108 staining required a 7-minute incubation period with 0.1% pronase.
• BT621 staining required a 7-minute incubation period with 0.02% protease.
An indirect immunoperoxidase staining technique was used for all antibodies. Slides 
were incubated with 20% normal horse serum (Vector laboratories, Burlingame, USA) 
for 15 minutes, with subsequent incubation with the primary antibody (diluted in 1% 
bovine serum albumin (Organon Technika, Boxtel, the Netherlands)/PBS) for 1 hour. 
Sections were washed in PBS for 15 minutes. Secondary horse anti-mouse biotinylated 
IgG antibody (ABC kit-mouse, Vector Laboratories) (dilution 1:200 in 1% BSA/PBS) 
was added for 30 minutes, and again a 15 minutes wash in PBS was performed. Sections 
were treated with avidin-biotin complex antibody (ABC kit-mouse, Vector Labora- 
tories)/(avidin/biotin diluted 1:50 in 1% BSA/PBS) for 30 minutes. Slides were washed 
in PBS for 15 minutes. To visualize staining for MIB-1, DE-K10, 1C7, and Ks8.12, 
RCK108 3-amino-9-ethylcarbazole (AEC; Calbiochem-Novabiochem Corporation, San 
Diego, USA) was used. Counterstaining occurred with Mayer’s haematoxylin (Sigma 
Chemicals, St. Louis, USA). Finally, sections were mounted in glycerol gelatin (Sigma 
Diagnostics, St. Louis, USA). Staining for the other markers was visualized with dia- 
minobenzoyl (Pierce, Rockford, USA). These slides were mounted in permount (Fisher 
Chemical, Fair Lawn, USA).
For global infiltrate scores a hematoxylin-eosin staining was performed as follows. 
After dewaxing in Histosafe and dipping in graded ethanol series a hematoxylin solution 
was added to the slides for 10 minutes, followed by a 10-minute washing step in tap 
water. Then an eosin solution was added to the slides for 90 seconds. After washing steps 
in ethanol and Histosafe, the slides were mounted in permount.
Immunohistochemical scoring methods
MIB-1 and DO-7 positive keratinocytes (nuclei) were counted per mm length of 
tissue section. Transglutaminase scores were assessed as the ratio of BT621 positive 
epidermal cell layers divided by the total number of epidermal cell layers. Transglutami­
nase scoring occurred both in the papillary and the interpapillary epidermis. For DE- 
K10, 1C7, Ks8.12, RCK108, 1F6 and 4B11 staining the following semi-quantitative scale 
was used: 0 = no staining, 1 = sporadic staining, 2 = minimal staining, 3 = moderate 
staining, 4 = moderate-pronounced staining, 5 = pronounced staining, 6 = whole epi­
dermis stained. With respect to CD4 and CD8 positive lymphocytes, scoring occurred both 
for global dermal and epidermal scores as well as for the subset of CD4, respectively CD8
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positive T-cells in the dermal infiltrate areas. For the subset of CD4, respectively CD8 posi­
tive T-cells in the dermal infiltrate areas the following 6-point score was used: 0 = no 
staining, 1 = sporadic staining, 2 = 1-25% staining, 3 = 26-50% staining, 4 = 51-75% 
staining, 5 = 76-99% staining, 6 = 100% staining.
Finally, total dermal infiltrate scores were performed by using a rather similar semi­
quantitative score on a 5-point scale: 0 = no infiltrate, 1 = minimal infiltrate, 2 = mod­
erate infiltrate, 3 = moderate-pronounced infiltrate, 5 = pronounced infiltrate. All immu- 
nohistochemical scoring was performed blinded by one evaluator.
Statistical analysis
In order to substantiate potential dose-related differences and differences with 
respect to the immunohistochemical parameters between the baseline evaluation and the 
evaluation after 12 weeks treatment, a two way Analysis of Variance (ANOVA) test was 
used. In case this test revealed significance, a post hoc comparison using the Duncan 
multiple range test was performed.
Figure 1:
MIB-1 staining in a tissue sample of a 
psoriatic plaque from one of the 
responders at the baseline visit.
Figure 2:
MIB-1 staining in a tissue sample of the 
same psoriatic plaque as depicted in 
figure 1 after 12 weeks treatment with 
bexarotene. A significant decrease in the 
number of MIB-1 positive keratinocytes 
compared to the baseline is clearly seen.
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Results
In a total of 29 patients biopsies were taken before and after 12 weeks treatment 
with bexarotene. Patients received the following doses: 0.5 mg/kg/day, 8 patients; 1 mg/ 
kg/day, 5 patients; 2 mg/kg/day, 8 patients; 3 mg/kg/day, 8 patients.
Evaluation of the parameter Ki-67 (MIB-1) showed a decrease in the number of pro­
liferating keratinocytes in 24 patients. In 5 patients an increase was observed; 4 of these 
patients were from the 0.5 mg/kg/day panel and one from the 3 mg/kg/day panel. In 
Figures 1 and 2 examples of MIB-1 staining are shown in tissue samples of lesional skin 
from one of the responders before and after 12 weeks treatment with bexarotene. Figure 
3 shows the mean MIB-1 scores for the 4 different dose panels. Statistical analysis 
demonstrated a significant decrease in MIB-1 scores over all panels (p<0.001). A trend 
in dose-response was observed (p = 0.080). The 1.0, 2.0, and 3.0 dose panels demon­
strated a statistically significant (p<0.05) higher reduction in Ki-67 scores compared to 
the 0.5 mg/kg/day panel; no significant differences between the 1.0, 2.0, and 3.0 mg/ 
kg/day dose panels were seen (Figure 4).
Figure 3:
Ki-67 count (mean ±  SEM) for the 4  different dose panels before and after 12 weeks treatment with bexarotene.
Ki-67
j  ■ ¿me
— I — □  3 m£
□  0.5 mg/kg/day N=8
□ 1 mg/kg/day N=5 
2 mg/kg/day N=8
g/kg/day N=8
Week 0 Week 12
Figure 4:
Reductions in Ki-67 count (mean ±  SEM) after 12 weeks bexarotene treatment for the 4  dose panels as percentage from 
baseline. Significant (p<0.05) stronger MIB-1 reductions for the higher dose panels compared to the 0.5 mg/kg/day panel 
are marked with an asterisk.
□  0.5 mg/kg/day N=8
□  1 mg/kg/day N=5 
■  2 mg/kg/day N=8
□  3 mg/kg/day N=8
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Keratinization and inflammation parameters before and after 12 weeks treatment 
with bexarotene are depicted in Figure 5. Keratin 13 (1C7) and keratin 19 (RCK108), 
markers for RAR retinoid-induced keratinization, were absent in all slides both before 
and after 12 weeks treatment (data not shown in Figure 5). Eccrine ducts and sweat 
glands in the tissue sections and esophageal tissue served as positive controls for these 
markers. Comparing baseline values with values after bexarotene treatment for all dose 
panels combined, a significant increase in keratin 10 expression (DE-K10), a marker for 
normal keratinization, was found (p = 0.005), as well as a significant decrease in hyper­
proliferation-associated keratin 16 (Ks8.12) (p = 0.007). Ks8.12 could be used as a mark­
er for keratin 16, as keratin 13 was absent in all slides and as keratin 15 is only present 
in minor amounts in the basal layer of the epidermis. In Figures 6 and 7 examples of 
keratin 10 staining are shown in tissue samples of lesional skin from one of the re­
sponders before and after 12 weeks treatment with bexarotene.
Total dermal infiltrate scores showed a significant reduction after 12 weeks treat­
ment with bexarotene (p<0.001). Specification for CD4 and CD8 positive lymphocytes 
showed a significant reduction in dermal CD4 positive T-cells (p = 0.001). No significant 
differences in epidermal CD4 scores were seen. For CD8 positive T-cells a significant 
decrease was found in epidermal scores (p = 0.011), but no changes were seen in dermal 
CD8 scores. No significant shift in T-cell populations was found when looked at the 
subset of CD4, respectively CD8 positive T-cells, in the dermal infiltrate areas. No signifi­
cant dose-response relationships as to these inflammation parameters could be demon­
strated.
Figure 5:
Keratinization and inflammation parameters (mean ±  SEM) before and after 12 weeks treatment with bexarotene for all 
patients (N=29). Significant changes (p<0.05) are marked with an asterisk.
Keratinization and inflammation parameters
□  W e e k  0  
■  W e e k  12
K10 K16 TDI CD4e CD4d CD4% CD8e CD8d CD8%
K10 = keratin 10; K16 = keratin 16; TDI = total dermal infiltrate; CD4e =epidermal CD4+ T-cells; CD4d = dermal CD4+ T- 
cells; CD4% = subset of CD4+ T-cells: CD8e =epidermal CD8+ T-cells; CD8d = dermal CD8+ T-cells; CD8% = subset of 
CD8+ T-cells
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Figure 7:
Keratin 10 staining in a tissue sample of 
the same psoriatic plaque as depicted in 
figure 6 after 12 weeks treatment with 
bexarotene. A significant improvement in 
keratin 10 staining is clearly seen.
Figure B:
Transglutaminase scores (mean ±  SEM) 
before and after 12 weeks treatment with 
bexarotene for all patients (N=29). 
Significant changes (p<0.05) are marked 
with an asterisk.
□ Week 0 
■ Week 12
TGMpap = transglutaminase score in papillary areas of epidermis; TGMinterpap = transglutaminase score in the 
interpapillary areas of epidermis.
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Overexpression of terminal differentiation parameter transglutaminase (BT621) sig­
nificantly decreased in the large interpapillary areas (p = 0.012) after bexarotene treat­
ment (Figure 8 ) . However, no significant differences were found in the smaller papillary 
areas. No significant dose response effects were observed with respect to transglutami­
nase. P53 protein was abundantly present in the psoriasis lesions. However, p53 expres­
sion remained unchanged during 12 weeks treatment with bexarotene for all dose panels 
(Figure 9).
p53
Figure 9:
p53 protein expression (mean ±  SEM) 
before and after 12 weeks treatment with 
bexarotene for all patients (N=29).
□  W e e k  0 
■  W e e k  12
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Discussion
In a non-randomized study where patients are enrolled in dose panels in consecutive 
order, differences in baseline values may be seen between the dose groups with respect 
to clinical and immunohistochemical parameters. In general, patients with severe pso­
riatic symptoms who easily fulfilled the inclusion criteria (e.g., at least 15% body surface 
area involvement) are expected to be included in the first two dose panels, while the later 
two dose panels are expected to contain patients with milder symptoms who just fulfilled 
the inclusion criteria. Therefore, in this study we expected that patients enrolled in the 
first dose groups, respectively the 1.0 and 2.0 mg/kg/day panels, would have more severe 
values of clinical and immunohistochemical psoriatic parameters at the baseline than the 
0.5 and 3.0 mg/kg/day panels.
The present study clearly shows that differences in baseline values for several para­
meters are present between some of the 4 dose groups. These differences in baseline 
values are in accordance with our hypothesis, as the 1.0 and 2.0 dose group show more 
severe values for several parameters than the 0.5 and 3.0 mg/kg/day panels and as this 
pattern is analogous for most parameters, including Ki-67, keratin 10, keratin 16, dermal 
CD4, modified PASI score and plaque elevation score. (The latter two parameters are 
reported in the corresponding multicenter clinical article).
Nevertheless, markers for Ki-67, keratin 10, keratin 16, transglutaminase, dermal 
CD4 count, and total dermal infiltrate scores clearly demonstrate improvement of pso­
riasis after bexarotene treatment with respect to proliferation, differentiation and inflam­
mation. Except for a weakly significant dose response effect for MIB-1, in just 7-8 pa­
tients per dose panel, no other significant dose-response effects were found.
No significant differences were observed in p53 protein expression after bexarotene 
treatment in this group of patients. In some other studies bexarotene has been demon­
strated to induce apoptosis. However, these studies were performed in malignant condi­
tions.7"8 Therefore, in psoriasis, bexarotene may not be able to influence apoptosis-asso- 
ciated p53 protein expression, or the number of patients and/or the doses used in the 
present study may be too low to detect such an effect.
Interestingly, no keratin 13 and/or keratin 19 expression, markers for conventional 
retinoid keratinization,9,10 was observed after bexarotene treatment. It is known that 
RAR-selective retinoids can induce keratin 13 expression in doses sufficient for clinical 
and immunohistochemical improvement.11-13 In this study efficacy has been demon­
strated for several immunohistochemical parameters of proliferation, differentiation, and 
inflammation, as well as for clinical parameters, including a modified PASI score and the 
plaque elevation score. Typical retinoid associated adverse events, such as cheilitis and 
hyperlipidaemia, which were observed in some patients, strengthen the conclusion that 
bexarotene at the doses tested has activity in psoriasis. As bexarotene may elicit different 
transcriptional responses compared to RAR-selective retinoids, it is possible that RXR- 
selective retinoids, in contrast to RAR-selective retinoids, do not induce expression of 
retinoid-associated keratins. On the other hand it is possible they may do this only in 
higher doses via heterodimer formation with the RAR subtypes.
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When comparing immunohistochemical results on epidermal proliferation, epider­
mal differentiation, and dermal inflammation in psoriasis after 12 weeks oral bexarotene 
treatment (the present study) with 12 weeks acitretin treatment (Kuijpers e t a l1), the 
following reduction percentages (bexarotene versus acitretin) are seen. Ki-67 35% ver­
sus 60%; Keratin 16 16% versus 77%; transglutaminase interpapillary 21 % versus 29%; 
transglutaminase papillary 4% versus 36%; dermal infiltrate 18% (total dermal infil­
trate) versus 65% (elastase). As demonstrated, the RXR-selective retinoid bexarotene 
has similar qualitative effects as the RAR-pathway favoring retinoid acitretin, although 
these data suggest that for the treatment of psoriasis the investigated concentrations of 
bexarotene in the present study are less effective than acitretin in a dose of 25-50 mg/day. 
Since bexarotene at the doses tested does not bind to the RARs, the observed effects are 
likely to be RXR-related or may be the result of binding of bexarotene to the RXR-RAR 
heterodimer.
In conclusion, we have demonstrated efficacy of oral bexarotene in psoriasis in doses 
up to 3.0 mg/kg/day during 12 weeks treatment for proliferation, differentiation, and in­
flammation parameters. However, no placebo was used in the present study and efficacy 
of the tested doses of this new compound seemed to be less when compared to regular 
doses of acitretin. Apart from a trend in dose-response for MIB-1 expression, no signifi­
cant dose-response effects were found. Data obtained from clinical practice demonstrate 
a large interindividual variation in the bioavailability of oral retinoids, suggesting that the 
optimal dose in individual patients might be highly variable, and thus a dose-response 
effect may not be observed in this relatively small number of patients. Therefore, further 
investigation of these immunohistochemical parameters in a higher number of bexa- 
rotene-treated patients, by using a placebo-controlled approach that includes higher dose 
levels and serum level measurements, is indicated to reveal potential dose-response 
effects of bexarotene. Furthermore, pharmacogenetic studies focussing on identification 
of the responding population may be worthwhile. The role of RXR-signaling in retinoid 
associated keratin expression remains to be elucidated.
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3.1
Clinical effects of oral acitretin in the 
treatment of actinic keratoses in renal 
transplant recipients
Abstract
After renal transplantation, the incidence of (pre)malignant skin lesions is 
high. Treatment with acitretin improves the number and aspect of actinic kera­
toses and appears to reduce the incidence of squamous cell carcinomas, but treat­
ment is hampered by frequent side effects. No optimal long-term dosing advice is 
available. 26 long-term renal transplant recipients were randomized to 1 year 
treatment with acitretin, either 0.4 mg/kg/day throughout the whole year, or 0.4 
mg/kg/day during the first three months, followed by 0.2 mg/kg/day for the 
remaining 9 months. On 9 different time points, the number of actinic keratoses 
and tumors was counted, and erythema and thickness of the lesions and the 
severity of side effects were scored. Patient’s judgement was recorded using visual 
analog scores. In both groups, the number of actinic keratoses decreased by nearly 
50%, but the number of new malignant tumors during the study year was similar 
to the number of tumors in the year before the study. Thickness of the keratoses 
decreased significantly in both groups. Acitretin dose had to be reduced in most 
patients because of the frequent occurrence of (mainly mucocutaneous) side ef­
fects. Patients’ contentment about the aspect of their skin increased significantly, 
with no differences between groups. Acitretin therapy decreased the number of 
actinic keratoses in renal transplant recipients, also at a low maintenance dose of 
0.2 mg/kg/day, and significantly decreased the degree of thickness of the lesions. 
However, the incidence of new skin malignancies remained unchanged. Despite 
the high incidence of mucocutaneous side effects, patient’s contentment with the 
aspect of their skin increased significantly.
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Introduction
After successful renal transplantation, the incidence of premalignant and malignant 
skin lesions is high. Especially actinic keratoses, keratoacanthomas and squamous cell 
carcinomas (SCC) are very common.1 The most important risk factors for the develop­
ment of these lesions are the long-term use of immunosuppressive drugs, sun exposure, 
and infection with human papillomavirus.2,3 As no causal therapy is available, thera­
peutic options are limited to local excision, cryotherapy, topical chemotherapeutic agents, 
and radiotherapy. Usually many lesions are present in one patient, making it difficult to 
treat all these lesions at the same time. Therefore the risk of transition from a prema- 
lignant lesion to a malignant lesion is high. Recent studies have suggested that retinoids 
may be effective for the treatment of actinic keratoses and the prevention of squamous 
cell carcinomas (SCC) in renal transplant recipients.4"5"6 However, long-term use of 
retinoids is often hampered by side effects,7 whereas lesions recur rapidly after the treat­
ment is stopped.4 No data are available regarding the optimal long-term dosing advice.
We have performed a randomized study in renal transplant recipients with histo­
logically proven actinic keratoses to compare maintenance doses of 0.2 and 0.4 mg/kg/ 
day of acitretin respectively. Both treatment regimens were equally effective and decreas­
ed the number of actinic keratoses and improved patient well being. However, no effect 
on the development of SCCs was observed.
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Materials and Methods
Patients
Adult renal transplant recipients with a stable graft function, who were on a stable 
dose of immunosuppressive therapy, were included. Patients should have a history of at 
least one squamous cell carcinoma of the skin and multiple (>10) actinic keratoses, of 
which at least one was histologically proven. Excluded were patients with a nephrotic 
syndrome, with hypercholesterolaemia (>9  mmol/l), hypertriglyceridaemia (>10 mmol/l), 
or elevated transaminase levels (ALT and/or AST more than twice the upper limit of 
normal) and patients with pregnancy (-wish), with excessive alcohol intake and patients 
using anti-epileptic drugs. The washout period for systemic retinoids was 3 months. 
Topical retinoid treatment had to be discontinued at least 4 weeks prior to study enroll­
ment.
Study design
This study was conducted as an open label clinical study to investigate the effect of 
long-term treatment with two different doses of oral acitretin on the number and aspect 
of actinic keratoses and the incidence of new tumors in renal transplant recipients. 
Patients were randomized to treatment with acitretin 0.4 mg/kg/day during the first 3 
months, followed by either treatment with 0.2 mg/kg/day or treatment with 0.4 mg/kg/ 
day during the next 9 months.
Assessments
Clinical parameter assessment occurred at the following visits: baseline, week 2, 
month 1, month 2, month 3, month 4.5, month 6, month 9, and month 12. At these visits 
the number of all actinic keratoses was counted in separate body areas, laboratory 
parameters were monitored according to the protocol developed by Dutch dermato­
logists,8 and suspicious lesions were biopsied or, if necessary, surgically removed. At 
baseline and again at 12 months, a spinal X-ray was performed.
The clinical picture of actinic keratoses in renal transplant recipients is often 
difficult to demarcate, as spectra with verrucae vulgares and verrucae planae can be seen 
as well as erythematous actinically damaged skin. Therefore, only the typical erythema­
tous, scaling and often thickened lesions were counted.
Furthermore, erythema and thickness of actinic keratoses in each body surface area 
was assessed. For these parameters we used a semi-quantitative score on a 5-point scale 
(0 = none, 1 = slight, 2 = moderate, 3 = moderate-severe, 4 = severe).
With respect to adverse event monitoring special attention was paid to muco-cuta- 
neous adverse events (S e e a p p e n d ix ) . These mucocutaneous adverse events were graded 
on a semi-quantitative scale also (0 = absent, 1 = mild, 2 = moderate, 3 = severe).
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To evaluate subjective findings of the patients with respect to “redness of the skin”, 
“roughness of the lesions”, “scaling of the lesions” and “general contentment with the 
skin” (including mucocutaneous side effects), visual analog scores (VAS) were per­
formed on a 10 point scale.
Randomization procedure
At baseline, patients were randomly assigned to one of the treatment groups, with 
stratification for age (> 50 versus < 50 years), skin-type (according to Fitzpatrick;9 type
1 and 2 versus type 3 and 4), and number of previous carcinomas (1 versus > 1). 
Randomization was carried out by opening a sealed envelope with the lowest available 
study number. Medical Ethics Committee approval was obtained and all patients gave 
written informed consent prior to study enrollment.
Statistical analysis
Analysis was performed following the intention to treat principle. Wilcoxon’s rank 
sum test, Wilcoxon’s signed ranks test, Fisher’s exact test and ANOVA for repeated 
measurements with post hoc Dunn’s test were used as appropriate. Calculations were 
performed using the SAS system, version 6.12 (SAS institute, Cary, NC, USA). Results 
are expressed as means ± standard deviation unless stated otherwise. A p-value < 0.05 
was considered statistically significant.
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Results
Demographics
Twenty-six patients were enrolled in the study. Demographic data of these patients 
are summarized in Table I. All patients were of Caucasian origin. No significant differ­
ences existed between the groups at baseline. The majority of patients also participated 
in a study focussing on the immunohistochemical effects of acitretin treatment on actinic 
keratoses (J.V. Smit e t al., in press).
Dosage
Initially this study was planned as a randomized study to assess the effect of long­
term acitretin treatment at a dose of 0.4 mg/kg/day or 0.2 mg/kg/day, after an initial 
treatment with 0.4 mg/kg/day for a period of 3 months. However, most patients could 
not tolerate the starting dose of 0.4 mg/kg/day due to mucocutaneous side effects (see 
below). We had to lower the dose in most patients already during the first 3 months. 
Fortuitously, the dose was lowered more in the low-dose group compared to the high-dose 
group, resulting in a significant difference in acitretin dose between the groups already 
after one month. The average actual dose of acitretin at 3 months was 0.35 ± 0.13 
mg/kg/day in patients randomized to continuation of the 0.4 mg/kg/day dose and 0.18 
± 0.11 mg/kg/day in patients randomized to the 0.2 mg/kg/day group (p = 0.004; Figure 
1). Beyond 3 months, acitretin dose decreased further in the high dose group but doses 
remained significantly different between the groups at all time points (Figure 1).
One patient in each group stopped acitretin treatment, one because of severe head­
ache, one because of mucocutaneous side effects. In five other patients (1 in the high­
dose group, 4 in the low-dose group) treatment with acitretin was interrupted for a few 
weeks, in four of them because of mucocutaneous side effects, and was restarted later in 
a low dose. The duration of interruption of treatment was on average 4 weeks, and 
occurred beyond three months of treatment in all five patients. Nineteen patients conti­
nued to take acitretin over the full study period, although in reduced doses in most cases. 
Only 3 patients in each group used the planned dose of acitretin throughout the study 
period.
Clinical efficacy parameters
In the 24 renal transplant recipients that completed the one-year study period, the 
number of newly formed tumors was counted and compared with the number of tumors 
in the 12 months before acitretin treatment. Thirty new SCCs developed during treat­
ment, versus 28 in the year before treatment (NS). Only 1 basal cell carcinoma (BCC)
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was diagnosed during the study, compared to 3 BCCs in the year before the study (NS). 
A non-significant reduction in the number of Bowen’s disease (9 during treatment ver­
sus 20 in the year before treatment) and keratoacanthomas (7 during treatment versus 
16 in the year before treatment) occurred during acitretin treatment. There were no sig­
nificant differences in the incidence of SCCs, BCCs, keratoacanthomas, or Bowen’s 
disease between the two dose groups during the study period.
Three out of 7 patients who did not have a SCC during the year before the study, 
remained free of SSC during the study; the other 4 patients had at least 1 SSC during the 
study. Seven out of 17 patients with at least 1 SCC during the year before the study 
remained free of SCCs; 10/17 had at least 1 new SCC.
At the start of the study, the number of actinic keratoses was 251 ± 190 in the high­
dose group and 280 ± 165 in the low-dose group (NS). The lesions were located mainly 
on the arms (high-dose group 58 ± 26%, low-dose group 66 ± 14%; NS) and the legs 
(high-dose group 25 ± 25%, low-dose group 20 ± 15%; NS). A rapid decrease in the 
number of keratoses occurred in both groups (Figure 2 ) , which was significant beyond 
two months in both groups (ANOVA: both p < 0.0001). No differences between the 
groups occurred at any time point, nor were there differences in effect between different 
body regions.
Table I:
D em ograph ic  data.
High dose (N=14) Low dose (N=12) P
Age (years) 54 ±  11 57 ±  8 NS
Sex (male/female) 8 /  6 5 /  7 NS
Years of immunosuppression 15 ± 7 17 ± 7 NS
Maintenance immunosuppression
Azathioprine/prednisone 12 7 NS
Cyclosporin/prednisone 1 4
Other 1 1
Creatinine (^mol/l) 121 ±  27 119 ±  51 NS
Skin-type 1 + 2* 3 5 NS
Skin-type 3 + 4* 11 7
Number of previous SCCs**
During year before study entry (No/patient) 1.5 ±  1.6 0.8 ±  0.8 NS
All previous SCCs** (No/patient) 2.8 ±  2.6 3.5 ±  3.6 NS
Previous systemic retinoid use
Within 1 year before study 0 0
More then 1 year before study 1 2
Previous local retinoid treatment 1 4
* Skin-type (according to Fitzpatrick9): On sun exposure, the skin 1 = always burns, never bronzes; 2 = always burns, 
rarely bronzes; 3 = always bronzes, rarely burns; 4  = always bronzes, never burns 
* *  SCC: squamous cell carcinoma. Values are given as means ±  SD.
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Months
Figure 1:
Acitretin dose (means ± SEM; * = doses 
significantly different between groups).
— — High 
- - ♦ - - Low
Months
Figure 2:
Number of actinic keratoses per treatment 
group (means ± SD; * = numbers 
significantly different compared to 
baseline).
Figure 3:
Erythema (3A) and thickness (3B) scores of actinic keratoses per treatment group (means ± SD; * = numbers significantly 
different compared to baseline).
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The degree of erythema and the thickness of the actinic keratoses throughout the 
study as observed by the investigators are depicted in Figure 3. No significant changes 
in erythema scores of the actinic keratoses were found (Figure 3a). Thickness of the 
lesions decreased significantly in both groups (both p < 0.01 for comparison with base­
line at all time points beyond 1 month of treatment; Figure 3b). No differences in 
response to acitretin treatment were observed with different immunosuppressive regi­
mens; however, the number of patients not using azathioprine plus prednisone is small. 
Figure 4 shows numerous hyperkeratotic actinic keratoses on the back of a hand in an 
average responder to acitretin at baseline. Figure 5 shows the same hand after 12 weeks 
treatment with acitretin. A significant improvement in aspect and number of the lesions 
is obviously.
Although this study was focussed on actinic keratoses, our clinical impression was 
that the extent of warty lesions, such as common-, plane-, and sessile warts, which are 
generally present in large numbers in renal transplant recipients with multiple skin 
lesions, did also improve on oral acitretin.
Figure 4:
Numerous hyperkeratotic actinic 
keratoses on the back of the hand 
in one of the subjects at baseline.
Figure 5:
The same hand as depicted in figure 4 
after 12 weeks’ treatment with acitretin.
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Figure 6:
Visual Analog Scores (all patients). 
Significant changes occurred in the 
roughness (p=0.002) and contentment 
(p=0.001) scores.
4— Contentment 
■m—  Roughness 
*  -R ed n e ss  
■x- - Scaling
Visual Analog Scores
Visual analog scores were available in 15/26 subjects (7/14 in the high dose group 
and 8/12 in the low dose group) at the scheduled follow up visits. Data are presented on 
all patients together, as there were no significant differences between the subgroups at 
any time point.
Roughness of the lesions decreased significantly during treatment with maximum 
efficacy after 2 months treatment (p = 0.002). The decrease in roughness slightly fluctu­
ated, but remained till the end of the study period (Figure 6 ) .
Small changes in redness and scaling of the lesions were noticed during the study. In 
the first months of treatment scaling seemed to increase; thereafter scaling decreased to 
values even below the baseline value. These changes remained however non-significant.
A global skin score for evaluation of the contentment of the patients with respect to 
effect and adverse events, showed a significant increase with maximum contentment af­
ter 2 months treatment (p = 0.001).
Side effects
Scoring of the severity of mucocutaneous side effects by the patients revealed within
2 weeks in both groups a significant increase of dryness of the lips, from “absent” to 
“mild” (p<0.001). The dryness of the lips remained “mild” over the whole study period, 
although the acitretin dose decreased over time. A significant increase in scaling of the 
skin was observed during the first two months in both groups (p<0.05). Dryness of the 
skin decreased significantly in both groups during the first two months (p<0.05), but
Months
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increased to the baseline level thereafter. No significant changes in the other items oc­
curred. Analyzing the number of patients developing a specific side effect within the first 
three months revealed significant rises in the number of patients complaining of dry lips, 
nasal crusts, and scaling of the hands (all p<0.01). Beyond 3 months, nearly half of the 
patients started complaining of mild hair loss and/or brittle nails (both p<0.01).
Renal function was stable in all patients and no significant change in the amount of 
proteinuria occurred. There were no liver function disturbances, nor a significant change 
in cholesterol or triglyceride concentration. No clinical or radiographic signs of skeletal 
damage were observed. In 2 patients, a significant decrease in hemoglobin level occurred; 
additional investigations revealed no explanation for the anemia. After completion of the 
study and interruption of the study medication, hemoglobin levels normalized spon­
taneously, suggesting a hitherto unknown side effect of acitretin.
Three female patients, who rarely had urinary tract infections in the years before the 
study, had recurrent symptomatic urinary tract infections during the study period, 
suggesting that the use of acitretin played a role (e.g. by thinning of vulvar and urethral 
mucosa). In one patient acitretin was interrupted temporarily because of an otherwise 
unexplained tendinitis of an Achilles’ tendon.
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Discussion
In this study, an important reduction was found by treatment with acitretin in the 
number of actinic keratoses in renal transplant recipients (RTRs) receiving long-term 
immunosuppressive therapy. This effect occurred within two months after starting treat­
ment, and could be maintained over the next 10 months by a low dose of 0.2 mg/kg/day 
acitretin. This reduction in the number of actinic keratoses by 50% is even larger than 
described by Bouwes Bavinck,4 who found a reduction in the number of keratoses of ap­
proximately 30% in patients with a previous SCC. In two smaller studies that evaluated 
the effect of systemic acitretin treatment in RTRs, the number of keratoses also appeared 
to be reduced by retinoid treatment; however, quantitative data are lacking.6,10 Apart 
from the reduction in the number of actinic keratoses, also a reduction in the degree of 
thickness was found.
In contrast with other studies,4"6"10 no reduction in the incidence of SCC was found 
when comparing the number of SCCs in the year before the study with the incidence in 
the year of the study. There was a slight reduction in the number of keratoacanthomas 
and Bowen’s disease as well as BCCs; this was however not significant.
Several hypotheses can be put forward to explain why a reduction in tumor 
incidence was not observed. First, the dose of acitretin could have been too low. However, 
the actual dose proved to induce mucocutaneous side effects in the majority of patients, 
indicating substantial acitretin availability. Also, the dose of acitretin in the patients in 
our high dose group was similar to the doses used by Gibson10 and McKenna6 (0.3 mg/ 
kg/day of etretinate and acitretin, respectively), and only slightly lower than the dose 
used by Bouwes Bavinck4 (30 mg/day). In addition, in our study no relation between the 
occurrence of new tumors and the use of a high or a low dose of acitretin could be found.
Second, it could be that in both dose groups tumor incidence remained unchanged 
during treatment with acitretin, where it would have increased if patients had been left 
untreated. This idea is supported by the data from the control group of Bouwes Bavinck, 
where the incidence of new tumors is much higher than in our treated groups.4 However, 
as no control group was included in our study, this option cannot be proven.
Other possible explanations like differences in demographic characteristics seem 
unlikely: all studies have been performed in neighboring countries, with comparable sun 
exposure. Time after transplantation and the immunosuppressive regimen are similar, 
with the majority of patients on azathioprine/prednisone. Therefore, we have no definite 
explanation for the unchanged tumor incidence in this study.
The use of acitretin appeared to be safe. As retinoids have several effects on the 
immune system, the theoretical risk of inducing transplant rejection exists. In our study, 
the only patient in whom a decrease in graft function occurred already had chronic trans­
plant dysfunction, and stopped treatment after 4 weeks due to mucocutaneous side 
effects. Thus it seems very unlikely that acitretin caused the decline in graft function in 
this case.
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With the doses used, we did not find any evidence of well-known side effects of reti­
noids like liver function disturbances, hyperlipoproteinemia, nor skeletal abnormalities. 
This is an important finding, as RTRs are already at high risk for developing these side 
effects as a complication of their continuous use of immunosuppressive agents. On the 
other hand, some of the apparent side effects in our patients have been reported only 
rarely or even not at all, like anemia, Achilles’ tendinitis and urinary tract infections.11
The great majority of side effects consisted of the well known mucocutaneous side 
effects of systemic retinoid use, as observed in patients with psoriasis and disorders of 
keratinization. However, in our study RTRs experienced these side effects at lower dos­
ages than used for the treatment of psoriasis, where the advised dosage is 25-50 mg/day. 
A possible explanation could be that the skin of RTRs is already altered by the long-term 
use of systemic corticosteroids, leading to easy bruisability and atrophy of the skin. Alter­
natively, the occurrence of side effects at relatively low doses could be caused by a differ­
ent pharmacokinetical profile of retinoids in RTRs. However, no literature data are avail­
able regarding this point.
Although many mucocutaneous side effects occurred that necessitated a dose reduc­
tion, patients’ contentment with the aspect of their skin was good. Especially the soften­
ing of the skin, the thinning of the lesions and the alterations in macroscopic aspect were 
important for patients’ contentment.
Taking together the incidence of mucocutaneous side effects, the efficacy in reduc­
ing the number of keratoses and the contentment of the patients, our dosing advice 
would be to start treatment with 0.25-0.30 mg/kg/day, and lower this dose if mucocu­
taneous side effects are severe or frequent. If only a modest therapeutic effect is seen, the 
dose should be increased to the maximal tolerated dose.
In conclusion, acitretin reduces the number of actinic keratoses in renal transplant 
recipients. This effect can be maintained at a low dose of acitretin (0.2 mg/kg/day). Al­
though the incidence of mucocutaneous side effects is high, patients’ contentment with 
their skin appearance improved. In contrast to earlier studies, no reduction in the num­
ber of new tumors was observed. Additional studies, including immunohistochemical 
studies, are needed to clarify the question whether retinoids merely have a cosmetic ef­
fect or really change the process of malignant degeneration of actinic keratoses in RTRs.
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Appendix
Items in the semi-quantitative score o f mucocutaneous adverse events:
Dryness of lips 
Dry mouth 
Dry nose /  crusts 
Conjunctivitis 
Dryness of skin 
Scaling of hands 
Scaling of other skin 
Loss of hair 
Brittleness of nails
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3.2
Immunohistochemical effects of oral acitretin in 
the treatment of actinic keratoses in renal transplant 
recipients
Abstract
After renal transplantation, the incidence of (pre)malignant skin lesions is 
high. Treatment with acitretin improves the number and aspect of actinic kera­
toses, and appears to reduce the incidence of squamous cell carcinomas. How­
ever, no histological and immunohistochemical studies have been performed to 
further substantiate these observations. In 33 renal transplant recipients, biopsies 
were taken before and after 3 months of treatment with acitretin in doses up to 
0.4 mg/kg/day. Histological and immunohistochemical parameters for dysplasia, 
epidermal thickness, proliferation, differentiation, apoptosis and dermal inflam­
mation were analyzed. After acitretin treatment, a significant reduction in epider­
mal thickness (p=0.002) and a significant increase in normal differentiation para­
meter K10 (p=0.02) was observed. Epidermal proliferation did not change, nor did 
apoptosis, inflammation, keratinocytic epidermal neoplasia score, or transgluta­
minase staining. Remarkably, at baseline in 11 actinic keratoses a single cell 
expression pattern of K13 and/or K19 was found. This pattern was associated with 
high levels of parameters indicative of high-risk lesions (p<0.05). After acitretin 
treatment an increase in K13 (p=0.006) and K19 (p=0.05) was found, together with 
a change in expression towards a focal or band-like staining pattern normally 
seen after retinoid treatment. The latter expression pattern was not associated 
with high-risk parameters. These data suggest we deal with two epiphenomena: 
malignant transformation-associated dedifferentiation (single cell expression) 
and retinoid-associated differentiation (focal or band-like expression). In conclu­
sion, acitretin improves the aspect of actinic keratoses via alteration of kerati- 
nization, resulting in peeling of the stratum corneum. No significant change in 
proliferation was found, which m ay explain for the rapid recurrence of actinic 
keratoses seen in other studies after cessation of acitretin treatment.
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Introduction
In renal transplant recipients (RTRs) receiving long-term immunosuppressive treat­
ment, an increased incidence of several benign wart-like lesions and (pre)malignant 
conditions has been found. The most frequently occurring (pre)malignant lesions are 
actinic keratosis (AK), Bowen’s disease, squamous cell carcinoma (SCC), keratoacan- 
thoma, basal cell carcinoma, and porokeratosis.1-2 Major etiological factors include pre­
vious sun exposure, the duration of immunosuppressive therapy, and human papilloma­
virus (HPV) infections.1'3 AKs are the lesions most frequently seen in this population 
and have been reported in up to 38% of these patients already after 5 years follow-up, 
and even increase thereafter.4 The percentage of AKs that will convert into a SCC within 
one year varies between 0.25% and 16% depending on the number, sort and duration of 
risk factors present, especially the use of immunosuppressive drugs.5
AKs in RTRs usually are multiple and behave more aggressive when compared to 
identical lesions in non-immunocompromized individuals.6 Treatment modalities like 
surgical excision, cryotherapy, or topical fluorouracil, are often difficult to perform in 
view of the multiple localizations and involvement of large body areas. Therefore, a sys­
temic treatment preventing malignant transformation is urgently needed.
Data obtained from 3 studies in RTRs where AKs were treated with systemic 
etretinate or its biologically active metabolite, acitretin, showed a significant decrease in 
the number and an improved aspect of the AKs.7"8"9 In 5 studies it was mentioned that 
these systemic retinoids also decreased the number of SCCs.7"8"9"10"11 However, only one 
of these studies was randomized and placebo-controlled.7 After cessation of systemic reti­
noid treatment a recurrence in the number and aspect of AKs7"9 and in SCCs9"10"11"8 was 
frequently seen.
Ideally, the criteria for improvement of AKs comprise both changes in clinical 
appearance and changes in relevant histopathological and immunohistochemical fea­
tures of the preneoplastic process. Clinical improvement without improvement of dys- 
plastic and proliferative characteristics may mask these premalignant keratoses and may 
mislead both patient and physician. Apart from data on Langerhans cells,12"13 no histo­
logical and immunohistochemical studies investigating the effect of systemic retinoids on 
AKs in RTRs have been performed to strengthen or contradict the clinical impression.
It is known that malignant transformation is represented by dedifferentiation, 
which is associated with a switch in synthesis of high molecular weight proteins, such as 
keratin 1 (K1) and keratin 10 (K10), towards low molecular weight proteins, such as 
keratin 13 (K13) and keratin 19 (K19).14 In normal human epidermis these keratins are 
absent,15 but they can be expressed in SCCs.16 No information is available on the 
expression of these low-molecular weight molecules in AKs.
Therefore, in the present study we evaluated both parameters for dysplasia, epider­
mal thickness, dermal infiltrate, epidermal proliferation, epidermal differentiation, and 
apoptosis, as well as parameters for dedifferentiation and retinoid-induced keratiniza- 
tion, the low molecular weight proteins K13 and K19 in AKs in RTRs.
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Materials and Methods
Study design
This study was conducted in adult RTRs with a stable graft function and a stable 
dose of immunosuppressive therapy. Patients initiated treatment with acitretin 0.4 
mg/kg/day, unless it was known from previous acitretin treatment that this dose was 
intolerable because of side effects. In that case the highest dose still tolerable by the 
patients was applied. The duration of treatment was 12 weeks. After this 12-week study 
period patients remained on acitretin therapy for another 9 months for further clinical 
evaluation.
Patients should have a history of at least one SCC of the skin and >10 AKs; or >20 
AKs if no previous SCC had occurred. Exclusion criteria were: excessive alcohol intake, 
the use of anti-epileptic drugs, nephrotic syndrome, hypercholesterolemia (> 9  mmol/l), 
hypertriglyceridemia (>10 mmol/l), elevated transaminase levels (ALT and/or AST 
more than twice upper limit of normal) and pregnancy (-wish). The washout period for 
systemic retinoids was 3 months. Topical retinoid treatment had to be discontinued at 
least 4 weeks prior to study enrollment to ensure an adequate epidermal turnover (in 
normal skin 2-3 weeks; in hyperproliferative disorders < 1 week17) with respect to 
potential previous retinoid-associated effects by these agents. Medical Ethics Committee 
approval was obtained and all patients gave written informed consent prior to study 
enrollment.
Biopsies and staining procedures
Punch biopsies of 4mm were taken under local anesthesia with xylocain/1% adrena­
line at baseline and after 3 months treatment. Biopsies were taken from AKs that were 
clinically identical at baseline and had the typical erythematous, scaling and mostly 
elevated aspect and from the same body region. Suspicious lesions that were present at 
baseline or that newly formed during the study, were biopsied for diagnosis or, if neces­
sary, surgically removed.
Biopsies were analyzed using standard histological techniques. The following histo­
logical parameters were assessed: thickness of the lesions, total dermal infiltrate score 
(TDI), and keratinocytic epidermal neoplasia score (KIN).18
The following immunohistochemical stainings were performed, using the avidin- 
biotin-complex (ABC) staining method and indirect immunoperoxidase techniques: Ki- 
67 (MIB-1, epidermal proliferation), pS3 (DO-7, apoptosis association), K10 (DE-K10, 
normal keratinization), K13 and K19 (1C7 and RCK108 respectively, retinoid-associated 
keratinization), K16 (LL02S, hyperproliferation-associated keratinization) and transglu­
taminase (BT621, terminal differentiation). Esophageal tissue, eccrine ducts, and sweat 
glands served as positive controls for K13 and 19 staining. Further details on the immu­
nohistochemical markers are provided in Table I.
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Table I:
A n tib od ies  used in the  study.
Antibody Specifity Marker for Concentration Source
MIB-1 Ki-67 Epidermal proliferation 1:50 Immunotech, Marseilles, France
DE-K10 Keratin 10 Normal keratinization 1:100 Monosan, Uden, Netherlands
1C7 Keratin 13 Retinoid-induced keratinization 1:10 Monosan, Uden, Netherlands
LL-025 Keratin 16 Hyperproliferation-associated
keratinization
1:10 Novocastra laboratories Ltd, 
Newcastle Upon Tyne, UK
RCK108 Keratin 19 Retinoid-induced keratinization 1:50 Monosan, Uden, Netherlands
BT621 Transglutaminase Terminal differentation 1:10 Biomedical Technologies Inc., 
Stoughton, MA, USA
DO-7 p53 Apoptosis 1:200 Dako, Glostrup, Denmark
Histological and immunohistochemical scoring
With respect to histological analysis, epidermal thickness (mm) was measured in the 
center of the AKs, and additionally assessed by counting the number of cell layers. TDI 
scores were performed by using a similar semi-quantitative score on a 5-point scale: 0 = 
no infiltrate, 1 = minimal infiltrate, 2 = moderate infiltrate, 3 = moderate-pronounced 
infiltrate, 4 = pronounced infiltrate. KIN scores were assessed according to Cockerell’s 
criteria for keratinocytic epidermal neoplasia.18 In brief, lesions were graded based on the 
degree and extent of dysplasia on a 4-point scale.
Immunohistochemical scoring was based on methods previously published19 and 
occurred along the complete length of the slides, but only in  the sections that showed 
typical histological signs of AKs. Transglutaminase scores were assessed in the center of 
the AKs as the ratio of BT621 positive epidermal cell layers divided by the total number 
of epidermal cell layers. Ki-67 and p53 positive keratinocytes (nuclei) were counted per 
mm length of section. For scoring of keratinization parameters K10, K13 and K16, the 
following semi-quantitative scale was used: 0 = no staining, 1 = sporadic staining 
( = single cell expression), 2 = minimal staining, 3 = moderate staining, 4 = moderate- 
pronounced staining, 5 = pronounced staining, 6 = whole epidermis stained.
All histological and immunohistochemical scoring occurred under blinded 
conditions. Demographic and dosage-related results are expressed as means ± standard 
deviation (SD); histological and immunohistochemical results are expressed as means ± 
standard error of the mean (SEM) unless stated otherwise.
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Statistical analysis
For assessment of statistical significant differences before and after 12 weeks treat­
ment with respect to the histological and immunohistochemical parameters, a Wilcoxon 
matched pairs test was used. Assessment of statistical significant correlations between 
parameters was performed by calculating Spearman’s rank correlation. Differences be­
tween K1S and/or K19 responders versus non-responders were analyzed by using the 
Mann-Whitney U-test. A p-value < 0.0S was considered statistically significant. Calcula­
tions were performed using Statistica version 9.0 (StatSoft Inc, 2S00 East 14th Street, 
Tulsa, OK 74104, USA).
Table II:
D em ograph ic  data.
Age (years)* 53.6 ± 9 .7
Sex (male/female) 15 : 18
Years of immunosuppression* 16.4 ± 6 .7
Maintenance immunosuppression
Azathioprine/prednisone 25
Cyclosporin/prednisone 6
Mycophenolate mofetil/prednisone 1
Cyclosporin/azathioprine 1
Number of previous SCCs (N/patient)
All previous SCCs 2.6 ± 2 .8
During year before study 1.0 ±  1.3
Previous systemic retinoid use
Within 1 year before study 0
More then 1 year before study 3
Previous local retinoid treatment 7
*  Values are given as m eans ±  SD.
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Results
Demographics
Demographic data are summarized in Table II. Thirty-three patients (15 men and 
18 women) were included in this study. Most patients also participated in a randomized 
study focussing on the clinical effects of acitretin on AKs (R. de Sévaux e t al, in press). 
The mean age was 53.6 ± 9.7 years. The follow-up period after renal transplantation 
was 16.4 ± 6.7 years. Twenty-nine patients had a history of one or more SCCs, with a 
mean of 2.6 ± 2.8 SCCs per patient (excluding keratoacanthomas). Maintenance immu­
nosuppressive treatment consisted of: prednisone plus azathioprine (25 patients), cyclo­
sporin plus prednisone (6 patients), mycophenolate mofetil plus prednisone (1 patient), 
and cyclosporin plus azathioprine (1 patient).
Dosage
Except for two patients who started with a lower dose (0.2 mg/kg/day) due to 
previous intolerability of higher acitretin doses, the remaining 31 patients initiated treat­
ment with acitretin 0.4 mg/kg/day. Most of these patients could not tolerate the starting 
dose of 0.4 mg/kg/day due to mucocutaneous side effects (mostly cheilitis, intensive peel­
ing, and eye irritation/conjunctivitis). Therefore, all patients received the maximum dose 
of acitretin that was still tolerated. The starting dose was 39.8 ± 8.6 mg/day (0.38 ± 
0.07 mg/kg/day). At the end of the 12 weeks treatment period the mean dose had been 
reduced to 20.2 ± 9.6 mg/day (0.26 ± 0.13 mg/kg/day).
Histological results
Biopsies taken at baseline and after 12 weeks of treatment with acitretin were avail­
able in 32 out of 33 patients. One patient withdrew from the study because of severe 
mucocutaneous side effects after 8 weeks of treatment. In 28 baseline samples a typical 
actinic keratosis was found, in 2 samples only hyperkeratosis without dysplasia was 
seen, one actinic keratosis had already progressed to a SCC, and one hyperkeratotic le­
sion appeared to be a common wart. One biopsy was not intact and was therefore ex­
cluded from evaluation. Therefore, 27 pairs of biopsies taken before and after acitretin 
treatment could be used for histological and immunohistochemical analysis.
On histological examination, a mean reduction in epidermal thickness of 44.0 % 
(p<0.01) was found after acitretin treatment. This reduction was completely caused by 
a decrease in stratum corneum thickness; no significant reduction could be seen in the 
other strata (Figure 1).
At baseline, minimal to moderate TDI scores were found in 85% of the AKs, where­
as the remaining 15% demonstrated a moderate-pronounced TDI. The infiltrates were
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Epidermal thickness
W e e k O  W e e k  12
Acitretin treatment
Figure 1:
E piderm al th ickne ss  as the  sum 
score o f s tra tu m  corneum  th ickne ss  
and th ickne ss  o f th e  o th e r strata in 
m illim e te r a t base line  and a fte r 12 
weeks tre a tm e n t w ith  a c itre tin  
(m ean ±  SEM ) (*  p <  0 .0 1 ; N = 2 7 ).
□  S tra tu m  co rn e u m  
■  O the r s tra ta
Figure 2:
S e m i-q u a n tita tive  scores fo r ke ra tin o cy tic  in traep ide rm a l neoplasia  (K IN ), to ta l derm a l in f iltra te  (TD I), and 
ke ra tins K 1 0 , K 1 3 , K 1 6 , and K 1 9  at base line  and a fte r 12 w eeks tre a tm e n t w ith  a c itre tin  (m ean ±  SEM ) 
(*  p <  0 .0 1 ; * * p  <  0 .0 5 ; N = 2 7 ).
□ Week 0 
■ Week 12
KIN TDI K10 K13
Acitretin treatment
K16 K19
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localized perivascular and in the upper dermis. After 12 weeks of treatment, no signifi­
cant alterations were seen in TDI scores (Figure 2).
The KIN score, a scoring system for dysplasia, did not change significantly during 
the study period. Before treatment the KIN score was 1.7 ± 0.2 versus 1.3 ± 0.2 after 
treatment (Figure 2).
900 -, 
800 -
Ki-67 p53
Acitretin treatment
Figure 4:
K i-6 7  and p 5 3  scores as th e  num ber 
o f pos itive  sta ined ce lls  per 
m illim e te r length  o f section  o f the  
s lides at base line  and a fte r 12 
w eeks tre a tm e n t w ith  a c itre tin  
(m ean ±  SEM ) (N = 2 7 ).
□ Week 0 
■ Week 12
Immunohistochemical results
At baseline, in most AKs the epidermal proliferation parameter Ki-67 revealed 
numerous proliferating cells mostly in the basal cell layer, but also to a variable extent 
depending on KIN score in the suprabasal regions of the epidermis. Ki-67 expression was 
restricted to the nuclei and featured a rather homogenous staining pattern in the hori­
zontal plane of the epidermis. An example of MIB-1 staining for Ki-67 expression is seen 
in Figure 3. Treatment with acitretin did not lead to a significant alteration in the num­
ber of Ki-67 positive keratinocytes (Figure 4). In 13 patients an increase in Ki-67 posi­
tive cells could be demonstrated, whereas in 14 patients a decrease in this number was 
found after acitretin treatment.
Apoptosis associated p53 protein at baseline was mostly observed in the basal and 
lower suprabasal cell layers of the epidermis, but in some AKs p53 expression throughout 
all epidermal cell layers was seen. P53 expression basically followed the pattern of Ki-67. 
However, incomplete staining areas for p53 were often observed, whereas the corre­
sponding Ki-67 staining in a consecutive slide was continuous along the complete length 
of the slide. Figure 5 clearly shows this focal staining of p53 in an actinic keratosis. 
Overall, the number of p53 positive cells was also much higher than the number of Ki- 
67 positive cells. Statistical analysis revealed no significant change in p53 staining after 
acitretin treatment (Figure 4).
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Figure 6:
In a c tin ic  keratoses ra the r com p le te  
suprabasal s ta in in g  o f K 1 0  is seen. 
In th is  s lid e  m in im a l s ta in in g  in the  
cen te r o f th e  s tra tu m  corneum  is 
seen, w h ich  may w ell be the  
beg inn ing  o f th e  fo rm a tion  o f a 
cu taneous horn.
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Changes in the different parameters of keratinization are depicted in Figure 2. 
Epidermal differentiation parameters at baseline showed the following patterns. Normal 
differentiation-associated K10 expression was only seen in the suprabasal compartment. 
Its staining pattern was less when compared to normal skin and often showed unstained 
foci. An example of K10 expression is shown in Figure 6. After acitretin treatment, a 
significant increase in K10 expression was found with a more complete staining pattern 
(p = 0.02).
Hyperproliferation-associated K16 was expressed in the suprabasal compartment of 
all AKs. Expression was moderate to pronounced, with staining of all suprabasal cell 
layers. Most intense staining for K16 was observed suprabasally in the hypertrophic cen­
ter of AKs directly below the stratum corneum. In Figure 7 an example of K16 expres­
sion is depicted. As Figure 8 demonstrates, staining can be seen in the basal cells. The 
degree of K16 expression before and after acitretin treatment was similar.
Figure 9:
In a c tin ic  keratoses m u lt ip le  
transg lu tam inase  positive  ce ll-laye rs  
are n o rm a lly  seen.
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In the untreated AKs, terminal differentiation-associated transglutaminase staining 
was seen in the stratum granulosum and stratum spinosum. The number of positive cell 
layers varied among the AKs from 1 to 15. Figure 9 represents a typical example of 
transglutaminase expression. In addition, also in individual AKs differences could be 
seen in the number of positive cell layers. In general, in the interpapillary areas the 
number of positive cell layers was the highest. No significant changes in transgluta­
minase scores could be detected after acitretin treatment.
F igure 10:
K 1 3  expression (1C 7) in tissue  sam ples o f a non -re tino id  trea ted  a c tin ic  keratosis (s ing le  ce ll expression; 
Figure 10A , 2 0 0 x ) and o f an a c itre tin  trea ted  a c tin ic  keratosis (increased expression; F igure 10B , 2 0 0 x ).
A B
Keratin 13 and keratin 19
At baseline, K13 expression was found in 8 patients and this was localized in the 
suprabasal cell layers of the AKs. The staining pattern in these sections was always 
sporadic with single cell expression mostly scattered in the epidermis. After acitretin 
treatment K13 expression was found in 14 patients featuring increased expression in the 
suprabasal regions of the epidermis. No K13 staining was observed in the basal cell com­
partment. This increase in K13 expression (in number and score) after acitretin treat­
ment was significant (p<0.01). In Figure 10, K13 expression is shown in a non-retinoid 
treated actinic keratosis and in an acitretin treated actinic keratosis.
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At baseline, in 4 patients K19 expression was found. Its grade of expression varied 
from sporadic to minimal, with typical single cell expression mainly located in the supra­
basal compartment. After acitretin treatment K19 could be detected in 10 AKs. After 
treatment K19 was primarily located in the basal cell layers with minimal expression in 
the suprabasal compartment. The expression of K19 increased (p = 0.05) from single cell 
to continuous staining (Figure 11).
With respect to the histological and immunohistochemical parameters no differ­
ences in response to acitretin treatment were observed with different immunosuppres­
sive treatment regimens; however, the number of patients not using azathioprine plus 
prednisone is small.
F igure 11:
K 1 9  expression (R C K 1 0 8 ) in tissue  sam ples o f a non -re tino id  trea ted  a c tin ic  keratosis (s ing le  ce ll 
expression; Figure 11A , 2 0 0 x ) and in an a c itre tin  trea ted  a c tin ic  keratosis increased expression; 
(F igure 11B , 2 0 0 x ).
A  B
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Correlations
In the baseline samples, a significant positive correlation was found between Ki-67 
and p53 (R = 0.61; p = 0.001), between Ki-67 and KIN score (R = 0.50; p = 0.013) and 
between KIN and p53 score (r  = 0.48; p = 0.02).
With respect to K13 expression, significant positive correlations were found with Ki-67 
(R = 0.41; p = 0.036) and with the number of SCCs in each patient that had developed in the 
12 months immediately before treatment (R=0.43; p = 0.024) in the baseline samples.
For K19 a similar positive correlation with Ki-67 (R = 0.56; p = 0.003) was found in the 
baseline samples as well as significant positive correlations with p53 (R = 0.56; p = 0.002) 
and KIN score (R = 0.53; p = 0.007). No statistical significant correlation between baseline 
K13 and K19 expression was found.
In order to assess whether induction of K13 and/or K19 in AKs by acitretin is cor­
related with a better response concerning a decrease in epidermal thickness, an increase 
in K10 expression, and/or the number of newly formed SCCs in this study, we had to 
compare K13 and/or K19 responders with non-responders. This was done by comparing 
patients who had at least grade 2 expressions in either K13 or K19 (N=10) with patients 
who were both K13 and K19 negative (N = 8) after acitretin treatment. Grade I (single 
cell) expression was excluded because this was also seen in untreated biopsies.
When comparing K13 and/or K19 responders with K13 plus K19 non-responders, 
no significant differences with respect to a decrease in epidermal thickness, an increase 
in K10 expression, and/or the number of newly formed SCCs were found in this study. 
After the above described correction for single cell expression in acitretintreated AKs a 
statistical significant correlation (R = 0.49; p = 0.039) between K13 and K19 could be 
demonstrated in these 18 patients.
No statistical significant correlations between the remaining histological and immu- 
nohistochemical parameters could be established.
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Discussion
Histological data obtained from this study demonstrated a 44% reduction in 
epidermal thickness of the AKs after acitretin treatment, but other histological para­
meters (TDI, KIN) remained unchanged. With respect to immunohistochemical data, we 
have demonstrated changes in keratinization parameters K10, K13, and K19. No effect 
on K16 and transglutaminase was seen after 12 weeks treatment. Moreover, acitretin 
treatment did not lead to significant changes in epidermal proliferation and p53 protein 
expression, two important hallmarks of AKs that are associated with the degree of 
dysplasia and the malignant transformation process. These results are in contrast to 
psoriasis, where a 12-week treatment period with systemic acitretin in a similar dose led 
to significant reduction in epidermal proliferation, transglutaminase, K16 and dermal 
inflammation in a group of 10 patients.19
From previous studies it is known that retinoids can improve the aspect of AKs by 
reducing its roughness.7-8-9 Our data indicate that this clinical improvement is caused by 
a decrease in thickness of the stratum corneum, whereas the other strata remain un­
changed with respect to thickness or the number of cell layers. In general, retinoids are 
known to alter normal differentiation of the cornifying epidermis towards an eso- 
phagealtype of differentiation by stimulating the synthesis of low molecular weight kera­
tins, such as K13, that are normally present in internal squamous epithelia.20"21
Concerning K13 and K19, these keratins are embryonic keratins that are normally 
not present in adult human epidermis.14,15 In studies with cultured keratinocytes, 
coupled induction of K13 and K19 by retinoids has been described.20,22 With respect to 
in vivo studies, K13 expression was induced by topical application of all-trans retinoic 
acid (ATRA) on photo-aged human skin23 and by systemic treatment in warts in RTRs. 
24 To our knowledge, no in vivo studies have been performed that report an induction of 
K19 by retinoids. The present study in AKs in RTRs also demonstrates that induction of 
K13 by acitretin is correlated with K19 induction, although, in contrast to fetal skin, 
expression of both parameters was also seen uncoupled. Uncoupled expression of K13 
and K19 has been reported previously in a human SCC cell line25 and in warts in RTRs.24 
Our data also suggest that induction of K13 in AKs by acitretin is more frequently seen 
than induction of K19. Earlier findings in human epidermal cultures indeed showed 
stronger induction of K13 than of K19 by retinoids with already a marked increase of 
K13 in response to very low levels of retinoids, while for K19 induction a higher concen­
tration was necessary.20
Apart from the induction of K13 and K19 by acitretin, striking is the single cell 
expression of these keratins already in several AKs at baseline. None of the patients who 
showed K19 expression at baseline, and only 2 out of 8 patients who showed K13 expres­
sion at baseline, had previously used retinoids. It has been suggested that the presence of 
these low molecular weight proteins in human skin can be a sign of malignant transfor­
mation.20,16 To assess whether K13 and/or K19 expression in non-retinoid treated AKs 
is positively correlated with malignant transformation, correlations between K13/K19
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and epidermal proliferation (Ki-67),26,27 (mutant) p53 expression,26,27 and KIN score18 
were analyzed. In addition, the frequency of newly formed SCCs in a patient with 
multiple AKs may also be indicative of an actinic keratosis to become malignant. In the 
present study, we found evidence that K13 expression in non-retinoid treated AKs is 
correlated with higher epidermal proliferation and a higher incidence of SCCs before 
treatment. Furthermore, K19 expression in non-retinoid treated AKs is correlated with 
higher epidermal proliferation, higher (mutant) p53 protein expression, and higher 
degree of dysplasia. Therefore, these data indicate that assessment of K13 and K19 in 
non-retinoid treated AKs may provide further information on the risk of malignant 
transformation and thus may be of interest for the identification of high-risk lesions.
It is intriguing that retinoid treatment induces keratins that are correlated with 
malignant transformation and on the other hand cause a reduction in skin cancer inci­
dence. ^ A 11,10,12 Therefore, it is likely that, with respect to K13 and K19 expression, we 
deal with epiphenomena, related to two distinct pathways: malignant transformation- 
associated dedifferentiation and retinoid-associated keratinization.
KIN scores based on histological criteria did not always correlate well with the 
clinical picture in this group of RTRs. While all 27 baseline biopsies were taken from 
typical AKs with evident erythematosquamous hallmarks, suggesting a grade II-III KIN 
score, in 2 biopsies no dysplasia (KIN 0), and in 10 biopsies a KIN grade I was found. 
Therefore, in RTRs, who often have numerous erythematosquamous and hypertrophic 
AKs, the directly visible clinical hallmarks of these lesions may not always reflect the 
grade of dysplasia in the epidermis of these lesions.
In some sections we found areas featuring numerous Ki-67 positive keratinocytes 
with sparse p53 positive keratinocytes, thus areas with a high level of epidermal proli­
feration and no sign of apoptosis or staining of mutant p53. Histologically, these areas 
consisted of KIN III dysplasia and may therefore be at increased risk for malignant trans­
formation.
Combining clinical-, histological-, and immunohistochemical data, it can be conclud­
ed that treatment with systemic acitretin improves AKs probably via alteration of the ke- 
ratinization process of the keratinocytes, leading to peeling of the hypertrophic stratum 
corneum of these lesions and clinically resulting in softening of the skin. No significant 
decrease in proliferation and dysplasia was found, which might be the explanation why 
recurrence of AKs is normally seen after cessation of acitretin treatment. Expression of 
low molecular weight keratins K13 and/or K19 in non-retinoid treated AKs is correlated 
with parameters that are indicative for high-risk AKs. Therefore, K13 and K19 may 
provide two new diagnostic parameters for assessment of AKs at particular risk for 
transformation into a SCC.
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3.3
Effects of cessation of oral acitretin on actinic 
keratoses and verrucae vulgares in renal transplant 
recipients
Abstract
The aim of this study was to investigate effects of temporary cessation of 
acitretin treatment in renal transplant recipients (RTRs) on skin (pre)cancer 
development and expression of keratin 13 and cell-cycle-associated proteins 
(MIB-1, p53 and p16INK4A). A  prospective, non-randomized clinical and immuno- 
histochemical design was used. Nine RTRs on acitretin treatment (mean duration 
2.3 ±0.6 years; mean dosage 18.3 ± 9.9 mg) were asked to interrupt their treatment 
for three months. Patients gave written informed consent. Patients were seen at 
intervals of 6 weeks, starting at the moment of acitretin withdrawal. Each visit 
epidermal lesions were counted; erythema and desquamation of perilesional skin 
and actinic keratoses (AKs) with induration of AKs were recorded, a visual ana­
logue score (VAS) for patient’s contentment was performed, and clinically com­
parable AKs were biopsied. The main outcome measurements were assessment of 
a change in the numbers of skin lesions and skin (pre)cancers after acitretin 
cessation and to compare expression of keratin 13 (K13), MIB-1, p53 and p16INK4A 
in keratinocytic intraepidermal neoplasia (KIN) of RTRs, with and without 
acitretin. After 3 months, the number of warts had increased significantly. VAS 
score had reduced significantly. No significant increase in number of AKs or SCCs 
was found. K13 expression decreased significantly; for zebroid K13 expression 
only a trend towards reduction was present. No significant alterations in expres­
sion of MIB-1, p53 or p16INK4A were found. It was concluded that acitretin w ith­
drawal in RTRs leads to 1. clinical deterioration within 3 months, without signifi­
cant increase in skin (pre)cancer, and 2. significant reduction of aberrant K13 
expression, without alteration in expression of cell-cycle-associated markers.
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Introduction
Retinoids, synthetic vitamin A analogues, interfere with epidermal growth and 
differentiation. These effects of retinoids on proliferation and differentiation make them 
of interest in the treatment of hyperproliferative skin diseases, such as psoriasis, dis­
orders of keratinization and as an antitumor drug.1
Renal transplant recipients (RTRs) are known to develop multiple warts, actinic 
keratoses (AKs) and non-melanoma skin cancers (NMSCs), especially on sun-exposed 
parts of the body,2-4 which lead to a major co-morbidity. In the past two decades, systemic 
treatment with retinoids has shown to be promising in chemoprevention of AKs and 
squamous cell carcinoma (SCC),5 also in RTRs.6-10
Several studies suggested a beneficial effect of systemic retinoid treatment (either 
etretinate or acitretin), with prevention of SSCs and reduction in the number of hyper- 
keratotic lesions in RTRs, especially in those with NMSC or severe lesions in their his­
tory.5, 6, 8-10
However, after stopping retinoid treatment the beneficial effect disappeared, with 
report of relapses varying from 4-12 months after discontinuation of retinoid therapy. 
5, 6, 9, 11 Therefore, some have recommended continuous treatment.7
So far it is unknown how retinoids exert their chemopreventive effect. Recently, we 
demonstrated that retinoids alter differentiation in almost 90% of warts of RTRs, with 
induction of keratin 13 (K13) expression,12 a keratin normally not present in the adult 
epidermis.13 A specific zebroid K13 expression pattern was associated with retinoid bio­
activity in warts of these patients. Whether comparable K13 expression patterns are 
present in retinoid-treated keratinocytic intraepidermal neoplasia (KIN) lesions of RTRs, 
remains to be established.
In view of the clinical efficacy of retinoids in NMSCs on RTRs, it is feasible that reti­
noids not only influence differentiation, but also interfere with cell-cycle-associated 
proteins. Thus far, effects of retinoids on expression of cell-cycle-associated markers in 
KIN lesions of RTRs have not been published. The most current and so far best docu­
mented cell-cycle-associated marker for intraepithelial neoplasia (especially in neoplasia 
of the uterine cervix) is the proliferation marker, MIB-1.14-16 Other cell-cycle-associated 
markers of interest with respect to KIN are the tumor suppressor p53 and p 1 6 INK4A. In 
AKs of both immunocompetent individuals and RTRs, frequent overexpression of the 
p53 tumor suppressor is reported.17, 18 Recent data have shown that besides the p53 path­
way, also the pathway involving the tumor suppressor p 1 6 INK4A is involved in skin carci­
nogenesis;19 in high-grade KIN lesions of both RTRs and immunocompetent individuals 
we found frequent p16INK4A overexpression (ow n  unpub lished  d a ta ) .
The present prospective study was designed to study the effects of 3 months with­
drawal of long term acitretin treatment on clinical aspect of the skin, the development of 
(pre) cancerous lesions in RTRs, and to assess its effects on histology and immunohisto- 
chemical expression of the three biomarkers MIB-1, p53 and p 1 6 INK4A in KIN lesions of 
RTRs. Furthermore, we examined whether K13 expression in acitretin-treated KIN le-
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sions showed a zebroid K13 pattern as previously found in warts during retinoid treat­
ment, and whether K13 expression reduced after acitretin withdrawal.
Materials and Methods
Patients
RTRs on systemic acitretin (mean duration of acitretin treatment 2.3 ± 0.6 year; 
mean dosage 18.3 ± 9.9 mg/day) were asked to interrupt their treatment for 3 months.
Initially, 11 out of 16 approached patients agreed to participate and in all cases 
written informed consent was obtained. However, one female withdrew after the first 
visit due to interfering breast cancer and 1 patient withdrew because of progression of 
AKs and SCCs, 6 weeks after the start of the study. Both patients were excluded from 
further evaluation because only baseline biopsies were obtained.
The characteristics of the remaining 9 patients (3 males, 6 females) that finally com­
pleted the 3-month study period, including data on previous retinoid therapy and type 
and duration of immunosuppression are listed in Table I.
Table I:
C haracte ris tics  o f the  9  p a rt ic ip a tin g  p a tien ts ; M =m a le ; F=fem ale ; yrs=years; A =aza th iop rine ; 
P =predn iso lone; S =s iro lim us ; A K = a c tin ic  keratoses.
Patient Age
(years)
Sex Duration imm. 
suppression 
(years)
Type imm. 
suppression
Dosage acitretin 
at TO (mg/day)
Dosage acitretin 
at TO (mg/kg)
Duration of 
acitretin treatment 
(years)
l 65 M 33 A+P 20 0.24 2.9
2 60 F H  6 A+P 35 0.30 2.9
3 53 F 27 P+S 20 0.29 2.8
4 64 H  8 A+P 10 0.20 1.5
5 64 F 24 A+P 15 0.16 2.6
6 48 F 22 A+P 15 0.15 2.6
7 60 21 A+P 15 0.19 2.3
8 51 F 26 C 25 0.26 1.9
9 60 F 13 A+P 10 0.13 1.5
Mean
(±SD)
58.3 20 (± 9.1) 18.3 (± 9.9) 0.21 (± 0.06) 2.3 (± 0.6)
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Design of the study
During the 3-month study period the patients were seen at three defined moments, 
with intervals of 6 weeks in between each visit. At time TO the study started and on this 
day systemic acitretin was stopped. Control visits were respectively 6 (T1), and 12 (T2) 
weeks after acitretin stop.
At each visit all warts and AKs in each patient were counted and scored by the same 
dermatological investigator, familiar with this type of patients and their skin lesions. 
Erythema and desquamation of lesional and perilesional normal skin and induration of 
lesional skin were judged, using a scale of 0-3 (0 = absent, 1 = minimal, 2 = moderate, 
3 = severe).
Patients were asked to give a subjective judgment of their skin condition using a 
visual analogue score (VAS), with a scale from 0-10 (0 = very discontented, 10 = very 
satisfied). At the end of each visit a 6 mm skin biopsy was taken; it was attempted to 
biopsy clinically identical (at baseline defined) AKs from the same location in all three 
sessions, preferentially from the forearm.
Of each participating RTR, the number of biopsied Bowen’s diseases (BDs) and 
NMSCs during the 3-month study period was compared with the number of lesions, 
which had occurred in the last 3 months with retinoid treatment.
Histopathology and immunohistochemistry
A KIN-classification was assigned to all skin biopsies.20,21 Immunohistochemical 
analysis was performed on all lesions using standard avidin-biotin-peroxidase complex 
system with diaminobenzidine (DAB) as the chromogen. In brief, 4 pm thick paraffin 
sections were deparaffinized, hydrated, and washed in buffered saline phosphate. The 
monoclonal antibodies used, the antigen they recognize, and pretreatment and dilutions 
are listed in Table II. After incubation with primary antibodies, sections were incubated 
for 30 minutes with (a 1:200 dilution of) biotinylated horse anti-mouse (Vector labora­
tories, Burlingham, CA), followed by a 45-minute incubation period with (a 1:50 dilution
Table II:
A n tib od ies  w ith  th e  recognized antigens, used d ilu tio n , p re trea tm en t, incuba tion  tim e  and tem pera tu re .
Antibody Antigen Source Dilution Pretreatment Incubation time 
and temperature
DO-7 P53 Neomarkers 1:400 microwave 4°C overnight
P16INK4A/MTS1 Ab-4 pigINK4A Neomarkers 1:100 microwave 4°C overnight
MIB-1 Ki-67 Progen 1:100 microwave 4°C overnight
2D7 (IgG2b) Keratin 13 G. van Muyen 1:1 microwave 4°C overnight
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of) avidin-biotin complex (Vector laboratories, Burlingham, CA). Sections were counter­
stained with Mayer’s haematoxylin.
Immunoreactivity was scored semi-quantitatively for all applied immunohistoche- 
mical markers, in the following manner:
M IB -1  and p53: for both staining was nuclear. Staining was scored as previously 
published by Keating e t a l . in cervical neoplasia22: 0 = only basal layer positivity, 1 = 
positivity confined to basal 1/3 of epidermis, 2 = positivity confined to basal 2/3 of 
epidermis or 3 = transepidermal positive staining.
K 1 3 : staining was cytoplasmic. Scoring was performed as described previously12; 0 
= negative staining, 1 = suprabasal single cell positivity, 2 = zebroid pattern.
P 1 6 INK4: staining was both nuclear and cytoplasmic. Staining was scored as for MIB-1 
and p53. Scoring of immunostaining was performed without knowledge of patient 
history.
Statistics
The Lilliefors test for normality disclosed that the data were not gaussian distrib­
uted. Therefore, non-parametric statistical procedures were used to analyze the data. 
Since the small series of patients included in this study the exact significance level is 
given or an unbiased estimate of exact significance level, calculated by repeatedly sam­
pling (=  Monte Carlo method). The relations between the grade of KIN and expression 
of K13, MIB-1, p53, and p 1 6 INK4A were assessed with both rank correlation analysis and 
the Jonckheere-Terpstra test, a distribution-free test for ordered alternatives.23
Table III:
T 0 = s ta rt o f the  s tudy; T 1 = 6  w eeks a fte r a c itre tin  w ithd ra w a l; T 2 = 1 2  w eeks a fte r a c itre tin  w ithd raw a l; 
p 1 = p  va lue  T 0 -T 1 (w ee k0 -6 ); p 2 = p  va lue  T 0 -T 2 (w eek  0 -1 2 ) ; S E M =standard  error o f the  m ean; A K s=  a c tin ic  
keratoses; VAS=visual analogue score. Figures in bold in d ic a tin g  s ta tis tic a lly  s ig n ific a n t fin d in g s .
Parameter TO
mean±SEM
T0
mean±SEM
T0
mean±SEM
P1 P2
Number of warts 1.6 ± 0.8 1.9 ±  1.0 2.7 ± 1.1 0.5 0.02
Number of AKs 129.6 ±  36.4 108.1 ±  26.7 109.6 ±  25.4 0.1 0.2
Erythema perilesional normal skin 0 .9  ± 0.3 0 .2  ± 0.2 0.2 ± 0.2 0.03 0.03
Desquamation perilesional normal skin 0.6 ±  0.2 0.3 ±  0.2 0.3 ±  0.2 0.3 0.3
Erythema AK 1.9 ±  0.4 1.7 ±  0.3 1.7 ±  0.3 0.4 0.4
Desquamation AK 1.1 ±  0.3 2.00 ±  0.3 1.6 ±  0.4 0.05 0.3
Induration AK 0.9  ± 0.2 2 .0  ± 0.2 1.9 ±  0.3 0 .004 0.05
VAS 5.6  ± 0 .7 4 .4  ± 0.7 3.1 ± 0 .6 0 .04 0 .004
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In this study a before-after design23 was used to study the effect of cessation of reti­
noid treatment on clinical and immunohistochemical parameters. Significance of effects 
on short term (after 6 weeks, p1) and longer term (after 12 weeks, p2) were calculated. 
A partial rank correlation analysis controlled for KIN grade was used to assess the effect 
of retinoid treatment cessation on the KIN-grade dependent immunohistochemical 
features.
For the KIN-grade, independent immunohistochemical features, and clinical para­
meters, the following statistical procedures were used to analyze the treatment cessation 
effect: two planned pair wise comparisons (T1 versus TO and T2 versus T0) were used 
to study the short and longer term effects (with significance levels p1 and p2 respectively 
as outlined above). The Wilcoxon matched-pairs signed-rank test and McNemar test 
were used for these pair wise comparisons. The latter test was used for the dichotomous 
dependent variables. With a limited number of planned pair wise comparisons the Bon- 
ferroni adjustment of the Type I error rate can be omitted.23 Because there is a definite 
expectation about the direction of the therapy cessation effect, a directional (one-tailed) 
alternative hypothesis was used. All statistical analyses were performed with SPSS 10.0 
for Windows. Results are expressed as means ± standard error of the mean (SEM), un­
less stated otherwise.
Figure 1:
Expression (patterns) of keratin 13 (K13) in keratinocytic intraepidermal neoplasia (KIN) lesions of renal transplant 
recipients at the start of the study (T0) and 6 (T1) and 12 (T2) weeks after acitretin withdrawal.
A. K13 positive versus negative cases. The number of K13 expressing KIN lesions significantly reduced 12 weeks 
after acitretin withdrawal (p=0.02).
B. K13 positive cases subdivided in cases having suprabasal single cell (SSC) expression or zebroid K13 expression. 
The latter pattern was previously found correlated with retinoid treatment in warts of renal transplant recipients12. 
For zebroid K13 expression a decreasing trend was present with 5/9 KIN having zebroid K13 expression at the start 
of the study and only 1/9 KIN at T1 and T2. This reduction in zebroid K13 expression was not significant, probably 
due to the small number of cases (p=0.10).
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Results
Clinical effects of interruption of systemic acitretin
The numbers of counted warts and AKs at each control visit are listed in Table III. 
Only for the number of warts a significant increase was seen after 3 months when com­
pared to the start of the study (p = 0.02); for AKs no significant change in the number of 
lesions was found.
Desquamation of clinically normal and lesional skin did not alter significantly 
during the 3-month study period (Table III). Erythema of normal skin reduced signifi­
cantly already after 6 weeks (p1 and p2 = 0.03): induration of AKs increased significant­
ly only in the first 6 weeks after acitretin withdrawal (p1 = 0.004): this trend sustained 
also after 3 months, although no longer significant (p2 = 0.05).
The mean VAS-score had reduced significantly after 6 weeks of acitretin withdrawal 
(p1 = 0.04), which persisted after 12 weeks (p2 = 0.004) (Table III).
During the 3-month study period, the patients developed 2 BDs, 5 SCCs and 1 basal 
cell carcinoma (BCC), compared to 2 SCCs in the 3 months pre-study period while still 
on acitretin therapy. Differences for the number of SCCs (p = 0.3) were not significant. 
However, numbers are small and follow-up is relatively short.
Histopathological and immunohistochemical effects of interruption of
systemic acitretin
Since immunohistochemical parameters can be dependent of KIN grade, we had to 
take this into account while studying the effects of cessation of acitretin. Of the 9 patients 
three biopsies at respectively T0, T1 and T2 were taken from clinically comparable AKs. 
Despite clinical resemblance of the biopsied AKs within one patient at each control visit, 
histological examination revealed sometimes variation in KIN grade. In 8 patients in all 
visits either KIN 1 or 2 was biopsied, in 1 patient each control visit a KIN 3 lesion was 
biopsied.
A correlation analysis showed that MIB-1 score strongly correlated with KIN grade 
(R = 1). All KIN 1 lesions showed a 1+ MIB-1 score, all KIN 2 lesions a 2+  and all KIN
3 lesions a 3+  MIB-1 score. Also p53 expression was positively correlated with KIN 
grade (R = 0.5, p = 0.01). K13 and p 1 6 INK4A expression were not significantly correlated 
with KIN grade (R = 0.33, p = 0.10 and R = -0.03, p = 0.90 respectively).
When taken the KIN grade into account, we found no significant correlation 
between the biopsy number and the expression of MIB-1, p53, and p16INK4A. Therefore, 
in this small patient group no influence of acitretin withdrawal on expression of these 
three biomarkers could be demonstrated. However, a negative correlation between K13 
expression and the time of biopsy (R = -0.50, p = 0.01) was present.
K13 expression decreased significantly from 1.44 + 0.24 to 0.33 + 0.24 after 12 
weeks (p = 0.02). At the start of the study 90% of KIN lesions were K13 positive, after 6
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Figure 2A:
KIN lesion of RTR, biopsied at the start of 
the study (first day of acitretin 
withdrawal); an abrupt transition from 
normal to lesional skin with 
hyperorthokeratosis and acanthosis is 
seen; a slightly disordered epidermal 
structure with atypia in the basal one 
third of the epithelium is present (HE, 
100x).
Figure 2B:
MIB-1 shows positive nuclear staining in 
the basal one-third layer of the epidermis 
(arrows). A and B, are consistent with KIN 
1(MIB-1, 100x).
Figure 2C:
In lesional skin, a zebroid K13 expression 
pattern is present with alternating 
columns of K13 positive and negative 
cells (K13, 100x).
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weeks SS% and after 12 weeks 22% (Figure 1A). If we only considered KIN lesions 
showing zebroid K1S expression, there was clearly a trend in decrease of the zebroid K1S 
expression pattern after acitretin withdrawal (p = 0.10): at the start of the study zebroid 
K1S expression was found in 5/9 patients (5G%), while after G weeks and 12 weeks of 
acitretin withdrawal zebroid K1S expression was only present in 1/9 patients (11%, 
Figure 1B and 2).
Histopathology of the skin biopsies with a zebroid K1S pattern at the start of the 
study, revealed in the areas of immunohistochemical K1S expression often compact 
hyperorthokeratosis, hypergranulosis, acanthosis and swelling with focally cytoplasmic 
vacuolization of the keratinocytes when compared to the K1S negative adjacent epi­
thelium (Figure 2 and S). These are known histological changes following topical and 
systemic retinoid treatment.24 The transition with the K1S negative epithelium was 
mostly sharp and abrupt.
Figure 3A:
KIN lesion of another RTR than in fig.1, 
also at the start of the study, showing 
dysplasia in the basal one third epidermal 
layer consistent with KIN1. 
Hyperorthokeratosis is evident at the 
surface (HE, 200x) with hypergranulosis. 
Keratinocytes show swelling with a bluish 
cytoplasmic hue (mucine-like material), 
focally with cytoplasmic vacuolization 
(arrows).
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Discussion
The present study shows that 3 months cessation of systemic acitretin treatment is 
followed by reduction of aberrant differentiation in KIN lesions of RTRs with significant 
decrease of K13 expression. Expression of the proliferation marker MIB-1, and of cell- 
cycle-associated proteins p53 and p 1& NK4A, all often found overexpressed in KIN17-25 
(p16NK4A, ow n unpub lished  d a ta ) , were not altered on acitretin withdrawal. These data 
suggest that retinoids in RTRs exert their effect by inducing aberrant differentiation 
(induction of K13, normally present in the suprabasal layers of internal stratified 
squamous epithelia, like the esophagus26) and not by decreasing proliferation or infu- 
encing important tumor suppressors in cutaneous carcinogenesis. Previously we found a 
particular zebroid K13 expression pattern related to retinoid treatment in warts of RTRs 
which we postulated to be indicative of retinoid bioactivity in warts of these RTRs;12 
almost 90% of warts in RTRs showed this typical zebroid K13 pattern in case of retinoid 
treatment. In the present study, concerned with KIN lesions, we found a much lower 
percentage of zebroid K13 pattern at the start of the study, than would be expected from 
the previous findings in warts; only 5/9 patients (56%) on acitretin showed zebroid K13 
expression. This zebroid K13 expression markedly reduced on acitretin withdrawal, with 
only 1/9 patients (11%) displaying this zebroid K13 pattern after 6 and 12 weeks, as we 
had already anticipated based on the previously found correlation between zebroid K13 
expression and retinoid treatment in warts. This marked reduction, however, proved not 
significant (p = 0.1), probably due to the small number of patients. Combining the two 
patterns of K13 expression, the decrease in K13 expression reached significance after 6 
and 12 weeks of acitretin withdrawal (p = 0.03 and p = 0.02 respectively).
The lower frequency of zebroid K13 expression presently found in KIN lesions 
when compared to warts, might be attributable to the dysplastic changes in KIN due to 
genetic alterations that might interfere with the retinoid receptor or interactions with the 
retinoid receptor or alterations in keratin gene regulation (e.g. K13) that would otherwise 
have been transcriptionally induced. Indeed, recently Xu e t al. found progressive de­
crease in nuclear retinoid receptors during skin squamous carcinogenesis.27 On the other 
hand in warts, (transforming) types of human papillomavirus might increase the sensi­
tivity of keratinocytes to retinoid effects.28 Future research on for instance warts and 
actinic keratoses within one patient during systemic acitretin treatment might elucidate 
whether there is an interlesional (warts versus AKs) variation in retinoid susceptibility, 
maybe related to retinoid receptor differences.
In parallel to the immunohistochemical decrease in K13 expression, clinical pro­
gression was seen with significant increase in warts. We could not demonstrate a signifi­
cant increase in number of AKs and SCCs when acitretin was interrupted for 3 months. 
The relatively small number of patients and the short study period could cause this. This 
possibility is being supported by the previous studies by Bouwes Bavinck, where a relapse 
of new skin cancers occurred between 3 and 6 months after acitretin withdrawal, and by 
Shuttleworth,10 who described the development of further lesions 6 months after etreti­
nate cessation.
186
R X R - A N D  R A R - S  E L E  C T I V E R E T I N O I D S  I N  P S O R I A S I S  A N D  ( P R E ) M  A L I G N  A N  T S K I N  D I S O R D E R S
VAS score also significantly decreased in the 3 months study period, reflecting a 
reduction in contentment of the patients with their skin condition.
Already after 6 weeks of acitretin withdrawal, erythema of normal perilesional skin 
diminished significantly, as could be expected since erythema is a well-known side effect 
of topical and oral retinoid treatment.5,29 After 3 months a trend towards increased 
induration of AKs was present; since we found no significant concomitant increase in 
SCCs, induration seems more likely due to increased hyperkeratosis (in the absence of 
retinoids) instead of infiltrative growth. Retinoids could indeed have an antihyper- 
keratotic effect, by induction of aberrant suprabasal K13 expression causing terminal 
differentiation towards non-keratinizing stratified squamous epithelia.26 This diminish­
ed hyperkeratosis with retinoids leads to better cosmetic appearance of the skin, impor­
tant for patient’s contentment. Increased induration in the absence of retinoids could 
make it more difficult for the clinician to differentiate AKs from invasive lesions (mask­
ing effect), necessitating more frequent biopsies in these RTRs, which are already subject 
to frequent skin biopsies.
So far, effects of systemic retinoids on epidermal proliferation in RTRs were only 
studied by means of 3H thymidine labeling index; Shuttleworth et a l10 found a significant 
increase in the labeling indices after 6 months of systemic etretinate treatment in normal 
sun-exposed skin, but not in sun protected skin in 6 RTRs; effects on dysplastic skin 
were not assessed. Besides Gibson et a l., who found no significant differences in histo­
logical features of SCCs,8 no other studies on chemoprevention by systemic retinoids in 
RTRs6,9,30 included histological or immunohistochemical evaluation of retinoid effects 
on skin lesions, to study for instance effects on proliferation or differentiation.
In the present study, clinically comparable actinic keratoses were biopsied, which on 
histological examination varied in KIN grade. When taken the KIN grade into account, 
we found no significant correlation between the time of biopsy and the expression of 
MIB-1, p53, and p16iNK4A. Therefore in this small patient group no influence of acitretin 
withdrawal on expression of these three biomarkers could be demonstrated.
In conclusion, this study demonstrates that 3 months cessation of acitretin therapy 
in RTRs, leads to a significant reduction of aberrant K13 expression, without alteration 
in expression of proliferation and cell-cycle-associated markers (MIB-1, p53, p 1 6 INK4A), 
in KIN lesions of RTRs. Therefore, our data imply that if retinoids in RTRs exert an ef­
fect, it is by modifying differentiation (K13 expression), without altering proliferation.
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3.4
Topical all-trans retinoic acid for actinic keratoses in 
immunocompetent patients
Abstract
All-trans retinoic acid (ATRA) has been claimed to ameliorate actinic kera­
toses clinically. However, little information is available on histological and im ­
munohistochemical parameters for proliferation, differentiation, inflammation 
and apoptosis. A  randomized double-blind placebo-controlled study was under­
taken to determine clinical, histological and immunohistochemical effects of 
short-term treatment of actinic keratoses with topical ATRA. In 9 patients, two 
symmetrical and comparable skin areas with multiple actinic keratoses were 
randomly assigned for treatment with ATRA cream 0.05% versus vehicle cream, 
once daily for 6 weeks. Biopsies were taken from clinically comparable actinic 
keratoses at baseline and after treatment. After 6 weeks treatment neither ATRA 
nor its vehicle significantly reduced the number of actinic keratoses. ATRA signi­
ficantly increased pruritus, erythema, and desquamation. Keratin 10 and keratin 
13 expression were significantly higher in the ATRA-treated actinic keratoses. No 
differences were observed between the two creams with respect to immunohisto­
chemical parameters for epidermal proliferation, apoptosis, and dermal inflam­
mation, and no changes compared to the baseline sections were observed for 
these parameters. The present study suggests that topical ATRA m ay have benefi­
cial effects in the treatment of actinic keratoses via alterations in keratinization 
rather than via effects on epidermal proliferation, inflammation, and apoptosis. 
Apart from an association with retinoid treatment, keratin 13, when it is ex­
pressed in non-retinoid treated actinic keratoses, m ay also be associated with 
malignant transformation in actinic keratoses.
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Introduction
Actinic keratoses (AKs) are erythemato-squamous and often hyperkeratotic, pre- 
malignant lesions that are mainly found on sunlight-exposed skin surfaces. They can 
transform into a squamous cell carcinoma (SCC). Between 0.25% and 16% of AKs will 
convert into a SCC within one year, depending on the number of risk factors present.1
Many studies report beneficial effects of topical all-trans retinoic acid (ATRA) in the 
treatment of AKs,2-4 although some studies do not confirm this.5;6 The study periods 
varied from several months to a few years. Little information is available on immuno- 
histochemical effects of ATRA in the treatment of AKs, especially where early effects are 
concerned. Treatment with topical ATRA frequently causes skin irritation already after 
several days of treatment, which may reduce patient compliance to treatment in an early 
stage.7-9
Therefore, in the present study we focussed on clinical and histological parameters, 
and immunohistochemical parameters for epidermal proliferation, keratinization, termi­
nal differentiation, and apoptosis of short-term therapy of AKs with topical ATRA.
Table I:
Monoclonal antibodies used In the study.
Antibody Specifity Concentration Source
MIB-1 Ki-67 1:50 Immunotech, Marseilles, France
DE-K10 Keratin 10 1:100 Monosan, Uden, Netherlands
1C7 Keratin 13 1:10 Monosan, Uden, Netherlands
LL-025 Keratin 16 1:10 Novocastra Laboratories Ltd, 
Newcastle Upon Tyne, UK
BT621 Transglutaminase 1:10 Biomedical Technologies Inc., 
Stoughton, MA, USA
DO-7 p53 1:200 DAKO, Glostrup, Denmark
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Materials and methods
Study design
A randomized double-blind placebo-controlled approach was used in this trial. 
Patients with multiple AKs in a symmetrical pattern on the dorsal area of their forearms 
and/or hands were randomized for treatment with topical ATRA cream 0.05% on the 
left forearm/hand or on the right forearm/hand. The color-matched vehicle cream of 
ATRA, which was prepared by the pharmacist, was used as placebo on the contra-lateral 
site. Application of both creams occurred once daily for 6 weeks. An independent 
research nurse carried out randomization by opening a sealed envelope that contained 
the application procedure, and prepared the labels for the creams (left versus right), so 
patient and investigator were unaware of the contents of the creams. Ethics Committee 
approval was obtained and all patients gave written informed consent prior to study 
enrollment.
Other dermatological conditions or the use of other topical agents or immunosup­
pressive drugs that might interfere with this study were contra-indicated. The washout 
period for topical treatments and emollients on the test areas was at least 2 weeks, with 
the exception of topical retinoids, where a washout period of 4 weeks was chosen to assure 
an adequate epidermal turnover (normal skin 2-3 weeks; hyperproliferative disorders <1 
week).10
Punch biopsies for immunohistochemical and histological scoring were taken at 
baseline and after 6-weeks treatment from clinically identical AKs located at the two pre­
defined areas. Clinical parameters (pruritus, erythema, desquamation and thickness of 
the AKs) in these areas were monitored biweekly during the application period and at 
the follow-up visit, which was performed 2 weeks after the final application. The number 
of AKs in the two test areas was counted each visit.
Biopsies and staining procedures
Punch biopsies were processed according to standard methods by using the avidin- 
biotin-complex (ABC) staining method and indirect immunoperoxidase techniques on 
paraffin-embedded sections. The following immunohistochemical parameters were as­
sessed: Ki-67 (MIB-1, epidermal proliferation), p53 (DO-7, apoptosis associated), Keratin
10 (K10) (DE-K10, normal keratinization), K13 (1C7, retinoid-associated keratin- 
ization11-13), K16 (LL025, hyperproliferation-associated keratinization), and transgluta­
minase (BT621, terminal differentiation) (Table I). Furthermore, total dermal infiltrate 
(TDI) scores and epidermal thickness were assessed. Sunlight-exposed normal skin was 
used as a control for all immunohistochemical parameters. Esophageal tissue was used 
as a positive control for K13 staining.
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Scoring methods
Pruritus, erythema, desquamation and thickness of the AKs were assessed by using 
a semi-quantitative score on a 5-point scale: 0 = none, 1 = slight, 2 = moderate, 3 = mod­
erate-severe, 4 = severe.
MIB-1 and p53 were counted as the number of positive cells per millimeter length of 
section. Keratins were scored by semi-quantitative analysis on a 7-point scale: 0 = no 
staining, 1 = sporadic staining, 2 = minimal staining, 3 = moderate staining, 4 = mod­
erate-pronounced staining, 5 = pronounced staining, 6 = whole epidermis stained. 
Transglutaminase scores were assessed as the ratio of BT621 positive epidermal cell 
layers divided by the total number of epidermal cell layers. Epidermal thickness was 
measured in millimeters. TDI was scored by using the following 5-point scale: 0 = no in­
filtrate, 1 = minimal infiltrate, 2 = moderate infiltrate, 3 = moderate-pronounced in­
filtrate, 4 = pronounced infiltrate. Immunohistochemical scoring occurred along the 
complete length of the slides. All histological and immunohistochemical scoring occurred 
under blinded conditions by two independent investigators.
Statistics
In order to substantiate differences between baseline biopsies and biopsies taken 
after 6 weeks treatment, as well as differences between ATRA-treated biopsies and 
vehicle-treated biopsies, the Wilcoxon matched pairs test was used. For statistical ana­
lysis of the clinical parameters a paired T-test was used. Assessment of a statistical 
significant correlation between Ki-67 and p53 was performed by calculating Spearman’s 
rank correlation. A p-value < 0.05 was considered statistically significant. Calculations 
were performed using Statistica version 9.0 (StatSoft Inc, 2300 East 14th Street, Tulsa, 
OK 74104, USA).
Pruritus
Time (weeks)
Figure 1:
Pruritus scores on a 5 point semi­
quantitative scale as experienced by the 
subjects during the 6-week treatment 
period and 2 weeks follow-up with topical 
ATRA, respectively vehicle (* significant 
difference between ATRA and vehicle; 
p < 0.05).
ATRA
Vehicle
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Results
Demographics
In total 9 patients were included: 3 women and 6 men. The average age was 63 ±
11 (mean ± SD) years. Patients have had AKs since 6.8 ± 3.7 (mean ± SD) years. In 3 
out of these patients one or more SCCs had developed before study inclusion and 5 out 
of these patients had a history of one or more basal cell carcinomas. In general, patients 
responded well to previous treatments, comprising cryotherapy and topical 5-fluor- 
ouracil. Before the washout period most patients used indifferent creams for smoothen- 
ing of the lesions and sunscreens for prevention of new AKs. Only one patient had pre­
viously used topical ATRA.
Clinical results
No significant differences in baseline values were seen between the two test areas. 
After 6 weeks treatment, the ATRA-treated AKs showed significant more pruritus 
(p = 0.04; Figure 1), more erythema (p< 0.001; Figure 2), and more desquamation 
(p<0.01; Figure 3) compared to the vehicle-treated lesions. In two patients application 
of the creams had to be reduced to every other day after 4 weeks of treatment because of 
skin irritation. Due to the irritation properties of ATRA, the area that was randomized 
for application of topical ATRA could be distinguished during the final stage of the study 
in some patients, somehow reducing the success of blinding. Both creams demonstrated 
significantly less thickness after 6 weeks treatment compared to the baseline (p = 0.03), 
but no differences with respect to thickness were observed between the two creams.
Two weeks after cessation of the applications the differences between the two creams 
had disappeared and values had returned to baseline levels. None of the two creams was 
able to significantly reduce the number of AKs during this study period (Figure 4).
Histological and immunohistochemical results
Histological and immunohistochemical data are summarized in Table II. Compared 
to normal skin, keratin 10 is less expressed in AKs, where areas without K10 expression 
can be seen in the suprabasal compartment. A statistically significant higher expression 
of K10 (p = 0.05) was found in ATRA-treated compared to untreated AKs.
In normal skin K13 is absent, but in AKs K13 expression was seen. Six out of 9 pa­
tients (67%) showed mild to moderate focal expression of K13 in the ATRA treated 
AKs. Remarkably, also 2 untreated AKs and 1 vehicle treated AK showed minimal K13 
expression (Figure 5). One of these patients had used tretinoincream 4 weeks prior to 
the study. The other two patients had not used topical retinoids, creams containing vita­
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min A, or oral intake of high doses of vitamin A during the previous year. K13 expression 
was significantly higher (p = 0.04) in ATRA-treated compared to vehicle-treated AKs.
All other histological and immunohistochemical parameters did not reveal any 
significant alterations when comparing the two creams or when comparing baseline and 
post-treatment situation. Ki-67 and p53 expression is increased in AKs compared to 
normal skin. In general, the expression pattern of p53 largely followed the distribution 
of Ki-67 positive nuclei. A statistically significant positive correlation between the 
number of Ki-67 positive nuclei and the number of p53 positive nuclei was found in this 
study (p = 0.02; R = 0.79). Hyperproliferation-associated K16 expression was, in contrast 
to normal skin, abundantly expressed both in the basal and suprabasal layers. Trans­
glutaminase was not only found in the granular layer, as seen in normal skin, but also in 
the spinal layer of the epidermis in the AKs. Furthermore, dermal infiltrate and thickness 
of the epidermis were higher in AKs than in normal skin.
Table II:
Histological and immunohistochemical parameters (Mean ±  SEM) for untreated AKs and AKs that have 
been treated for 6 weeks with topical ATRA, respectively vehicle.
Parameter Scoring method Untreated ATRA Vehicle Normal skin
(reference number)
Ki67 positive cells/mm 165 ± 4 7 *** 175 ± 26 185 ± 50 28(24)
Keratin 10 7-point scale 4.1 ± 0.2* 4.9 ± 0.1* 4.1 ± 0.3 5.0(25)
Keratin 13 7-point scale 0.6 ± 0.4 1.0 ± 0.4** 0.1 ± 0.1** 0(26)
Keratin 16 7-point scale 3.8 ± 0.3 3.8 ± 0.2 3.6 ± 0.2 0(24)
Transglutaminase positive-/total cell layers 0.18 ± 0.04 0.18 ± 0.03 0.21 ± 0.04 0.20(27)
p53 positive cells/mm 418 ± 115*** 626 ± 163 588 ± 195 20
(own unpubl. data)
Epidermal thickness mm 0.44 ± 0.09 0.33 ± 0.08 0.37 ± 0.08 0.30
(own unpubl. data)
Dermal infiltrate 5-point scale 2.0 ± 0.4 2.0 ± 0.4 2.2 ± 0.5 1.0
(own unpubl. data)
* Significant difference between ATRA-treated AKs and untreated AKs (p < 0.05);
** Significant difference between ATRA-treated AKs and vehicle-treated AKs (p < 0.05);
*** Significant correlation between Ki67 and p53 in untreated AKs (p < 0.01).
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Erythema
Time (weeks)
Figure 2:
Erythema scores on a 5 point semi­
quantitative scale for the ATRA- and 
vehicle treated test areas during the 
6-week treatment period and 2 weeks 
follow-up (* significant difference 
between ATRA and vehicle; p < 0.05).
Desquamation
Time (weeks)
Figure 3 :
Desquamation scores on a 5 point semi­
quantitative scale for the ATRA- and 
vehicle treated test areas during the 
6-week treatment period and 2 weeks 
follow-up (* significant difference 
between ATRA and vehicle; p < 0.05).
Number of AKs
Time (weeks)
Figure 4 :
The number of AKs at the ATRA- and 
vehicle treated test areas during the 
6-week treatment period and 2 week’s 
follow-up.
ATRA
Vehicle
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Figure 5:
Scattered expression of K13 in an 
untreated AK without previous use of 
retinoids. In the suprabasal compartment 
of the epidermis several dark-stained K13 
positive keratinocytes can be seen (arrow) 
(100x).
Discussion
In this study, that is focussed on short-term effects of topical ATRA, a significant 
higher expression of K13 and significant skin irritation was seen in ATRA-treated AKs 
compared to vehicle-treated AKs, suggesting the study design was adequate to reveal 
early retinoid effects. Nevertheless, although important hallmarks of AKs are a hyper­
proliferative state, an increased expression of (especially mutant-type) p53,14 and dis­
turbed differentiation, only an alteration in differentiation parameters was seen in this 
study, as represented by an increase in K10 and in K13 expression. No decrease in epider­
mal proliferation was found after 6 weeks treatment with ATRA, even though retinoids 
are known to suppress proliferation in psoriasis and other hyperproliferative skin condi­
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tions15 and as AKs are hyperproliferative conditions that feature high levels of Ki-67 
positive keratinocytes.16 Furthermore, no alterations in apoptosis associated p53 protein 
expression were seen, despite the fact that retinoids can induce apoptosis and may act as 
a chemopreventive treatment.17;18 A positive relationship between epidermal prolifera­
tion and p53 protein in AKs has been reported in several studies.19;20 The present study 
reconfirms this relationship. Other parameters, including hyperproliferation-associated 
K16, transglutaminase, dermal infiltrate, and epidermal thickness, did not change either. 
In contrast to other clinical studies, no reduction in the number of AKs was found, but 
this may be explained by the relatively short study period.
With respect to keratinization, retinoids are known to alter normal differentiation 
of the cornifying epidermis towards an esophageal-type of differentiation. Retinoids 
stimulate synthesis of low molecular weight keratins, such as K13, which are normally 
present in internal squamous epithelia, and inhibit the production of higher molecular 
weight proteins, normally present in adult human skin.12;21
Remarkably, as this study demonstrates, untreated AKs and vehicle treated AKs can 
also incidentally express K13 in the absence of retinoid therapy. In human skin K13 
expression has been found in poorly differentiated SCCs but not in well-differentiated 
SCCs.22 Dedifferentiation can be a feature of malignant transformation, which is as­
sociated with a switch in synthesis of high molecular weight proteins towards low mo­
lecular weight proteins.23 Bearing this in mind, expression of the low molecular weight 
K13 in a non-retinoid treated AK may well be sign of a more dedifferentiated state of this 
AK, and thus a lesion with an increased risk for transformation towards a SCC. It is 
somehow contradictory that ATRA in one way may have chemopreventive capacities in 
the treatment of AKs and SCCs, and on the other hand may induce a keratin that is pos­
tulated to be associated with malignant transformation. However, an explanation for this 
phenomenon could be that we deal with two independent epiphenomena, related to two 
distinct pathways: malignant transformation associated dedifferentiation and (benign) 
retinoid-associated keratinization. In that situation, it is attractive to speculate whether 
K13 expression in non-retinoid-treated AKs may provide additional information on the 
risk of malignant transformation of AKs for use as a diagnostic parameter. It is obvious 
that further studies are necessary to resolve this issue.
Integrating the clinical, histological and immunohistochemical findings of this study 
in AKs, we observed differences in keratinization between ATRA and its vehicle. We 
could not demonstrate reductions or alterations in the number of AKs, nor in important 
hallmarks of AKs, such as epidermal proliferation and p53 expression, during 6-week 
treatment with topical ATRA. This implicates that topical ATRA does not alter epider­
mal proliferation and p53 expression, but only changes the process of keratinization in 
AKs during a 6-week treatment period. Studies with longer treatment duration or higher 
concentrations of ATRA are needed to further elucidate these findings. However, the 
relevance of this treatment regimen may be limited, while ATRA causes substantial skin 
irritation.
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3.5
Combination of topical calcipotriol and all-trans 
retinoic acid in actinic keratoses in renal transplant 
recipients
Abstract
A double bind placebo-controlled study was undertaken to determine clini­
cal, histological and immunohistochemical effects of topical calcipotriol and all- 
trans retinoic acid (ATRA) in the treatment of actinic keratoses in renal trans­
plant recipients. In 13 renal transplant recipients 4 comparable skin areas with 
multiple actinic keratoses were treated twice daily for 6 weeks by using the fol­
lowing double-blind approach: 1. Calcipotriol cream. 2. ATRA 0.02%. 3. Calcipo­
triol cream (mornings) and ATRA cream 0.02% (evenings). 4. Vehicle cream. 
Examination of the test areas was carried out biweekly and punchbiopsies were 
taken before and after treatment. No single treatment resulted in a reduction of 
the number of actinic keratoses. Both clinically and immunohistochemically 
(epidermal proliferation, keratinization, inflammation and apoptosis) no signi­
ficant differences were found between the 4 treatment regimens. The present 
study indicates that short-term topical treatment with calcipotriol cream and/or 
ATRA cream 0.02% is not effective in actinic keratoses in renal transplant recipi­
ents.
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Introduction
In patients receiving immunosuppression following renal transplantation, actinic 
keratoses have been reported in 38% after 5 years follow-up.1 However, it has been spe­
culated that with time nearly all these patients will develop actinic keratoses. The major 
etiological factors for the origin of these lesions are previous sunlight exposure, the dura­
tion of immunosuppression and HPV infections.2,3 In general, the percentage of actinic 
keratoses that will convert into a squamous cell carcinoma (SCC) within one year varies 
between 0.25% and 20%, depending on the number of risk factors present.4-5 Since 
actinic keratoses in renal transplant recipients are, as a rule, multiple and behave more 
aggressive when compared to identical lesions in non-immunocompromized individuals, 
these patients are in need of a chemopreventive treatment that is quickly effective (with­
in weeks) and well tolerated.5
It has been suggested that actinic keratoses might be potential targets for vitamin D 
and retinoids.6 Several clinical studies have shown efficacy of topical retinoids in the 
treatment of actinic keratoses.7"8 But other studies did not confirm this clinical impres­
sion.9,10 No histological and immunohistochemical studies with topical retinoids on 
actinic keratoses in the population of renal transplant recipients have been performed so 
far to strengthen or contradict the presumed efficacy. The criteria for improvement of 
actinic keratoses have to comprise both the clinical appearance and relevant histopatho- 
logical and immunohistochemical features of the preneoplastic process. Clinical improve­
ment alone without improvement of proliferative characteristics may mask the keratoses 
and can result in a recurrence of lesions after cessation of treatment.11,12 No studies have 
been performed on vitamin D derivatives in the treatment of actinic keratoses. The aim 
of the present study was to find out whether monotherapy or a combination of topical 
ATRA and the vitamin D3 derivative calcipotriol provides an approach for actinic 
keratoses which is effective from clinical, histological and immunohistochemical per­
spective in a treatment period of 6 weeks and that is well tolerated by the patients.
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Materials and methods
Study design
Thirteen renal transplant recipients with multiple actinic keratoses were included in 
this double-blind, placebo-controlled study. All patients applied each of the following 
treatment regimens for 6 weeks to 4 comparable and distinct areas of actinic keratoses 
on the extremities: (I) calcipotriol cream 50|ag/g twice daily, (II) ATRA cream 0.02% 
twice daily, (III) the combination of calcipotriol 50|ag/g cream once daily and ATRA 
cream 0.02% once daily, and (IV) cremor cetomacrogolis twice daily. With respect to the 
combination therapy, calcipotriol cream was used in the morning and all-trans retinoic 
acid cream was used in the evening. ATRA in a concentration of 0.2% was selected, 
since the skin of renal transplant recipients often is atrophic and subsequently irritant 
reactions can be severe. The washout period for any topical treatment on the test areas 
was 2 weeks. A follow-up visit was performed 2 weeks after treatment discontinuation. 
Medical Ethics Committee approval was obtained and all patients gave informed consent 
prior to study enrollment.
Formulations
Calcipotriol 50|ag/g cream (Daivonex®, cream) was obtained from LEO Pharma, 
Weesp, The Netherlands. The pharmacist formulated ATRA cream 0.02%. The cream 
base consisted of cremor cetomacrogolis, alcohol ketonatus and butylhydroxytolueen. As 
placebo cream, cremor cetomacrogolis was used, which approached the physical-chemi­
cal characteristics of the other two creams. The pharmacist manufactured the creams 
color-matched with a randomization scheme.
Clinical efficacy and adverse events
Pruritus, erythema, induration and desquamation of the actinic keratoses in the test 
areas were assessed biweekly during the application period and at the follow-up visit, 
which was scheduled 2 weeks after the final application. For these parameters we used 
a semi-quantitative score on a 5-point scale (0 = none, 1 = slight, 2 = moderate, 3 = 
moderate-severe, 4 = severe). Furthermore, the number of actinic keratoses in the test 
areas was counted each visit.
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Immunohistochemical techniques and scoring methods
Three millimeter biopsies taken at the baseline and after 6-weeks treatment from 
clinically identical actinic keratoses of the 4 test areas were processed by using indirect 
immunoperoxidase techniques on paraffin-embedded sections, and were analyzed based 
on previously published scoring methods by two blinded investigators.13 Esophageal 
tissue was used as a positive control for keratin 13 staining. With respect to proliferation 
(MIB-1 for Ki67), and apoptosis (DO-7 for p53 protein) the number of positive cells per 
millimeter length of section was counted. Keratinization (DE-K10 for keratin 10, 1C7 for 
keratin 13, and LL-025 for keratin 16) and dermal infiltrate scores were assessed by 
semiquantitative scoring techniques. Terminal differentiation (BT621 for transglutami­
nase) was assessed as the number of stained epidermal cell layers divided by the total 
number of epidermal cell layers. Epidermal thickness was measured in millimeters.
Statistical analysis
In order to substantiate the differences between the baseline situation and the 
situation after 6 weeks treatment, with respect to the clinical and immunohistochemical 
parameters, an Analysis of Variance (ANOVA) test was used.
Table I:
Monoclonal antibodies used In the study.
Antibody Specifity Concentration Source
MIB-1 Ki-67 1:50 Immunotech, Marseilles, France
DE-K10 Keratin 10 1:100 Monosan, Uden, Netherlands
1C7 Keratin 13 1:10 Monosan, Uden, Netherlands
LL-025 Keratin 16 1:10 Novocastra Laboratories Ltd, 
Newcastle Upon Tyne, UK
BT621 Transglutaminase 1:10 Biomedical Technologies Inc., 
Stoughton, MA, USA
DO-7 p53 1:200 DAKO, Glostrup, Denmark
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Results
The mean age of the 13 subjects was 47.5 (37 -  68 years). The mean number of 
years after transplantation was 19.7 (6 -  29 years). Patients had actinic keratoses since 
9.0 ± 4.6 years (mean ± SEM) after transplantation. In 7 out of these patients invasive 
squamous carcinomas had occurred before study inclusion. In 1 patient a squamous cell 
carcinoma developed from an actinic keratosis in the calcipotriol-treated area during the 
application period of the study.
Clinical parameters showed no significant differences between the 4 treatments, al­
though, overall significantly more erythema (p = 0.04; Figure 1) and less induration 
(p = 0.007; Figure 2) were observed after 6-weeks treatment compared to the baseline. 
No differences in desquamation and in the number of actinic keratoses could be found 
(Figure 3). Mild pruritus was seen in all test areas during treatment, except for the sites 
that were only treated with the vehicle, and had disappeared 2 weeks after treatment 
discontinuation (Figure 4).
Histological and immunohistochemical data-analysis revealed no significant differ­
ences between each of the 4 treatments or between baseline and post-treatment situation, 
for the following parameters: MIB-1, DE-K10, LL-025, BT621, DO-7, epidermal thick­
ness, and dermal infiltrate (Table II). In some actinic keratoses very typical and different 
staining patterns for DO-7 (Figure 5) and MIB-1 (Figure 6) were observed in consecu­
tive slides, suggesting that the correlation between p53 and Ki-67, which has been found 
in several studies, may vary in individual areas of actinic keratoses in renal transplant re­
cipients. Keratin 13 expression (1C7) was observed in 3 ATRA-treated actinic keratoses, 
in 3 ATRA-calcipotriol-treated actinic keratoses, and in 2 calcipotriol-treated actinic 
keratoses. No keratin 13 expression was found in the untreated actinic keratoses and in 
the vehicle treated actinic keratoses.
Figure 1:
Erythema scores of the actinic keratoses 
for the 4 treatments at the test areas 
during the study. (* Indicates a significant 
increase in erythema after 6 weeks 
treatment compared to the baseline 
(p < 0.05); ** indicates a significant 
reduction in erythema after cessation of 
the cream applications compared to the 
week 6 visit (p < 0.05)).
■  ATRA + Calcipotriol
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Induration
Baseline Week 2 Week 4 Week 6 Follow-up
Figure 2:
Induration scores of the actinic keratoses 
for the 4 treatments at the test areas 
during the study. (* Indicates a significant 
reduction in induration of the actinic 
keratoses compared to baseline 
(p < 0.01)).
I ATRA 
I Calcipotriol 
I ATRA + Calcipotriol 
I Vehikel
Number of ac tin ic  keratoses
Baseline Week 2 Week 4 Week 6 Follow-up
Figure 3:
The number of actinic keratoses for the 4 
treatments at the test areas during the 
study.
I ATRA 
I Calcipotriol 
I ATRA + Calcipotriol 
I Vehikel
Figure 4:
Pruritus scores for the 4 treatments at the 
test areas during the study.
I ATRA 
I Calcipotriol 
I ATRA + Calcipotriol 
I Vehikel
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Table II:
Histological and immunohistochemical parameters (Mean ±  SEM) for the untreated actin ic keratoses and 
after 6 weeks treatm ent w ith ATRA cream, calcipotriol cream, ATRA-calcipotriol combination and vehicle 
cream.
Parameter Scoring method Untreated ATRA Calcipotriol Combination Vehicle
Dermal infiltrate 5-point scale 2.2 ± 0.2 1.9 ± 0.3 1.8 ± 0.3 1.8 ± 0.2 1.6 ± 0.2
Keratin 10 7-point scale 4.6 ± 0.2 4.6 ± 0.2 4.5 ± 0.2 4.5 ± 0.2 4.3 ± 0.2
Keratin 13 7-point scale 0 0.3 ± 0.2 0.3 ± 0.2 0.4 ± 0.2 0
Keratin 16 7-point scale 3.8 ± 0.3 3.4 ± 0.4 3.7 ± 0.4 3.8 ± 0.3 3.9 ± 0.2
Transglutaminase positive-/total cell layers 0.37 ± 0.03 0.37 ± 0.03 0.37 ± 0.02 0.38 ± 0.03 0.36 ± 0.03
Ki-67 positive cells/mm 218 ± 29 272 ± 64 189 ± 27 270 ± 45 227 ± 32
p53 positive cells/mm 388 ± 40 252 ± 32 247 ± 43 364 ± 58 313 ± 53
Epidermal thickness mm 0.57 ± 0.08 0.38 ± 0.07 0.45 ± 0.09 0.35 ± 0.06 0.51 ± 0.10
Figure 5:
P53 protein expression (DO-7) in an 
untreated actinic keratosis: the focal 
expression pattern is clearly visible.
Figure 6:
Ki-67 expression (MIB-1) in a consecutive 
slide of the same untreated actinic 
keratosis as shown in previous figure: 
the Ki-67 expression pattern spreads 
throughout the epidermis and does not 
correlate with p53 protein expression.
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Discussion
The present study demonstrated no significant differences in clinical, histological 
and immunohistochemical parameters between the 4 different therapies during a 6-week 
treatment period. Post-treatment values for these parameters did not reveal a significant 
improvement, apart from a minimal reduction in induration, that was not represented in 
general histological features such as epidermal thickness, and that was probably caused 
by a softening effect of the creams. Integrating these findings, it can be concluded that a 
6-week treatment with calcipotriol 50|ag/g cream, ATRA 0.02% cream or the combina­
tion of both, is not effective in the treatment of actinic keratoses in renal transplant 
recipients. In contrast, a 6-week treatment of topical retinoic acid in ichthyoses, and cal- 
cipotriol in psoriasis, has been reported to result in marked clinical improvement, reduc­
tion of epidermal hyperproliferation, and a decrease of several abnormalities with respect 
to inflammation and keratinization. First clinical and histological efficacy has already 
been found after 2-4 weeks treatment.13-14
It is remotely possible that a prolonged treatment schedule might show an effect for 
some parameters. However, the dynamics of actinic keratoses rapidly progressing to 
squamous cell carcinomas in renal transplant recipients makes such an option not ade­
quate. Treatment with formulations containing higher concentrations of ATRA might be 
more effective, however treatment with such a cream causing irritation, obviously re­
duces compliance to treatment. In conclusion, the common believe that topical retinoids 
and vitamin D3 analogues might be of value in actinic keratoses of renal transplant recipi­
ents appears to be unsubstantiated. Topical 5-fluorouracil (Efudix®) and cryo-therapy 
remain the first therapeutic approaches in actinic keratoses in these patients.
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3.6
Keratin 13 and keratin 19 expression in verrucae 
vulgares and morbus Bowen in renal transplant 
recipients and immunocompetent patients
Abstract
The aim of the present study was to compare frequency and expression pat­
terns of keratins K13 and K19 in cutaneous warts of renal transplant recipients 
(RTRs) and immunocompetent individuals (ICIs). In RTRs the effect of retinoids 
on both keratins was assessed. For this retrospective, non-randomized immuno- 
histochemical study, excisions of cutaneous warts from RTRs and ICIs were 
retrieved from the archives of the department of Pathology, University Medical 
Center Nijmegen, the Netherlands. Twenty-one warts from both RTRs and ICIs 
were examined. In 10 specimens from RTRs, patients received either systemic 
acitretin or topical all-trans retinoic acid. A  significant higher percentage of RTR- 
related warts expressed K13 when compared to warts of ICIs, 86% versus 14% 
(p<0.001). In RTR-related warts, retinoid treatment correlated significantly with 
a particular strong strikingly segmental (“zebroid”) K13-expression pattern. With­
out retinoids, K13 was mostly restricted to suprabasal single cells. K19 was ab­
sent in all warts of both patient groups. It was concluded that: 1.Retinoids strong­
ly correlate with K13 in a characteristic “zebroid” pattern in RTR-related warts, 
making K13 a sensitive marker for retinoid bioactivity in skin(lesions) of RTRs. 2. 
In non-retinoid treated renal transplant patients, K13 is also frequently found in 
warts, but without the dramatic “zebroid” pattern noted with retinoid treated 
warts.
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Introduction
Epithelial keratins comprise a heterogenous group of acidic (type I) and neutral-to- 
basic (type II) proteins. As a general rule, they are coexpressed in specific pairings, each 
pair consisting of a type I and type II keratin. For instance, in the normal adult skin, 
keratin pairs K5/K14 predominate in the basal layer and K1/K10 in the suprabasal com- 
partment.1
The type I keratins K13 and K19, are usually expressed separately in adult epithelia. 
Combined expression occurs only in fetal skin. Both keratins are thought to be absent in 
normal skin of adults except for certain body sites such as penile foreskin that still 
contains K13. Furthermore, K13 in adults is abundantly present in internal stratified 
epithelia and associated (with terminal differentiation) with suprabasal expression.1-4 
K19 expression in adults is found in simple epithelia, such as most glandular epithelia.
In the past years several murine and in vitro studies have demonstrated that vitamin 
A and its derivatives (retinoids) are important regulators of epidermal differentiation 
and influence keratin gene expression. In cultured keratinocytes, the induction of an 
embryonic type of differentiation by retinoids with reinduction of keratin 13 and 19 
expression has been well documented.5-6 In vivo topical application of retinoids on photo­
aged human skin also showed induction of K13.7
Although retinoids are used as chemopreventive agents for inhibiting skin cancer in 
renal transplant recipients,8-9 to the best of our knowledge there are no studies regarding 
the effects of retinoids on keratin expression in skin or skin lesions of these patients.
Renal transplant recipients (RTRs) are known to develop multiple warts and skin 
neoplasms. Immunosuppressive treatment, sun exposition and viral infection with hu­
man papillomavirus are all implicated in the etiology of cutaneous tumorigenesis in 
RTRs.10-14 The frequent simultaneous occurrence of warts and skin cancers in renal 
transplant recipients led us to the assumption that the verrucae or warts in renal trans­
plant recipients might be more prone to become malignant than equivalent lesions in 
normal immunocompetent individuals (ICIs). The existence of high and low risk 
papillomas was previously shown in mice models on cutaneous carcinogenesis.15 Inter­
estingly, these high-risk papillomas showed expression of K13 which was absent in low 
risk papillomas.
The present study shows that RTR-associated warts in contrast to warts in normal 
ICIs indeed show pronounced K13 expression. This suggests that altered keratin ex­
pression may reflect an important molecular event inherent in malignant degeneration 
of warts in RTRs. Furthermore, this K13 expression in warts of RTRs strongly correlates 
with retinoid therapy but in contrast to findings in animal studies and in cultured human 
keratinocytes,5 we could not demonstrate influence of retinoids on K19 expression in 
these patients. Retinoid related K13 expression in epithelial skin lesion of RTRs displays 
a highly characteristic (zebroid) pattern, making K13 a useful marker for evaluating the 
effect of retinoid treatment in these patients.
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Materials and methods
Tissues
For this retrospective immunohistochemical study we retrieved formalin fixed and 
paraffin embedded skin excisions of warts from renal transplant recipients (21 excisions, 
18 patients, average age 50.8 years, mean duration of immunosuppression 16.4 years) 
and from normal immunocompetent individuals (21 excisions, 19 patients, average age 
33.3 years) out of our archival material at the department of Pathology, University 
Medical Center Nijmegen St. Radboud, the Netherlands.
Retinoid treatment
Retinoids were only used by renal transplant recipients. Nine RTRs (10 excisions) 
received retinoid treatment. In 3 patients (4 excisions) topical all-transretinoic acid (con­
centration 0.025-0.05%) was used and 6 patients received systemic acitretin (dose at 
time of biopsy varying from 10-35 mg). Patients on systemic acitretin participated in a 
clinical trial, not related to the present study, studying the effects of systemic retinoid on 
cutaneous carcinogenesis in RTRs. Inclusion criteria for this trial were either the pres­
ence of at least one SCC in the patients’ history or the presence of 10 or more actinic 
keratoses, at least one confirmed histologically. Initially most patients on acitretin started 
with a dose of 30-35 mg/day, a dosage that in an earlier study proved to prevent squa­
mous cell carcinomas in renal transplant recipients.8 However, in a relative large number 
of patients doses of acitretin had to be lowered because of mucocutaneous side-effects 
(peeling of palms and soles and/or cheilitis). Retinoid and non-retinoid-treated patients 
showed no obvious differences with respect to duration, dosage and type of immuno­
suppression, all factors implied in the etiology of skin cancers in immunosuppressed 
patients (data not shown).
Histopathology
Histology of all studied lesions was revised according to World Health Organization 
(WHO) definitions of verrucae.16 The verrucae consisted predominantly of common 
warts or verrucae vulgares with a smaller group of verrucae plana especially in the ICIs, 
usually located on hands and feet. Condylomata acuminata or anogenital warts were not 
included.
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Immunohistochemistry
Immunohistochemical analysis was performed on all excisions by using standard 
avidin-biotin-peroxidase complex system with either diaminobenzidine (DAB) and/or 3- 
amino-9-ethylcarbazole (AEC) as the chromogens. In brief, 4-micron thick paraffin 
sections were deparaffinized, hydrated and washed in buffered phosphate. For K13 stain­
ing sections were cooked in buffered citrate (10mM, pH 6.0) in the microwave oven for 
twice 5 minutes (600 Watt). After a cooling down period of (at least) 20 minutes and 
preincubation with 20% normal horse serum for 15 minutes, the sections were incubat­
ed with undiluted primary antibody, overnight at 4°C. We used two mouse monoclonal 
primary antibodies, 1C7 (IgG2a) and 2D7 (IgG2b), both recognizing K13.17 As positive 
control normal esophageal tissue was used. After incubation with primary antibodies 
sections were incubated for 30 minutes with (a 1: 200 dilution of) biotinylated horse 
anti-mouse (Vector laboratories, Burlingham, CA), followed by a 45-minute incubation 
with (a 1:50 dilution of) avidin-biotin complex (Vector laboratories, Burlingham, CA). 
For development with AEC, ABC concentrations were doubled.
For K19 immunohistochemistry (mouse) monoclonal antibody, RCK108 (DAKO) 
was used. Besides different pretreatment (0.1% pronase for 10 min.), the same procedure 
as for K13 was followed. Eccrine ducts and sweat glands served as positive internal con­
trols. Sections were counterstained with Mayer’s hematoxylin for 2 minutes.
Scoring of immunohistochemical results
Immunoreactivity was scored as negative, slightly positive in a suprabasal single cell 
pattern (< 10% lesional keratinocytes positive) or strongly positive in a suprabasal seg­
mental columnar pattern (zebroid pattern). Scoring was performed without knowledge 
of patient history and use of retinoid therapy.
Statistics
The Pearson Chi-square (X2) test was used in all statistical analysis and significance 
was set at p<0.05.
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Results
General aspects of immunostaining for K13 and K19
In all cases, immunostaining for K13 was restricted to the cytoplasm. Slight varia­
tions in staining intensity were observed in lesional skin when comparing antibodies 
1C7 and 2D7, with overall stronger staining with the 2D7 antibody. Principally, however 
the staining pattern of lesional skin with both antibodies was identical. Normal eso­
phagus, which was used as positive control, showed strong diffuse suprabasal staining.
K19 immunostaining was also localized in the cytoplasm. Eccrine ducts and sweat 
glands, serving as internal controls, showed marked positivity.
Expression of K13 and K19 in warts of RTRs versus ICIs and effects
of retinoid treatment
There was a statistically significant difference in K13 expression between warts of 
RTRs when compared to warts of ICIs (p<0.001). A high percentage (86%) of the warts 
from RTRs showed K13 expression, whilst in benign warts of ICIs almost all lesions were 
negative except for 3 out of 21 cases with suprabasal single cell positivity (14%) (Table 
I and Figure 1). This statistical difference in K13 positivity stayed present when we left 
retinoid treated patients out; 82% K13 positivity in non-retinoid-treated RTRs versus 
14% in the controls (p<0.001). Besides number of positive excisions, also the propor­
tion of positive lesional cells differed and was far more pronounced in the warts from 
transplant patients: the 3 positive warts of ICIs showed only suprabasal single cell posi­
tivity (Figure 2); in RTRs, half of the 18 positive warts also showed this single supra­
basal cell positivity, while the other half showed strong positive staining in a remarkable 
pattern of segmental positive suprabasal full-epithelium thickness columns, a pattern we 
termed zebroid (Figure 1B, D and Figure 2). This particular pattern was not linked to 
eccrine ducts or hair follicle structures; the latter actually seemed to be spared. This 
zebroid pattern (statistically) correlated (p<0.001) with retinoid treatment (topical and 
systemic) when comparing retinoid treated RTRs (warts and ISSCCs) with non-retinoid 
treated RTRs (Table II). Only 1 patient without (anamnestically traceable) retinoid 
treatment exhibited the same K13 expression pattern.
Most warts were superficially excised with no perilesional skin available. In 1 reti­
noid treated RTR the perilesional skin showed K13 positivity comparable with the above 
described zebroid pattern.
All warts in both groups were negative for K19 with retinoids having no demon­
strable effect on K19 expression (Figure 1C, D).
215
R X R -  A N D  R A R - S E L E  C T I V E R E T I N O I D S  I N  P S O R I A S I S  A N D  ( P R E ) M A L I G N A N T  S K I N  D I S O R D E R S
Table I:
K13 positive and negative warts in RTRs and ICIs.
Warts of RTRs (N=21) Warts of ICIs (N=21)
K 13 positive 18 (86%) 3 (14%)
K 13 negative 3 (14%) 18 (86%)
Figure 1:
A. Hematoxylin-eosin staining of a wart from a retinoid-treated renal transplant recipient (RTR) (original 
magnification X40).
B. Immunohistochemical analysis of a wart from a retinoid-treated RTR for K13 (monoclonal antibody 2D7, DAB as 
the chromogen) showing the particular strong 3+ positive zebroid pattern of alternating suprabasal columns of 
K13-positive and K13-negative keratinocytes. This zebroid pattern proved significantly correlated to retinoid 
treatment in RTRs (original magnification X40).
C-D. Wart of retinoid treated RTR showing uncoupled regulation of K13 and K19 expression by retinoids with strong 
zebroid pattern K13 positivity (D), while K19 expression is absent (C). The arrow (C) point to K19-positive sweat 
glands, which serve as internal control (original magnification X40).
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Warts in RTRs. Strong K i3  positivity (zebroid pattern) and not zebroid K i3  positivity vs. retinoid therapy.
Table II:
Retinoid treated warts (N=10) Non-retinoid treated warts (N=11)
K 1B zebroid pattern 9 (90%) i  (W /o)
K 1B not zebroid pattern i  (9%) 10 (91%)
Figure 1 (continued):
E. Hematoxylin-eosin staining of a wart from an immunocompetent individual (ICI) (original magnification X40).
F. Immunohistochemical analysis of a wart from an ICI for K i3  (2D7, DAB) showing suprabasal single cell positivity 
(arrow). This pattern of K i3  expression was also typical of warts from non-retinoid-treated RTRs (original 
magnification X40).
G. In situ squamous cell carcinoma (ISSCC) of an RTR showing K i3  (2D7) expression partially centered around 
hair follicle structures (original magnification X40). This staining pattern differs considerably from the retinoid 
therapy-related zebroid K i3  pattern.
H. Perilesional skin specimen from an ISSCC of an RTR receiving retinoid treatment. Immunohistochemical analysis 
of K13 (2D7) shows the same zebroid pattern as in lesional skin of most warts of retinoid-treated RTRs (original 
magnification X40).
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Discussion
Data from numerous animal and in vitro studies with cultured human keratinocytes 
have indicated that retinoids influence epidermal proliferation and differentiation.5,6,18- 
20 Retinoids repressed expression of differentiation-specific keratins (K1/K10) and 
strikingly reinduced K13 and K19 expression, two keratins that are only coexpressed in 
fetal skin but not normally present in epidermis of adults.2,4 In contrast to these findings 
of coupled K13 and K19 induction by retinoids, Agarwal was the first to report un­
coupled regulation of K13 and K19 expression in a human squamous cell carcinoma cell 
line.21
Interestingly, our in vivo data with immunohistochemical evaluation of K13 and 
K19 expression in warts of RTRs versus ICIs, showed that retinoids used as a chemopro- 
tective agent in the transplant recipients for preventing skin cancer, also only strongly 
relate to K13 and not K19 expression. Our finding of retinoid-related uncoupled K13 and 
K19 expression in these patients could be threefold. First, the retinoid concentration in 
our patients could be sufficient to enhance K13 expression but not K19 expression. 
Earlier findings in human epidermal cultures indeed showed stronger induction of K13 
than of K19 by retinoids with already a marked increase of K13 in response to very low 
levels of retinoids, while for K19 induction a higher threshold retinoid concentration was 
necessary.6 Although in a considerable number of our patients on systemic retinoids 
dosages had to be lowered in the course of treatment because of severe mucocutaneous 
side-effects, also in patients still receiving the higher dosages of acitretin no induction of
Figure 2:
K13 expression patterns in warts of renal 
transplant recipients (RTRs) versus 
immunocompetent individuals (ICIs).
□  K13 negative 
i l l  Single cell patern
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K19 was found. Second, response of keratinocytes to retinoids in vitro might not be re­
presentative for the response in vivo and retinoids in humans in vivo might not induce 
an embryonic type of differentiation and only selectively induce K13. In the only 
previously performed in vivo study on effects of retinoids, in photo-aged skin, only K13 
and not K19 expression was studied.7 Finally, this differentiation towards “esophageal- 
type” of epithelium in contrast to so-called “embryonic-type” of differentiation found in 
animals and in vitro, could be specific for skin and skin lesions in RTRs: earlier studies 
already showed that effects of retinoids differed in normal keratinocytes when compared 
to diseased keratinocytes.19
Retinoid treatment significantly correlated with a specific pattern of K13 expression 
in skin lesions of transplant recipients. This pattern, which we termed zebroid, because 
of alternating suprabasal columns of K13 positive and negative keratinocytes, is sugges­
tive of a genetic mosaicism, reflecting a clonal expansion of genetically altered stem cells. 
In warts and slightly dysplastic skin of RTRs, segments of epidermis may contain kera­
tinocytes with a genetic abnormality making them more susceptible to inductive actions 
of retinoids. Future studies might reveal the underlying genes that are involved in this 
process and if for instance (transforming types of) human papillomavirus (HPV) might 
play a role.22
The interpretation of the biological impact of K13 expression in retinoid and non­
retinoid treated warts of RTRs could be twofold. The first interpretation relates presence 
of K13 in skin to differentiation, in parallel to internal squamous epithelia in which K13 
is restricted to the suprabasal epithelial compartment and associated with differentiation. 
Retinoids, by inducing K13 expression c.q. directing keratinocytes towards (esophageal) 
differentiation, might act chemopreventive by “freezing” of cells in this differentiated 
state and preventing them to (further) dedifferentiate. Indeed previous studies on reti­
noid effects on epidermal keratinocytes have shown that in response to retinoid treat­
ment higher molecular weight keratins, typically encountered in squamous epithelia dis­
appear, and synthesis of two new low molecular weight keratins, a 40 -  and 52-kD 
keratin, corresponding to K19 and K13 respectively, is enhanced.6,23,24 In the absence of 
vitamin A, the opposite occurs, with enhanced terminal ep iderm a l type  of differen­
tiation.25 Retinoid induced “esophageal-type" of differentiation, could provide an explana­
tion for the cosmetically skin improvement of lesional skin in these transplant recipients 
who often had multiple hyperkeratoses before treatment: esophageal epithelium is, in 
contrast to the keratinizing epidermis, a non-keratinizing squamous epithelium. By in­
ducing a non-keratinizing differentiation, retinoids could lower the number of hyper- 
keratotic skin lesions. As a side-effect, in normal skin the diminished cutaneous keratin- 
ization caused by retinoids leads to desquamation of palms and soles which normally 
show the most prominent keratinization. On the lips, the outer cutaneous side becomes 
more vulnerable because of differentiation towards wet epithelium leading to cheilitis, 
another known side-effect of acitretin also present in our patients.8-9-26
The second interpretation relates presence of K13 to a more dedifferentiated and 
potentially malignant phenotype. Regarding cutaneous carcinogenesis, malignant trans­
formation is indeed heralded by a switch from production of high molecular weight
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(MW) keratins normally present in adult skin (K1/K10) to low MW keratins also charac­
teristic of fetal skin and simple epithelia (e.g. K8/K18 and K19).1 Presence of K13, a low 
MW embryonic keratin, would fit within this concept. It is tempting to attribute a rele­
vance to the high frequency of K13 in warts of RTRs and speculate it may be related to 
the higher susceptibility of warts in these patients to become malignant. This would be 
in analogue to mouse models on skin carcinogenesis in which aberrant K13 expression 
is a consistent finding in chemically and v-Ha-ras-induced papillomas and squamous cell 
carcinomas.15-27-28 In in situ squamous cell carcinomas (ISSCC) of RTRs and ICIs we 
indeed found frequent K13 expression in respectively 75 % and 45 % of lesions (20 
ISSCC tested within each group, data not shown), which is in concert with this second 
hypothesis. The pattern of K13 expression in ISSCCs ofboth groups was strikingly differ­
ent from the retinoid therapy related K13 expression (zebroid pattern, compare Figure 
1B and G). Only 4 RTRs with ISSCCs used retinoids, and in these patients the retinoid 
related zebroid K13 pattern was most pronounced or only present in perilesional only 
slightly dysplastic skin (Figure 1H).
When this latter interpretation would be applicable to retinoid related K13 expres­
sion, retinoids might actually be dangerous for these patients. This is contradicted by 
studies on long term safety of retinoid therapy, since no increased incidence of skin can­
cer is reported.29 Studies on skin cancer chemoprophylaxis in RTRs with retinoid actual­
ly showed reduction in the skin cancer incidence.8
In conclusion, this retrospective in vivo study on embryonic keratin expression in 
warts of renal transplant recipients shows that retinoids strongly relate to K13- but not 
K19 expression. By keeping keratinocytes in this “esophageal-type” of differentiation 
retinoids might act chemopreventive. Retinoids correlate with a highly distinctive and 
strong K13 expression, which we termed zebroid, making K13 a useful marker for evalu­
ating retinoid treatment in these patients. The alternating zebroid K13 pattern is sugges­
tive of an underlying genetic mosaicism. Even in the absence of retinoids, a significant 
higher percentage of K13 positivity is found in warts of RTRs when compared to warts 
of ICIs. Future prospective, randomized and well-controlled studies need to establish the 
relevance of this finding and whether K13, in analogue to mouse models on skin car­
cinogenesis, might become a predictive marker for malignant progression.
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UVB-IRRADIATION EXPERIMENTS 
WITH RAR- AND RXR-SELECTIVE 
RETINOIDS
This chapter was based on the following publications:
Jürgen V. Smit, Elke M.G.J. de Jong, Gijs, J. de Jongh,
Peter C.M. van de Kerkhof.
Topical all-trans retinoic acid does not influence minimal erythema doses for UVB light 
in normal skin.
Acta Derm Venereol 2000 Jan-Feb;80(1):66-7.
Jürgen V  Smit, Elke M.G.J. de Jong, Peter C.M. van de Kerkhof 
Effects of oral bexarotene (Targretin®) on the minimal erythema dose for broad-spectrum 
UVB-light.
Skin Pharmacol Appl Skin Physiol 2003: (In press)
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4.1
UVB-irradiation in topical all-trans retinoic acid 
treated normal skin
Abstract
The study was a double-blind, placebo-controlled, within subject compari­
son, of 15 healthy volunteers, that focussed on clinical effects of topical all-trans 
retinoic acid (ATRA) on UVB-light-induced inflammation. Three distinct skin 
areas on the ventrolateral parts of the upper legs were treated for 10 days as fol­
lows: 1. ATRA (tretinoincream 0.05 %) twice daily; 2. vehicle cream twice daily; 
3. no treatment. On day 8 of the application period irradition occurred with a 
series of 6 ascending intensities of UVB-light adjusted for the skin-type of the 
patient on each of the 3 test areas. Clinical scoring for erythema was performed 
on day 8 (before irradiation), day 9 and day 10; assessment of the minimal ery­
thema dose (MED) occurred on day 9 and day 10. Before irradiation (day 8) the 
grade of erythema in ATRA-treated skin was significantly higher compared to its 
vehicle (p < 0.01). However, after UVB-irradiation no significant differences were 
found between ATRA-treated skin, vehicle-treated skin and untreated skin with 
respect to m inimal erythema doses, both 24 and 48 hours after irradiation. No 
significant changes in the grade of post-irradiation erythema between the three 
different treatment regimens were found. Furthermore, a typical perifollicular ery­
thema pattern was seen in ATRA-treated skin compared to a diffuse erythema 
pattern that was visible after UVB-irradiation. The present study suggests that 
ATRA 0.05% has no effect on UVB-induced erythema.
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Introduction
Retinoids are used in several skin disorders, such as acne, psoriasis and ichthyoses. 
It is well-established that retinoids interfere with epidermal proliferation,1,2 keratiniza- 
tion3 and inflammation control.4 Retinoids influence UV-induced skin changes.5 Topical 
ATRA improves photodamaged skin.5,6
Parallel with the therapeutic effect, topical retinoids often cause irritation with 
erythema and some scaling.7 Although the irritant effect is probably not involved in the 
therapeutic action of retinoids, it is remotely possible that the irritation property of 
ATRA could be, in part, accountable for some therapeutic effects.1,7
In this study we would like to challenge the common belief that topical retinoids 
enhance UV-induced inflammation. We therefore evaluated the minimal erythema dose 
(MED) for UVB-irradiation on topical ATRA (tretinoin cream) pre-treated skin com­
pared with vehicle cream pre-treated skin and untreated skin. The degree of erythema at 
different times before and after UVB-irradiation was scored in the three different skin 
areas.
The following questions were addressed: 1) To what extent does a 7 days treatment 
of normal skin with ATRA cream or its vehicle alone induce erythema? 2) To what 
extent do these creams influence the minimal erythema dose (MED) for UVB-irradia­
tion? 3) What are the dynamics of erythema 24 and 48 hours after UVB-irradiation in 
ATRA-treated skin, vehicle-treated skin and untreated skin?
Figure 1:
Day 1 2 3  4 5 6 7 8 9  10 Schematic view of the study procedures
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Materials and methods
The study was a double-blind, placebo-controlled study. Approval of the Ethics 
Committee was obtained. A total of 15 healthy volunteers (8 men and 7 women) partici­
pated in this trial. The mean age was 25 years (range 21 - 30 years). Skin-types of the pa­
tients varied from type I to type III according to Fitzpatrick’s classification.8
An area of 8 x 20 cm on the ventral upper part of one leg, was treated twice daily 
with ATRA (tretinoin cream 0,05%), which is a frequently used clinical concentration, 
for 10 days. An area of the same size on the upper part of the other leg was treated with 
the vehicle of tretinoin cream (per 100 gram: cremor cetomacrogolis 88 gram, alcohol 
ketonatus 12 gram and butylhydroxytolueen 40 mg) also twice daily and for 10 days. The 
application of both creams on the legs was selected at random and was applied in a 
double-blind manner. From the beginning of the application, until 4 days after the last 
application of the creams, the volunteers were instructed to avoid sunlight exposure and 
not to wash the applied skin for at least one hour after each application.
On day 8 of treatment, irradiation of the skin was performed in 12 evaluable subjects 
to determine the minimal erythema dose (MED) with 3 series of 6 increasing intensities 
UVB-light related to the skin-type of the subjects: one series on ATRA-treated skin, one 
series on vehicle-treated skin and one series on non-treated skin on the lateral side of the 
upper part of one leg. Each dose was given to a piece of skin of 4 cm2. For UVB-irradia­
tion, broad-spectrum UV21 lamps (Waldmann UV7001K cabin, 285-350 nm) were used.
Before irradiation on day 8, on day 9 and on day 10 the skin was examined for 
erythema by visual scoring. The MED was defined as the lowest UVB dose that caused 
a distinct erythema with sharp margins over the irradiated area 24, respectively 48 hours, 
after irradiation. For erythema the following scale was used: 0 = no erythema, 1 = weak 
erythema, 2 = moderate erythema and 3 = strong erythema. Visual scoring occurred 
under similar conditions of light and temperature. In Figure 1 a schematic view of the 
study procedures is depicted.
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Skin-irritation (pre-irradiation erythema)
ATRA Vehicle
Figure 2:
Pre-irradiation erythema scores for test 
areas treated with ATRA and its vehicle 
for the 15 individuals.
MED values
Figure 3:
Minimal erythema doses (mean ± SEM) 
for UVB-light at test areas treated with 
ATRA, vehicle and untreated skin 24 and 
48 hours after irradiation.
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Results and discussion
Previous studies showed that erythema induced by topically applied retinoids is 
frequently seen during the first weeks of treatment and usually subsides with continued 
treatment. This erythematous reaction is clinically similar to a mild irritant dermatitis9 
and therefore it is also designated as “retino id  d e rm a titis " .10 In this study the Wilcoxon 
matched-pairs signed-ranks test showed a significant difference (p < 0.01) between 
ATRA and its vehicle with respect to the induction of erythema (skin-irritation) before 
UVB-irradiation (Figure 2) . Thus, this study reconfirms the irritative effect of ATRA 
following twice daily application during 7 days.
Dermatologists tend to avoid ATRA applications in conjunction with UV exposure 
in order to avoid additive irritation. Some studies investigated the relationship between 
pre-treatment with ATRA and UVB-irradiation, regarding this expected additive irrita­
tion or intensity of erythema.11,12 However, no data are known about the question wheth­
er ATRA can influence the value of the minimal erythema dose for UVB-light itself.
The present study showed no significant difference (p > 0.05) as to MED values 
both 24 and 48 hours after UVB-irradiation between ATRA-treated skin, vehicle-treated 
skin and untreated skin (Figure 3) using the ANOVA test. When looked at the relation­
ship between skin-type and MED value, a significant higher MED value was found in 
skin-type 3 versus skin-type 1 and 2 (p<0.01).
As both ATRA in itself can induce erythema of the skin, it might be difficult to grade 
post UVB-irradiation erythema in retinoid treated areas. However, a marked difference 
in erythema pattern between ATRA-induced erythema and UVB-induced erythema was 
found. UVB-induced erythema showed a diffuse erythema, while ATRA-induced ery­
thema showed a marked erythema restricted to the perifollicular areas. This perifollicu­
lar pattern may be related to the actions of ATRA on the pilosebacious duct and can be 
seen in other irritants as well, e.g. glycolic acid.13 These two distinct patterns of erythema 
permitted to score both parameters independently and separately.
The present study shows that topical treatment with ATRA does not influence the 
response to a single exposure to UVB-light and does not change the minimal erythema 
dose.
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4.2
UVB-irradiation in oral bexarotene-treated 
uninvolved psoriatic skin
Abstract
Photo(chemo)therapy and oral retinoid therapy for psoriasis or cutaneous T- 
cell lymphoma (CTCL) are frequently combined to obtain an enhanced therapeu­
tic effect with lower safety risks. Bexarotene, a new RXR-selective retinoid (rexi- 
noid), has been developed for the treatment of CTCL and has recently been 
investigated in the treatment of psoriasis. In the present study the UV-modulating 
properties of bexarotene were evaluated by assessment of the minimal erythema 
dose (MED) for UVB-light. In 11 patients participating in a phase II study of oral 
bexarotene 0.5 mg/kg/day (7 patients) or 3.0 mg/kg/day (4 patients) for plaque­
type psoriasis, MED-tests were performed on uninvolved psoriatic skin on the 
lower back of the subjects before and after 12 weeks treatment. Clinical scores of 
erythema and determination of the MED 24 hours after irradiation did not show  
statistically significant changes between the exposed areas before and after bexa- 
rotene treatment or between the two doses tested. No photosensitising reactions 
were observed. This study demonstrates that a single exposure to UVB-irradia- 
tion is well-tolerated in patients treated with bexarotene 0.5 -  3.0 mg/kg/day and 
suggests it is not necessary to take precautions with respect to short term effects 
of sun exposure during bexarotene treatment. Further study of bexarotene-photo- 
(chemo)therapy in CTCL and psoriasis is warranted.
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Introduction
Bexarotene (Targretin®, LGD1069) is a novel retinoid that selectively binds and 
activates the RXR receptors.1 RXR signalling is fundamentally different from retinoid 
signalling via the RAR receptors.2 RXR retinoids can form heterodimers with several 
other nuclear receptors (e.g., RAR, PPAR, VDR, TR) and these heterodimers have DNA 
binding domains that act different from the RAR binding domains and different genes 
may be activated. RAR activity can be seen at high doses of bexarotene around 6 
mg/kg/day.
Bexarotene was approved for the treatment of refractory cutaneous T-cell lympho­
ma.3 In plaque-type psoriasis we have demonstrated some efficacy4. In patients with 
cutaneous T-cell lymphoma and psoriasis retinoid treatment is often combined with UV- 
irradiation and may reduce the cumulative UVB or UVA dose necessary to achieve 
disease clearance. The combination treatment can reduce the short-term side effects of 
retinoids and the longer-term carcinogenic and skin-ageing effect of phototherapy.5-8 UV 
absorption of bexarotene begins at 310 nm, slowly rising to 280 nm, with a distinct peak 
at 202 nm.
Despite the benefits of combination therapy, some studies suggest that retinoids 
might induce photosensitivity. Ferguson e t a l showed a phototoxic potential of acitretin.9 
On the other hand Diffey et a l suggested that photosensitivity due to isotretinoin did not 
occur.10 Retinoids may thin the stratum corneum of the skin and lead to an enhanced 
cutaneous reaction to UV-light. In anticipation of a possible highly effective combination 
of bexarotene in combination with phototherapy, we evaluated the potential of bexaro- 
tene to modulate UV-induced erythema by measuring MED before and after bexarotene 
treatment.
Table I:
UVB-irradiation series according to skin-type (Fitzpatrick).
Skin-type UVB-irradiation series J/cm2
1 0.02 0.04 0.06 0.08 0.10 0.12 0.14 0.16 0.18
2 0.03 0.06 0.09 0.12 0.15 0.18 0.21 0.24 0.27
3 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45
4 0.07 0.14 0.21 0.28 0.35 0.42 0.49 0.56 0.63
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Materials and methods
The evaluation of the MED was performed on a subset of patients in a phase II dose- 
response study to investigate bexarotene capsules as a monotherapy in the treatment of 
adult patients with moderate to severe plaque-type psoriasis. In this evaluation, the 
influence of bexarotene on the minimal erythema dose (MED) for broad-spectrum UVB- 
light and the intensity of erythema after irradiation in non-lesional psoriatic skin were 
investigated. Ethics Committee approval for this trial was obtained and all patients gave 
informed consent for the MED evaluation prior to study enrollment.
Patients of two sequential dose-defined treatment panels: 0.5 mg/kg/day, the lowest 
dose and 3.0 mg/kg/day, the highest dose were evaluated. The treatment period was 12 
weeks. The following washout periods were defined: systemic retinoids: 3 months (etre­
tinate: 1 year); PUVA, UVB, methotrexate or cyclosporin: 4 weeks; emollients (on the 
test sites) and topical anti-psoriatic therapies (on lesional psoriatic skin): 1 week. Patients 
had to avoid prolonged exposure to the sun or UV-light during the study.
Irradiation tests were performed on the day before treatment and after 12 weeks of 
treatment with bexarotene. Bexarotene treatment was initiated once the baseline MED 
had been determinded. Bexarotene capsules were taken at dinner, as this is the normal 
intake schedule for systemic retinoids. Post-treatment irradiation tests where performed 
18 hours after the final bexarotene intake (during midday), to approach the timepoint 
when exposure to sunlight occurs normally. Irradiation tests were performed as follows: 
2.5 cm diameter circles of uninvolved skin were irradiated using broad-spectrum UV21 
lamps (Waldmann UV7001K cabin, 285-350 nm). This was carried out on the lower back 
/  upper buttocks on non-lesional psoriatic skin by using a series of 9 ascending intensities 
of UVB-light adjusted for the skin-type of the patient (Table I) .
Scoring occurred as follows: twenty-four hours after each UVB-irradiation the 
intensity of the erythema for each irradiated area was measured by visual scoring using 
a 5-point scale: 0 = no erythema, 1 = weak erythema, 2 = moderate erythema, 3 = 
dark erythema and 4 = very dark erythema. The total erythema score before and after 
treatment was assessed as the sum-score of all individual irradiated areas. The MED was 
defined as the lowest UVB dose that caused a distinct border to the area of erythema 24 
hours after irradiation (erythema grade 1). Visual scoring was performed under stand­
ardized conditions of light and temperature.
A paired T-test was used to analyse the differences in the minimal erythema doses 
and the intensities of erythema between the baseline and after 12 weeks of treatment.
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P a t i e n t
Figure 1:
MED values for broadspectrum UVB-light 
before and after 12 weeks treatment in 
the 0.5 mg/kg/day bexarotene panel.
Baseline 
Week 12
MED Bexarotene 3 .0  mg/kg/day
0,20 
0,15 
Í  0,10 
0,05 
0,00
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Patient
Figure 2:
MED values for broadspectrum UVB-light 
before and after 12 weeks treatment in 
the 3.0 mg/kg/day bexarotene panel.
Baseline 
Week 12
1 2 3 4 5 6 7 
Patient
Figure 3:
Erythema values for broadspectrum UVB- 
light before and after 12 weeks treatment 
in the 0.5 mg/kg/day bexarotene panel.
Baseline 
Week 12
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Results
A total number of 11 male-patients with moderate to severe plaque psoriasis partici­
pated in the study. The mean age was 42 years (range 25 -  65 years). Seven patients 
received 0.5 mg/kg/day bexarotene and 4 patients received 3.0 mg/kg/day bexarotene. 
Their skin-types were varying from type II to type III according to Fitzpatrick’s classifi­
cation.11
The irradiation was well tolerated in all patients, although, 4 patients reported some 
itching 24 hours after irradiation in particular within the areas that received the highest 
intensities UVB-light. No significant differences in the incidence of itching were experi­
enced between the UVB-irradiated areas before and after bexarotene treatment or be­
tween the two doses tested.
Figure 1 shows the MED before and after treatment with 0.5 mg bexarotene for all 
individual patients. In 3 patients the MED was slightly lower after treatment, in 1 patient 
it was higher and in the remaining 3 patients there were no differences in MED between 
baseline and 12 weeks of treatment with bexarotene. The mean MED before treatment 
was 0.10 ± 0.01 J/cm2 (mean ± SEM); after treatment it was 0.09 ± 0.01 J/cm2 (mean 
± SEM).
Figure 2 shows the MED before and after treatment of 3.0 mg bexarotene for all in­
dividual patients. In all but one patient the MED was lower after treatment. Before treat­
ment the mean MED was 0.14 ± 0.02 J/cm2 (mean ± SEM). The mean MED after 12 
weeks treatment with bexarotene was 0.09 ± 0.01 J/cm2 (mean ± SEM). However, 
there was no statistical difference in the limited sample sizes between baseline MED’s 
and MED’s after 12 weeks of treatment with bexarotene. No significant dose-response 
effect could be shown.
Following 12 weeks treatment with bexarotene, 4 out of 7 patients of the 0.5 mg 
panel had a decrease in erythema scores, 2 patients had an increase in erythema and 1 
patient had no differences in erythema between baseline and week 12 (Figure 3). The 
mean erythema score before treatment was 16.3 ± 1.6 (mean ± SEM) for these 7 pa­
tients and after treatment it was 16.4 ± 1.4 (mean ± SEM).
At the 3.0 mg/kg dose, all 4 patients showed an increase in erythema scores follow­
ing bexarotene treatment (Figure 4). The mean erythema score in this group before 
treatment was 12.3 ± 1.7 (mean ± SEM) and after treatment it was 17.8 ± 1.9 (mean 
± SEM). Statistical analysis, however, did not show any significant differences in ery­
thema scores between baseline and week 12 and a dose-response relationship was not 
found either.
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Erythema Bexarotene 3 .0  mg/kg/day
2
Patient
Figure 4:
Erythema values for broadspectrum UVB- 
light before and after 12 weeks treatment 
in the 3.0 mg/kg/day bexarotene panel.
Baseline 
Week 12
Discussion
The present study provides evidence that bexarotene in the dose-range 0.5 -  3.0 
mg/kg/day is not interfering with the erythematous response to a single irradiation of 
UVB.
Some clinical data suggested that retinoids induce cutaneous photosensitivity,12-13 
although other reports are contradictory and do not demonstrate a photosensitization.10 
Phototesting a group of subjects taking oral isotretinoin proved negative.10 Furthermore, 
retinoid effects like erythema of the skin and dryness and increased epidermal fragility 
may bias or enhance the clinical picture of retinoid induced photosensitivity.
In a previous study, where we applied all-trans retinoic acid to the skin of healthy 
volunteers, we found no significant effect of all-trans retinoic acid on the minimal erythe­
ma dose for broad-spectrum UVB light.14 With respect to the intensity of erythema, 
Juhlin and Shroot found a significant decrease 12 hours after 0.2 J of UVB-irradiation in 
an area previously treated with 0.01% ATRA under occlusion for 4 days.15 However, 
twenty-four and 48 hours after UVB-irradiation no significant modulation of erythema 
could be observed. Meunier, Voorhees and Cooper concluded that after UVB-irradiation 
with 1 MED no significant differences in erythema were found between areas tested 
with ATRA 0.1%, vehicle and untreated skin.16
Although a tendency for an increase in erythema (p = 0.066) and a decrease in MED 
(p = 0.091) in the bexarotene 3.0 mg/kg/day dose panel was observed in 4 patients, this 
decrease was not statistically significant. No dose response relationship between MED 
and the dose of bexarotene was found and no abnormal responses to UVB-irradiation 
were seen.
Therefore, the present study suggests that patients treated with bexarotene 0.5 -  3.0 
mg/kg/day do not need to take precautions with respect to short term effects of sun 
exposure. Further studies are warranted to investigate the efficacy of bexarotene-photo- 
(chemo)therapy in cutaneous T-cell lymphoma and psoriasis, especially at higher dose 
levels of bexarotene.
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SUMMARY AND  
GENERAL DISCUSSION
The effect o f retinoids on clinical and immunohistochemical parameters for 
proliferation, differentiation, and inflam mation, is the central theme of this 
thesis. In  Paragraph 1.21 three aim s were defined.
The firs t aim  focused on clinical and immunohistochemical effects o f the 
RXR-selective retinoid bexarotene in  the treatment o f plaque-type psoriasis. 
In  Chapter 2  this issue has been discussed in detail. In  Paragraph 5.1 a brief 
sum m ary o f the prim ary outcome is given, including suggestions for future  
studies.
The second a im  was to investigate the mode o f action o f RAR-selective 
retinoid treatment in actinic keratoses in immunocompetent and immuno- 
suppressed patients. In  Chapter 3 the effects o f topical and systemic retinoids 
on these disorders were discussed. In  Paragraph 5.2 the results are 
sum m arized and will be discussed further.
The third aim  dealt w ith the U V-modulating properties o f RAR-selective 
retinoids and RXR-selective retinoids after a single exposure to broadband 
UVB. These issues were discussed in detail in  Chapter 4; in Paragraph 5.3 the 
major conclusions have been summarized.
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5.1
RXR-selective retinoids in the treatment of 
plaque-type psoriasis
Clinical efficacy, adverse events and immunohistochemical effects of oral
bexarotene in plaque-type psoriasis
It is known from clinical and immunohistochemical studies that psoriasis is a reti­
noid sensitive disease and, therefore, retinoids are a major treatment strategy for this dis­
order. So far, in contrast to RAR-selective retinoids, RXR-selective retinoids have not 
been investigated in the treatment of psoriasis. As mentioned in Chapter 1, the total con­
centration of RXR in human skin is 5 times higher than the total concentration of RAR 
and is decreased in psoriatic lesions. RXR-signaling is of major importance and occurs in 
concerted action with vitamin D3 signaling. These observations, in combination with 
reported efficacy of RXR-selective retinoids in cutaneous T-cell lymphoma and in animal 
studies, justified an investigation on the efficacy and side effects of the RXR-selective 
retinoid bexarotene in plaque-type psoriasis.
In Chapter 2 clinical efficacy of oral bexarotene has been demonstrated in doses 
ranging from 0.5 to 3 mg/kg/day as shown by significant improvement in a modified pso­
riasis area and severity index (mPASI), plaque elevation (PEL), and physicians global 
assessment (PGA) during the 12 to 24 weeks treatment period. The onset of response 
varied for these parameters between 2 to 8 weeks and the clinical improvement was 
maintained for another 8 to 16 weeks. A significant decrease in the psoriasis disability 
index, visualizing the subjective improvement experienced by the patients themselves, 
strengthened these data. However, no significant dose-response effect for these clinical 
parameters could be found in this group of patients, which might be explained by inter­
individual variation with respect to the bioavailability of oral bexarotene, as is the case 
with acitretin, the retinoid inducing RAR transactivation. Therefore, the dose has to be 
individualized in order to reach optimal efficacy. It is possible that studying a larger group 
of subjects, adjusting the dose to blood levels, is necessary to reveal a potential dose- 
response effect for these parameters.
On the other hand, it is also possible that the optimal dose of bexarotene for plaque­
type psoriasis, is higher than the doses that were evaluated in this study. Typical retinoid- 
associated adverse events like pruritus and cheilitis were found in only 14%, respectively 
10% of the patients. Both percentages are much lower than the percentages seen in treat­
ment with oral RAR-selective retinoids, suggesting that these patients might have 
received a dose of bexarotene that is below the optimum, or that RXR-activation does not 
coincide with these adverse events to the same level as RAR-activation does.
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No serious adverse events were seen and bexarotene was well tolerated overall. On 
the other hand, 56% of the patients had an increase in triglycerides during the study and 
had to be treated with atorvastatin. Furthermore, 92% of the patients in the 3 mg dose 
panel demonstrated a decrease in FT4 values, which is an indication that bexarotene- 
induced hypothyroidism, due to heterodimer formation with the thyroid receptors, may 
be a serious limitation for oral application of this drug. The fact that a decrease in FT4 
values was seen especially in the highest dose panel and in only 15% of the subjects in 
the lowest dose group, indicates that bexarotene-induced hypothyroidism is a dose de­
pended phenomenon, which was already shown in previous studies for other indica­
tions. With respect to the other adverse events no significant differences between the 4 
different dose panels were observed.
When these data are combined with the data obtained from the corresponding 
immunohistochemical study of bexarotene in plaque-type psoriasis that focused on epi­
dermal proliferation, differentiation, and dermal inflammation, the clinical efficacy of 
bexarotene for this disease is strengthened by the immunohistochemical findings. Signifi­
cant reductions in Ki-67, keratin 16, transglutaminase, dermal CD4, epidermal CD8 and 
global inflammation scores were seen after bexarotene treatment, in combination with a 
significant increase in keratin 10. A borderline significant dose-response effect for Ki-67 
was observed. However, the other immunohistochemical markers did not show a dose 
response effect. No alterations in apoptosis associated pS3 expression were observed, 
suggesting bexarotene does not improve psoriasis via an increase in apoptosis of the kera- 
tinocytes.
Interestingly, no induction of keratin 13 and keratin 19 was seen in our samples. 
The present study suggests that RXR-activation does not induce these keratins which are 
induced by RAR-activation. On the other hand it cannot be ruled out that higher doses 
of bexarotene than used in our study are necessary to express induction of keratin 13 and 
keratin 19. However, acitretin, at doses sufficient to demonstrate clinical and immuno­
histochemical efficacy in psoriasis already induces these keratins.
Future studies with RXR-selective retinoid treatment in psoriasis and
other hyperkeratotic disorders
In order to further clarify the potential of oral bexarotene as a new treatment for 
psoriasis and to reveal a potential dose-response effect, clinical and immunohistochemi- 
cal studies are indicated that focus on higher doses of bexarotene in a larger group of 
patients and by using a placebo-controlled approach. A study reconciling blood levels of 
bexarotene might be indicated. As mentioned before, hypertriglyceridaemia and hypo­
thyroidism may be a serious limitation of oral bexarotene treatment.
In order to circumvent the systemic side effects, topical treatment with bexarotene 
represents a promising treatment of psoriasis. Future trials investigating the role of 
topical bexarotene or other RXR-selective retinoids for psoriasis are warranted. In a later 
phase, if such studies prove to be positive, one might think of a combination of either oral 
or topical RXR-selective retinoids and other commonly used treatments for psoriasis, as
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described in Chapter 1. Especially the combination of RXR-selective retinoids and calci- 
potriol or other vitamin D derivatives are likely to have a synergistic effect as these 
ligand-activated receptors form heterodimers.
In addition, RXR-selective retinoids may be of importance for a broad spectrum of 
retinoid sensitive diseases, such as ichthyosis vulgaris, acne, and Darier’s disease. It is 
worthwhile to investigate the potential of topical or systemic bexarotene in these skin 
conditions.
Finally, an intriguing field is the development of RXR subtype-selective retinoids. 
The RXR family comprises three receptor subtypes: a, P, and y. Each receptor subtype 
has a different chemical structure that controls unique as well as overlapping target 
genes. Therefore, efficacy and side-effects may vary among these RXR subtypes. By creat­
ing RXR subtype-selective retinoids, it may well be possible to bypass or minimize side- 
effects like hypothyroidism and hyperlipidaemia. Especially RXRa-selective retinoids 
may represent an innovation in treatment of skin disorders, as RXRa is abundantly 
present in adult human skin.
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5.2
RAR-selective retinoids in the treatment of 
(pre)malignant skin disorders
The relevance of topical all-trans retinoic acid and calcipotriol in actinic
keratoses in immunocompetent and immunosuppressed patients
Topical retinoids have been reported to be beneficial for photodamaged skin; clinical 
appearance and histological features proved to be improved by topical retinoids. With 
respect to actinic keratoses, resulting from long-term exposure to UV-light, less informa­
tion is available on the effect of topical retinoids. Most of the studies that have been per­
formed on these lesions focussed on clinical parameters only. Immunohistochemical data 
on the effects of topical retinoids on actinic keratoses, regarding parameters for epider­
mal proliferation, differentiation, dermal inflammation and apoptosis, were not available 
so far. Preferably, the criteria for improvement of actinic keratoses have to comprise both 
the clinical appearance and relevant histopathological and immunohistochemical feat­
ures of the preneoplastic process, as clinical improvement without improvement of dys- 
plastic and proliferative characteristics may mask these premalignant keratoses and may 
mislead both patient and physician, who are satisfied with the cosmetic improvement. 
Furthermore, retinoids frequently cause skin irritation, which might reduce patient 
compliance and may restrict its applicability in the treatment of these lesions.
In Chapter S we assessed clinical and immunohistochemical parameters in topical 
all-trans retinoic acid-treated actinic keratoses, both in (immunocompromized) renal 
transplant recipients and in non-immunocompromized patients. In non-immunocom- 
promized patients we concluded that short-term (6 weeks) treatment with 0.05% all- 
trans retinoic acid (ATRA) once daily in a cream base did not reduce the number of acti­
nic keratoses located on the forearms and hands, while causing skin irritation in some 
patients. A small but statistically significant increase in differentiation parameter K10 
was seen (p = 0.049) after ATRA treatment and a significantly higher staining for K13, 
when compared to vehicle-treated actinic keratoses (p = 0.043). No alteration was found 
in epidermal proliferation (Ki-67), apoptosis (p53), hyperproliferation associated kera- 
tinization (K16), terminal differentiation (transglutaminase), epidermal thickness or 
dermal inflammation.
In a group of renal transplant recipients, who were treated with topical ATRA 
0.02 % twice daily for actinic keratoses located on the forearms and hands during 6 
weeks, after treatment no significant improvement in the same clinical and immuno- 
histochemical parameters as mentioned above was found, especially no significant induc­
tion of K10 and/or K13. In this group of renal transplant patients we also evaluated the
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efficacy of topical calcipotriol 0.05 mg/gram twice daily as monotherapy, or once daily in 
the morning in combination with topical ATRA 0.02% in the evening. Again, no signifi­
cant change in clinical or immunohistochemical parameters was seen between baseline 
and post-treatment lesions for both calcipotriol monotherapy and the combination 
therapy.
Combining these studies, at baseline no significant differences were observed be­
tween non-immunocompromized patients and renal transplant recipients with respect to 
the investigated parameters. With respect to efficacy, a change towards normal kerati- 
nization (K10) as well as induction of retinoid-associated keratinization (K13) was 
observed after ATRA-treatment in actinic keratoses of immunocompetent patients. We 
could not demonstrate a significant effect on epidermal proliferation (Ki-67) and apop­
tosis (p53), or on the number of lesions, after treatment with commonly used doses of 
topical ATRA. Therefore, the reported beneficial clinical effects of topical ATRA in the 
treatment of actinic keratoses in several studies may be explained by alterations in 
keratinization rather than by alterations in epidermal proliferation, inflammation, and/ 
or apoptosis. Topical calcipotriol as monotherapy, or in combination with topical ATRA, 
did not show any significant improvement in the investigated parameters in these actinic 
keratoses. This is in contrast to other hyperkeratotic disorders, such as psoriasis, where 
calcipotriol has been reported to improve epidermal proliferation and differentiation 
even in a 6-week treatment period. We cannot rule out that long-term treatment with 
these agents, or application of higher doses, may have some effect on these parameters, 
especially when investigated in a large number of patients. However, as significant irrita­
tion has been observed in some patients using ATRA, we question the relevance of high­
er doses and longer treatment durations with ATRA with respect to compliance to treat­
ment. Therefore, we do not recommend these applications for actinic keratoses, but favor 
other treatments, such as cryotherapy and topical 5-fluorouracil (Efudix®).
The relevance of systemic acitretin in the treatment of actinic keratoses
and common warts in renal transplant recipients
It has been reported that systemic retinoids, such as acitretin and isotretinoin, are 
chemopreventive treatment modalities that clinically reduce the number of actinic kera­
toses and may inhibit the development of non-melanoma skin cancers. Especially in 
renal transplant recipients, systemic retinoids may be relevant due to the high number of 
actinic keratoses generally present in these patients and due to the high incidence of 
malignancies in this population. However, little information is available on histological 
and immunohistochemical effects of systemic retinoid treatment for actinic keratoses. As 
explained before, clinical improvement without improvement in dysplastic and prolifer­
ative characteristics may mask these premalignant keratoses and may mislead both 
patient and physician. Therefore, it is important to assess clinical as well as histological 
and immunohistochemical parameters in patients with actinic keratoses that were treat­
ed with systemic retinoids.
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In Chapter 3 the results are described of 26 renal transplant recipients that were 
treated with oral acitretin in a randomized setting. All patients started with 0.4 mg/kg/ 
day during the first 12 weeks, an effective dose by data obtained from previous studies. 
After the initial 12 weeks treatment half of the patients were planned to continue with 
a dose of 0.2 mg/kg/day, whereas the remaining half continued with the initial dose of 
0.4 mg/kg/day. However, in contrast to other studies, in most patients we had to reduce 
this dose already within 12 weeks of treatment due to mucocutaneous side effects. We 
concluded that 0.25-0.30 mg/kg/day is likely to be a better starting dose that is well 
tolerated. Acitretin was safely used in this group of patients, without the occurrence of 
severe adverse events related to the drug. No deterioration of renal graft function was 
seen. Clinical parameters revealed a significant improvement in thickness of the actinic 
keratoses (p<0.01) and in the number of lesions that featured the typical erythemato- 
squamous hallmarks (p < 0.0001) in both groups. Although not scored, warts also 
seemed to improve during the study. No significant decrease in the number of non-mela­
noma skin cancers was found during the study period of 12 months, compared to the 
year before treatment. Visual analogue scores showed that the patients in general ex­
perienced benefit from acitretin treatment already in the first 2-3 months with respect to 
roughness (p = 0.002) and general skin contentment (p = 0.001). After the first months 
of treatment no additional benefit was noticed for the remaining study period. No 
differences with respect to clinical efficacy parameters and side effects were seen be­
tween the two dose groups, suggesting a low maintenance dose of 0.2 mg/kg/day after 3 
months initiation with higher doses is adequate for maintaining clinical improvement. 
Treatment was safe.
The corresponding immunohistochemical study in actinic keratoses, as described in 
paragraph 3.2, which was performed in 33 renal transplant recipients, demonstrated that 
the clinical improvement of the actinic keratoses during acitretin treatment originated 
from a reduction in stratum corneum thickness, probably due to changes in the keratin- 
ization process. Significant improvement in K10 (p = 0.02) and induction of K13 (p < 
0.01) and K19 (p = 0.05) indicate that a direct effect on keratinization is the underlying 
mechanism. However, no significant reduction or alteration in epidermal proliferation 
(Ki-67), apoptosis (p53), hyperproliferation associated keratinization (K16), terminal 
differentiation (transglutaminase), and dermal inflammation was seen.
Data obtained from the cessation study of systemic acitretin in the treatment of 
actinic keratoses (paragraph 3.3) that was performed in 9 renal transplant recipients, 
demonstrated no significant increase in the number of actinic keratoses or squamous cell 
carcinomas 3 months after acitretin treatment had been stopped. This in contrast to the 
number of warts that was significantly increased after this period (p = 0.02). Induration 
of actinic keratoses increased significantly only in the first 6 weeks after acitretin with­
drawal (p = 0.004). A VAS score, representing patient contentment, reduced significantly
12 weeks after cessation (p = 0.004). With respect to immunohistochemical parameters, 
significant reduction of K13 expression was seen 6 weeks after cessation of acitretin, 
without alteration in expression of MIB-1, p53 or p 1 6 INK4A. Combining these data, acitre- 
tin withdrawal in RTRs leads to clinical deterioration within 3 months, without signifi­
cant increase in skin (pre)cancer, and from immunohistochemical point of view, it leads
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to a significant reduction of K13 expression, without alteration in expression of cell- 
cycle-associated markers.
In conclusion, systemic treatment with acitretin improves the aspect of actinic kera­
toses and warts in RTRs by alterations in keratinization, comprising an improvement 
towards normal differentiation as well as induction of retinoid-associated differentiation. 
Acitretin does not influence epidermal proliferation, apoptosis, and dermal inflammation 
in our studies. Clinically, a reduction in the number of typical actinic keratoses, featuring 
erythema, desquamation, and thickened horny scales, is seen during acitretin treatment, 
although erythematous maculae often persist. These maculae still represent features of 
actinic keratoses, such as dysplasia and high proliferation levels, assessed by histological 
and immunohistochemical investigations. Thus, actinic keratoses are clinically masked 
by acitretin. The reduction of hyperkeratosis, in theory, might also mask squamous cell 
carcinomas and other non-melanoma skin cancers. However, it is our impression that 
these lesions are still easily detected clinically, as they rapidly progress despite retinoid 
treatment. But in slower progressing SCCs and especially in actinic keratoses with micro­
invasion, a masking effect may indeed exist. The masking effect could also explain the 
sudden increase in the number of (typical) actinic keratoses and squamous cell carci­
nomas that has been reported after cessation of acitretin treatment in some other studies.
Therefore, long-term treatment seems necessary, with the lowest effective dose 
possible.
The relevance of retinoid-associated keratin expression in (pre)malignant 
skin disorders
K13 and K19 are not expressed in adult human epidermis, but can be found in 
embryonic epidermis and are induced by retinoids. From Chapter 3 it can be learned that 
non-retinoid treated actinic keratoses may also express K13 and/or K19. In the acitretin 
study on actinic keratoses in RTRs, expression of K13 and K19 in non-retinoid treated 
actinic keratoses was seen in 30%, respectively 15%, of the biopsies. In this study only 
patients were included with at least 10 AKs and one or more SCCs, or more than 20 AKs 
without an SCC in their medical history. In the study in RTRs where actinic keratoses 
were treated with topical ATRA and/or calcipotriol, no K13 expression was observed in 
the non-retinoid treated actinic keratoses. In that study patients with a relatively low 
number of actinic keratoses and squamous cell carcinomas were included. K13 expres­
sion, unlike K19 expression was also observed in non-retinoid treated common warts 
and with a significant higher incidence in renal transplant recipients (82%) than in non- 
immunocompromized patients (14%), as described in paragraph 3.6. Data from the 
cessation study of acitretin in actinic keratoses showed a significant reduction in K13 ex­
pression 6 weeks after acitretin has been stopped (p = 0.02). However, in one patient at 
this time point and in another patient 12 weeks after cessation a focal expression pattern 
of K13 was still visible.
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Most patients with K13 and/or K19 positive actinic keratoses or common warts at 
baseline have not used topical or systemic retinoids prior to the study, however, a minor­
ity of the patients were on retinoid treatment and needed a washout period (4 weeks for 
topical retinoids; 3 months for systemic retinoinds) in order to participate. Therefore, 
there must be another explanation for the expression of these keratins in baseline biop­
sies than a retinoid effect. Interestingly, expression of these keratins in baseline (non­
retinoid treated) actinic keratoses and common warts featured low expression levels with 
single cell positivity, whereas expression of these keratins after retinoid treatment 
showed a more extensive focal or band-like expression pattern.
Other (animal) studies pointed out that expression of low-molecular weight kera­
tins, such as K13 and K19, could be found in skin malignancies as a sign of a more dedif­
ferentiated state. Therefore, expression of K13 and/or K19 in a non-retinoid treated pre- 
malignant lesion is possibly a sign of a more dedifferentiated lesion and thus a lesion with 
an increased risk for malignant progression. Therefore, we looked at other parameters 
that have been positively identified to be associated with high-risk actinic keratoses. 
Indeed, we found significant associations between K13 and/or K19 expression and sev­
eral high-risk parameters, including Ki-67, p53, KIN, and the number of recently devel­
oped squamous cell carcinomas. The significant higher expression of K13 in common 
warts from renal transplant recipients compared to common warts in the normal 
population, fits to this hypothesis, as certain types of HPV are postulated to be associated 
with malignant transformation, especially in renal transplant recipients.
Therefore, it can be concluded that K13 and K19 are two new parameters that can 
be relevant in the identification of high-risk actinic keratoses. It is likely that K13 and 
K19 expression are epiphenomena related to two distinct pathways: malignant transfor­
mation and retinoid-associated keratinization. The pattern of K13 and/or K19 expres­
sion may be helpful to differentiate between these two pathways.
Future studies may focus on the behavior of actinic keratoses and squamous cell 
carcinomas during retinoid treatment. To what extent do retinoids in the clinical man­
agement of the patients indeed mask these lesions? It is also relevant to investigate the 
efficacy of RXR-selective retinoids, such as bexarotene, in the treatment of actinic kera­
toses. Furthermore, even though topical calcipotriol was not effective in the treatment of 
actinic keratoses, the combination of a vitamin D3 derivative and an RXR-selective 
retinoid may be worthwhile to investigate, because of the heterodimer formation of their 
nuclear receptors.
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5.3
Modulation of UV-induced inflammation by retinoids
Modulation of UVB-induced erythema and the minimal erythema dose
(MED) for UVB-light by topical all-trans retinoic acid
Despite the fact that the role of RAR-selective retinoids in combination with photo- 
(chemo)therapy has been extensively studied in many dermatological conditions and 
that these treatment regimens are commonly used nowadays, up to now little informa­
tion is available on the UV-modulating capacities of retinoids. It is known that retinoids 
influence inflammation and may induce a phenomenon called ‘retinoid dermatitis’, that 
comprises features like increased desquamation and erythema of the skin. Furthermore, 
retinoid treatment may lead to a decrease in epidermal thickness, and thus, may increase 
efficacy of photo(chemo)therapy in especially hyperkeratotic dermatological conditions 
by increasing penetration of UV-light through the skin.
In this thesis we found a significant increase in erythema after one week treatment 
of normal skin with twice daily topical applications of all-trans retinoic acid 0.05%, as 
compared to its vehicle. A typical perifollicular erythema pattern was seen, which can be 
interpreted as retinoid-induced dermatitis. After UVB-irradiation no statistically signifi­
cant differences could be found in MED between ATRA pre-treated skin, vehicle pre­
treated skin and untreated skin both 24 and 48 hours after irradiation. With respect to 
the intensity of erythema following these three different treatment regimens, no signifi­
cant differences were found either. Thus, apart from an increase in (perifollicular) ery­
thema due to retinoid treatment, no evidence exists that all-trans retinoic acid, after topi­
cal application, enhances erythema after a single exposure to UVB-light.
Modulation of UVB-induced erythema and the minimal erythema dose
(MED) for UVB-light by oral bexarotene
It is clear that RXR-selective retinoids may be an innovation in retinoid treatment 
for a broad spectrum of dermatological conditions. As RAR-selective retinoids are fre­
quently combined with photo (chemo) therapy in order to potentiate the therapeutic 
effect of PUVA or UVB therapy, it is interesting to speculate to what extent RXR-selective 
retinoids also may potentiate photo(chemo)therapy. Therefore, it is important to know 
whether RXR-selective retinoids modulate UV-induced erythema.
In this thesis we described the effect of the RXR-selective retinoid bexarotene on 
UVB-induced inflammation by assessment of the MED and the degree of erythema. The
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single exposure of a series of 9 increasing intensities of broadspectrum UVB-light on the 
lower part of the back was well tolerated and no photosensitizing reactions were ob­
served.
After 3 months of treatment with either 0.5 or 3 mg bexarotene per kg/day a tenden­
cy for an increase in erythema and a decrease in MED in the bexarotene 3 mg/kg/day 
dose panel was observed in a total of 4 patients, but these alterations were not statistically 
significant. No dose response relationship between MED and the dose of bexarotene was 
found and no abnormal responses to UVB-irradiation were seen. However, we cannot 
rule out that, especially higher concentrations of bexarotene, studied in a larger number 
of patients may reveal some alterations of the MED and the degree of erythema. On the 
other hand, our data suggest that patients treated with bexarotene 0.5 -  3 mg/kg/day do 
not need to take precautions with respect to short-term effects of sun exposure and 
suggest that combination therapy of RXR-selective retinoids and UV-therapy is possible.
Further studies are warranted to investigate the efficacy ofbexarotene-photo(chemo)- 
therapy in cutaneous T-cell lymphoma and psoriasis especially at higher dose levels of 
bexarotene. Apart from the combination of oral treatment with bexarotene with UV- 
treatment, topical application of bexarotene may represent another attractive option. 
Future trials may focus on RXR subtype-selective retinoids in combination with photo- 
(chemo)therapy.
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Samenvatting en conclusies
Het effect van retinoïden op klinische en immunohistochemische parameters voor 
proliferatie, differentiatie en inflammatie, vormt het centrale thema van dit proefschrift. 
In paragraaf 1.21 werden 3 doelstellingen geformuleerd.
De eerste doelstelling had betrekking op klinische en immunohistochemische effec­
ten van het RXR-selectieve retinoïd bexaroteen in de behandeling van psoriasis vulgaris. 
In hoofdstuk 2 werd hier dieper op in gegaan. In paragraaf 5.1 is een korte samenvatting 
van deze resultaten beschreven, inclusief suggesties voor toekomstige studies.
Het tweede doel richtte zich op onderzoek naar de onderliggende mechanismen van 
RAR-selectieve retinoïden in de behandeling van actinische keratosen in immuuncompe- 
tente en immuungecompromitteerde patiënten. In hoofdstuk 3 werden de effecten van 
topicale en systemische retinoïden op deze aandoeningen uiteengezet. In paragraaf 5.2 
worden deze resultaten opgesomd en nader bediscussieerd.
Bij de derde doelstelling stonden de UV-modulerende eigenschappen van RAR en 
RXR-selectieve retinoïden centraal na een eenmalige blootstelling aan breedspectrum 
UVB licht. Deze items werden belicht in hoofdstuk 4; in paragraaf 5.3 worden de resul­
taten van deze studies besproken.
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RXR-selectieve retinoïden in de behandeling van 
psoriasis vulgaris
Klinische effectiviteit, bijwerkingen en immunohistochemische effecten 
van systemisch bexaroteen in psoriasis vulgaris
Het is bekend van klinische en immunohistochemische studies dat psoriasis een 
aandoening is die doorgaans een goede respons laat zien op retinoïden en dat daarom 
retinoïden een belangrijke plaats innemen in de behandeling van deze ziekte. In tegen­
stelling tot RAR-selectieve retinoïden zijn RXR-selectieve retinoïden tot op heden nog 
niet onderzocht in de behandeling van psoriasis vulgaris. Zoals beschreven in hoofdstuk 
1, heeft de retinoïd X receptor unieke kenmerken en is bovendien de totale concentratie 
RXR in humane huid 5 maal hoger dan de totale concentratie van RAR, terwijl de ex­
pressie in de psoriasis laesie verlaagd is. Verder heeft RXR-activatie een centrale regule­
rende rol in de epidermis waarbij de interactie met vitamine D3 signaaltransductie 
relevant is. Deze observaties, in combinatie met de gerapporteerde effectiviteit van RXR- 
selectieve retinoïden in  andere dermatologische aandoeningen en in  dierexperimenteel 
onderzoek, maken het onderzoek naar de effectiviteit en bijwerkingen van het RXR-se- 
lectieve retinoïd bexaroteen in psoriasis vulgaris betekenisvol.
In hoofdstuk 2 hebben we de effectiviteit van systemisch bexaroteen gedemon­
streerd in doseringen variërend van 0,5 tot 3 mg/kg/dag gedurende een behandelperiode 
van 12 tot 24 weken, zoals de significante verbeteringen in de gemodificeerde psoriasis 
area and severity index (mPASI), plaque elevation (PEL), en physicians global assess­
ment (PGA), laten zien.
Het begin van de respons varieerde voor deze parameters van 2 tot 8 weken en 
klinische verbetering hield gemiddeld genomen aan gedurende 8 tot 16 weken (einde van 
de evaluatieperiode). Een significante afname in de psoriasis disability index, welke een 
maat is voor de subjectieve verbetering van de patiënten zelf, versterkt deze data, hoewel 
geen significant dosisrespons effect voor deze klinische parameters kon worden aange­
toond. Dit laatste kan mogelijk verklaard worden door interindividuele variatie in 
biologische beschikbaarheid van bexaroteen per os, zoals eveneens gezien wordt bij oraal 
acitretine, een retinoïd dat RAR-transactivatie stimuleert. Daarom is het mogelijk dat de 
dosis per patiënt afzonderlijk dient te worden bepaald om optimale effectiviteit te be­
reiken. Onderzoek in een grotere patiëntenpopulatie met bepaling van bexaroteen bloed­
spiegels is wellicht noodzakelijk om eventuele dosisrespons effecten aan te kunnen tonen 
met betrekking tot bovengenoemde parameters.
Aan de andere kant is het ook mogelijk dat de optimale dosis van bexaroteen voor 
psoriasis vulgaris hoger ligt dan de doseringen welke in deze studie werden geëvalueerd. 
Typische retinoïdgeassocieerde bijwerkingen, zoals jeuk en schrale lippen, werden ge­
vonden in slechts 14%, respectievelijk 10%, van de patiënten. Beide percentages zijn 
veel lager dan de percentages welke gezien worden in  de behandeling met orale RAR-
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selectieve retinoïden. Dit suggereert dat deze patiënten een suboptimale dosering kregen, 
dan wel dat RXR-activatie niet gepaard gaat met dezelfde mate van mucocutane bij­
werkingen als RAR-activatie.
Wanneer gekeken wordt naar bijwerkingen in zijn algemeenheid, werden geen ern­
stige bijwerkingen gezien en werd bexaroteen over het algemeen goed verdragen. Aan de 
andere kant liet 56% van de patiënten een stijging zien van de triglyceriden in het serum 
gedurende de behandeling, en diende dit (protocollair) behandeld te worden met atorvas- 
tatine. Verder had 92% van de patiënten uit de 3 mg groep een verlaging van het vrije T4 
gehalte in het serum, hetgeen er op kan duiden dat bexaroteen geïnduceerde hypo- 
thyreoïdie door heterodimeerformatie van de RXR met de schildklierhormoonreceptor, 
een serieuze beperkende factor kan vormen voor toepassing van dit medicijn in psoriasis. 
Het feit dat een afname in vrij T4 met name gezien werd in de groep patiënten die de 
hoogste concentratie bexaroteen ontvingen en slechts in 15% van de patiënten uit de 
laagste doseringsgroep, duidt er op dat bexaroteen geïnduceerd hypothyreoïdisme moge­
lijk een dosisafhankelijk fenomeen is. Studies waarin bexaroteen gebruikt werd voor 
andere aandoeningen, hebben dit inderdaad al eerder aangetoond. Met betrekking tot de 
andere bijwerkingen, werden geen significante verschillen gezien tussen de 4 verschillen­
de doseringsgroepen.
Wanneer deze data gecombineerd worden met de resultaten verkregen uit de corres­
ponderende immunohistochemische studie van bexaroteen in psoriasis vulgaris, waarbij 
epidermale proliferatie, differentiatie en dermale inflammatie centraal stonden, onder­
steunt dit de gevonden klinische effectiviteit van bexaroteen voor deze aandoening. Sig­
nificante reductie in Ki-67, keratine 16, transglutaminase, dermaal CD4, epidermaal CD8 
en inflammatie werd gezien na behandeling met bexaroteen, in combinatie met een signi­
ficante toename in keratine 10. In deze immunohistochemische studie werd een signi­
ficant dosisrespons effect voor Ki-67 waargenomen. Echter, de overige markers toonden 
geen dosisrespons relatie. Interindividuele variatie in de biologische beschikbaarheid van 
oraal bexaroteen zou ook hier een verklaring kunnen vormen. Geen veranderingen in 
apoptosegeassocieerde expressie van p53 werden gezien, hetgeen suggereert dat het the­
rapeutische effect van bexaroteen in psoriasis vulgaris niet voortvloeit uit een toename 
van apoptotische keratinocyten.
Een interessant gegeven is het feit dat geen inductie van keratine 13 en keratine 19 
werd gezien in de epidermis van onze biopten. De huidige studie suggereert dat RXR 
activatie niet leidt tot inductie van deze keratinen, in tegenstelling tot RAR activatie. Aan 
de andere kant kan het niet uitgesloten worden dat hogere doseringen bexaroteen dan 
werden gebruikt in deze studie nodig zijn voor inductie van keratine 13 en keratine 19. 
Daar staat echter weer tegenover dat acitretine, in doseringen welke juist hoog genoeg 
zijn om klinische en immunohistochemische effecten te bewerkstelligen in psoriasis, 
deze keratinen wel reeds kan induceren.
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Toekomstige onderzoeksbenaderingen met RXR-selectieve retinoïden in de
behandeling van psoriasis en andere hyperkeratotische aandoeningen
Om het maximale effect van systemisch bexaroteen voor psoriasis te verhelderen en 
ter bepaling van een eventueel dosisrespons effect, zijn klinische en immunohisto- 
chemische studies geïndiceerd die focussen op hogere concentraties bexaroteen in grotere 
studiepopulaties middels een gerandomiseerde en placebogecontroleerde opzet. Hierbij is 
het tevens van belang om de resultaten te relateren aan de feitelijke bloedspiegels van 
bexaroteen. Zoals reeds eerder genoemd, vormen hypertriglyceridaemie en hypothyre- 
oïdie mogelijk een beperkende factor in de behandeling van psoriasis met bexaroteen.
Ten einde deze systemische bijwerkingen te omzeilen, vormen topicale toepassingen 
van bexaroteen mogelijk een veelbelovende therapie. Toekomstige studies gericht op topi- 
cale applicatie van bexaroteen of andere RXR-selectieve retinoïden zijn daarom relevant. 
In later fase, wanneer dergelijke studies een positief resultaat laten zien, zou men kun­
nen denken aan combinatie van systemisch of topicaal bexaroteen met andere beproefde 
behandelingen voor psoriasis, zoals beschreven in hoofdstuk 1. Met name de combinatie 
van een RXR-selectief retinoïd met calcipotriol of een ander vitamine D derivaat is inte­
ressant; deze stoffen kunnen immers heterodimeren vormen en derhalve mogelijk syner­
gistisch werken.
Naast een eventuele toepassing van bexaroteen in psoriasis, zijn RXR-selectieve reti- 
noïden mogelijk ook relevant in de behandeling van een breed scala aan retinoïdgevoelige 
aandoeningen, zoals ichthyosis vulgaris, acne, en morbus Darier. Het is interessant om 
de effectiviteit van bexaroteen, systemisch of topicaal, te onderzoeken in deze huidziek­
ten.
Tenslotte vormt de ontwikkeling van RXR subtype selectieve retinoïden een belang­
rijk onderzoeksterrein. De RXR familie omvat drie receptor subtypen: a , ß en y. Elk 
receptorsubtype heeft een aparte chemische structuur welke unieke als ook overlappende 
genen controleert. Daarom kunnen de effectiviteit en bijwerkingen variëren tussen deze 
RXR subtypen. Door de ontwikkeling van RXR subtype selectieve retinoïden is het wel­
licht mogelijk om bijwerkingen als hypothyreoïdie en hyperlipidaemie te omzeilen of te 
beperken. Met name RXRa-selectieve retinoïden representeren mogelijk een innovatie 
in de behandeling van huidziekten, aangezien RXRa veelvuldig voorkomt in volwassen 
humane huid.
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RAR-selectieve retinoïden in de behandeling van 
(pre)maligne huidaandoeningen
De relevantie van topicaal all-trans retinoic acid en calcipotriol 
in actinische keratosen in immuuncompetente en 
in immuungecompromitteerde patiënten
Diverse klinische en histologische onderzoeken laten zien dat topicale retinoïden 
een positief effect hebben op door UV-licht beschadigde huid. Met betrekking tot acti- 
nische keratosen, lesies die ontstaan door UV-schade, is er echter minder informatie 
bekend over het effect van topicale retinoïden. De meeste studies welke zijn verricht naar 
de effecten van topicale retinoïden op actinische keratosen hadden enkel betrekking op 
klinische parameters. Immunohistochemische gegevens over effecten van topicale reti- 
noïden op actinische keratosen, met betrekking tot parameters voor epidermale proli­
feratie, differentiatie, dermale inflammatie en apoptose, waren niet voor handen.
Idealiter zouden criteria voor een therapeutisch effect op actinische keratosen zowel 
klinische als relevante immunohistochemische kenmerken van het preneoplastische pro­
ces moeten omvatten, aangezien klinische verbetering zonder verbetering van dysplas­
tische en proliferatieve karakteristieken deze premaligne keratosen zou kunnen maske­
ren en derhalve zowel arts als patiënt kan misleiden. Een relevant aspect van retinoïden 
vormen de mucocutane bijwerkingen, welke de compliance van de patiënt kunnen ver­
minderen en zodoende een beperkende factor zouden kunnen vormen voor het gebruik 
van retinoïden bij deze huidaandoening.
In hoofdstuk S werden klinische en immunohistochemische parameters onderzocht 
in actinische keratosen die behandeld werden met topicaal ATRA, zowel in (immuun- 
gecompromitteerde) nierrecipiënten als in niet-immuungecompromitteerde patiënten. In 
niet immuungecompromitteerde patiënten leidde 6 weken behandeling met 0,05% 
ATRA in een crèmebasis éénmaal daags niet tot een statistisch significante reductie qua 
aantal actinische keratosen gelokaliseerd op de onderarmen en handruggen, terwijl wel 
huidirritatie werd gezien in enkele patiënten. Een kleine, maar statistisch significante 
toename in differentiatie parameter K10 werd gezien na behandeling met ATRA (p = 
0,049) en een significant hogere aankleuring van het door retinoïden induceerbare K13, 
wanneer vergeleken werd met vehikel behandelde actinische keratosen (p = 0,043). 
Geen veranderingen werden gezien in epidermale proliferatie (Ki-67), apoptose (p53), 
hyperproliferatie geassocieerde keratinisatie (K16), terminale differentiatie (transgluta­
minase), epidermale dikte en dermale inflammatie.
In een populatie nierrecipiënten die behandeld werden met topicaal ATRA 0,02% 
twee maal daags voor hun actinische keratosen gelokaliseerd op de handruggen en onder­
armen, werd na 6 weken behandeling geen significante verbetering gezien in dezelfde, 
hierboven genoemde klinische, histologische en immunohistochemische parameters; met
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name geen significante inductie van K10 en/of K13. In deze populatie nierrecipiënten 
werd eveneens het effect van calcipotriol 0,05 mg/gram twee maal daags als monothera­
pie, of één maal daags ‘s ochtends in combinatie met topicaal ATRA 0,02% in de avond 
geëvalueerd. Wederom werden geen significante wijzigingen in klinische of immunohis- 
tochemische parameters gezien voor en na behandeling, zowel voor calcipotriol mono­
therapie als voor de combinatie therapie.
Na combinatie van de resultaten van deze studies, werden geen significante verschil­
len gezien in uitgangswaarden van de hierboven genoemde parameters tussen de nierre- 
cipiënten en de niet immuungecompromitteerden. Met betrekking tot effectiviteit werd 
na behandeling met ATRA in actinische keratosen van immuuncompetente patiënten 
een toename gezien van de normale differentiatie als ook een toename van de retinoïd- 
geassocieerde keratinisatie. Een significant effect op epidermale proliferatie (Ki-67) en 
apoptose (p53), of op het aantal laesies, kon evenwel niet worden aangetoond na behan­
deling met gangbare concentraties ATRA. Daarom kunnen de in andere studies gerap­
porteerde klinische therapeutische effecten van topicaal ATRA in de behandeling van 
actinische keratosen mogelijkerwijs verklaard worden door veranderingen in kerati- 
nisatie in plaats van door veranderingen in epidermale proliferatie, inflammatie, en/of 
apoptose. Topicaal calcipotriol als monotherapie, of in combinatie met topicaal ATRA, 
leidde niet tot een significante verbetering van de onderzochte parameters in deze actini- 
sche keratosen. Dit in tegenstelling tot andere hyperkeratotische huidaandoeningen 
zoals psoriasis, waar calcipotriol effectief bleek te zijn met betrekking tot epidermale pro­
liferatie en differentiatie, zelfs na een relatief korte behandelduur van 6 weken. Er kan 
evenwel niet uitgesloten worden dat langdurige behandeling met deze crèmes of applica­
tie met hogere concentraties, enig effect kan hebben, met name wanneer gekeken wordt 
in grotere patiëntenpopulaties. Aan de andere kant is het zo dat aangezien significante 
huidirritatie werd gezien in diverse patiënten die met ATRA behandeld werden, de vraag 
rijst in hoeverre hogere concentraties en langere applicatieperioden therapietrouw zul­
len verminderen. Daarom, bevelen wij deze applicaties niet aan voor de behandeling van 
actinische keratosen, maar geven de voorkeur aan andere middelen als cryotherapie en 
topicaal 5-fuoruracil (Efudix®).
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De relevantie van systemisch acitretine in de behandeling van actinische
keratosen en verrucae vulgares in nierrecipiënten
Er is beschreven dat systemische retinoïden, zoals acitretine en isotretinoïne, een 
chemopreventief effect hebben, aangezien ze klinisch het aantal actinische keratosen 
kunnen reduceren en bovendien de ontwikkeling van non-melanoma huidkanker kun­
nen inhiberen. Met name in niertransplantatiepatiënten kan de betekenis van systemi­
sche retinoïden van belang zijn, gezien het grote aantal actinische keratosen dat norma­
liter aanwezig is in deze patiënten, alsmede vanwege de hoge incidentie van malignitei- 
ten in deze populatie. Er is echter weinig informatie aanwezig over histologische en 
immunohistochemische effecten van systemische retinoïden in de behandeling van acti- 
nische keratosen. Zoals reeds eerder werd genoemd, zou klinische verbetering zonder 
verbetering qua dysplastische en proliferatieve karakteristieken deze premaligne actini- 
sche keratosen kunnen maskeren en dus zowel arts als patiënt kunnen misleiden. 
Daarom is het belangrijk om naast klinische parameters eveneens histologische en im- 
munohistochemische parameters te evalueren in patiënten met actinische keratosen die 
behandeld werden met systemische retinoïden.
In hoofdstuk 3 staan de resultaten vermeld van 26 nierrecipiënten die behandeld 
werden met oraal acitretine in een gerandomiseerde setting. Alle patiënten werden be­
handeld met een aanvangsdosering van 0,4 mg/kg/dag gedurende de eerste 12 weken, 
zoals data verkregen uit andere studies adviseerden. Na de eerste 12 weken behandeling 
zou de helft van de patiënten continueren met 0,2 mg/kg/dag, terwijl de andere helft van 
de patiënten continueerde met de aanvangsdosis van 0,4 mg/kg/dag. Echter, in tegenstel­
ling tot andere studies, was een dosisreductie reeds in de eerste 12 weken noodzakelijk 
vanwege mucocutane bijwerkingen. Wij concludeerden dat met het oog op tolerantie 
0,25-0,30 mg/kg/dag wellicht een betere aanvangsdosis is. Acitretine bleek veilig te kun­
nen worden gebruikt in deze patiënten; er deden zich geen ernstige bijwerkingen voor 
welke gerelateerd waren aan acitretine. Achteruitgang van de nierfunctie trad niet op 
tijdens acitretine gebruik. Klinische parameters lieten zowel een significante verbetering 
zien qua dikte van de actinische keratosen (p<0,01) als een daling in het aantal laesies 
met de typische erythematosquameuze kenmerken (p<0.0001) in beide groepen. Hoe­
wel wij deze niet gescoord hebben, leken ook verrucae te verbeteren gedurende de studie. 
Een significante afname in het aantal non-melanoma huidkankers werd niet gevonden 
gedurende de studie periode, vergeleken met het jaar voorafgaand aan de studie. Visual 
analogue scores demonstreerden dat de patiënten over het algemeen een positief effect 
bemerkten van acitretine behandeling reeds in de eerste 2-3 maanden met betrekking tot 
ruwheid van de laesies (p = 0,002) en algemeen welbevinden ten aanzien van de huid 
(p = 0,001). Na de eerste maand van behandeling werd geen additioneel effect bemerkt 
na continuering met acitretine tot aan het einde van de studieperiode. Tussen de beide 
groepen werden geen verschillen gezien in klinische parameters en bijwerkingen, het­
geen suggereert dat een lage onderhoudsdosis van 0,2 mg/kg/dag na een 3 maanden 
durende initiatie met een hogere dosis adequaat is om het klinische effect te onder­
houden.
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De corresponderende immunohistochemische studie in actinische keratosen, zoals 
beschreven in paragraaf 3.2, en welke werd uitgevoerd in 33 nierrecipiënten, liet zien dat 
klinische verbetering van deze laesies gedurende acitretine behandeling voortkwam uit 
een reductie in de dikte van het stratum corneum, waarschijnlijk ten gevolge van veran­
deringen in het keratinisatieproces. Significante verbetering in K10 (p = 0,02) en induc­
tie van K13 (p<0,01) en K19 (p = 0,05) wijzen erop dat een directe interferentie met 
keratinisatie het onderliggende mechanisme is. Echter, epidermale proliferatie (Ki-67), 
apoptose (p53), hyperproliferatie geassocieerde keratinisatie (K16), terminale differen­
tiatie (transglutaminase), en dermale inflammatie, bleven onveranderd. Data verkregen 
uit de cessatiestudie van systemisch acitretine in de behandeling van actinische kerato- 
sen (paragraaf 3.3), welke werd verricht in 9 nierrecipiënten, toonde geen significante 
toename in het aantal actinische keratosen of plaveiselcelcarcinomen 3 maanden nadat 
acitretine gestopt was. Dit in tegenstelling tot het aantal wratten dat wel significant was 
toegenomen na deze periode (p = 0,02). Induratie van de actinische keratosen nam signi­
ficant toe gedurende de eerste 6 weken na stoppen met acitretine (p = 0,004). Een VAS 
score, welke het algemeen welbevinden representeerde, was significant gereduceerd 12 
weken na cessatie. Met betrekking tot de immunohistochemische parameters werd een 
significante reductie gezien in K13 expressie 6 weken na stoppen met acitretine, terwijl 
de expressie van MIB-1, p53 en p 1 6 INK4A onveranderd bleven. Al met al leidde stoppen 
met acitretinebehandeling in nierrecipiënten tot klinische verslechtering binnen 3 maan­
den, zonder een significante toename in huidkanker en premaligne afwijkingen, en van­
uit immunohistochemisch perspectief bovendien tot een significante daling in K13 ex­
pressie, zonder verandering in expressie van celcyclus geassocieerde markers.
Concluderend kan gesteld worden dat systemische behandeling met acitretine het as­
pect van actinische keratosen en wratten kan verbeteren door veranderingen in keratini- 
satie, welke bestaan uit een stimulatie van de normale differentiatie als ook een inductie 
van retinoïd-geassocieerde differentiatie. Acitretine heeft geen invloed op epidermale 
proliferatie, apoptose en dermale inflammatie in onze studies. Klinisch werd tijdens be­
handeling met acitretine een reductie gezien van het aantal karakteristieke actinische 
keratosen, welke gekenmerkt worden door erytheem, desquamatie en veelal een dikke 
laag hoorn, alhoewel vaak erythemateuze maculae persisteerden. Deze maculae vertoon­
den na histologisch en immunohistochemisch onderzoek nog immer de kenmerken van 
actinische keratosen, zoals dysplasie en toegenomen epidermale proliferatie. Actinische 
keratosen worden door acitretine behandeling dus enigszins gemaskeerd. Theoretisch 
zou acitretine eveneens plaveiselcelcarcinomata en andere non-melanoma huidkankers 
kunnen maskeren. In de praktijk blijven deze aandoeningen echter gemakkelijk klinisch 
herkenbaar, aangezien zij doorgaans snel progressief zijn, ondanks retinoïd behandeling. 
Toch zou in de langzaam groeiende plaveiselcelcarcinomen, met name die welke klinisch 
sterk lijken op actinische keratosen of die welke hieruit ontstaan zijn, inderdaad een 
maskerend effect uit kunnen gaan van acitretine. Deze data verklaren ook de plotselinge 
toename in aantal van (karakteristieke) actinische keratosen en plaveiselcelcarcinomen 
welke gerapporteerd zijn na het stoppen met acitretine in sommige studies. Behandeling 
gedurende lange tijd lijkt derhalve aangewezen met de laagst mogelijke, effectieve dosis.
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De betekenis van retinoïd-geassocieerde keratine expressie in (pre)maligne
huidaandoeningen
K13 en K19 komen normaliter niet tot expressie in volwassen humane epidermis, 
maar komen wel voor in embryonale epidermis en kunnen tevens geïnduceerd worden 
door retinoïden. Hoofdstuk S toont dat niet-retinoïd behandelde actinische keratosen 
eveneens K13 en/of K19 tot expressie kunnen brengen. In de studie met acitretine voor 
actinische keratosen in nierrecipiënten werden K13 en K19 expressie gezien in 30%, res­
pectievelijk 15% van de biopten. In deze studie werden enkel patiënten geïncludeerd met 
een hoge prevalentie van actinische keratosen en meestal eveneens multipele plavei- 
selcelcarcinomen in hun voorgeschiedenis. In de studie waar actinische keratosen van 
nierrecipiënten werden behandeld met topicaal ATRA en/of calcipotriol, werd geen K13 
expressie gezien in niet-retinoïd behandelde actinische keratosen. In deze studie namen 
patiënten deel met een relatief geringer aantal actinische keratosen en plaveiselcelcarci- 
nomen. K13 expressie, in tegenstelling tot K19 expressie, werd eveneens gezien in niet- 
retinoïd behandelde verrucae vulgares en bovendien met een hogere incidentie in nier- 
recipiënten (82%) dan in niet-immuungecompromitteerden (14%), zoals beschreven in 
paragraaf 3.6. Data verkregen van de cessatie studie met acitretine in actinische kera- 
tosen toonde een significante reductie in K13 expressie 6 weken nadat acitretine gestopt 
was (p = 0,02). Echter in 1 patiënt werd na 6 weken stoppen met acitretine nog steeds 
een focaal expressie patroon van K13 gezien; in een andere patiënt werd dit nog in enige 
mate gezien na 12 weken gestopt te zijn.
De meeste patiënten met K13 en/of K19 positieve actinische keratosen of verrucae 
vulgares in de uitgangsbiopten hadden nimmer topicale of systemische retinoïden ge­
bruikt in het verleden. Een enkeling gebruikte ten tijde van de screening topicale of sys­
temische retinoïden en onderging derhalve een washout periode (4 weken voor topicale 
retinoïden; 3 maanden voor systemische retinoïden) om te kunnen participeren aan on­
derzoek. Daarom zou er een andere verklaring moeten zijn voor de expressie van deze 
keratinen in de uitgangsbiopten. Een interessante bevinding is dat deze keratinen, wan­
neer aanwezig in niet-retinoïd behandelde uitgangsbiopten van actinische keratosen en 
verrucae vulgares, typische expressie in losliggende, individuele cellen tonen, terwijl na 
retinoïdbehandeling een uitgebreider, meer focaal of bandvormig expressie patroon 
wordt gezien.
Andere (dierexperimentele) studies wijzen er op dat expressie van laagmoleculaire 
keratinen, zoals K13 en K19, gezien kunnen worden in huidmaligniteiten als uiting van 
een meer gededifferentieerd stadium. Daarom is expressie van K13 en/of K19 in een 
niet-retinoïd behandelde premaligne laesie mogelijkerwijs een teken van gevorderde de- 
differentiatie en herbergt deze laesie dus een groter risico om maligne te ontaarden. Mede 
hierom keken wij eveneens naar parameters welke positief geassocieerd zijn met actini- 
sche keratosen die een hoger risico hebben op maligne transformatie. Inderdaad vonden 
we statistisch significante associaties tussen K13 en/of K19 expressie enerzijds en enkele 
van deze parameters, waaronder Ki-67, p53, KIN, en eveneens het aantal recent ge­
ëvolueerde plaveiselcelcarcinomen. De significant hogere expressie van K13 in verrucae
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vulgares van nierrecipiënten ten opzichte van deze expressie in verrucae vulgares in de 
normale populatie, past eveneens bij deze hypothese, aangezien bepaalde types humaan 
papillomavirus verondersteld wordt geassocieerd te zijn met maligne transformatie, met 
name in nierrecipiënten.
Al met al kan er geconcludeerd worden dat K13 en K19 mogelijk twee nieuwe para­
meters zijn die een rol kunnen spelen bij de identificatie van actinische keratosen die een 
hoog risico hebben op maligne transformatie. Het is waarschijnlijk dat K13 en K19 ex­
pressie epifenomenen zijn welke gerelateerd zijn aan 2 onafhankelijke onderliggende 
mechanismen: maligne transformatie en retinoïd-geassocieerde keratinisatie. Het pa­
troon van K13 en/of K19 expressie kan een aanwijzing zijn om te differentiëren tussen 
deze beide mechanismen.
Toekomstige studies zouden zich kunnen richten op het gedrag van actinische kera- 
tosen en plaveiselcelcarcinomen tijdens retinoïd behandeling. In welke mate maskeren 
retinoïden inderdaad deze laesies? Het is bovendien relevant om ook de effectiviteit van 
RXR-selectieve retinoïden zoals bexaroteen, te evalueren in de behandeling van actini- 
sche keratosen. Ondanks het feit dat topicaal calcipotriol niet effectief bleek in de behan­
deling van actinische keratosen, zou ook de combinatie van een vitamine D3 derivaat en 
een RXR-selectief retinoïd interessant zijn om te onderzoeken vanwege de heterodimeer 
formatie van beider nucleaire receptoren.
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Modulatie van UV-geïnduceerde inflammatie door 
retinoïden
Modulatie van UVB-geïnduceerd erytheem, in het bijzonder de minimale 
erytheem dosis (MED), door topicaal all-trans retinoic acid
Ondanks het feit dat de functie van RAR-selectieve retinoïden in combinatie met 
foto(chemo)therapie veelvuldig onderwerp van studie is geweest in veel dermatologische 
aandoeningen en ondanks het feit dat deze combinatietherapie heden ten dage veel ge­
bruikt wordt, is er weinig informatie beschikbaar over de UV-modulerende eigenschap­
pen van retinoïden Het is bekend dat retinoïden inflammatie induceren en kunnen lei­
den tot een fenomeen genoemd “retino ïd  d e rm a ti tis ", met kenmerken als toegenomen 
desquamatie en erytheem van de huid. Verder kan retinoïd behandeling leiden tot een 
afname in epidermale dikte, en kan dus op deze wijze de effectiviteit van foto(chemo)- 
therapie met name in hyperkeratotische huidaandoeningen versterken via toegenomen 
penetratie van UV-licht door de huid.
In dit proefschrift vonden we een significante toename in erytheem na een week be­
handeling met twee maal daags topicaal all-trans retinoic acid 0,05% op normale huid 
ten opzichte van haar vehikel. Bovendien werd een typisch patroon van perifolliculair 
erytheem gezien, welke geïnterpreteerd kan worden als retinoïd geïnduceerde dermatitis. 
Na UVB belichting werden er geen significante verschillen gevonden in MED waarden 
tussen met ATRA voorbehandelde huid, met vehikel voorbehandelde huid en niet voor­
behandelde huid, zowel 24 uur als 48 uur na belichting. Met betrekking tot de intensiteit 
van het erytheem na behandeling met elk der bovengenoemde voorbehandelingen werd 
eveneens geen significant verschil gezien. Concluderend zijn er, los van een toename in 
(perifolliculair) erytheem ten gevolge van retinoïd behandeling, geen aanwijzingen dat 
topicaal ATRA de mate van UVB-geïnduceerd erytheem na een eenmalige belichting kan 
beïnvloeden.
Modulatie van UVB-geïnduceerd erytheem, in het bijzonder de minimale 
erytheem dosis (MED), door oraal bexaroteen
Het is waarschijnlijk dat RXR-selectieve retinoïden een innovatie vormen in reti- 
noïd behandeling van een breed scala aan huidaandoeningen. Aangezien RAR-selectieve 
retinoïden frequent gecombineerd worden met foto(chemo)therapie ter versterking van 
het effect van PUVA of UVB behandeling, is het interessant te speculeren in welke mate 
RXR-selectieve retinoiden eveneens foto(chemo)therapie versterken. Daarom is het be­
langrijk te weten of RXR-selectieve retinoiden UV-geïnduceerd erytheem moduleren.
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In dit proefschrift is het effect beschreven van het RXR-selectieve retinoïd bexaro- 
teen op UVB-geïnduceerde inflammatie door bepaling van de MED en de graad van ery- 
theem. Eenmalige expositie aan een reeks van 9 in intensiteit toenemende belichtingen 
met breedspectrum UVB op de onderrug werd goed verdragen en geen fotosensitiviteits- 
reacties werden gezien.
Na 3 maanden behandeling met hetzij 0,5-, hetzij 3 mg bexaroteen per kg per dag 
werd een tendens waargenomen tot toename in de mate van erytheem en daling van de 
MED waarde in de 4 patiënten die 3 mg bexaroteen per kg per dag kregen; deze verande­
ringen waren echter niet statistisch significant. Een dosisrespons relatie tussen MED en 
de dosis van bexaroteen werd niet gevonden en evenmin werden er abnormale reacties 
gezien op UVB belichting. Er kan evenwel niet uitgesloten worden dat met name hogere 
concentraties bexaroteen in grotere populaties toch een effect zouden kunnen onthullen 
op de MED waarde en de gradatie van erytheem. Aan de andere kan suggereren de uit­
komsten van deze studie dat patiënten die behandeld worden met bexaroteen 0,5 -  3 mg/ 
kg/dag geen extra beschermende maatregelen hoeven te nemen met betrekking tot de 
korte termijn effecten van zonlichtexpositie en lijkt combinatietherapie van RXR-selec- 
tieve retinoiden met UV-therapie mogelijk.
Aanvullende studies gericht op de effectiviteit van bexaroteen in combinatie met 
foto(chemo)therapie in cutaan T-cel lymfoom en psoriasis zijn zinvol, met name daar 
waar het gaat om hogere concentraties bexaroteen. Naast de combinatie van orale behan­
deling met bexaroteen en UV-belichting zou ook topicale toediening van bexaroteen een 
aantrekkelijk alternatief kunnen vormen. Toekomstige onderzoeken zouden zich kun­
nen richten op RXR subtype selectieve retinoiden in combinatie met foto(chemo)- 
therapie.
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Dankwoord
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kritischer te kijken naar de uitkomsten van wetenschappelijk onderzoek. Het maakt je 
daarom een beter arts en dat komt bovenal de patiënt ten goede.
Wetenschappelijk onderzoek is een proces dat bestaat uit vele fasen. Ook is onder­
zoek doen geen solitaire aangelegenheid. Bij de totstandkoming van dit proefschrift zijn 
in elk der fasen andere personen in meerdere of mindere mate betrokken geweest; zon­
der hen zou dit proefschrift niet geworden zijn tot hetgeen het nu is. Ik zou graag een­
ieder persoonlijk hiervoor willen bedanken, maar vanuit praktisch perspectief is dat 
helaas ondoenlijk. Toch wil ik enkele mensen bij naam hier speciaal danken.
Prof. dr. dr. P.C.M. van de Kerkhof, mijn promotor, was degene die mij de kans bood 
om dit onderzoek te kunnen doen en hiermee feitelijk de basis legde voor dit proefschrift. 
Peter, met bewondering heb ik de afgelopen jaren gekeken naar je onuitputtelijke 
enthousiasme om zowel in tij als ontij de voortgang van promotieonderzoek altijd hoog 
in het vaandel te hebben. Had ik een artikel of stuk geschreven, dan had je het de volgen­
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ik zonder oponthoud direct verder kon. Peter, ik wil je hartelijk danken voor je construc- 
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betekend en die ik ook nu in mijn opleiding tot dermatoloog mag genieten.
Dr. E.M.G.J. de Jong, mijn co-promotor, was de initiërende en (e)moverende kracht 
achter de actinische keratosen studies. Elke, jij zette op onze afdeling een nieuwe lijn van 
onderzoek neer welke gefocust is op huid(pre)maligniteiten al of niet gerelateerd aan im- 
munosuppressivagebruik. Ik voel me bevoorrecht dat ik daarin heb mogen participeren 
en aan de wieg daarvan heb mogen staan, ook al was het “actinische keratosen kindje” 
in den beginnen wel eens een “huilbaby” die de nodige aandacht opeiste. Hoewel je part­
time werkt, Elke, was je er toch altijd om met een groot probleemoplossend vermogen en 
intermenselijke betrokkenheid de weg der promotie begaanbaar te houden. Ik ben je voor 
dit alles veel dank verschuldigd.
Ruud de Sevaux, hoewel ik in het begin, tijdens het gemeenschappelijke dermato- 
logie-nefrologiespreekuur, het wel eens moeilijk vond om vorm te geven aan mijn net 
verworven status van arts met een door de wol geverfde arts als jij naast me en een jou 
reeds bekende patiëntenpopulatie, heb ik veel van je kunnen leren en kijk ik terug op een 
vruchtbare en constructieve samenwerking. Mede door jouw oog voor detail en statis­
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tische kennis zijn de acitretine studies, ondanks tegenslagen met zaken als randomisatie, 
toch tot een goed einde gekomen. Ik wil je hartelijk danken voor de fijne samenwerking, 
je inzet en je behulpzaamheid bij tal van onderzoeksaspecten.
Willeke Blokx, met jouw komst kwam er meer leven en diepgang met betrekking tot 
de histopathologische aspecten in de actinische keratosen en verruca studies. Je snelheid 
van werken deed me wel eens verbazen, maar wellicht komt dat voort uit je enthousias­
me voor de dermatopathologie. Bedankt voor het trekken van de kar op de momenten dat 
ik hem wegens andere bezigheden even op de parkeerplaats had gezet!
Manon Franssen, ik weet nog goed dat we, toen jij op onze afdeling kwam, de deur 
bij elkaar plat liepen. Ik heb je in die tijd leren kennen als een fijne en plezierige collega 
en ik wil je danken voor de activiteiten die je hebt verricht met betrekking tot de Targre­
tin studies. Dankzij jouw inspanning op flowcytometriegebied kreeg het Targretin- 
onderzoek bovendien een extra dimensie.
Fransje, Roland, Quintus, Mandy, Michelle, Milan, Martina, Wynand en Tim, mijn 
collega AGIO's en AGNIO's, en diegenen die ondertussen als jonge klaren zijn uitgezaaid 
over den lande, wil ik bedanken voor de socio-academische momenten. Jullie stonden en 
staan altijd garant voor een fijne collegiale basis en vaak ook meer dan dat.
Marisol Kooijmans, als researchverpleegkundige was jij de zon die ons deed schitte­
ren: zonder jouw inzet (en koffie!) liep de machine een stuk minder snel. Hartelijk dank 
voor je goede zorgen en betrokkenheid op alle fronten. Ook Hanneke Metsers, die in het 
begin de studies begeleide als researchverpleegkundige wil ik danken; Hanneke, met 
jouw gevoel voor orde en protocollen liep uiteindelijk zelfs de Targretin-trial op rollen!
Ook de collega’s van het lab wil ik bedanken voor de gezelligheid en behulpzaam­
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genoot Arno Pol, voor de gezelligheid op kamer 28.
Gijs de Jongh en Jan Boezeman, hartelijk dank voor jullie inzet qua statistische 
onderbouwing van de diverse studieresultaten.
Susan Cox en Ivy van Berlo, jullie wil ik bedanken voor jullie werkzaamheden in het 
kader van de wetenschappelijke stage projecten. Ik weet nog goed de momenten dat we 
na werktijd in de structuren van de wolken onze talloze gescoorde coupes nog meenden 
te zien!
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Mijn dank gaat ook uit naar het administratief- en secretarieel personeel, de 
afdelingsfotografen, de verpleging, en de stafleden dermatologie, die op de achtergrond 
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(InDesign). Met betrekking tot financieel support van mijn dissertatie, gaat mijn dank 
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helaas nu niet meer zal beseffen, wil ik bedanken voor hun mental coaching en algemene 
steun.
Jeanette, aan jou om de rij te sluiten, maar je staat allerminst op een onverkiesbare 
plaats: zonder jouw betrokkenheid, oprechtheid en zorgzaamheid, was dit boekje er wel­
licht nog niet geweest!
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